<SEC-DOCUMENT>0001654954-23-003044.txt : 20230316
<SEC-HEADER>0001654954-23-003044.hdr.sgml : 20230316
<ACCEPTANCE-DATETIME>20230316165101
ACCESSION NUMBER:		0001654954-23-003044
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		64
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230316
DATE AS OF CHANGE:		20230316

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ENDRA Life Sciences Inc.
		CENTRAL INDEX KEY:			0001681682
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				260579295
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1208

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37969
		FILM NUMBER:		23739522

	BUSINESS ADDRESS:	
		STREET 1:		3600 GREEN COURT
		STREET 2:		SUITE 350
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48105
		BUSINESS PHONE:		734-335-0468

	MAIL ADDRESS:	
		STREET 1:		3600 GREEN COURT
		STREET 2:		SUITE 350
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48105

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Endra Inc.
		DATE OF NAME CHANGE:	20160805
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ndra_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ndra="http://novaworks.com/20221231"><head><title>ndra_10k.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html"/></head><body style="text-align:left;font:10pt times new roman"><div style="display:none;text-align:left;font:10pt times new roman;" id="XBRLDIV"><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2022-01-01to2022-12-31">0001681682</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="From2022-01-01to2022-12-31">--12-31</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="From2022-01-01to2022-12-31">FY</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="From2022-01-01to2022-12-31">2022</ix:nonNumeric><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" unitRef="USDPShares" decimals="INF">0.0001</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" unitRef="Shares" decimals="0">80000000</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" unitRef="Shares" decimals="0">3169103</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" unitRef="Shares" decimals="0">2127725</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31_us-gaap_PreferredClassAMember" unitRef="USDPShares" decimals="INF">0.0001</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31_us-gaap_PreferredClassBMember" unitRef="USDPShares" decimals="INF">0.0001</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31_us-gaap_PreferredClassAMember" unitRef="Shares" decimals="0">10000</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31_us-gaap_PreferredClassBMember" unitRef="Shares" decimals="0">1000</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31_us-gaap_PreferredClassBMember" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_PreferredClassBMember" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31_us-gaap_PreferredClassAMember" unitRef="Shares" decimals="0">141397</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredClassAMember" unitRef="Shares" decimals="0">141397</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredClassAMember" unitRef="Shares" decimals="0">141397</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredClassBMember" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredClassBMember" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="From2022-01-01to2022-12-31"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>[Note 12 - Subsequent Events]</strong></p></ix:nonNumeric><ix:nonFraction name="ndra:SharesAvailableForIssuanceIncreasedUnderTheOmnibusPlan" contextRef="AsOf2023-01-01" unitRef="Shares" decimals="0">867966</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="0">10000</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31" unitRef="Shares" decimals="0">10000000</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" unitRef="USDPShares" decimals="INF">0.0001</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_SeriesCPreferredStockMember" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="0">141</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="0">141</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="USDPShares" decimals="INF">0.0001</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="USDPShares" decimals="INF">0.0001</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="0">141</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31_us-gaap_SeriesCPreferredStockMember" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31_us-gaap_SeriesCPreferredStockMember" unitRef="Shares" decimals="0">100000</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31_us-gaap_SeriesCPreferredStockMember" unitRef="USDPShares" decimals="INF">0.0001</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember" unitRef="USDPShares" decimals="INF">0.0001</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="0">1000</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USDPShares" decimals="INF">0.0001</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USDPShares" decimals="INF">0.0001</ix:nonFraction><ix:nonFraction name="ndra:ExpectedDividendYield" contextRef="From2022-01-01to2022-12-31" unitRef="Pure" decimals="INF">0</ix:nonFraction><ix:nonFraction name="ndra:RentSpace" contextRef="From2017-10-01to2017-10-10_ndra_JanuaryOneTwentyFifteenMember" unitRef="sqft" decimals="INF">3950</ix:nonFraction><ix:nonFraction name="ndra:RentSpace" contextRef="From2021-03-01to2021-03-15_ndra_JanuaryOneTwentyFifteenMember" unitRef="sqft" decimals="INF">3248</ix:nonFraction><ix:nonFraction name="ndra:MonthlyRent" contextRef="From2017-10-01to2017-10-10_ndra_JanuaryOneTwentyFifteenMember" unitRef="USD" decimals="0">7798</ix:nonFraction><ix:nonFraction name="ndra:MonthlyRent" contextRef="From2021-03-01to2021-03-15_ndra_JanuaryOneTwentyFifteenMember" unitRef="USD" decimals="0">15452</ix:nonFraction><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="From2017-10-01to2017-10-10_ndra_JanuaryOneTwentyFifteenMember">2019-12-31</ix:nonNumeric><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="From2021-03-01to2021-03-15_ndra_JanuaryOneTwentyFifteenMember">2025-12-31</ix:nonNumeric><ix:nonNumeric name="ndra:WeightedAverageRemainingLeaseTerm" contextRef="From2022-01-01to2022-12-31_ndra_JanuaryOneTwentyFifteenMember">P3Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="ndra-20221231.xsd"/></ix:references><ix:resources><xbrli:context id="From2022-01-01to2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_ndra_JanuaryOneTwentyFifteenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ndra:JanuaryOneTwentyFifteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-03-01to2021-03-15_ndra_JanuaryOneTwentyFifteenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ndra:JanuaryOneTwentyFifteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2017-10-01to2017-10-10_ndra_JanuaryOneTwentyFifteenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ndra:JanuaryOneTwentyFifteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-04-01to2019-04-28_ndra_EmploymentgreementsMember_ndra_RenaudMalobertiMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ndra:EmploymentgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ndra:RenaudMalobertiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-04-28_ndra_EmploymentgreementsMember_ndra_RenaudMalobertiMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ndra:EmploymentgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ndra:RenaudMalobertiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2019-04-01to2019-04-15_ndra_EmploymentAgreementsMember_ndra_MichaelThorntonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ndra:EmploymentAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ndra:MichaelThorntonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_ndra_EmploymentgreementsMember_ndra_RenaudMalobertiMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ndra:EmploymentgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ndra:RenaudMalobertiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-04-01to2019-04-15_ndra_EmploymentgreementsMember_ndra_RenaudMalobertiMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ndra:EmploymentgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ndra:RenaudMalobertiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2017-05-01to2017-05-12_ndra_EmploymentAgreementsMember_ndra_FrancoisMichelonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ndra:EmploymentAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ndra:FrancoisMichelonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_ndra_EmploymentAgreementsMember_ndra_FrancoisMichelonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ndra:EmploymentAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ndra:FrancoisMichelonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_ndra_EmploymentAgreementsMember_ndra_MichaelThorntonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ndra:EmploymentAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ndra:MichaelThorntonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2017-05-01to2017-05-12_ndra_EmploymentAgreementsMember_ndra_MichaelThorntonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ndra:EmploymentAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ndra:MichaelThorntonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_ndra_WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ndra:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_ndra_WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ndra:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_srt_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_srt_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-06-01to2021-06-21_ndra_JuneTwentyTwentyOneATMAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ndra:JuneTwentyTwentyOneATMAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_ndra_JuneTwentyTwentyOneATMAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ndra:JuneTwentyTwentyOneATMAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_ndra_JuneTwentyTwentyOneATMAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ndra:JuneTwentyTwentyOneATMAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_us-gaap_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_us-gaap_SeriesCPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-04-01to2020-04-27_ndra_TDBankLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ndra:TDBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-04-27_ndra_TDBankLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ndra:TDBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-01-01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_ndra_SharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ndra:SharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_ndra_SharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ndra:SharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_ndra_WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ndra:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_ndra_WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ndra:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_ndra_OptionsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ndra:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_ndra_OptionsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ndra:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_ndra_StockPayableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:StockPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_ndra_SeriesBPreferredStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:SeriesBPreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_ndra_PreferredsStockSeriesAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:PreferredsStockSeriesAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_ndra_StockPayableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:StockPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_ndra_SeriesBPreferredStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:SeriesBPreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_ndra_PreferredsStockSeriesAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:PreferredsStockSeriesAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_ndra_StockPayableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:StockPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_ndra_SeriesBPreferredStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:SeriesBPreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_ndra_PreferredsStockSeriesAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:PreferredsStockSeriesAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_ndra_StockPayableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:StockPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_ndra_SeriesBPreferredStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:SeriesBPreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_ndra_PreferredsStockSeriesAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:PreferredsStockSeriesAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_ndra_StockPayableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:StockPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_ndra_SeriesBPreferredStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:SeriesBPreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_ndra_PreferredsStockSeriesAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:PreferredsStockSeriesAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_PreferredClassBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_PreferredClassAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_us-gaap_PreferredClassBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_us-gaap_PreferredClassAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-03-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-03-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001681682</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="CAD"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"/></tr><tr><td style="BORDER-BOTTOM: 2px solid;"/></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNITED STATES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>WASHINGTON, D.C. 20549</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt">FORM <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentType">10-K</ix:nonNumeric></span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">(Mark One)</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">For the Fiscal Year Ended: <strong><span style="text-decoration:underline"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen">December 31, 2022</ix:nonNumeric></span></strong>&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">For the transition period from __________________ to __________________</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Commission file number: <span style="text-decoration:underline"><strong><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityFileNumber">001-37969</ix:nonNumeric></strong></span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:40%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:90%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityRegistrantName">ENDRA Life Sciences Inc.</ix:nonNumeric></span></strong></p></td></tr><tr style="height:15px"><td style="width:90%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Exact Name of Registrant as Specified in Its Charter)</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></strong></p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityTaxIdentificationNumber">26-0579295</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(State or Other Jurisdiction of Incorporation or Organization)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(I.R.S. Employer Identification No.)</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine1">3600 Green Court</ix:nonNumeric>, <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine2">Suite 350</ix:nonNumeric>, <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressCityOrTown">Ann Arbor</ix:nonNumeric>, <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressStateOrProvince">MI</ix:nonNumeric></strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressPostalZipCode">48105-1570</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Address of Principal Executive Offices)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Zip Code)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">(<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:CityAreaCode">734</ix:nonNumeric>) <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:LocalPhoneNumber">335-0468</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Registrant&#8217;s telephone number, including area code)</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Title of each class</strong></p></td><td style="width:5%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Trading Symbol</strong></p></td><td style="width:5%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Name of each exchange on which registered</strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:Security12bTitle">Common Stock, par value $0.0001 per share</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:TradingSymbol">NDRA</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">The <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Stock Market LLC</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Securities registered pursuant to Section 12(g) of the Act: None</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.5in">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric> &#9746;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.5in">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric> &#9746;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.5in">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric> &#9746; No &#9744;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.5in">If securities are registered pursuant to Section this 2(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.5in">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). &#9744;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.5in">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.5in">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric> &#9746; No &#9744;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.5in">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of "large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:30%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Large accelerated filer </p></td><td style="width:20%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#9744; </p></td><td style="width:30%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Accelerated filer </p></td><td style="width:20%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#9744; </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen">Non-accelerated Filer</ix:nonNumeric>&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#9746; </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Smaller reporting company </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric>&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Emerging growth company </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric>&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.5in">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.5in">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.5in">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. &#9744;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.5in">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act): Yes <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> No &#9746;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.5in">The aggregate market value of voting and non-voting common equity held by non-affiliates of the registrant, as of June 30, 2022, was approximately $<ix:nonFraction contextRef="AsOf2023-03-16" name="dei:EntityPublicFloat" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,628,360</ix:nonFraction> based on the closing sales price of the common stock on such date as reported on the Nasdaq Capital Market.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.5in">As of March 16, 2023, there were <ix:nonFraction contextRef="AsOf2023-03-10" name="dei:EntityCommonStockSharesOutstanding" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,169,103</ix:nonFraction> shares of the registrant&#8217;s common stock outstanding.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">DOCUMENTS INCORPORATED BY REFERENCE</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">None.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"/></tr><tr><td style="BORDER-BOTTOM: 5px solid;"/></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"/></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="TOCMF">ENDRA LIFE SCIENCES INC.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>TABLE OF CONTENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:8%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Page</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a1"><strong>PART I </strong></a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a2">Item 1.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a2">Business.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a3">Item 1A.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a3">Risk Factors.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">18</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a4">Item 1B. </a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a4">Unresolved Staff Comments.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">37</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline"><a href="#a5">Item 2. </a></span><span style="text-decoration:underline"></span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline"><a href="#a5">Properties.</a></span><span style="text-decoration:underline"></span></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">38</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline"><a href="#a6">Item 3. </a></span><span style="text-decoration:underline"></span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline"><a href="#a6">Legal Proceedings.</a></span><span style="text-decoration:underline"></span></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">38</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline"><a href="#a7">Item 4. </a></span><span style="text-decoration:underline"></span></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline"><a href="#a7">Mine Safety Disclosures.</a></span><span style="text-decoration:underline"></span></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">38</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a8"><strong>PART II</strong></a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">39</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a9">Item 5.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a9">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">39</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a10">Item 6.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a10">[Reserved]</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">39</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline"><a href="#a11">Item 7.</a></span><span style="text-decoration:underline"></span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline"><a href="#a11">Management's Discussion and Analysis of Financial Condition and Results of Operations.</a></span><span style="text-decoration:underline"></span></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">40</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline"><a href="#a12">Item 7A.</a></span><span style="text-decoration:underline"></span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline"><a href="#a12">Quantitative and Qualitative Disclosures About Market Risk.</a></span><span style="text-decoration:underline"></span></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">45</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline"><a href="#a13">Item 8. </a></span><span style="text-decoration:underline"></span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline"><a href="#a13">Financial Statements and Supplementary Data.</a></span><span style="text-decoration:underline"></span></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">46</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a14">Item 9. </a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a14">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">47</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a15">Item 9A. </a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a15">Controls and Procedures.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">47</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a16">Item 9B. </a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a16">Other Information.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">48</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a17">Item 9C.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a17">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">48</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a18"><strong>PART III</strong></a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">49</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a19">Item 10.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a19">Directors, Executive Officers and Corporate Governance.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">49</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a20">Item 11.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a20">Executive Compensation.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">52</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a21">Item 12. </a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a21">Security Ownership of Certain Beneficial Owners and Management and Related Stockholders Matters.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">56</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a22">Item 13. </a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a22">Certain Relationships and Related Transactions, and Director Independence.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">58</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a23">Item 14.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a23">Principal Accountant Fees and Services.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">58</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a24"><strong>PART IV</strong></a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">59</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a25">Item 15. </a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a25">Exhibits, Financial Statements and Schedules.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">59</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a26">Item 16. </a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a26">Form 10-K Summary.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">60</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">This Annual Report on Form 10-K (this &#8220;Annual Report&#8221;) contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the &#8220;safe harbor&#8221; created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;seek,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;goal,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;anticipate,&#8221; &#8220;strategy&#8221;, &#8220;future&#8221;, &#8220;likely&#8221; or other comparable terms and references to future periods. All statements other than statements of historical facts included in this Annual Report regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expectations for revenues, cash flows and financial performance, the anticipated results of our development efforts and the timing for receipt of required regulatory approvals and product launches.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">our limited commercial experience, limited cash and history of losses;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">our ability to obtain adequate financing to fund our business operations in the future;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">our ability to achieve profitability;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">our ability to develop a commercially feasible application based on our Thermo-Acoustic Enhanced Ultrasound (&#8220;TAEUS&#8221;) technology;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">market acceptance of our technology;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">uncertainties associated with COVID-19 or future pandemics, including possible effects on our operations;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the effect of macroeconomic conditions on our business;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">results of our human studies, which may be negative or inconclusive;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">our ability to find and maintain development partners;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">our reliance on third parties, collaborations, strategic alliances and licensing arrangements to complete our business strategy;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the amount and nature of competition in our industry;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">our ability to protect our intellectual property;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">potential changes in the healthcare industry or third-party reimbursement practices;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">delays and changes in regulatory requirements, policy and guidelines<span style="text-decoration:underline">,</span> including potential delays in submitting required regulatory applications or other submissions with respect to U.S. Food and Drug Administration (&#8220;FDA&#8221;) or other regulatory agency approval;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">our ability to maintain CE mark certification, and secure required FDA and other governmental approvals, for our TAEUS applications;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">our ability to comply with regulation by various federal, state, local and foreign governmental agencies and to maintain necessary regulatory clearances or approvals;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">our ability to maintain compliance with Nasdaq listing standards;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">our dependence on our senior management team; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the other risks and uncertainties described in the Risk Factors and in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations sections of this Annual Report.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Any forward-looking statement made by us in this report is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>RISK FACTOR SUMMARY</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Below is a bulleted summary of our principal risk factors, however this list does not fully represent all of our known risk factors. We encourage you to carefully review the full risk factors contained in this Annual Report in their entirety for additional information regarding the material factors that make an investment in our securities speculative or risky. These risks and uncertainties include, but are not limited to, the following:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Risks Related to our Business</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">We have a history of operating losses, we may never achieve or maintain profitability, and we will need to raise significant additional capital if we are going to continue as a going concern.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Our efforts may never result in the successful development of commercial applications based on our TAEUS technology, on which our success is substantially dependent.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Our TAEUS platform applications may not achieve adequate market acceptance by the physicians, patients, third-party payors and others in the medical community.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The outbreak of COVID-19, or future pandemics, could adversely impact our business, including our pre-sales activities, clinical trials and ability to obtain regulatory approvals.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">We may not remain commercially viable if there is an inadequate level of reimbursement by governmental programs and other third-party payors for our planned products or associated procedures.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">We have limited resources and depend on third parties to design and manufacture, and seek regulatory approval of, our TAEUS applications.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">We will need to develop marketing and distribution capabilities both internally and through our relationships with third parties in order to sell any of our TAEUS products receiving regulatory approval.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Competition in the medical imaging market is intense and we may be unable to successfully compete.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">We intend to market our TAEUS applications, if approved, globally, in which case we will be subject to the risks of doing business outside of the United States.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">We depend on our senior management team and the loss of one or more key employees or an inability to attract and retain highly skilled employees could harm our business.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Misdiagnosis, warranty and other claims, as well as product field actions and regulatory proceedings, initiated against us could increase our costs, delay or reduce our sales and damage our reputation.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Risks Related to Intellectual Property and Other Legal Matters</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">If we are unable to protect our intellectual property, which entails significant expense and resources, then our financial condition, results of operations and the value of our technology and products could be adversely affected.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Policing unauthorized use of our proprietary rights can be difficult, expensive and time-consuming, and we might be unable to determine the extent of this unauthorized use.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Intellectual property rights may not provide adequate protection, which may permit third parties to compete against us more effectively.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Risks Related to Government Regulation</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">If we fail to obtain and maintain necessary regulatory clearances or approvals for our TAEUS applications, or if clearances or approvals for future applications and indications are delayed or not issued, our commercial operations will be harmed.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Healthcare reform measures could hinder or prevent our planned products' commercial success.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">If we fail to comply with healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Risks Related to Owning Our Securities, Our Financial Results and Our Need for Financing</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Our quarterly and annual results may fluctuate significantly, may not fully reflect the underlying performance of our business and may result in volatility in the price of our securities.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Our stock price has fluctuated in the past, has recently been volatile and may be volatile in the future for reasons unrelated to our operating performance or prospects, and as a result, investors in our common stock could incur substantial losses.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">We may be subject to securities litigation, which is expensive and could divert management attention.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">If we are unable to implement and maintain effective internal control over financial reporting, including by remediating current material weaknesses in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our securities may decrease.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plan, could result in dilution of the percentage ownership of our stockholders and could cause the price of our securities to fall.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Our charter documents and Delaware law may inhibit a takeover that stockholders consider favorable.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>General Risk Factors </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Our business is affected by macroeconomic conditions.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Our cash and cash equivalents could be adversely affected if the financial institutions in which we hold our cash and cash equivalents fail.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The ongoing military action by Russia in Ukraine could have negative impact on the global economy, which could materially adversely affect our business, operations, operating results and financial condition.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Our business and operations are subject to risks related to climate change.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Our business could be negatively impacted by corporate social responsibility and sustainability matters.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; &#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="a1">PART I</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">As used in this Annual Report, unless the context otherwise requires, the terms &#8220;ENDRA,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and the &#8220;Company&#8221; refer to ENDRA Life Sciences Inc., a Delaware corporation, and its subsidiaries.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="a2">Item 1. Business</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span style="text-decoration:underline">Overview</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We were incorporated as a Delaware corporation in 2007. We are leveraging experience with pre-clinical enhanced ultrasound devices to develop technology for increasing the capabilities of clinical diagnostic ultrasound in order to broaden patient access to the safe diagnosis and treatment of a number of significant medical conditions in circumstances where expensive X-ray computed tomography (&#8220;CT&#8221;) and magnetic resonance imaging (&#8220;MRI&#8221;) technology, or other diagnostic technologies such as surgical biopsy, are unavailable or impractical.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">In 2010, we began marketing and selling our Nexus 128 system, which combined light-based thermoacoustics and ultrasound to address the imaging needs of researchers studying disease models in pre-clinical applications. Building on this expertise in thermoacoustics, we have developed a next-generation technology platform&#8212;Thermo Acoustic Enhanced Ultrasound, or TAEUS&#9415; &#8212;which is intended to enhance the capability of clinical ultrasound technology and support the diagnosis and treatment of a number of significant medical conditions that currently require the use of expensive CT or MRI imaging or where imaging is not practical using existing technology. We ceased production, service support and parts for our Nexus 128 system in 2019 in order to focus our resources exclusively on the development of our TAEUS technology.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Our TAEUS technology uses radio frequency (&#8220;RF&#8221;) pulses to stimulate tissues, using a small fraction (less than 1%) of the amount of energy that would be transmitted into the body during an MRI scan. The use of RF energy allows our TAEUS technology to penetrate deep into tissue, enabling the imaging of human anatomy at depths equivalent to those of conventional ultrasound. The RF pulses are absorbed by tissue and converted into ultrasound signals, which are detected by an external ultrasound receiver and a digital acquisition system that is part of the TAEUS system. The detected ultrasound is processed into images and other forms of data using our proprietary algorithms and displayed to complement conventional gray-scale ultrasound images.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">ENDRA uses suppliers of components, such as Blatek Industries, Inc. and Elite RF, LLC,&#160; and contract manufacturers, such as Starfish Product Engineering, Inc., to assemble and test ENDRA's TAEUS&#174; liver system for commercial sale.&#160; Suppliers are vetted before engaging in work with ENDRA and reviewed annually, as part of ENDRA&#8217;s quality management system, to assure their performance meets ENDRA's needs.&#160; ENDRA has implemented internal processes to monitor designs, inventory and supply of key components needed to manufacture its TAEUS&#174; liver system.&#160; ENDRA plans its production in accordance with anticipated market demand and availability and lead times of needed materials.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">As described below, our first TAEUS platform application focuses on quantifying fat in the liver and stage progression of nonalcoholic fatty liver disease (&#8220;NAFLD&#8221;) which, untreated, can progress to Nonalcoholic Steatohepatitis (&#8220;NASH&#8221;), fibrosis, cirrhosis and liver cancer. In April 2016, we entered into a Collaborative Research Agreement with General Electric Company, acting through its GE Healthcare business unit and the GE Global Research Center (collectively, &#8220;GE Healthcare&#8221;), under which GE Healthcare has agreed to assist us in our efforts to commercialize this application. In November 2017, we contracted with the Centre for Imaging Technology Commercialization (&#8220;CIMTEC&#8221;) to initiate human studies, through Canada-based Robarts Research Institute, with our TAEUS device targeting NAFLD. In October 2018, we received an Investigational Testing Authorization (&#8220;ITA&#8221;) from Health Canada to commence the first human studies in healthy volunteers with our TAEUS clinical system targeting NAFLD, guiding our algorithm development, and comparing our technology to MRI. The feasibility study was conducted in collaboration with Robarts Research Institute in London, Ontario, Canada. We reported the completion and top-level findings of this study in September 2019. The data collected from the study, including additional usability inputs, was included in our TAEUS liver device technical file submission for device CE mark, which we received for our NAFLD TAEUS application in March 2020. ENDRA has eight current or completed clinical research partnerships with research hospitals in North America, Europe and Asia for the conduct of clinical studies comparing our TAEUS clinical system to MRI-Proton Density Fat Fraction (&#8220;MRI-PDFF&#8221;) in the measurement of liver fat. In June 2020, we completed a 510(k) Premarket Notification submission to the FDA for the NAFLD TAEUS application. Following meetings with the FDA in connection with its review of our application, we determined that the 510(k) pathway was not the optimal option due to the novel nature of our NAFLD TAEUS application and, in February 2022, announced that we would pursue the de novo pathway for FDA reclassification and clearance of our NAFLD TAEUS application.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Each of our TAEUS platform applications will require regulatory approvals before we are able to sell or license the application. Based on certain factors, such as the installed base of ultrasound systems, availability of other imaging technologies, such as CT and MRI, economic strength and applicable regulatory requirements, we intend to seek initial approval of our applications for sale in the European Union, followed by the United States and China.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Diagnostic Imaging Technologies</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Diagnostic imaging technologies such as CT, MRI and ultrasound allow physicians to look inside a person&#8217;s body to guide treatment or gather information about medical conditions such as broken bones, cancers, signs of heart disease or internal bleeding. The type of imaging technology a physician uses depends on a patient&#8217;s symptoms and the part of the body being examined. CT technology is well suited for viewing bone injuries, diagnosing lung and chest problems, and detecting cancers. MRI technology excels at examining soft tissue in ligament and tendon injuries, spinal cord injuries, and brain tumors. CT scans can take as little as 5 minutes, while an MRI scan can take up to 30 minutes.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Unfortunately, while CT and MRI systems are versatile and create high quality images, they are also expensive and not always accessible to patients. A CT system costs approximately $1 million and an MRI system can cost up to $3 million. CT and MRI systems are large and can weigh several tons, typically requiring significant modifications to existing healthcare facilities to safely site the CT and MRI equipment. Because of their size and weight, CT and MRI systems are usually fixed-in-place at major medical facilities. As a result, they are less accessible to primary care and rural clinics, economically developing markets, and patient bedsides. As of 2018, there were only approximately 63,000 CT systems and 50,000 MRI systems in the world, approximately 50% of which were located in the U.S. and Japan.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">While CT and MRI systems create high quality images, their use is not always practical. For example, the diagnosis and treatment of the estimated 1.8 billion people suffering from NAFLD requires ongoing surveillance of the patients&#8217; livers to assess the progression of the disease and the efficacy of treatment. However, the use of CT and MRI systems to perform that surveillance is impractical for a number of reasons, including the high cost of the scan and the limited availability of CT and MRI systems. Patient exposure to the ionizing radiation generated by a CT system must be limited for safety reasons. Similarly, because of the strong magnetic field created by an MRI machine, patients with metal joint replacements or cardiac pacemakers may be limited for safety reasons in their use of&#160;an MRI system.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Ultrasound Technology</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">An ultrasound machine transmits sound waves, which bounce off tissues, organs and blood in the body. The ultrasound machine captures these echoes and uses them to create an image. Ultrasound technology excels at imaging the structure of internal organs, muscles and bone surfaces. Due to its utility, cost-effectiveness and safety profile, ultrasound imaging is frequently used in a physician&#8217;s examination room or at a patient&#8217;s bedside as a first-line diagnostic tool, which has resulted in an overall increase in the number of ultrasound scans performed.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Ultrasound systems are more broadly available to patients than either CT or MRI systems. There are an estimated 1.6 million diagnostic ultrasound systems globally in use today. Ultrasound systems are relatively inexpensive compared to CT and MRI systems, with smaller portable ultrasound systems costing as little as $10,000 and new cart-based ultrasound systems costing between $75,000 and $200,000. Ultrasound systems are also more mobile than CT and MRI systems and many are designed to be moved by an operator from room to room, or closer to patients. Ultrasound technology does not present the same safety concerns as CT and MRI technology, since ultrasound does not emit ionizing radiation and ultrasound contrast agents are generally considered to be safe.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">However, ultrasound&#8217;s imaging capabilities are more limited compared to CT and MRI technology. For example, ultrasound systems cannot measure tissue temperature during thermal ablation surgery or quantify fat to diagnose early-stage liver disease&#8212;instances where CT and MRI systems are used.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Ultrasound Market</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The global diagnostic ultrasound device market size was valued at $7.3 billion in 2022 and is anticipated to expand at a CAGR of 4.07% from 2022 to 2030. There are an estimated 1.6 million&#160; diagnostic ultrasound systems in global use in 2022. These numbers include both portable and cart-based ultrasound systems, and cover all types of diagnostic ultrasound procedures, including systems intended for cardiology, prenatal and abdominal use. We do not currently intend to address cart-based ultrasound systems focused on applications in prenatal care, nor certain portable ultrasound applications such as emergency room medicine, where we believe our TAEUS technology may not substantially impact patient care. Accordingly, we estimate&#160;our addressable market for one or more of our current or future TAEUS applications as approximately&#160;700,000 ultrasound systems currently in use throughout the world.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We believe that demand for ultrasound systems is driven primarily by the following factors:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Population growth and age demographics that increase the demand for diagnostic screening for cancer, cardiology, and prenatal applications.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Economic development broadening investment in healthcare in underserved markets such as China and Latin America, where ultrasound technology has significant appeal due to its price point and flexibility at point-of-care.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Expanding ultrasound applications and improving image quality that drive demand for new ultrasound technologies, such as software enhancements, bi-axial probes, and dedicated single application systems.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Positive insurance reimbursement rate trends for ultrasound diagnostics due to the technology&#8217;s safety and cost-effectiveness.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Unmet Need</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We believe that the limited availability of high-utility and cost-effective imaging technology represents a significant unmet medical need. We believe that expanding the capability of ultrasound technology to perform more of the imaging tasks presently available only on expensive CT and MRI systems will help to satisfy this unmet need.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span style="text-decoration:underline">Our Solutions</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Our TAEUS technology uses a pulsed energy source&#8212;specifically, radio-frequency (&#8220;RF&#8221;) &#8212;to generate ultrasonic waves in tissue. These waves are then detected with ultrasound equipment and used to create high-contrast images and other forms of data using our proprietary algorithms. Unlike conventional ultrasound, which creates images based on the scattering properties of tissue, thermoacoustic imaging provides tissue absorption maps of the pulsed energy, similar to those generated by CT scans. Ultrasound is only utilized to transmit the absorption signal to the imaging system outside of the body.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Our TAEUS Technology Platform for Clinical Applications</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">To increase the utility of our thermoacoustic technology, in 2013 we began to develop our TAEUS technology platform. Unlike the near-infrared light pulses used in our earlier photoacoustic systems, our TAEUS technology uses RF pulses to stimulate tissues, using a small fraction of the energy transmitted into the body during an MRI scan. Using RF energy enables our TAEUS technology to penetrate deep into tissue, enabling the imaging of human anatomy at depths equivalent to those of conventional ultrasound. The RF pulses are absorbed by tissue and converted into ultrasound signals, which are detected by an external ultrasound receiver and a digital acquisition system that is part of the TAEUS system. Our RF-based thermoacoustics imaging is not adversely affected by blood-filled organs, enabling our TAEUS technology to be used in clinical liver applications, among others. The detected ultrasound can then be processed into ultrasound overlays or quantitative data that may be translated into clinically useful metrics using our proprietary algorithms and displayed to complement conventional gray-scale ultrasound images. The TAEUS imaging concept is illustrated below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="ndra_10kimg5.jpg" alt="ndra_10kimg5.jpg"/></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">After required regulatory approvals, our TAEUS technology can be added as an accessory to existing ultrasound systems, helping to improve clinical decision-making on the front lines of patient care, without requiring substantially new clinical workflows or large capital investments. We are also developing TAEUS for incorporation into new ultrasound systems manufactured by companies such as GE Healthcare, described more fully below.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We believe that our TAEUS technology has the potential to add a number of new capabilities to conventional ultrasound and thereby enhance the utility of both existing and new ultrasound systems and extend the use of ultrasound technology to circumstances that either currently require the use of expensive CT or MRI imaging systems, where imaging is not practical using existing technology, or where other assessment tools such as surgical biopsy are required. To demonstrate the capabilities of our TAEUS platform, we have conducted various internal ex-vivo laboratory experiments and limited internal in-vivo large animal studies. In our ex-vivo and in-vivo testing, we have demonstrated that the TAEUS platform has the following capabilities and potential clinical applications:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Tissue Composition: Our TAEUS technology enables ultrasound to distinguish fat from lean tissue. This capability would enable the use of TAEUS-enhanced ultrasound for the early identification, staging and monitoring of NAFLD, a precursor to NASH, liver fibrosis, cirrhosis and liver cancer.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Temperature Monitoring: Our TAEUS technology enables traditional ultrasound to visualize changes in tissue temperature, in real time. This capability would enable the use of TAEUS-enhanced ultrasound to guide thermoablative therapy, which uses heat or cold to affect tissue, such as in the treatment of cardiac atrial fibrillation, or removal of cancerous liver and kidney lesions, with greater accuracy, and perform cosmetology procedures such as lipolysis of abdominal fat.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Vascular Imaging: Our TAEUS technology has the potential to enable visualization of blood vessels from any angle, using only a saline solution contrasting agent, unlike Doppler ultrasound, which requires precise viewing angles. This capability would enable the use of TAEUS-enhanced ultrasound to assist in identifying arterial plaques or malformed vessels.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Tissue Perfusion: Our TAEUS technology has the potential to image blood flow at the capillary level in a region, organ or tissue. This capability could be used to assist physicians in characterizing abnormalities in tissue perfusion symptomatic of damaged tissue, such as internal bleeding from trauma, or diseased tissue, such as certain cancers. </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="font-size:10pt;font-family:times new roman;margin:0px">Because of the large number of traditional ultrasound systems currently in global use, we are first developing our TAEUS technology for sale as an aftermarket accessory that works with existing ultrasound systems. Because our TAEUS technology is designed to enhance the utility of, not replace, conventional ultrasound, we believe healthcare providers will be able to increase the utilization of, and generate new revenue from, their existing ultrasound systems once we obtain required regulatory approval for specific applications. We further believe that clinicians will be attracted to our technology because it will enable them to perform more procedures with existing ultrasound equipment, thereby retaining more imaging patients in their clinics rather than referring patients out to a regional medical center for a CT or MRI scan.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">ENDRA&#8217;s first clinical product is designed to interface with a conventional ultrasound scanner, utilizing the scanner&#8217;s B-mode imaging to guide the selected region for assessment of liver fat content. The following sub-systems will comprise ENDRA&#8217;s first generation product.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.5in"><strong>Radio Frequency (RF) Source and Computer:</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The RF source consists of a low power waveform generator and an amplifier. Together, these components provide the characteristic pulses required to excite thermoacoustic signals in tissue. The computer provides processing capability to both utilize the conventional ultrasound data for navigation to the measurement site of interest, and the calculations required to convert digitized thermoacoustic signals to measurements of fat in liver tissue. The entire sub-system will reside in a single enclosure, on wheels, and sit adjacent to the ultrasound imaging system.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.5in"><strong>Specialized Transducer:</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">A single channel &#8220;receive only&#8221; ultrasound transducer is specifically designed and optimized for thermoacoustic imaging. The transducer sub-system will detect thermoacoustic signals excited by the RF source within the liver. The transducer assembly includes electronics for signal amplification, digitization, and signal processing. The specialized transducer will work in concert with the conventional ultrasound probe used for liver imaging.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.5in"><strong>RF Applicator:</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The RF applicator transmits pulses of energy, provided by the RF source, into tissue. The applicator is positioned in proximity to the target region for measurement.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Future TAEUS platforms are&#160;expected to provide two dimensional imaging with a transducer composed of multiple receive elements. The RF source and applicator would be similar to those in the first generation product but the multi-element transducer would allow for multiple applications including: reading tissue composition, temperature, vascular flow, tissue perfusion, and other potential applications. Ultimately, we expect our technology will be incorporated into conventional ultrasound systems and our business model will transition from producing stand-alone systems to licensing our technology, IP and specialized components to ultrasound OEMs. Existing ultrasound equipment already includes power supplies, computation, high speed electronics, and ultrasound transducers, which may be leveraged by our thermoacoustic imaging applications. The RF source and applicator are the principal hardware components that will be added to OEM ultrasound systems for the OEM fully integrated form of our product.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We are following a model that mirrors the approach used by companies in the past to introduce new ultrasound imaging capabilities to existing conventional ultrasound scanners. Color Doppler, elastography, 3-D imaging, and high channel count systems were all introduced by new companies (not already involved in conventional ultrasound imaging). Historically, ultrasound imaging has grown through the introduction of unique technology and capabilities that expanded the applications and use of clinical ultrasound in a form that often added separate hardware to existing ultrasound systems. Ultimately, as these new technologies gained acceptance in the marketplace they were incorporated into OEM-designed and built systems that were sold by the leading ultrasound imaging vendors.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span style="text-decoration:underline">TAEUS System for the Early Assessment and Monitoring of Nonalcoholic Fatty Liver Disease, or NAFLD</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Our first TAEUS platform application focuses on quantifying fat in the liver and stage progression of NAFLD which, untreated, can progress to NASH, fibrosis, cirrhosis and liver cancer. In 2022, over 2 billion people globally were estimated to be affected by NAFLD. The World Gastroenterology Organisation considers NAFLD/NASH a global pandemic affecting rich and poor countries alike. Obesity, hepatitis, and diabetes are leading contributors to the development of NAFLD.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Left untreated, an estimated 30% of NAFLD cases progress to NASH, a condition in which liver fat causes inflammation and decreased liver function, possibly resulting in fatigue, weight loss, muscle pain and abdominal pain. Excess liver fat remains a root cause of and key clinical concern for both NASH and NAFLD.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Approximately 25% of NASH cases progress to liver fibrosis, in which liver inflammation causes scar tissue which eventually prevents the liver from functioning properly. The scar tissue blocks the flow of blood through the liver and slows the processing of nutrients, hormones, drugs, and naturally produced toxins. It also slows the production of proteins and other substances made by the liver. Once a patient develops cirrhosis of the liver, the only life-saving therapy is a liver transplant. Additionally, cirrhosis patients may develop liver cancer. In January 2023, the American Cancer Society estimated that liver cancer kills over 700,000 people annually. Because of the increased incidence of obesity, hepatitis and diabetes throughout the world, NAFLD has become the most common chronic liver disease and an important cause of cirrhosis and liver cancer worldwide.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Despite the increased incidence of NAFLD and its role in the development of NASH, cirrhosis and liver cancer, we believe that no low-cost, accurate and safe method exists for measuring fat in the liver. Current liver enzyme blood tests are indicative, but cannot reliably confirm early stage NAFLD or NASH, and liver enzyme levels are normal in a large percentage of patients with NAFLD. Existing ultrasound technology can only measure fat qualitatively in the liver at moderate to severe levels, typically greater than 30% liver fat, and ultrasound has low accuracy when used on obese patients. While early stage NAFLD and NASH can be confirmed by an MRI scan, an MRI scan is expensive, and MRI systems are not widely available or practical for many patients. A surgical biopsy can be used to confirm NAFLD and NASH, but is also expensive, involves a painful procedure and exposes patients to the risk of infection and bleeding. Furthermore, MRIs and surgical biopsies are impractical for repeated screening and monitoring of liver disease. We believe these limitations negatively impact the diagnosis and treatment of patients with NAFLD.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Billions of dollars are spent annually on the global diagnosis and treatment of NAFLD and related liver diseases. In the United States, annual direct medical costs for NAFLD were estimated in 2016 to be $103 billion, and in the Europe-4 countries (Germany, France, Italy, and United Kingdom), about &#8364;35 billion. Patients diagnosed with NAFLD and related liver diseases are typically treated with available therapies such as statins, insulin sensitizers and other compounds and are encouraged to adopt lifestyle changes to reduce their weight and improve their overall health. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">In addition, patients receiving treatment for NAFLD-spectrum liver diseases must continue to be monitored to assess disease progression and the efficacy of treatment. Because of the high cost and limited global availability, CT and MRI technology is not typically used for this function.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We believe our TAEUS technology will enable primary care physicians, radiologists and hepatologists to diagnose NAFLD earlier and monitor patients with NAFLD-spectrum liver diseases more accurately and cost-effectively than is possible with existing technology.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">A pipeline of 30+ pharmaceutical compounds targeting liver disease are in development by companies such as Viking&#160;Therapeutics, Inventiva, Madrigal Pharmaceuticals, Inc., Akero Therapeutics and Regeneron Pharmaceuticals. The pharmaceutical industry&#8217;s increased presence in the liver disease space represents a synergistic opportunity for ENDRA, as early detection of NAFLD could enable prescription of drug treatment at the most advantageous time for patients. The companies can also benefit from simpler, non-invasive measurements of biomarkers, such as liver fat, in the clinical stage. To this end, in March 2021 ENDRA announced a collaboration agreement with Hepion Pharmaceuticals to incorporate TAEUS as an add-on technology to support Hepion&#8217;s patient screening and biomarker measurements during its Phase 2b study of its lead drug candidate.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">In April 2016, we entered into a Collaborative Research Agreement with General Electric Company, acting through its GE Healthcare business unit and the GE Global Research Center (collectively, &#8220;GE Healthcare&#8221;). Under the terms of the agreement, GE Healthcare has agreed to assist us in our efforts to commercialize our TAEUS technology for use in a fatty liver application by, among other things, providing equipment and technical advice, and facilitating introductions to GE Healthcare clinical ultrasound customers. In return for this assistance, we have agreed to afford GE Healthcare certain rights of first offer with respect to manufacturing and licensing rights for the target application. More specifically, we have agreed that, prior to commercially releasing our NAFLD TAEUS application, we will offer to negotiate an exclusive ultrasound manufacturer relationship with GE Healthcare for a period of at least one year of commercial sales. The commercial sales would involve, within our sole discretion, either our commercially selling GE Healthcare ultrasound systems as the exclusive ultrasound system with our TAEUS fatty liver application embedded, or GE Healthcare being the exclusive ultrasound manufacturer to sell ultrasound systems with our TAEUS fatty liver application embedded. The agreement with GE Healthcare does not prevent us from selling our TAEUS fatty liver application technology to distributors or directly to non-manufacturer purchasers. Additionally, the agreement provides that (1) prior to offering to license any of our TAEUS fatty liver application intellectual property to a third party, we will first offer to negotiate to license our TAEUS fatty liver application intellectual property to GE Healthcare and (2) prior to selling any equity interests to a healthcare device manufacturer, we must first offer to negotiate in good faith to sell such equity interests to GE Healthcare. The agreement is subject to termination by either party upon not less than 60 days&#8217; notice. On December 16, 2022, we and GE Healthcare entered into an amendment to our agreement, extending its term to December 16, 2024.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">In 2018, we received authorization to commence the first human studies in healthy volunteers with our TAEUS clinical system targeting NAFLD, guiding our algorithm development, and comparing our technology to MRI. The feasibility study was conducted in collaboration with the Robarts Research Institute in London, Canada. We reported the completion of this 50-subject study and top-level findings in September 2019. The data collected from the study, including additional usability inputs, was included in our TAEUS liver device technical file submission for device CE mark. Additionally, in 2019 we entered into clinical evaluation agreements with Rocky Vista University College of Osteopathic Medicine (RVUCOM) and the University of Pittsburgh Medical Center (UPMC) and in 2020 with the Medical College of Wisconsin (MCW), Universit&#228;tsmedizin der Johannes Gutenberg-Universit&#228;t Mainz and Centre Hospitalier Universitaire d'Angers, France (CHU Angers).&#160; In 2021 we established clinical evaluation agreements with Inselspital University Hospital in Bern, Switzerland, and King's College Hospital - London, in the United Kingdom. In 2022 we established a clinical collaboration with Shanghai General Hospital (China).&#160; In 2022 we established a research collaboration agreement with Ludwig Maximilian University of Munich, Germany.&#160;&#160;&#160;&#160; </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We received CE mark approval for our TAEUS FLIP (Fatty Liver Imaging Probe) system in March 2020, indicating that the TAEUS FLIP system complies with all applicable European Directives and Regulations in the European Union (&#8220;EU&#8221;) and other CE mark geographies, including the 27 EU member states. In support of our commercialization efforts in the EU, we have 4 sales representatives in France, the United Kingdom, and Germany and expect to expand marketing efforts into other CE markets as we grow. We actively attend various trade shows and clinical conferences across the UK and EU to drive our marketing presence amongst medical professionals that constitute our target market. We have also entered into agreements with clinical evaluation sites in Switzerland, Germany, UK and France to collect clinical evidence with the aim to underscore the clinical utility of the TAEUS device for assessing NAFLD. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We are pursuing FDA premarket clearance of our TAEUS FLIP system to enable sales in the United States. We submitted a 510(k) Premarket Notification application to the FDA in June 2020. Our submission happened to coincide with the onset of the COVID-19 pandemic, which strained the FDA&#8217;s resources, causing it to prioritize COVID-19 related work and resulting in a backlog of non-COVID-19 premarket files pending review. Following meetings with the FDA in connection with its review of our application, in February 2022 we determined that the 510(k) pathway was not the optimal option for our TAEUS FLIP system due to its novel nature and announced that we would pursue the de novo pathway for FDA reclassification and clearance of our NAFLD TAEUS application.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span style="text-decoration:underline">Other Potential Clinical Applications for our TAEUS Technology</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Temperature Monitoring of Thermoablative Surgery</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We also intend to develop a TAEUS platform application to guide thermal ablation surgery, such as in the treatment of cardiac atrial fibrillation, chronic pain and lesions of the liver, thyroid, kidneys and other soft tissues. We plan to target clinical users of thermoablative technology, including interventional radiologists, cardiologists, gynecologists and surgical oncologists.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Thermoablation involves the use of heat or cold to remove malfunctioning or diseased tissue in surgical oncology, cardiology, neurology, gynecology, urology and cosmetology applications. Thermoablative technologies include RF, microwave, laser and cryogenic ablation. The global radiofrequency ablation devices market size was valued at $3.59 billion in 2021 and is expected to surpass $10.21 billion by 2030, representing&#160;a CAGR of 11% during the forecast period (2022- 2030).</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">However, RF and other thermoablative surgery technologies pose risks, including under-treatment of diseased tissue and unintended thermal damage to areas outside the treatment area. For example, it has been reported that patients receiving RF ablation of liver tumors have experienced thermal injury to the diaphragm, gallbladder, bile ducts and gastrointestinal tract, some of which have resulted in patient deaths.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Clinicians must rely on printed manufacturer guidelines to plan procedures using thermal ablation technologies or, when available, monitor tissue temperature changes in real-time with MRI imaging or surgical temperature probes. We believe these existing methods either lack real-time precision or are impractical due to cost, poor availability and other factors.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We believe that the ability to visualize changes in tissue temperature in real time could potentially enhance the effectiveness and safety of thermoablation therapies and that our TAEUS technology platform combined with traditional ultrasound has the potential to guide thermoablation surgery more cost-effectively and more accurately than existing methods.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Image below: Depiction of ex-vivo TAEUS tissue temperature analysis overlaid on traditional ultrasound image.</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="ndra_10kimg6.jpg" alt="ndra_10kimg6.jpg"/></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Vascular Imaging</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We believe that our TAEUS technology can be used to image blood vessels and distinguish them from the surrounding tissue. In addition to our NAFLD and thermoablation applications, we intend to develop a cardiovascular application based on our TAEUS technology that, with the use of a standard saline contrast agent, can enable existing ultrasound systems to perform a number of cardiovascular diagnostic functions, such as identifying arterial plaque or blocked or malformed vessels, as well as safely guiding biopsies away from vital vasculature.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Conventional ultrasound imaging systems use Doppler imaging in a variety of vascular applications. Doppler ultrasound, which images the velocity of blood, is effective in larger vessels and regions where blood velocity is high. However, Doppler ultrasound is not sufficiently sensitive for use in very small vessels or in vascular imaging applications where blood velocities are very low. For these applications, contrast enhanced CT and MRI angiography is used which requires the patient to be injected with a contrast agent, iodinated compounds and gadolinium, respectively. Contrast-enhanced CT and MRI scans both require referral for examination after initial screening with ultrasound and carry risks associated with their respective contrast agents. We believe that our TAEUS platform has the potential to offer the advantages of CT and MR contrast enhanced imaging at the point of care using only a safe electrolyte solution as the contrast agent.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Tissue Perfusion or &#8220;Leakiness&#8221;</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We believe that our TAEUS technology can be used to image tissue perfusion, or the absorption of fluids into an organ or tissue. We intend to develop an application for our TAEUS platform that would enable ultrasound detection of microvasculature fluid flows symptomatic of tissue compromised by trauma or disease.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">When a person&#8217;s body is affected by disease or trauma, blood and other fluids may leak from damaged tissues in subtle ways. Traditional ultrasound cannot effectively image these disruptions in microvascular permeability, but we believe ultrasound combined with our TAEUS technology can.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We believe that, using our TAEUS technology, physicians will be able to quickly and clearly see tissue compromised by disease, such as cancer or trauma, especially with the use of a standard saline contrast agent, when CT or MRI is not readily available.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span style="text-decoration:underline">Intellectual Property</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We rely on a combination of patent, copyright, trademark and trade secret laws and other agreements with employees and third parties to establish and protect our proprietary intellectual property rights. We require our officers, employees and consultants to enter into standard agreements containing provisions requiring confidentiality of proprietary information and assignment to us of all inventions made during the course of their employment or consulting relationship. We also enter into nondisclosure agreements with our commercial counterparties and limit access to, and distribution of, our proprietary information.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We are committed to developing and protecting our intellectual property and, where appropriate, filing patent applications to protect our technology. Our issued and pending patents claims are directed at the following areas related to our technology:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Methods to induce and enhance thermoacoustic signal generation;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">System configurations, devices and novel hardware for transmission of RF pulses into tissue and detection of acoustic signals;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Methods for integrating our devices with existing conventional ultrasound systems; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Methods and algorithms for signal processing, image formation and analysis.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">As of December 31, 2022, we maintained a patent portfolio consisting of thirty-three (33) patents issued in the United States and twenty-three (23) issued patents in foreign jurisdictions, five (5) patent applications pending in the United States and thirty-one (31) patent applications pending in foreign jurisdictions relating to our technology. These patents and patent applications largely cover certain innovations relating to fat imaging, fat quantitation, and temperature monitoring in the liver and other tissues.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Each of our utility patents generally has a term of 20 years from its respective priority (earliest filing) date. Design patents have a term of 14 years from a respective filing date. Among our issued utility patents in the U.S., the first patent is set to expire in 2033 and the last patent is set to expire in 2041.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span style="text-decoration:underline">Sales and Marketing</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">In parallel to securing all necessary government marketing approvals, we have hired a small sales and marketing team to engage and support channel partners and clinical customers in primary geographic markets &#8211; initially in France, the UK, and Germany, expected to be followed in the U.S. after FDA approval. As we previously did with our Nexus 128 system, we also intend to partner with several geographically-focused independent medical device equipment distributors to market and sell our TAEUS applications in secondary markets. For instance, we have entered into a distribution agreement with a third-party covering future sales in Vietnam. We believe that these distributors have existing customer relationships, a strong knowledge of diagnostic imaging technology and the capabilities to support the installation, customer training and post-sale service of capital equipment and software.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We also intend to work with original equipment manufacturers, or OEMs, of capital medical equipment (<em>e.g</em>., ultrasound equipment and thermal ablation equipment) to sell our TAEUS technology alongside their own new systems and into their existing installed base systems. We believe that these OEMs will find our applications attractive as the applications could enable them to generate additional revenue from their installed systems - as they currently do with aftermarket accessory portfolios. We believe our relationship with GE Healthcare will facilitate this strategy.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Based on our design work and our understanding of the ultrasound accessory market, we intend to price our initial NAFLD TAEUS application at a price point approximating $35,000 to $55,000, which should enable clinical purchasers to recoup their investment in less than one year by performing a relatively small number of additional ultrasound procedures.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Some of our future TAEUS offerings are expected to be implemented via a hardware platform that can run multiple individual software applications that we plan to offer TAEUS users for a one-time licensing fee, enabling users to perform more procedures with their existing ultrasound equipment and retaining more patients in their clinics rather than referring them out to a regional imaging medical center for a CT or MRI scan.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We also intend to offer a license for our TAEUS technology to OEMs, such as ultrasound and thermoablative capital equipment makers, for incorporation in their new capital equipment systems.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span style="text-decoration:underline">Engineering, Design and Manufacturing</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Development of TAEUS Device</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We contracted with StarFish Product Engineering, Inc. (&#8220;StarFish&#8221;), a medical device contract manufacturing company, to develop ENDRA&#8217;s prototype TAEUS device into a clinical product that met CE regulatory requirements required for commercial launch. We leveraged StarFish&#8217;s expertise for the preparation and submission of our CE Technical File documentation, submitted in December 2019, which enabled us to secure the CE Mark for the TAEUS liver application in March 2020. We also leveraged StarFish&#8217;s expertise for preparation of documentation for the 510(k) submission made to the FDA in June 2020. The relation with StarFish has expanded to include the contract manufacture of the TAEUS&#174; liver system. As the contract manufacturer, StarFish sources components internally or via third party suppliers.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Regulatory Approval Pathway and Human Study</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Each of our TAEUS platform applications will require regulatory approvals before we are able to sell or license the application. Based on certain factors, such as the installed base of ultrasound systems, availability of other imaging technologies, such as CT and MRI, economic strength and applicable regulatory requirements, we sought initial approval of our applications for sale in the European Union, followed by the United States and plan to seek additional approval in China.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The first TAEUS application we intend to commercialize is our NAFLD TAEUS application. Our initial target market for this application is the European Union. For commercial reasons and to support our application for CE marking, we contracted with CIMTEC, a medical imaging research group, to conduct human studies through Canada-based Robarts Research Institute to demonstrate our NAFLD TAEUS application&#8217;s ability to distinguish fat from lean tissue. In September 2019, we announced the completion and reported top-level findings of Robarts Research Institute&#8217;s initial healthy subject study and data collection of 50 subjects, which was included in our TAEUS liver device technical file submission for device CE mark. We received CE mark approval for our NAFLD TAEUS application in March 2020. We have registered the product in each target EU market.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">In May 2021, Regulation (EU)2017/745 on medical devices (the &#8220;Medical Device Regulation&#8221; or &#8220;MDR&#8221;) came into effect. The MDR amended the prior existing regulatory framework in the EU and imposes significant additional obligations on medical device-related companies. Changes imposed by the MDR include more restrictive requirements for clinical evidence and pre-market assessment of safety and performance, revised classifications to indicate risk levels, stricter requirements for third party testing by government accredited groups for some types of medical devices, and tightened and streamlined quality management system assessment procedures, including post marketing surveillance obligations. These new rules&#160;also impose additional requirements on our business, such as a requirement to conduct clinical trials to maintain our existing and obtain new or renewed conformity assessment certification&#160;for existing and new products. Also, the MDR provides for additional post-market surveillance obligations, and further requirements for the traceability of products, transparency, refined responsibilities for economic operators (including manufacturer, distributors and importers) as well as a tightened and more comprehensive quality management system.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">In March 2020 we received a positive certification from a government-accredited group (&#8220;Notified Body&#8221;) for our NAFLD TAEUS application, enabling us to market this application in the EU with the necessary CE Mark. The certification, which has been issued under the then applicable framework of the Medical Device Directive but taking into consideration the transitionary provisions of the MDR, will expire in May 2024 and re-certification under the MDR will be required in order to continue marketing of the application in the EU. There is currently a significant lag for recertification of medical devices under the MDR, due to the requirement to have the competent Notified Bodies be re-designated for purposes of the MDR, as&#160;there is a shortage of available Notified Bodies that have already been re-designated for all the medical devices requiring (re-)certification. In light of this development, in February&#160;2023, the European Parliament adopted a Regulation&#160;to amend&#160;the MDR transition period and to remove the sell-off provisions in the MDR. Specifically, through the newly adopted Regulation the validity of the CE certification&#160;for Class I, Class IIa and certain Class IIb&#160;devices (which includes ENDRA&#8217;s Class IIa device)&#160;has been extended until December 31, 2028, subject to certain conditions (including, among others, continued compliance with the MDR, no significant changes to design or intended purpose, a&#160;quality management system, and engagement with a Notified Body&#160;to obtain conformity assessment). ENDRA is working with its Notified Body to ensure a timely MDR CE Mark transition, while aligning to the extended transition deadline.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">In June 2020, we submitted to the FDA our application under the Federal Food, Drug and Cosmetic Act (the &#8220;FD&amp;C Act&#8221;) to sell our NAFLD TAEUS application in the United States. The application was submitted for clearance under Section 510(k) of the FD&amp;C Act. Following meetings with the FDA in connection with its review of our application, we determined that the 510(k) pathway was not the optimal option due to the novel nature of our TAEUS system and, in February 2022, announced that we would pursue the de novo pathway for FDA approval of our NAFLD TAEUS application. We are currently in the process of preparing a submission for the classification of our NAFLD TAEUS application as a Class II device under a de novo review, which process is described below under &#8220;<em>FDA Approval or Clearance of Medical Devices</em>&#8221;. This de novo submission will include as support clinical data gathered from human studies&#160;comparing liver fat measurements by our TAEUS device to measurements by MRI-PDFF. We expect that the FDA&#8217;s grant of our initial de novo request will allow us to sell the NAFLD TAEUS application in the U.S. with general imaging claims. However, we will need to obtain additional FDA clearances to be able to make diagnostic claims for fatty tissue content determination. Accordingly, to support our commercialization efforts we expect that, following receipt of the FDA&#8217;s grant of our initial de novo request, we would submit one or more additional applications to the FDA, each of which would need to include additional clinical trial data, so that following receipt of the necessary clearances we may make those diagnostic claims. We believe these additional applications will be eligible for submission under Section 510(k) following the reclassification that would be established by the FDA&#8217;s grant of the anticipated de novo request for our NAFLD TAEUS device.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span style="text-decoration:underline">Regulation</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>European Union</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The primary regulatory environment in Europe is the European Union, which consists of 27 member states encompassing most of the major countries in Europe. In the European Union, applications incorporating our TAEUS technology are regulated as Class IIa medical devices by the European Medicines Agency (the &#8220;EMA&#8221;) and the European Union Commission. As described above, our NAFLD TAEUS application has received, and we expect our future applications will need to receive, a CE mark from an appropriate Competent Authority or Notified Body, as the case may be, as a result of successful review of one or more submissions prepared by our contract engineering and manufacturer(s), so that such applications can be marketed and distributed within the European Economic Area. Each of our applications will be required to be regularly recertified for CE marking, which recertification may require an annual audit. The audit procedure, which will include on-site visits at our facility, and the contract manufacturer&#8217;s(s&#8217;) facility(ies), will require us to provide the contract manufacturer(s) with information and documentation concerning our quality management system and all applicable documents, policies, procedures, manuals, and other information.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">In the European Union, the manufacturer of medical devices is subject to current Good Manufacturing Practice, or cGMP, as set forth in the relevant laws and guidelines of the European Union and its member states. Compliance with cGMP is generally assessed by a Notified Body accredited by a Competent Authority. For a Class IIa device, typically, quality system evaluation is performed by the Notified Body, which also provides the certifications necessary to fix a CE mark to the products. The Notified Body may conduct inspections of relevant facilities, and review manufacturing procedures, operating systems and personnel qualifications. In addition to obtaining approval for each application, in many cases each device manufacturing facility must be audited on a periodic basis by the Notified Body. Further inspections may occur over the life of the application.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>FDA Regulation</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Each of our products must be approved or cleared by the FDA before it is marketed in the United States. Before and after approval or clearance in the United States, our applications are subject to extensive regulation by the FDA under the FD&amp;C Act and/or the Public Health Service Act, as well as by other regulatory bodies. The FDA regulations govern, among other things, the development, testing, manufacturing, labeling, safety, storage, record-keeping, market clearance or approval, advertising and promotion, import and export, marketing and sales, and distribution of medical devices and pharmaceutical products.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>FDA Approval or Clearance of Medical Devices</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">In the United States, medical devices are subject to varying degrees of regulatory control and are classified in one of three classes depending on the extent of controls the FDA determines are necessary to reasonably ensure their safety and efficacy:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Class I: general controls, such as labeling and adherence to quality system regulations;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Class II: special controls, clearance of a premarket notification, or 510(k) submission, specific controls such as performance standards, patient registries and post-market surveillance and additional controls such as labeling and adherence to quality system regulations; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Class III: special controls and approval of a premarket approval, or PMA, application.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We expect all of our products to be classified as, or subject to reclassification as, Class II medical devices and thus require FDA authorization prior to marketing by means of a 510(k) clearance or de novo request, rather than a PMA application.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">To request marketing authorization by means of a 510(k) clearance, we must submit a notification demonstrating that the proposed device is substantially equivalent to another legally marketed medical device, has the same intended use, and is as safe and effective as a legally marketed device and does not raise different questions of safety and effectiveness than a legally marketed device. 510(k) submissions generally include, among other things, a description of the device and its manufacturing, device labeling, medical devices to which the device is substantially equivalent, safety and biocompatibility information and the results of performance testing. In some cases, a 510(k) submission must include data from human clinical studies. Marketing may commence only when the FDA issues an order finding substantial equivalence. Historically, the typical 510(k) review time has been approximately nine to twelve months from the date of the initial 510(k) submission. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">In many instances, the 510(k) pathway for product marketing requires only non-clinical testing as proof of substantial equivalence to a lawfully marketed predicate device for a given indication. However, in some instances the FDA may require clinical studies to demonstrate substantial equivalence to the predicate device. Whether clinical data is provided or not, the FDA may decide to reject the substantial equivalence argument we present. If that happens, the device is automatically designated as a Class III device, unless the sponsor requests a risk-based classification determination for the device in accordance with the &#8220;de novo&#8221; process, which may determine that the new device is of low to moderate risk and that it can be appropriately be regulated as a Class I or II device. In the de<em>&#160;</em>novo process, the FDA must determine that general and special controls are sufficient to provide reasonable assurance of the safety and effectiveness of a device which has no predicate. Upon receipt of a de novo request, the FDA will conduct an acceptance review to assess the completeness of the application and whether its meets the minimum threshold of acceptability. If the de novo request is accepted for substantive review, the FDA will conduct a classification review of legally marketed device types and analyze whether an existing legally marketed device of the same type exists, which information is used to confirm the subject device is eligible for de novo classification. During the course of review, the FDA may address any issues through interactive review or send a formal request for additional information in order for the review to proceed. If a de novo request is granted, the device may be legally marketed, and a new classification is established. If the device is classified as Class II, the device may serve as a predicate for future 510(k) submissions. If the device is not approved through de novo review, then it must go through the standard PMA process for Class III devices, which generally requires extensive pre-clinical and clinical trial data and involves an inspection of the manufacturer&#8217;s facilities for compliance with quality system requirements as well as a review period during which an FDA advisory committee may be convened to review the application and make a recommendation to the FDA regarding its approval. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">After a device receives 510(k) clearance, including following classification as a Class I or II device upon an approved de novo request, any product modification that could significantly affect the safety or effectiveness of the product, or that would constitute a significant change in intended use, requires a new 510(k) clearance. If the FDA determines that the changed product does not qualify for 510(k) clearance, then a company must submit, and the FDA must approve, a PMA before marketing can begin.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Clinical Trials of Medical Devices</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Depending on the nature of the device, one or more clinical trials may be necessary to support a 510(k) submission and, potentially, for EU CE certification, as well as generally required for PMA applications. Clinical studies of unapproved or uncleared medical devices or devices being studied for uses for which they are not approved or cleared (investigational devices) must be conducted in compliance with FDA requirements (and/or, if conducted in another jurisdiction, the applicable laws and regulations of the jurisdiction in which the trial is conducted). If an investigational device could pose a significant risk to patients, the sponsor company must submit an investigational device exemption application to the FDA prior to initiation of the clinical study. An investigational device exemption application must be supported by appropriate data, such as animal and laboratory test results, showing that it is safe to test the device on humans and that the testing protocol is scientifically sound. The investigational device exemption will automatically become effective 30 days after receipt by the FDA unless the FDA notifies the company that the investigation may not begin. Clinical studies of investigational devices may not begin until an institutional review board has approved the study.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">During the study, the sponsor must comply with the FDA&#8217;s investigational device exemption requirements. These requirements include investigator selection, trial monitoring, adverse event reporting, and record keeping. The investigators must obtain patient informed consent, rigorously follow the investigational plan and study protocol, control the disposition of investigational devices, and comply with reporting and record keeping requirements. The sponsor, the FDA, or the institutional review board at each institution at which a clinical trial is being conducted may suspend a clinical trial at any time for various reasons, including a belief that the subjects are being exposed to an unacceptable risk. During the approval or clearance process, the FDA typically inspects the records relating to the conduct of one or more investigational sites participating in the study supporting the application.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em><strong>Post-Approval U.S. Regulation of Medical Devices</strong></em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">After a device is cleared or approved for marketing, numerous and pervasive regulatory requirements continue to apply. These include:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the FDA&#8217;s Quality Systems Regulation (&#8220;QSR&#8221;), which governs, among other things, how manufacturers design, test, manufacture, exercise quality control over, and document manufacturing of their products;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">labeling and claims regulations, which prohibit the promotion of products for unapproved or &#8220;off-label&#8221; uses and impose other restrictions on labeling; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the Medical Device Reporting regulation, which requires reporting to the FDA of certain adverse experiences associated with use of the product.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em><strong>Post-Approval EU Regulation of Medical Devices</strong></em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Notwithstanding the certification and the CE marking on approved medical devices, economic operators such as the manufacturers, importers or distributors of our products are subject to certain ongoing and/or post marketing obligations. These include:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#8226;</p></td><td style="vertical-align:top;">the manufacturer maintaining an authorized representative in the EU;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#8226;</p></td><td style="vertical-align:top;">maintaining an appropriate system for obtaining, reviewing, assessing and appropriately collecting and registering reports from patients, users, distributors or healthcare professionals of suspected incidents, complaints, non-confirming products, recalls and/or withdrawals;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#8226;</p></td><td style="vertical-align:top;">preparing and maintaining SOPs for product withdrawal, recall or other field safety corrective and preventive actions (&#8220;CAPA&#8221;) as well as maintaining a system to manage CAPA that ensures collection and evaluation of internal and external quality information, the identification of failure causes and the implementation of enduring corrective actions to eliminate failure causes and to prevent recurrence;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#8226;</p></td><td style="vertical-align:top;">ensuring supply chain traceability and ensure proper quality monitoring of any distributors; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#8226;</p></td><td style="vertical-align:top;">regular (and, if required, ad <em><strong>hoc) reporting to the competent authorities in accordance with MDR.</strong></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Good Manufacturing Practices Requirements</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Manufacturers of medical devices are required to comply with the good manufacturing practices set forth in the QSR promulgated under Section 520 of the FD&amp;C Act. The QSR requires, among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation. The manufacturing facility for an approved product must be registered with the FDA and meet QSR requirements to the satisfaction of the FDA pursuant to a pre-PMA approval inspection before the facility can be used. Manufacturers, including third party contract manufacturers, are also subject to periodic inspections by the FDA and other authorities to assess compliance with applicable regulations. Failure to comply with statutory and regulatory requirements subjects a manufacturer to possible legal or regulatory action, including the seizure or recall of products, injunctions, consent decrees placing significant restrictions on or suspending manufacturing operations, and civil and criminal penalties. Adverse experiences with the product must be reported to the FDA and could result in the imposition of marketing restrictions through labeling changes or in product withdrawal. Product approvals or clearances may be withdrawn if compliance with regulatory requirements is not maintained or if problems concerning safety or efficacy of the product occur following the approval.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>China Regulation</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">China&#8217;s regulatory approval framework includes nationwide approval based on a showing that the device for which approval is sought has been previously approved in the country of origin. Alternatively, we understand it is also possible to receive approval at the provincial level or to work exclusively with hospitals that do not require such nationwide or provincial approval. We intend to explore these potential paths to regulatory compliance in China.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Other Regulations</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We and our contractors also must comply with numerous federal, state and local laws relating to matters such as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and hazardous substance disposal. Furthermore, we are subject to various reporting requirements including those prescribed by the Affordable Care Act and the Dodd-Frank Wall Street Reform and Consumer Protection Act. We cannot be sure that we will not be required to incur significant costs to comply with these laws and regulations in the future or that these laws or regulations will not adversely affect our business, financial condition, and results of operations. Unanticipated changes in existing regulatory requirements or the adoption of new requirements could adversely affect our business, financial condition, and results of operations.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We will also become subject to regulations and product registration requirements in many foreign countries in which we may sell our products, including in the areas of product standards, packaging requirements, labeling requirements, import and export restrictions and tariff regulations, duties and tax requirements. Additionally, third parties designing, manufacturing or conducting human studies of our devices will be subject to local regulations, such as those of Health Canada. The time required to obtain clearance required by foreign countries may be longer or shorter than that required for EMA or FDA clearance, and requirements for licensing a product in a foreign country may differ significantly from EMA and FDA requirements.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Environmental </em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Our manufacturing processes involve the use, generation, and disposal of hazardous materials and wastes, including alcohol, adhesives, and cleaning materials. As such, we are subject to stringent federal, state, and local laws relating to the protection of the environment, including those governing the use, handling, and disposal of hazardous materials and wastes. Future environmental laws may require us to alter our manufacturing processes, thereby increasing our manufacturing costs. We believe that our products and manufacturing processes at our facilities comply in all material respects with applicable environmental laws. However, the risk of environmental liabilities cannot be completely eliminated. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span style="text-decoration:underline">Competition</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">While we believe that we are the only company developing RF-based thermoacoustic ultrasound products, we will face direct and indirect competition from a number of competitors, many of whom have greater financial, sales and marketing and other resources than we do.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Manufacturers of CT and MRI systems include multi-national corporations such as Royal Philips, Siemens AG and Fujifilm Corporation, many of whom also manufacture and sell ultrasound equipment. In the NAFLD diagnosis market we will compete with makers of surgical biopsy tools, such as Cook Medical and Sterylab S.r.l. In the thermal ablation market, we will compete with manufacturers of surgical temperature probes, such as Medtronic plc and St. Jude Medical, Inc.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span style="text-decoration:underline">Employees</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">As of December 31, 2022, we had 21 employees, all of whom are employed on a full-time basis. Thirteen full-time employees were engaged in research and development activities, four full-time employees were engaged in sales activities, two full-time employees were engaged in product assembly, and&#160;two full-time employees were engaged in administrative activities. Geographically, we employ fifteen people in the United States, three people in Canada, one person in France, one person in Germany and one person in the United Kingdom. None of our employees are covered by a collective bargaining agreement, and we believe our relationship with our employees is good.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We also employ technical advisors, on an as-needed basis, to supplement existing staff. We believe that these technical advisors provide us with necessary expertise in clinical ultrasound applications, ultrasound technology, and intellectual property.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="a3">Item 1A. Risk Factors</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Investing in our common stock involves a high degree of risk. You should carefully consider the following risks and all other information contained in this Annual Report, including our financial statements and the related notes, before investing in our securities. The risks and uncertainties described below are not the only ones we face, but include the most significant factors currently known by us that make investing in our securities speculative or risky. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, also may become important factors that affect us. If any of the following risks materialize, our business, financial condition and results of operations could be materially harmed. In that case, the trading price of our securities could decline, and you may lose some or all of your investment.</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span style="text-decoration:underline">Risks Related to Our Business</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>We have a history of operating losses, we may never achieve or maintain profitability, and we will need to raise significant additional capital if we are going to continue as a going concern.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We have limited commercial experience upon which investors may evaluate our prospects. We have only generated limited revenues to date and have a history of losses from operations. As of December 31, 2022, we had an accumulated deficit of $81.9 million. Our independent registered public accounting firm, in its report on our financial statements for the year ended December 31, 2022, has raised substantial doubt about our ability to continue as a going concern.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We will require additional capital in the near term to continue as a going concern to proceed with the commercialization of our planned TAEUS applications and to meet our growth and profitability targets. We have expended and expect to continue to expend significant resources on hiring of personnel, payroll and benefits, continued scientific and potential product research and development, potential product testing and pre-clinical and clinical investigations, expenses associated with the development of relationships with strategic partners, intellectual property development and prosecution, marketing and promotion, capital expenditures, working capital, and general and administrative expenses. We also expect to incur costs and expenses related to consulting, laboratory development, and the hiring of scientists and other operational personnel.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>We may not be able to secure financing on favorable terms, or at all, to meet our future capital needs and our failure to obtain financing when needed could force us to delay, reduce or eliminate our product development programs and commercialization efforts.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We will need to raise additional capital in order to finance the full commercialization of our NAFLD TAEUS application and to complete the development of any other TAEUS application through public or private equity offerings, debt financings, corporate collaboration and licensing arrangements or other financing alternatives.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">To date, we have financed our operations primarily through the net proceeds from offerings of common and preferred stock and convertible notes. We do not know when or if our operations will generate sufficient cash to fund our ongoing operations. Therefore, we will require additional capital in order to: (i) continue to conduct research and development activities; (ii) continue to conduct clinical studies; (iii) fund the costs of seeking regulatory approval of TAEUS applications; (iv) expand our sales and marketing infrastructure; (v) acquire complementary business technology or products; and (vi) respond to business opportunities, challenges, increased regulatory obligations or unforeseen circumstances. Our future funding requirements will depend on many factors, including, but not limited to:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the costs, timing and outcomes of regulatory reviews associated with our future products, including TAEUS applications;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the progress, timing, costs and outcomes of our clinical trials, including the ability to timely enroll patients in such clinical trials;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the costs and expenses of expanding our sales and marketing infrastructure;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the costs and timing of developing variations of our TAEUS applications and, if necessary, obtaining regulatory clearance of such variations;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the degree of success we experience in commercializing our products, particularly our TAEUS applications;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the extent to which our TAEUS applications are adopted by hospitals for use by primary care physicians, hepatologists, radiologists and oncologists for diagnosis of fatty liver disease and the thermal ablation of lesions;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the number and types of future products we develop and commercialize;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the extent and scope of our general and administrative expenses;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the outcome, timing and cost of regulatory approvals, including the potential that the FDA or comparable regulatory authorities may require that we perform more studies than those that we currently expect;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the amount of sales and other revenues from technologies and products that we may commercialize, if any, including the selling prices for such potential products and the availability of adequate third-party reimbursement;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">selling and marketing costs associated with our potential products, including the cost and timing of expanding our marketing and sales capabilities;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the terms and timing of any potential future collaborations, licensing or other arrangements that we may establish;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">cash requirements of any future acquisitions and/or the development of other products;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the costs of operating as a public company;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the cost and timing of completion of commercial-scale, outsourced manufacturing activities; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the time and cost necessary to respond to technological and market developments.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We may raise funds in equity or debt financings or enter into credit facilities in order to access funds for our capital needs. Any debt financing obtained by us in the future would cause us to incur debt service expenses and could include restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and pursue business opportunities. If we raise additional funds through issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution in their percentage ownership of our Company, and any new equity securities we issue could have rights, preferences and privileges senior to those of holders of our common stock. See &#8220;<em>Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plan, could result in dilution of the percentage ownership of our stockholders and could cause the price of our securities to fall.</em>&#8221; below. In addition, if we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or products or to grant licenses on terms that may not be favorable to us and our collaborators and strategic partners may not perform as expected.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">General market conditions or the market price of our common stock may not support capital raising transactions such as a public or private offering of our common stock or other securities. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, we may terminate or delay the development of one or more of our products, or delay establishment of sales and marketing capabilities or other activities necessary to commercialize our products, or materially curtail or reduce our operations. We could be forced to sell or dispose of our rights or assets. Any inability to raise adequate funds on commercially reasonable terms could have a material adverse effect on our business, results of operation and financial condition, including the possibility that a lack of funds could cause our business to fail and liquidate with little or no return to investors.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Our efforts may never result in the successful development of commercial applications based on our TAEUS technology.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Our TAEUS technology is still in development. We have received regulatory clearance for the commercial sale of our NAFLD application in the European Union but otherwise do not have any applications for our TAEUS technology approved for sale. Applications for our TAEUS technology, even if approved for sale, may never become commercially viable or generate significant revenue. Our ability to generate significant revenues and, ultimately, achieve profitability will depend on whether we can obtain additional capital when we need it, complete the development of our technology, receive all required regulatory approvals for our TAEUS applications and find customers who will purchase our future products or strategic partners that will incorporate our technology into their products. Even if we develop commercially viable applications for our TAEUS technology, which may include licensing, we may never recover our research and development expenses and we may never be able to produce material revenues or operate on a profitable basis.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Our research and development efforts remain subject to all of the risks associated with the development of new products based on emerging technologies, including, without limitation, unanticipated technical or other problems, the inability to develop a product that may be sold at an acceptable price point and the possible insufficiency of funds needed in order to complete development of these products. Technical problems may result in delays and cause us to incur additional expenses that would increase our losses. If we cannot complete, or if we experience significant delays in developing applications based on, our TAEUS technology, particularly after incurring significant expenditures, our business may fail.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Our success is substantially dependent on the success of applications for our TAEUS platform.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Our ability to generate meaningful revenues in the future will depend on the successful development and commercialization of our TAEUS platform applications. The commercial success of our TAEUS platform applications and our ability to generate revenues will depend on many factors, including the following:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">our successful development of applications for our TAEUS technology, such as those we intend to pursue for the diagnosis of NAFLD and the monitoring of thermal ablation surgery, and the acceptance in the marketplace by physicians and patients of such applications;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the successful design and manufacturing of a device or devices which enable the use of our TAEUS technology by physicians on their patients;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">receipt of necessary regulatory approvals;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">sufficient coverage or reimbursement by third-party payors;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">our ability to successfully market our products;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">our ability to demonstrate that our TAEUS applications have advantages over competing products and procedures;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the amount and nature of competition from competing or alternative imaging products; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">our ability to establish and maintain commercial manufacturing, distribution and sales force capabilities.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Our TAEUS platform applications may not achieve adequate market acceptance by the physicians, patients, third-party payors and others in the medical community.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Our TAEUS applications that receive regulatory approval may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If our TAEUS applications do not achieve an adequate level of acceptance, we may not generate significant product revenues or any profits from sales. The degree of market acceptance of products based on our TAEUS platform will depend on a number of factors, including:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">potential or perceived advantages or disadvantages compared to alternative products;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">pricing relative to competitive products and availability of third-party coverage or reimbursement;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the timing of bringing our product to market as compared to possible other new entrants to the market;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">our ability to effectively raise market awareness and explain product benefits and whether we have resources sufficient to do so;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">relative convenience, dependability and ease of administration; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">willingness of the target patient population to try new products and of physicians to utilize such products.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Our revenues will be adversely affected if, due to these or other factors, the products we are able to commercialize do not gain significant market acceptance.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em><strong>Public health crises, such as</strong></em>&#160;<em><strong>COVID-19</strong></em><em><strong>, can adversely impact our business, including our pre-sales activities, clinical trials and ability to obtain regulatory approvals.</strong></em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="font-size:10pt;font-family:times new roman;margin:0px">Public health crises such as pandemics or similar outbreaks could adversely impact our business. For instance, the&#160;COVID-19 pandemic impacted our clinical trial activities by delaying patient enrollment and visits due to the prioritization of hospital resources toward the COVID-19 outbreak, travel restrictions, and the inability to access sites for initiation and monitoring. In addition, the COVID-19 pandemic had an effect on the business at the FDA and other health authorities by causing them to reallocate resources to addressing the pandemic, which resulted in delays of reviews and approvals of submissions such as that for&#160;our NAFLD TAEUS application. The level and nature of the disruption caused by COVID-19 and any other pandemic is unpredictable, may be cyclical and long-lasting and vary from location to location. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">In addition to the foregoing effects, as a result of future COVID-19 outbreaks or other pandemics we have and may in the future experience disruptions that could severely impact our business, preclinical studies and clinical trials, including:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">interruption of key clinical trial activities and attendance at industry events due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">delays or difficulties in enrolling patients in clinical trials of our TAEUS FLIP device;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">interruption or delays in the operations of the FDA and comparable foreign regulatory agencies, which may impact approval timelines;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">absenteeism or loss of employees at the Company, or at our collaborator companies, due to health reasons or government restrictions or otherwise, that are needed to develop, validate, manufacture and perform other necessary functions for our operations;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">supply chain disruptions making it difficult for our collaborator companies to order and receive materials needed for the manufacture of our TAEUS product;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">government responses including orders that make it difficult for us, our supplier and our potential customers to remain open for business, and other seen and unforeseen actions taken by government agencies;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">equipment failures, loss of utilities and other disruptions that could impact our operations or render them inoperable; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">effects of a local or global recession or depression that could depress economic conditions for a prolonged period and limit access to capital by the Company.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Even if not rising to the level of a global pandemic, the outbreak of illness locally at the location of our offices or clinical trials could have a material adverse impact on our operations and financial condition and results.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>We may not remain commercially viable if there is an inadequate level of reimbursement by governmental programs and other third-party payors for our planned products or associated procedures.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Medical imaging products are purchased principally by hospitals, physicians and other healthcare providers around the world that typically bill various third-party payors, including governmental programs (<em>e.g.</em>, Medicare and Medicaid in the United States), private insurance plans and managed care programs, for the services provided to their patients.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Third-party payors and governments may approve or deny coverage for certain technologies and associated procedures based on independently determined assessment criteria. Reimbursement decisions by payors for these services are based on a wide range of methodologies that may reflect the services&#8217; assessed resource costs, clinical outcomes and economic value. These reimbursement methodologies and decisions confer different, and sometimes conflicting, levels of financial risk and incentives to healthcare providers and patients, and these methodologies and decisions are subject to frequent refinements. Third-party payors are also increasingly adjusting reimbursement rates, often downwards, indirectly challenging the prices charged for medical products and services. There can be no assurance that our products will be covered by third-party payors, that adequate reimbursement will be available or, even if payment is available, that third-party payors&#8217; coverage policies will not adversely affect our ability to sell our products profitably.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>We have limited data regarding the efficacy of our TAEUS platform applications. If any of our applications that receive regulatory approval do not perform in accordance with our expectations, we are unlikely to successfully commercialize our applications.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Since our success depends in large part on the medical and third-party payor&#160;community&#8217;s acceptance of our TAEUS applications, even if we receive regulatory approval for our applications, we believe that we will need to obtain additional clinical data from users of our applications to persuade medical professions to use our applications. We may also be required to conduct post-approval clinical testing to obtain such additional data. Clinical testing is expensive, can take a significant amount of time to complete and can have uncertain outcomes. Negative results of these clinical studies could have a material, adverse impact on our business.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>We cannot be certain that results from limited animal and human studies of any of our TAEUS applications will be indicative of future studies or that any of our TAEUS applications will be successfully commercialized.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">To successfully commercialize any application based on our TAEUS platform technology, we expect it will be necessary to conduct various pre-clinical and human studies to demonstrate that the product is safe and effective for human use. However, there can be no assurance that results from these studies are indicative of results that would be achieved in future animal studies or human clinical studies of this or any future TAEUS applications, which may be required in order for our applications incorporating our technology to obtain or maintain regulatory approval&#160;&#160;&#160;&#160; . Even if clinical trials or other studies demonstrate the safety and effectiveness of any applications of our technology and the necessary regulatory approvals are obtained, the commercial success of any of such application will depend upon their acceptance by patients, the medical community, and third-party payers and on our partners&#8217; ability to successfully manufacture and commercialize a device for such application.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Our limited commercial experience makes it difficult to evaluate our business, predict our future results or forecast our financial performance and growth.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We discontinued our initial pre-clinical Nexus 128 product in 2019 and our NAFLD TAEUS device has obtained CE mark approval but has not yet been fully commercialized. This limited commercial experience makes it difficult to evaluate our business, predict our future results or forecast our financial performance and growth. If our assumptions regarding the risks and uncertainties we face, which we use to plan our business, are incorrect or change due to circumstances in our business or our markets, or if we do not address these risks successfully, our operating and financial results could differ materially from our expectations and our business could suffer.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>We have formed, and may in the future form or seek, strategic alliances and collaborations or enter into licensing arrangements, and we may not realize the benefits of such alliances, collaborations or licensing arrangements.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In April 2016, we entered into a Collaborative Research Agreement with GE Healthcare, under which GE Healthcare has agreed to support our efforts to commercialize our TAEUS technology for use in an NAFLD application by, among other things, providing equipment and technical advice, and facilitating introductions to GE Healthcare clinical ultrasound customers. This agreement does not commit GE Healthcare to a long-term relationship and it may disengage with us at any time. This agreement has a term lasting until December 16, 2024 and is subject to termination by either party upon not less than 60 days&#8217; notice. See the section of this Annual Report titled &#8220;TAEUS System for Early Assessment and Monitoring of Nonalcoholic Fatty Liver Disease, or NAFLD&#8221; under &#8220;Item 1. Business&#8221; for further description of this agreement.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We intend in the future to form or seek additional strategic alliances, create joint ventures or collaborations or enter into licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our technologies and applications.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Any of these relationships may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, restrict our ability to collaborate with other third parties or otherwise disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. If we license technologies or applications, we may not be able to realize the intended benefit of such transactions. Further, strategic alliances and collaborations are subject to numerous risks, which may include the following:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">collaborators may not pursue development and commercialization of our technologies and applications or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in their strategic focus due to the acquisition of competitive products, availability of funding, or other external factors, such as a business combination that diverts resources or creates competing priorities;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon the development of an application, repeat or conduct new clinical trials, or require a new formulation of an application for clinical testing;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our applications and technologies;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">a collaborator with marketing and distribution rights to one or more applications may not commit sufficient resources to their marketing and distribution;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">disputes may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of our technologies and applications, or that result in costly litigation or arbitration that diverts management attention and resources;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable applications or technologies; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">As a result, if we enter into collaboration agreements and strategic partnerships or license our applications or technologies, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Any delays in entering into new strategic partnership agreements related to our applications could delay the development and commercialization of our technologies and applications in certain geographies or for certain applications, which would harm our business prospects, financial condition and results of operations.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>We have limited resources and depend on third parties to design and manufacture, and seek regulatory approval of, our TAEUS applications. If any third party fails to successfully design, manufacture or obtain regulatory approval of TAEUS applications, our business will be materially harmed.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We do not currently have, nor do we plan to acquire, the infrastructure or capability to design or manufacture our TAEUS applications. To support our design and manufacturing efforts, we have contracted StarFish Product Engineering, Inc., a medical device contract manufacturing company, rather than design or manufacture our TAEUS applications ourselves. We have limited control over the efforts and resources that these and any other third-party OEMs will devote to developing and manufacturing our TAEUS applications and their capabilities to serve our needs, including quality control, quality assurance and qualified personnel. In addition, for any future applications of our TAEUS technology we currently expect to depend on OEMs to acquire CE marks for the device or devices that they develop and manufacture which are necessary to permit marketing of those devices in the European Union followed by corresponding FDA approval.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">An OEM may not be able to successfully design and manufacture the products it develops based on our TAEUS technology, may not devote sufficient time and resources to support these efforts or may fail in gaining the required regulatory approvals of our TAEUS applications. The failure by an OEM to perform in accordance with our expectations would substantially harm the value of our TAEUS technology, brand and business.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">23</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>We will need to develop marketing and distribution capabilities both internally and through our relationships with third parties in order to sell any of our TAEUS products receiving regulatory approval. If we experience problems in developing these capabilities, our ability to sell our products could be limited.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We have limited experience selling our products and will need to develop marketing, sales and distribution capabilities in order to sell our TAEUS applications that receive the necessary regulatory approval. We have limited experience managing a sales force and customer support operations and may be unable to attract, retain and manage the collaborative manufacturing and distribution arrangements or the specialized workforce necessary to successfully commercialize our products. In addition, our sales and marketing organization must effectively explain the uses and benefits of our products as compared to alternatives in order to promote market acceptance and demand for our products. Although we have begun to hire a small internal sales and marketing team to engage and support channel partners and clinical customers, further developing these functions will be time consuming and expensive and our efforts may not be successful.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We intend to partner with others to assist us with some or all of these functions. However, we may be unable to find appropriate third parties with which to enter into these arrangements and any such third parties may not perform as expected.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Furthermore, third-party distributors that are in the business of selling other medical products may not devote a sufficient level of resources and support required to generate awareness of our TAEUS applications and grow or maintain product sales. If these distributors are unwilling or unable to market and sell our products, or if they do not perform to our expectations, we could experience delayed or reduced market acceptance and sales of our products. In addition, disagreements with our distributors or non-performance by these third parties could lead to costly and time-consuming litigation or arbitration and disrupt distribution channels for a period of time and require us to re-establish a distribution channel.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>If we are unable to manage the growth of our business, our future revenues and operating results may be harmed.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Because of our small size, growth in accordance with our business plan, if achieved, will place a significant strain on our financial, technical, operational and management resources. As we expand our activities, there will be additional demands on these resources. The failure to continually upgrade our technical, administrative, operating and financial control systems or the occurrence of unexpected expansion difficulties, including issues relating to our research and development activities and retention of experienced scientists, managers and technicians, could have a material adverse effect on our business, financial condition and results of operations and our ability to timely execute our business plan. If we are unable to implement these actions in a timely manner, our results may be adversely affected.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Competition in the medical imaging market is intense and we may be unable to successfully compete.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">In general, competition in the medical imaging market is very significant and characterized by extensive research and development and rapid technological change. Competitors in this market include very large companies with significantly greater resources than we have. To successfully compete in this market we will need to develop TAEUS applications that offer significant advantages over alternative imaging products and procedures for such applications.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">While we believe the technology behind our TAEUS platform is unique in the industry, developments by other medical imaging companies of new or improved products, processes or technologies may make our products or proposed products obsolete or less competitive. Alternative medical imaging devices may be more accepted or cost-effective than our products. Competition from these companies for employees with experience in the medical imaging industry could result in higher turnover of our employees. If we are unable to respond to these competitive pressures, we could experience delayed or reduced market acceptance of our products, higher expenses and lower revenue. If we are unable to compete effectively with current or new entrants to these markets, we will be unable to generate sufficient revenue to maintain our business.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">24</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Changes in the healthcare industry could result in a reduction in the size of the market for our products or may require us to decrease the selling price for our products, either of which could have a negative impact on our financial performance.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Trends toward managed care, healthcare cost containment, and other changes in government and private sector initiatives in Europe, the United States and China are placing increased emphasis on lowering the cost of medical services, which could adversely affect the demand for or the prices of our products. For example:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">major third-party payors of hospital and non-hospital based healthcare services could revise their payment methodologies and impose stricter standards for reimbursement of imaging procedures charges and/or a lower or more bundled reimbursement;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">there has been a consolidation among healthcare facilities and purchasers of medical devices who prefer to limit the number of suppliers from whom they purchase medical products, and these entities may decide to stop purchasing our products or demand discounts on our prices;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">there is economic pressure to contain healthcare costs in markets throughout the world; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">there are proposed and existing laws and regulations in international and domestic markets regulating pricing and profitability of companies in the healthcare industry.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">These trends could lead to pressure to reduce prices for our products and could cause a decrease in the demand for our products in any given market that could adversely affect our revenue and profitability, which could harm our business.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>We intend to market our approved TAEUS applications globally, and are therefore subject to the risks of doing business outside of the United States.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Because we intend to market our approved TAEUS applications globally, our business is subject to risks associated with doing business globally. Accordingly, our business and financial results in the future could be adversely affected due to a variety of factors, including:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">changes in a specific country&#8217;s or region&#8217;s political and cultural climate or economic condition;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">local outbreaks of sickness or disease, including COVID-19;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">war or terrorist attack, including cyberterrorism;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">unexpected changes in laws and regulatory requirements in local jurisdictions;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">difficulty of effective enforcement of contractual provisions in local jurisdictions;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">inadequate intellectual property protection in certain countries;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">trade-protection measures, import or export licensing requirements such as Export Administration Regulations promulgated by the United States Department of Commerce and fines, penalties or suspension or revocation of export privileges;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">effects of applicable local tax structures and potentially adverse tax consequences; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">significant adverse changes in currency exchange rates.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>We depend on our senior management team and the loss of one or more key employees or an inability to attract and retain highly skilled employees could harm our business.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Our success largely depends upon the continued services of our executive management team and key employees. The loss of one or more of our executive officers or key employees could harm us and directly impact our financial results. Our employees may terminate their employment with us at any time. Our executive management team has significant experience and knowledge of medical devices and ultrasound systems, and the loss of any team member could impair our ability to design, identify, and develop new intellectual property and new scientific or product ideas. Additionally, if we lose the services of any of these persons, we would likely be forced to expend significant time and money in the pursuit of replacements, which may result in a delay in the implementation of our business plan and plan of operations. We can give no assurance that we could find satisfactory replacements for these individuals on terms that would not be unduly expensive or burdensome to us.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">To execute our growth plan, we must attract and retain highly qualified personnel. Competition for skilled personnel is intense, especially for engineers with high levels of experience in designing and developing medical devices. In addition, we will need to identify and hire sales executives and competition for commercial and marketing talent is significant. We may experience difficulty in hiring and retaining employees with appropriate qualifications. Many of the companies with which we compete for experienced personnel have greater resources than we have. In addition, we invest significant time and expense in training our employees, which increases their value to competitors who may seek to recruit them. If we fail to attract new personnel or fail to retain and motivate our current personnel, our business and future growth prospects would be harmed.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">25</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We are exposed to the risk of fraud, misconduct or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and negligent conduct that fails to: comply with the FD&amp;C Act and similar laws of other countries, or the rules and regulations of the FDA and other similar foreign regulatory bodies; provide true, complete and accurate information to the FDA and other similar foreign regulatory bodies; comply with manufacturing standards we establish; comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws; or report financial information or data accurately or to disclose unauthorized activities to us. For any products for which we obtain regulatory approval and begin commercializing in Europe, China or the United States, respectively, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commissions, certain customer incentive programs and other business arrangements generally. It is not always possible to identify and deter misconduct by employees and other parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Misdiagnosis, warranty and other claims, as well as product field actions and regulatory proceedings, initiated against us could increase our costs, delay or reduce our sales and damage our reputation, adversely affecting our financial condition.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Our business exposes us to the risk of malpractice, warranty or product liability claims inherent in the sale and support of medical device products, including those based on claims that the use or failure of one of our products resulted in a misdiagnosis or harm to a patient. Such claims may cause financial loss, damage our reputation by raising questions about our products&#8217; safety and efficacy, adversely affect regulatory approvals and interfere with our efforts to market our products. Although to date we have not been involved in any medical malpractice or product liability litigation, we may incur significant liability if such litigation were to occur. We may also face adverse publicity resulting from product field actions or regulatory proceedings brought against us. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability or related claims, we may incur substantial liabilities or be required to limit distribution of our products. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">decreased demand for our products;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">injury to our reputation and negative media attention;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">initiation of investigations by regulators;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">costs to defend the related litigation;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">a diversion of management&#8217;s time and our resources;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">substantial monetary awards to trial participants or patients;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">loss of revenue;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">exhaustion of any available insurance and our capital resources;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the inability to commercialize a product at all or for particular applications; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">a decline in the price of our securities.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Although we currently maintain liability insurance in amounts we believe are commercially reasonable, any liability we incur may exceed our insurance coverage. Our insurance policies may also have various exclusions, and we may be subject to a claim for which we have no coverage. Liability insurance is expensive and may cease to be available on acceptable terms, if at all. A malpractice, warranty, product liability or other claim or product field action not covered by our insurance or exceeding our coverage could significantly impair our financial condition. In addition, a product field action or a liability claim against us could significantly harm our reputation and make it more difficult to obtain the funding and commercial relationships necessary to maintain our business.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">26</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Our internal computer systems, or those used by third-party manufacturers or other contractors or consultants, may fail or suffer security breaches.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Despite the implementation of security measures, our internal computer systems and those of our future manufacturers and other contractors and consultants are vulnerable to damage from computer viruses and unauthorized access. Although to our knowledge we have not experienced any such material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our research and development programs and our business operations. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our products could be delayed.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Risks Related to Intellectual Property and Other Legal Matters</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>If we are unable to protect our intellectual property, which entails significant expense and resources, then our financial condition, results of operations and the value of our technology and products could be adversely affected.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Much of our value arises out of our proprietary technology and intellectual property for the design, manufacture and use of medical imaging systems, including development of our TAEUS applications. We rely on patent, copyright, trade secret and trademark laws to protect our proprietary technology and limit the ability of others to compete with us using the same or similar technology. Third parties may infringe or misappropriate our intellectual property, which could harm our business.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">As of December 31, 2022, we maintained a patent portfolio consisting of thirty-three (33) patents issued in the United States and twenty-three (23) issued patents in foreign jurisdictions, five (5) patent applications pending in the United States and thirty-one (31) patent applications pending in foreign jurisdictions relating to our technology. These patents and patent applications mostly cover certain innovations relating to fat imaging, fat quantitation, and temperature monitoring in the liver and other tissues.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Each of our utility patents generally has a term of 20 years from its respective priority (earliest filing) date. Design patents have a term of 14 years from a respective filing date. Among our issued utility patents in the United States, the first patent is set to expire in 2033 and the last patent is set to expire in 2041.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Expenses related to a patent portfolio include periodic maintenance fees, renewal fees, annuity fees, various other governmental fees on patents and/or applications due in several stages over the lifetime of patents and/or applications, as well as the cost associated with complying with numerous procedural provisions during the patent application process. We may or may not choose to pursue or maintain protection for particular inventions. In addition, there are situations in which a failure to make certain payments or noncompliance with certain requirements in the patent process can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Policing unauthorized use of our proprietary rights can be difficult, expensive and time-consuming, and we might be unable to determine the extent of this unauthorized use.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Policing unauthorized use of our intellectual property is difficult, costly and time-intensive. We may fail to stop or prevent misappropriation of our technology, particularly in countries where the laws may not protect our proprietary rights to the same extent as do the laws of the United States. Proceedings to enforce our patent and other intellectual property rights in non-U.S. jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business. If we cannot prevent other companies from using our proprietary technology or if our patents are found invalid or otherwise unenforceable, we may be unable to compete effectively against other manufacturers of ultrasound systems, which could decrease our market share. In addition, the breach of a patent licensing agreement by us may result in termination of a patent license.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We may not be able to prevent the unauthorized disclosure or use of our technical knowledge or other trade secrets by consultants, vendors or former or current employees, despite the existence generally of confidentiality agreements and other contractual restrictions. Monitoring unauthorized use and disclosure of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be adequate.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">27</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">In addition to our patent activities, we rely upon, among other things, unpatented proprietary technology, processes, trade secrets and know-how. Any involuntary disclosure to or misappropriation by third parties of our confidential or proprietary information could enable competitors to duplicate or surpass our technological achievements, potentially eroding our competitive position in our market. We seek to protect confidential or proprietary information in part by confidentiality agreements with our employees, consultants and third parties. While we require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information and technology to enter into confidentiality agreements, we cannot be certain that this know-how, information and technology will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. These agreements may be terminated or breached, and we may not have adequate remedies for any such termination or breach. Furthermore, these agreements may not provide meaningful protection for our trade secrets and know-how in the event of unauthorized use or disclosure. To the extent that any of our staff was previously employed by other pharmaceutical, medical technology or biotechnology companies, those employers may allege violations of trade secrets and other similar claims in relation to their former employee&#8217;s therapeutic development activities for us.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>We may in the future be a party to intellectual property litigation or administrative proceedings that could be costly and could interfere with our ability to sell our TAEUS applications.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The medical device industry has been characterized by extensive litigation regarding patents, trademarks, trade secrets, and other intellectual property rights, and companies in the industry have used intellectual property litigation to gain a competitive advantage. It is possible that U.S. and foreign patents and pending patent applications or trademarks controlled by third parties may be alleged to cover our products, or that we may be accused of misappropriating third parties&#8217; trade secrets. Other medical imaging market participants, many of which have substantially greater resources and have made substantial investments in patent portfolios, trade secrets, trademarks, and competing technologies, may have applied for or obtained or may in the future apply for or obtain, patents or trademarks that will prevent, limit or otherwise interfere with our ability to make, use, sell and/or export our products or to use product names. We may become a party to patent or trademark infringement or trade secret claims and litigation as a result of these and other third party intellectual property rights being asserted against us. The defense and prosecution of these matters are both costly and time consuming. Vendors from whom we purchase hardware or software may not indemnify us in the event that such hardware or software is accused of infringing a third party&#8217;s patent or trademark or of misappropriating a third party&#8217;s trade secret.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Further, if such patents, trademarks, or trade secrets are successfully asserted against us, this may harm our business and result in injunctions preventing us from selling our products, license fees, damages and the payment of attorney fees and court costs. In addition, if we are found to willfully infringe third-party patents or trademarks or to have misappropriated trade secrets, we could be required to pay treble damages in addition to other penalties. Although patent, trademark, trade secret, and other intellectual property disputes in the medical device area have often been settled through licensing or similar arrangements, costs associated with such arrangements may be substantial and could include ongoing royalties. We may be unable to obtain necessary licenses on satisfactory terms, if at all. If we do not obtain necessary licenses, we may not be able to redesign our TAEUS applications to avoid infringement.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Similarly, interference or derivation proceedings provoked by third parties or brought by the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) may be necessary to determine the priority of inventions or other matters of inventorship with respect to our patents or patent applications. We may also become involved in other proceedings, such as re-examination, inter partes review, or opposition proceedings, before the USPTO or other jurisdictional body relating to our intellectual property rights or the intellectual property rights of others. Adverse determinations in a judicial or administrative proceeding or failure to obtain necessary licenses could prevent us from manufacturing and selling our TAEUS applications or using product names, which would have a significant adverse impact on our business.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Additionally, we may need to commence proceedings against others to enforce our patents or trademarks, to protect our trade secrets or know-how, or to determine the enforceability, scope and validity of the proprietary rights of others. These proceedings would result in substantial expense to us and significant diversion of effort by our technical and management personnel. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. We may not be able to stop a competitor from marketing and selling products that are the same or similar to our products or from using product names that are the same or similar to our product names, and our business may be harmed as a result.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Intellectual property rights may not provide adequate protection, which may permit third parties to compete against us more effectively.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">In order to remain competitive, we must develop and maintain protection of the proprietary aspects of our technologies. We rely on a combination of patents, copyrights, trademarks, trade secret laws and confidentiality and invention assignment agreements to protect our intellectual property rights. Any patents issued to us may be challenged by third parties as being invalid, or third parties may independently develop similar or competing technology that avoids our patents. Should such challenges be successful, competitors might be able to market products and use manufacturing processes that are substantially similar to ours. Consequently, we may be unable to prevent our proprietary technology from being exploited abroad, which could affect our ability to expand to international markets or require costly efforts to protect our technology. To the extent our intellectual property protection is incomplete, we are exposed to a greater risk of direct competition. In addition, competitors could purchase our products and attempt to replicate some or all of the competitive advantages we derive from our development efforts or design around our protected technology. Our failure to secure, protect and enforce our intellectual property rights could substantially harm the value of our TAEUS platform, brand and business.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">28</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Risks Related to Government Regulation</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Failure to comply with laws and regulations could harm our business.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Our business is or in the future may be subject to regulation by various federal, state, local and foreign governmental agencies, including agencies responsible for monitoring and enforcing employment and labor laws, workplace safety, environmental laws, consumer protection laws, anti-bribery laws, import/export controls, securities laws and tax laws and regulations. In certain jurisdictions, these regulatory requirements may be more stringent than those in the United States. Noncompliance with applicable regulations or requirements could subject us to investigations, sanctions, mandatory recalls, enforcement actions, adverse publicity, disgorgement of profits, fines, damages, civil and criminal penalties or injunctions and administrative actions. If any governmental sanctions, fines or penalties are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, operating results and financial condition could be harmed. In addition, responding to any action will likely result in a significant diversion of management's attention and our resources and substantial costs. Enforcement actions and sanctions could further harm our business, operating results and financial condition.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>If we fail to obtain and maintain necessary regulatory clearances or approvals for our TAEUS applications, or if clearances or approvals for future applications and indications are delayed or not issued, our commercial operations will be harmed.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The medical devices that we manufacture and market will be subject to regulation by numerous worldwide regulatory bodies, including the EMA, FDA and other comparable regulatory agencies. Additionally, third parties designing, manufacturing or conducting human studies of our devices will be subject to local regulations, such as those of Health Canada. These agencies and regulations require manufacturers of medical devices to comply with applicable laws and regulations governing development, testing, manufacturing, labeling, marketing and distribution of medical devices. Devices are generally subject to varying levels of regulatory control, based on the risk level of the device. Governmental regulations specific to medical devices are wide-ranging and govern, among other things:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">product design, development and manufacture;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">laboratory, pre-clinical and clinical testing, labeling, packaging storage and distribution;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">premarketing clearance or approval;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">record keeping;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">product marketing, promotion and advertising, sales and distribution; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">post-marketing surveillance, including reporting of deaths or serious injuries and recalls and correction and removals.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The European Union has revised its regulatory system for medical devices by implementing regulation (EU) 2017/745 on medical devices (&#8220;Medical Device Regulation&#8221; or &#8220;MDR&#8221;) and regulation (EU) 2017/746 on in vitro diagnostic medical devices. The MDR became effective on May 26, 2021&#160;(the &#8220;Date of Application&#8221; or &#8220;DoA&#8221;). The changes to the regulatory system implemented by the MDR include stricter requirements for clinical evidence and pre-market assessment of safety and performance, refined classifications to indicate risk levels, requirements for third party testing by Notified Bodies, tightened and streamlined quality management system assessment procedures and additional requirements for the quality management system, additional requirements for traceability of products and transparency as well a refined responsibility of economic operators.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We are currently in a transitional period, where our existing certified products will be required to continue to comply with applicable medical device directives (including the Medical Devices Directive and the Active Implantable Medical Devices Directive) and with the Medical Device Regulation and to obtain CE mark certification in order to market medical devices. The CE mark is applied following approval from a Notified Body or declaration of conformity. It is an international symbol of adherence to quality assurance standards and compliance with applicable European Medical Devices Directives or the MDR, as the case may be. CE mark approvals issued prior to May 26, 2021 will, subject to certain conditions (including, among others, continued compliance with the MDR, no significant changes to design or intended purpose, a quality management system, and engagement with a notified body to obtain conformity assessment), remain valid until December 31, 2028. In March 2020, we received CE mark approval for our TAEUS FLIP (Fatty Liver Imaging Probe) System. The CE marking indicates that TAEUS complies with all applicable regulations in the EU, and other CE mark geographies, including the 27 EU member states. We believe that future TAEUS applications will qualify for sale in the European Union as Class IIa medical devices. The MDR requires a clinical evaluation for all medical devices and clinical trials for selected medical devices to be (re-)certified under the rules of the MDR. Depending on the classification of our applications, future CE mark certifications or recertification of our applications may require additional clinical evaluations or trials, as the case may be.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">29</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We are also required to comply with the regulations of each other country where we commercialize products, such as the requirement that we obtain approval from the FDA and the China Food and Drug Administration before we can launch new products in the United States and China, respectively.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">International sales of medical devices manufactured in the United States that are not approved by the FDA for use in the United States, or that are banned or deviate from lawful performance standards, are subject to FDA export requirements. Exported devices are subject to the regulatory requirements of each country to which the device is exported. Frequently, regulatory approval may first be obtained in a foreign country prior to application in the United States due to differing regulatory requirements; however, other countries, such as China for example, require approval in the country of origin first.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Before a new medical device or a new intended use for an existing product can be marketed in the United States, a company must first submit and receive either 510(k) clearance or premarketing approval, or PMA, from the FDA, unless an exemption applies.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Our NAFLD TAEUS device will be reviewed under a &#8220;de novo&#8221; process for a risk-based classification determination whether the device is of low to moderate risk and that it can be appropriately regulated as a Class II device and thereby eligible for 510(k) clearance. While the 510(k) pathway for product marketing typically requires only non-clinical testing proof of substantial equivalence to a lawfully marketed predicate device for a given indication, a de novo review is more likely to require clinical studies to support a reclassification to a lower risk class. Even with the clinical data we expect to provide with the de novo submission for our NAFLD TAEUS device, the FDA may decide to reject the request to classify the device into Class II. If that happens, the device will be regulated as a Class III device and we will be required to fulfill more rigorous PMA requirements. Thus, although at this time we do not anticipate that we will be required to do so, it is possible that our NAFLD TAEUS device may require approval by means of a PMA.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We may not be able to obtain the necessary clearances or approvals or may be unduly delayed in doing so, which could harm our business. Furthermore, even if we are granted regulatory clearances or approvals, they may include significant limitations on the indicated uses for the product, which may limit the market for the product. Therefore, even if we believe we have successfully developed our TAEUS technology, we may not be permitted to market TAEUS applications in the United States if we do not obtain FDA regulatory clearance to market such applications. Delays in obtaining clearance or approval could increase our costs and harm our revenues and growth.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">In addition, we are required to timely file various reports with the FDA, including reports required by the medical device reporting regulations that require us to report to certain regulatory authorities if our devices may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur. If these reports are not filed timely, regulators may impose sanctions and sales of our products may suffer, and we may be subject to product liability or regulatory enforcement actions, all of which could harm our business.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">If we initiate a correction or removal for one of our devices to reduce a risk to health posed by the device, we would be required to submit a publicly available Correction and Removal report to the FDA and, in many cases, similar reports to other regulatory agencies. This report could be classified by the FDA as a device recall which could lead to increased scrutiny by the FDA, other international regulatory agencies and our customers regarding the quality and safety of our devices. Furthermore, the submission of these reports has been and could be used by competitors against us in competitive situations and cause customers to delay purchase decisions or cancel orders and would harm our reputation.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The FDA and the Federal Trade Commission (the &#8220;FTC&#8221;) also regulate the advertising and promotion of our planned products to ensure that the claims we make are consistent with our regulatory clearances, that there are adequate and reasonable data to substantiate the claims and that our promotional labeling and advertising is neither false nor misleading in any respect. If the FDA or FTC determines that any of our advertising or promotional claims are misleading, not substantiated or not permissible, we may be subject to enforcement actions, including warning letters, and we may be required to revise our promotional claims and make other corrections or restitutions.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">30</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The FDA and state authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements could result in enforcement action by the FDA or state agencies, which may include any of the following sanctions:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">adverse publicity, warning letters, fines, injunctions, consent decrees and civil penalties;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">repair, replacement, refunds, recall or seizure of our products;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">operating restrictions, partial suspension or total shutdown of production;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">refusing our requests for 510(k) clearance or premarket approval of new products, new intended uses or modifications to existing products;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">withdrawing 510(k) clearance or premarket approvals that have already been granted; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">criminal prosecution.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">If any of these events were to occur, our business and financial condition would be harmed.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Our TAEUS applications may require recertification or new regulatory clearances or premarket approvals and we may be required to recall or cease marketing our TAEUS applications until such recertification or clearances are obtained.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Most countries outside of the United States require that product approvals be recertified on a regular basis, generally every five years. The recertification process requires that we evaluate any device changes and any new regulations or standards relevant to the device and, where needed, conduct appropriate testing to document continued compliance. Where recertification applications are required, they must be approved in order to continue selling our products in those countries.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">In the United States, material modifications to the intended use or technological characteristics of our TAEUS applications will require new 510(k) clearances or premarket approvals or require us to recall or cease marketing the modified devices until these clearances or approvals are obtained. Based on FDA published guidelines, the FDA requires device manufacturers to initially make and document a determination of whether or not a modification requires a new approval, supplement or clearance; however, the FDA can review a manufacturer&#8217;s decision. Any modification to an FDA-cleared device that would significantly affect its safety or efficacy or that would constitute a major change in its intended use would require a new 510(k) clearance or possibly a premarket approval.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We may not be able to obtain recertification or additional 510(k) clearances or premarket approvals for our applications or for modifications to, or additional indications for, our TAEUS technology in a timely fashion, or at all. Delays in obtaining required future governmental approvals would harm our ability to introduce new or enhanced products in a timely manner, which in turn would harm our future growth. If foreign regulatory authorities or the FDA require additional approvals, we may be required to recall and to stop selling or marketing our TAEUS applications, which could harm our operating results and require us to redesign our applications. In these circumstances, we may be subject to significant enforcement actions.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>If any OEMs fail to comply with the FDA&#8217;s Quality System Regulations or other regulatory bodies&#8217; equivalent regulations, manufacturing operations could be delayed or shut down and the development of our TAEUS platform could suffer.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The manufacturing processes of OEMs are required to comply with the FDA&#8217;s Quality System Regulations and other regulatory bodies&#8217; equivalent regulations, which cover the procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of our TAEUS applications. They may also be subject to similar state requirements and licenses and engage in extensive recordkeeping and reporting and make available their manufacturing facilities and records for periodic unannounced inspections by governmental agencies, including the FDA, state authorities and comparable agencies in other countries. If any OEM fails such an inspection, our operations could be disrupted and our manufacturing interrupted. Failure to take adequate corrective action in response to an adverse inspection could result in, among other things, a shut-down of our manufacturing operations, significant fines, suspension of marketing clearances and approvals, seizures or recalls of our products, operating restrictions and criminal prosecutions, any of which would cause our business to suffer. Furthermore, these OEMs may be engaged with other companies to supply and/or manufacture materials or products for such companies, which would expose our OEMs to regulatory risks for the production of such materials and products. As a result, failure to meet the regulatory requirements for the production of those materials and products may also affect the regulatory clearance of a third-party manufacturers&#8217; facility. If the FDA or a foreign regulatory agency does not approve these facilities for the manufacture of our products, or if it withdraws its approval in the future, we may need to find alternative manufacturing facilities, which would impede or delay our ability to develop, obtain regulatory approval for or market our products, if approved. Additionally, our key component suppliers may not currently be or may not continue to be in compliance with applicable regulatory requirements, which may result in manufacturing delays for our product and cause our results of operations to suffer.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Our TAEUS applications may in the future be subject to product recalls that could harm our reputation.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Governmental authorities in Europe, the United States and China have the authority to require the recall of commercialized products in the event of material regulatory deficiencies or defects in design or manufacture. A government-mandated or voluntary recall by us could occur as a result of component failures, manufacturing errors or design or labeling defects. Recalls of our TAEUS applications would divert managerial attention, be expensive, harm our reputation with customers and harm our financial condition and results of operations. A recall announcement would negatively affect the price of our securities.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">31</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Healthcare reform measures could hinder or prevent our planned products' commercial success.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">There have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system in ways that could harm our future revenues and profitability and the future revenues and profitability of our potential customers. In the EU, the Medical Devices Directive is being replaced with the more expansive Medical Devices Regulation, which may increase the costs of obtaining and maintaining required regulatory approvals for our products. We cannot predict what other healthcare initiatives, if any, will be implemented by EU member countries, or the effect any future legislation or regulation will have on us.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">In the United States, federal and state lawmakers regularly propose and, at times, enact legislation that would result in significant changes to the healthcare system, some of which are intended to contain or reduce the costs of medical products and services. For example, one of the most significant healthcare reform measures in decades, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (the &#8220;Affordable Care Act&#8221;), was enacted in 2010. The Affordable Care Act contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement changes and fraud and abuse measures, all of which will impact existing government healthcare programs and will result in the development of new programs. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">It remains unclear whether changes will be made to the Affordable Care Act, or whether it will be repealed or materially modified. For example, the Tax Cuts and Jobs Act of 2017 modified certain aspects of the Affordable Care Act and the Biden Administration and U.S. Congress may take further action regarding the Affordable Care Act. Therefore, we cannot assure you that the Affordable Care Act, as currently enacted or as may be further amended or discontinued in the future, will not harm our business and financial results and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">There likely will continue to be legislative and regulatory proposals at the federal and state levels directed at containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future or their full impact. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may harm:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">our ability to set a price that we believe is fair for our products;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">our ability to generate revenues and achieve or maintain profitability; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the availability of capital.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>If we fail to comply with healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third party payors, certain federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights are and will be applicable to our business. We could be subject to healthcare fraud and abuse and patient privacy regulation by both the federal government and the states in which we conduct our business. Other jurisdictions such as the European Union have similar laws. The regulations that will affect how we operate include:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the federal healthcare program Anti-Kickback Statute, which prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs, such as the Medicare and Medicaid programs;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the federal False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, false claims, or knowingly using false statements, to obtain payment from the federal government;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">32</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the federal Physician Payment Sunshine Act, created under the Affordable Care Act, and its implementing regulations, which require manufacturers of drugs, medical devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the U.S. Department of Health and Human Services, or HHS, information related to payments or other transfers of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The Affordable Care Act, among other things, amends the intent requirement of the Federal Anti-Kickback Statute and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. In addition, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the Federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal and similar foreign healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could harm our ability to operate our business and our results of operations.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Compliance with environmental laws and regulations could be expensive. Failure to comply with environmental laws and regulations could subject us to significant liability.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Our research and development and manufacturing operations may involve the use of hazardous substances and are subject to a variety of federal, state, local and foreign environmental laws and regulations relating to the storage, use, discharge, disposal, remediation of, and human exposure to, hazardous substances and the sale, labeling, collection, recycling, treatment and disposal of products containing hazardous substances. In addition, our research and development and manufacturing operations produce biological waste materials, such as human and animal tissue, and waste solvents, such as isopropyl alcohol. These operations are permitted by regulatory authorities, and the resultant waste materials are disposed of in material compliance with environmental laws and regulations. Liability under environmental laws and regulations can be joint and several and without regard to fault or negligence. Compliance with environmental laws and regulations may be expensive and non-compliance could result in substantial liabilities, fines and penalties, personal injury and third part property damage claims and substantial investigation and remediation costs. Environmental laws and regulations could become more stringent over time, imposing greater compliance costs and increasing risks and penalties associated with violations. We cannot assure you that violations of these laws and regulations will not occur in the future or have not occurred in the past as a result of human error, accidents, equipment failure or other causes. The expense associated with environmental regulation and remediation could harm our financial condition and operating results.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Risks Related to Owning Our Securities, Our Financial Results and Our Need for Financing</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Our quarterly and annual results may fluctuate significantly, may not fully reflect the underlying performance of our business and may result in volatility in the price of our securities.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Our operating results will be affected by numerous factors such as:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">variations in the level of expenses related to our proposed products;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">status of our product development efforts;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">execution of collaborative, licensing or other arrangements, and the timing of payments received or made under those arrangements;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">33</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">intellectual property prosecution and any infringement lawsuits to which we may become a party;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">regulatory developments affecting our products or those of our competitors, including the timing and success of obtaining various regulatory approvals for our products&#8217; testing, production and marketing;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">our ability to obtain and maintain FDA clearance and approval from foreign regulatory authorities for our products, which have not yet been approved for marketing;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">market acceptance of our TAEUS applications;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the availability of reimbursement for our TAEUS applications;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">our ability to attract new customers and grow our business with existing customers;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the timing and success of new product and feature introductions by us or our competitors or any other change in the competitive dynamics of our industry, including consolidation among competitors, customers or strategic partners;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the amount and timing of costs and expenses related to the maintenance and expansion of our business and operations;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">changes in our pricing policies or those of our competitors;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">general economic, industry and market conditions;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the hiring, training and retention of key employees, including our ability to expand our sales team;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">litigation or other claims against us;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">our ability to obtain additional financing; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">advances and trends in new technologies and industry standards.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Any or all of these factors could adversely affect our cash position requiring us to raise additional capital which may be on unfavorable terms and result in substantial dilution. Additionally, the risks surrounding our business, as well as the limited market for our common stock, have resulted, and will likely continue to result, in volatility in the price of our common stock and warrants. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Our stock price has fluctuated in the past, has recently been volatile and may be volatile in the future for reasons unrelated to our operating performance or prospects, and as a result, investors in our common stock could incur substantial losses.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Our stock price has fluctuated in the past, has recently been volatile and may be volatile in the future. From January 1, 2022 through December 31, 2022, intra-day trading prices of shares of our common stock, on a Reverse Stock Split-adjusted basis (as discussed below in Item 7 under &#8220;Nasdaq Capital Market Listing and Reverse Stock Split&#8221;), on the Nasdaq Capital Market fluctuated from a low of $3.16 to a high of $15.80,&#160;and may continue to fluctuate significantly in the future. The stock market in general and the market for healthcare companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may experience losses on their investment in our common stock.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Additionally securities of certain companies have experienced significant and extreme volatility in stock price due to a sudden increase in demand for stock resulting in aggregate short positions in the stock exceeding the number of shares available for purchase, forcing investors with short exposure to pay a premium to repurchase shares for delivery to share lenders. This is known as a &#8220;short squeeze.&#8221; These short squeezes have led to the price per share of those companies to trade at a significantly inflated rate that is disconnected from the underlying value of the company. Many investors who have purchased shares in those companies at an inflated rate face the risk of losing a significant portion of their original investment as the price per share declines steadily as interest in those stocks abates. While we have no reason to believe our shares would be the target of a short squeeze, there can be no assurance that they will not be in the future, and you may lose a significant portion or all of your investment if you purchase our shares at a rate that is significantly disconnected from our underlying value.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">34</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>We may be subject to securities litigation, which is expensive and could divert management attention.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">In the past, companies that have experienced volatility in the market price of their securities have been subject to an increased incidence of securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>There is a limited market for our common stock.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Although our common stock is traded on the Nasdaq Capital Market, the volume of trading has historically been limited. Our average daily trading volume of our shares from January 1, 2022 to December 31, 2022 was approximately 51,768&#160;shares. Thinly traded stock can be more volatile than stock trading in a more active public market. While we have made efforts to increase trading in our stock, we cannot predict the extent to which an active public market for our common stock will develop or be sustained. Therefore, a holder of our common stock who wishes to sell his or her shares may not be able to do so immediately or at an acceptable price.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>If securities or industry analysts do not publish research reports about our business, or if they issue an adverse opinion about our business, the price of our securities and trading volume could decline.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The trading market for our securities is influenced by the research and reports that industry or securities analysts publish about us or our business. We do not currently have and may never obtain research coverage by securities and industry analysts. If no or few analysts commence research coverage of us, or one or more of the analysts who cover us issues an adverse opinion about our company, the price of our securities would likely decline. If one or more of these analysts ceases research coverage of us or fails to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause the price of our securities or trading volume to decline.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em><strong>If we are unable to implement and maintain effective internal control over financial reporting, including by remediating current material weaknesses in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, and the market price of our securities may decrease and we may become subject to litigation or enforcement actions.</strong></em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal controls. Section 404 of the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;) requires that we evaluate and determine the effectiveness of our internal control over financial reporting and provide a management report on our internal control over financial reporting.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Currently, we have material weaknesses in our internal control over financial reporting and, as a result, we may not detect errors on a timely basis and our financial statements may be materially misstated. Specifically, we have insufficient personnel resources within the accounting function to segregate the duties over financial transaction processing and reporting. We intend to improve our internal control over financial reporting; however, the process is time-consuming, costly and complicated. We are constrained in the improvements we are able to make due to our limited resources. Until our internal controls are improved our ability to maintain effective internal controls over financial reporting will be limited.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Until such time as we are no longer a smaller reporting company, our auditors will not be required to attest as to our internal control over financial reporting. If we continue to identify material weaknesses in our internal control over financial reporting, if we are unable to comply with the requirements of Section 404 in a timely manner, if we are unable to assert that our internal control over financial reporting is effective or, if required, if our independent registered public accounting firm is unable to attest that our internal control over financial reporting is effective, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could decrease. We could also become subject to stockholder or other third-party litigation as well as investigations by the stock exchange on which our securities are listed, the Securities and Exchange Commission (the &#8220;SEC&#8221;) or other regulatory authorities, which could require additional financial and management resources and could result in fines, trading suspensions or other remedies.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We are subject to the periodic reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified by the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">35</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>We have not paid dividends in the past and have no immediate plans to pay dividends.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We plan to reinvest all of our earnings, to the extent we have earnings, in order to further develop our technology and potential products and to cover operating costs. We do not plan to pay any cash dividends with respect to our securities in the foreseeable future. We cannot assure you that we will, at any time, generate sufficient surplus cash that would be available for distribution to the holders of our common stock as a dividend.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>We incur significant costs as a result of being a public company that reports to the SEC and our management is required to devote substantial time to meet compliance obligations.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">As a public company listed in the United States, we incur significant legal, accounting and other expenses relating to our compliance obligations. We are subject to reporting requirements of the Exchange Act and the Sarbanes-Oxley Act, as well as rules subsequently implemented by the SEC and Nasdaq that impose significant requirements on public companies, including requiring the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. In addition, there are significant corporate governance and executive compensation-related provisions in the Dodd-Frank Act Wall Street Reform and Protection Act that contribute to our legal and financial compliance costs, make some activities more difficult, time-consuming or costly and also place undue strain on our personnel, systems and resources. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Furthermore, these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our board of directors, our board committees or as executive officers.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em><strong>Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plan and our at-the-market equity offering program, could result in dilution of the percentage ownership of our stockholders and could cause the price of our securities to fall.</strong></em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We expect that significant capital will be needed in the future to continue our planned operations. To the extent we raise capital by issuing common stock, convertible securities or other equity securities, our stockholders may experience substantial dilution, and new investors could gain rights superior to our existing stockholders.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Our charter documents and Delaware law may inhibit a takeover that stockholders consider favorable.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Certain provisions of our Fourth Amended and Restated Certificate of Incorporation, as amended (our &#8220;Certificate of Incorporation&#8221;) and Amended and Restated Bylaws (our &#8220;Bylaws&#8221;) and applicable provisions of Delaware law may delay or discourage transactions involving an actual or potential change in control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best interests. The provisions in our Certificate of Incorporation and Bylaws:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">authorize our board of directors to issue preferred stock without stockholder approval and to designate the rights, preferences and privileges of each class; if issued, such preferred stock would increase the number of outstanding shares of our capital stock and could include terms that may deter an acquisition of us;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">limit who may call stockholder meetings;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">do not provide for cumulative voting rights;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">provide that all vacancies in our board of directors may be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">provide that stockholders must comply with advance notice procedures with respect to stockholder proposals and the nomination of candidates for director;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">provide that stockholders may only amend our Certificate of Incorporation upon a supermajority vote of stockholders; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">provide that the Court of Chancery of the State of Delaware will be the exclusive forum for certain legal claims.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">36</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">In addition, section 203 of the Delaware General Corporation Law limits our ability to engage in any business combination with a person who beneficially owns 15% or more of our outstanding voting stock unless certain conditions are satisfied. This restriction lasts for a period of three years following any such person&#8217;s share acquisition. These provisions may have the effect of entrenching our management team and may deprive stockholders of the opportunity to sell their shares to potential acquirers at a premium over prevailing prices. This potential inability to obtain a control premium could reduce the price of our common stock.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>General Risk Factors</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Our business is affected by macroeconomic conditions.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Various macroeconomic factors could adversely affect our business and the results of our operations and financial condition, including changes in inflation, interest rates and foreign currency exchange rates and overall economic conditions and uncertainties, including those resulting from the current and future conditions in the global financial markets. For instance, we experienced inflationary pressures in 2022 and expect such pressures to continue in 2023. Cost inflation, including increases in raw material prices, labor rates, and transportation costs may impact our profitability. Our ability to recover these cost increases through price increases is significantly limited by the process by which we are reimbursed for our products and services by government and private payers. The volatility of the capital markets could also affect the value of our investments and our ability to liquidate our investments in order to fund our operations.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Increasing interest rates and reduced access to capital markets could also adversely affect the ability of our suppliers, distributors, licensors, collaborators, contract manufacturers and other commercial partners to remain effective business partners or to remain in business. The loss of a critical business partner, or a failure to perform by a critical business partner, could have a disruptive effect on our business and could adversely affect our results of operations.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong><em>Our cash and cash equivalents could be adversely affected if the financial institutions in which we hold our cash and cash equivalents fail.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">We regularly maintain cash balances at third-party financial institutions in excess of the Federal Deposit Insurance Corporation insurance limit. Any failure of a depository institution to return these deposits on demand, or if a depository institution is subject to other adverse conditions in the financial or credit markets, could impact access to our invested cash or cash equivalents and could adversely impact our operating liquidity and financial performance.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The ongoing military action by Russia in Ukraine could have negative impact on the global economy, which could materially adversely affect our business, operations, operating results and financial condition.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">In February&#160;2022, Russian forces launched significant military action against Ukraine, and sustained conflict and disruption in the region is possible. The impact to Ukraine as well as actions taken by other countries, including new and stricter sanctions imposed by Canada, the United Kingdom, the European Union, the United States and other countries and companies and organizations against officials, individuals, regions, and industries in Russia and Ukraine, and actions taken by Russia in response to such sanctions, and each country&#8217;s potential response to such sanctions, tensions, and military actions could adversely affect the global economy and financial markets and thus could affect our business, operations, operating results and financial condition as well as the price of our common stock and our ability to raise additional capital when needed on acceptable terms. The extent and duration of the military action, sanctions and resulting market disruptions, including supply chain disruptions, are impossible to predict, but could be substantial. Any such disruptions caused by Russian military action or resulting sanctions may magnify the impact of other risks described in this Annual Report on Form 10-K.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Our business and operations are subject to risks related to climate change.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The effects of global climate change present risks to our business. Natural disasters, extreme weather and other conditions caused by or related to climate change could adversely impact our supply chain, the courier delivery services we use, the availability and cost of raw materials and components, energy supply, transportation, or other inputs necessary for the operation of our business. Climate change and natural disasters could also result in physical damage to our facilities as well as those of our suppliers, health care providers and other business partners, which could cause disruption in our business and operations. Our facilities and our laboratory equipment would be costly to replace and could require substantial lead time to repair or replace. Although we believe we possess adequate insurance for the disruption of our business from causalities, such insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Our business could be negatively impacted by corporate social responsibility and sustainability matters.</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">There has been an increased focus from investors, customers, employees and other stakeholders concerning corporate social responsibility and sustainability matters, including addressing climate change and diversity in company management, which may result in increases in our costs to operate our business or restrict certain aspects of our activities. The standards by which corporate social responsibility and sustainability efforts and related matters are measured are developing and evolving, and certain areas are subject to assumptions that could change over time and the extent and severity of climate change impacts are unknown. In addition, we could be criticized for the scope of such initiatives or goals or a lack of diversity on our board of directors or among our executive officers, or perceived as not acting responsibly in connection with these matters. Any such matters could have a material adverse impact on our future results of operations, financial position and cash flows.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="a4">Item 1B. Unresolved Staff Comments</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Not applicable.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">37</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="a5">Item 2. Properties</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Our principal office is located at 3600 Green Court, Suite 350, Ann Arbor, Michigan 48105-1570. We previously leased approximately 3,950 square feet of office and light industrial/research space, which expanded to approximately 7,200 square feet effective May 1, 2021, under a lease that is due to expire in December 2025. The rent is $16,393 per month effective January&#160;1, 2023, subject to moderate annual increases.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We also maintain an office in London, Ontario, Canada under a lease that is terminable by either party with 60 days&#8217; written notice. The rent is approximately $900 per month per the agreement with the landlord, subject to moderate annual increases at the discretion of the landlord.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We believe that, with respect to both of our facilities, equivalent suitable space is available at similar rents.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="a6">Item 3. Legal Proceedings</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We are not currently a party to any pending legal proceedings that we believe will have a material adverse effect on our business or financial conditions. We may, however, be subject to various claims and legal actions arising in the ordinary course of business from time to time.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="a7">Item 4. Mine Safety Disclosures</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Not applicable.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">38</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="a8">PART II</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="a9">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Market Information</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Our common stock has been listed on the Nasdaq Capital Market under the symbol &#8220;NDRA&#8221; since June 28, 2017 upon the separation of units sold in our initial public offering. Prior to that date, our common stock traded together with warrants issued in our initial public offering as units beginning on May 9, 2017. Our publicly traded warrants expired on May 12, 2022.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">As of March 16, 2023, there were 22 holders of record of our common stock.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Dividend Policy</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We have never paid cash dividends on our securities and we do not anticipate paying any cash dividends on our shares of common stock in the foreseeable future. We intend to retain any future earnings for reinvestment in our business. Any future determination to pay cash dividends will be at the discretion of our board of directors, and will be dependent upon our financial condition, results of operations, capital requirements and such other factors as our board of directors deems relevant.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="a10">Item 6. [Reserved]</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">39</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="a11">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>The following discussion of our financial condition and results of operations should be read in conjunction with the financial statements and the related notes thereto included elsewhere in this Annual Report. This discussion and analysis contain forward-looking statements that are based on our management&#8217;s current beliefs and assumptions, which statements are subject to substantial risks and uncertainties. Our actual results may differ materially from those expressed or implied by these forward-looking statements as a result of many factors, including those discussed in &#8220;Risk Factors&#8221; in Item 1A of this Annual Report. Please also see &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; and &#8220;Risk Factor Summary&#8221; at the beginning of this Annual Report.</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Overview</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are leveraging experience with pre-clinical enhanced ultrasound devices to develop technology for increasing the capabilities of clinical diagnostic ultrasound, to broaden patient access to the safe diagnosis and treatment of a number of significant medical conditions in circumstances where expensive X-ray CT and MRI technology, or other diagnostic technologies such as surgical biopsy, are unavailable or impractical. Building on our expertise in thermoacoustics, we have developed a next-generation technology platform&#8212;Thermo Acoustic Enhanced Ultrasound, or TAEUS&#8212;which is intended to enhance the capability of clinical ultrasound technology and support the diagnosis and treatment of a number of significant medical conditions that currently require the use of expensive CT or MRI imaging or where imaging is not practical using existing technology.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The first-generation TAEUS application is a standalone ultrasound accessory designed to cost-effectively quantify fat in the liver and stage progression of nonalcoholic fatty liver disease (&#8220;NAFLD&#8221;), which can otherwise only be achieved today with impractical surgical biopsies or MRI scans. Subsequent TAEUS offerings are expected to be implemented via a second generation hardware platform that can run multiple clinical software applications that we will offer TAEUS users for a one-time licensing fee&#8212;adding ongoing customer value to the TAEUS platform and a growing software revenue stream for our Company. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Each of our TAEUS platform applications will require regulatory approvals before we are able to sell or license the application. Based on certain factors, such as the installed base of ultrasound systems, availability of other imaging technologies, such as CT and MRI, economic strength and applicable regulatory requirements, we intend to seek initial approval of our applications for sale in the European Union and the United States, followed by China.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In March 2020, we received CE mark approval for our TAEUS FLIP (&#8220;Fatty Liver Imaging Probe&#8221;) System, enabling its marketing and sales in the European Union and other CE mark geographies, including the 27 EU member states.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In June 2020, we submitted a 510(k) Application to the FDA for our TAEUS FLIP System. In February 2022, we announced that we will pursue FDA reclassification and clearance of our TAEUS&#174; FLIP System through the FDA&#8217;s &#8220;de novo&#8221; process. We voluntarily withdrew our 510(k) application and plan to submit an application for de novo review, which will include additional clinical data, as soon as practicable in 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Financial Operations Overview</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Revenue</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">No revenue has been generated by our TAEUS technology, which we have not commercially sold as of December 31, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Research and Development Expenses</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our research and development expenses primarily include wages, fees and equipment for the development of our TAEUS technology platform and the proposed applications. Additionally, we incur certain costs associated with the protection of our products and inventions through a combination of patents, licenses, applications and disclosures. These costs and expenses include:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">employee-related expenses, such as salaries, bonuses and benefits, consultant-related expenses such as consultant fees and bonuses, stock-based compensation, overhead related expenses and travel-related expenses for our research and development personnel;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">expenses incurred under agreements with contract research organizations (&#8220;CROs&#8221;), contract manufacturing organizations (&#8220;CMOs&#8221;) as well as consultants that support the implementation of our clinical and non-clinical studies;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">manufacturing and packaging costs in connection with conducting clinical trials;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">formulation, research and development expenses related to our TAEUS technology; and</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">costs for sponsored research.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We plan to incur research and development expenses for the foreseeable future as we expect to continue the development of TAEUS and pursue FDA approval of the NAFLD TAEUS system. At this time, due to the inherently unpredictable nature of clinical development and regulatory approvals, we are unable to estimate with certainty the costs we will incur and the timelines we will require in our continued development efforts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">40</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Sales and Marketing Expenses</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Sales and marketing expenses consist primarily of headcount and consulting costs, and marketing and tradeshow expenses. Currently, our marketing efforts are through our website and attendance of key industry meetings and conferences. In connection with the commercialization of our TAEUS applications, we are building a small sales and marketing team to train and support global ultrasound distributors, and expect to execute traditional marketing activities such as promotional materials, electronic media and participation in industry events and conferences. As of December 31, 2022, we had a full-time sales representative in each of the United Kingdom, France and Germany. We expect to continue actively adding to our sales representation and support headcount for operations in the EU in the coming quarters, and plan to begin staffing our sales efforts in the United States once we have obtained FDA approval for the sale of the NAFLD TAEUS device in that region.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;<em><span style="text-decoration:underline">General and Administrative Expenses</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">General and administrative expenses consist primarily of salaries and related expenses for our management and personnel, and professional fees, such as for accounting, consulting and legal services. We anticipate that our general and administrative expenses will increase in the future as we support our continued research and development activities, expand our sales and marketing operations, and continue as a public company. These increases would likely include increased costs related to the hiring of personnel, including compensation and employee-related expenses, including stock-based compensation, and fees to outside consultants, lawyers and accountants, among other expenses. Additionally, we anticipate continued costs associated with being a public company, including expenses related to services associated with maintaining compliance with The Nasdaq Capital Market and SEC requirements, directors and officers insurance, increased legal and accounting costs and investor relations costs.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Critical Accounting Policies and Estimates</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Use of Estimates</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Management makes estimates that affect certain accounts including deferred income tax assets, accrued expenses, fair value of equity instruments and reserves for any other commitments or contingencies. Any adjustments applied to estimates are recognized in the period in which such adjustments are determined.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em><span style="text-decoration:underline">Share-based Compensation</span></em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our Omnibus Plan permits the grant of stock options and other stock awards to our employees, consultants and non-employee members of our board of directors. Each January 1 the pool of shares available for issuance under the Omnibus Plan automatically increases by an amount equal to the lesser of (i) the number of shares necessary such that the aggregate number of shares available under the Omnibus Plan equals 25% of the number of fully-diluted outstanding shares on the increase date (assuming the conversion of all outstanding shares of preferred stock and other outstanding convertible securities and exercise of all outstanding options and warrants to purchase shares) and (ii) if the board of directors takes action to set a lower amount, the amount determined by the board. On January 1, 2023, the pool of shares issuable under the Omnibus Plan automatically increased by 867,966 shares from 454,204 shares to 1,322,169 shares. As of December 31, 2022, there were 62,302 shares of common stock remaining available for issuance under the Omnibus Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We record share-based compensation in accordance with the provisions of the Share-based Compensation Topic of the FASB Codification. The guidance requires the use of option-pricing models that require the input of highly subjective assumptions, including the option&#8217;s expected life and the price volatility of the underlying stock. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option valuation model which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, and future dividends, and the resulting charge is expensed using the straight-line attribution method over the vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Stock compensation expense recognized during the period is based on the value of share-based awards that were expected to vest during the period adjusted for estimated forfeitures. The estimated fair value of grants of stock options and warrants to non-employees is charged to expense, if applicable, in the financial statements.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">41</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Debt Discount and Detachable Debt-Related Warrants</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for debt discounts originating in connection with conversion features that are embedded in certain previously outstanding notes and warrants in accordance with ASC Subtopic 470-20, <em>Debt with Conversion and Other Options</em>. These costs are classified on the consolidated balance sheet as a direct deduction from the debt liability. The Company amortized these costs over the term of the securities as interest expense-debt discount in the consolidated statement of operations. Debt discounts relate to the relative fair value of warrants issued in conjunction with the debt and are also recorded as a reduction to the debt balance and accreted over the expected term of the securities to interest expense.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em><span style="text-decoration:underline">Recent Accounting Pronouncements</span></em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">See Note 2 of the accompanying financial statements for a discussion of recently issued accounting standards.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Results of Operations</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em><span style="text-decoration:underline">Years ended December 31, 2022 and 2021</span></em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Revenue</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We had no revenue during the years ended December 31, 2022 and 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Cost of Goods Sold</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We had no cost of goods sold during the years ended December 31, 2022 and 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Research and Development</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Research and development expenses were $6,554,194 for the year ended December 31, 2022, as compared to $5,482,531 for the year ended December 31, 2021, an increase of $1,071,663, or 20%. The costs include primarily wages, fees and equipment for the development of our TAEUS product line. Research and development expenses increased from the same period due to increased wage and related expenses.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Sales and Marketing</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Sales and marketing expenses were $1,429,150 for the year ended December 31, 2022, as compared to $1,075,376 for the year ended December 31, 2021, an increase of $353,774, or 33%. The increase was primarily due to additional headcount and pre-selling activities for our TAEUS product line. Currently, our marketing efforts are through our website and attendance of key industry meetings.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>General and Administrative</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our general and administrative expenses for the year ended December 31, 2022 were $5,174,215, compared to $4,940,398 for the year ended December 31, 2021, an increase of $233,817, or 5%. Our wage and related expenses for the year ended December 31, 2022 were $2,123,291, compared to $1,966,666 for the year ended December 31, 2021. Wage and related expenses in the year ended December 31, 2022 included $259,339 for accrued bonuses and $416,508 of stock compensation expense related to the issuance and vesting of options, compared to $193,764 for bonuses and $497,947 of stock compensation expense related to the issuance and vesting of options, for the year ended December 31, 2021. Our professional fees, which include legal, audit, and investor relations, for the year ended December 31, 2022 were $2,047,964, compared to $2,050,351 for the year ended December 31, 2021. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Gain on Extinguishment of Debt</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ending December 31, 2021, we received notice that the U.S. SBA approved forgiveness of our loan received under the PPP in accordance with the terms and provisions of the PPP, and recorded a gain on extinguishment of debt of $308,600.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Net Loss</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As a result of the foregoing, for the year ended December 31, 2022, we recorded a net loss of $13,179,092, compared to a net loss of $11,231,250 for the year ended December 31, 2021.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Near-Term Liquidity and Capital Resources</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Since inception, we have incurred losses and expect to continue to incur losses for the foreseeable future. As of December 31, 2022, we had an accumulated deficit of $81,869,902 and had $4,889,098 in cash. To date we have funded our operations through private and public sales of our securities and will need to raise additional funds in order to execute on our business plan, fully commercialize our TAEUS technology, and generate revenues.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">42</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We continue to evaluate and manage our capital needs to support our clinical, regulatory and operational activities, progress EU commercialization, and prepare for U.S. commercialization upon FDA approval of our NAFLD TAEUS device. We need additional capital to allow us to continue to execute our commercialization plans beyond the second quarter of 2023. We are considering potential financing options that may be available to us, including additional sales of our common stock through our At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC, dated June 21, 2021 (the &#8220;June 2021 ATM Agreement&#8221;); however, as of the date of this Annual Report, based on the market value of our public float, we are prevented from making additional sales under our shelf registration statement by General Instruction I.B.6 of Form S-3. Except for the June 2021 ATM Agreement, we have no commitments to obtain any additional funds, and there can be no assurance funds will be available in sufficient amounts or on acceptable terms. If we are unable to obtain sufficient additional financing in a timely fashion and on terms acceptable to us, our financial condition and results of operations may be materially adversely affected and we may not be able to continue operations or execute our stated commercialization plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The consolidated financial statements included in this Form 10-K have been prepared assuming we will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying consolidated financial statements, during the year ended December 31, 2022, we incurred net losses of $13,179,092 and used cash in operations of $12,769,371. In light of our cash balance as of December 31, 2022, we will need to raise additional capital in order to fund operations through the next twelve months, and prior to any ability to fund operations from revenue generated from the sale of our products. The financial statements do not include any adjustments that might be necessary should we be unable to continue as a going concern.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Operating Activities</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2022, we used $12,769,371 of cash in operating activities primarily as a result of our net loss of $13,179,092, offset by share-based compensation of $1,199,838, depreciation expense of $96,661, amortization of right of use assets of $137,597, fixed assets write-off of $1,391, and net changes in operating assets and liabilities of $(1,025,766).</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">During the year ended December 31, 2021, we used $11,122,384 of cash in operating activities primarily as a result of our net loss of $11,231,250, offset by share-based compensation of $1,444,572, gain on extinguishment of debt of $308,600, depreciation expense of $116,238, amortization of right of use assets of $108,177, fixed assets write-off of $9,874, and net changes in operating assets and liabilities of $(1,261,395).</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Investing Activities</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2022, we used $202,577 in investing activities related to purchases of equipment.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">During the year ended December 31, 2021, we used $45,000 in investing activities related to purchases of equipment.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Financing Activities</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2022, our financing activities provided $8,399,512 in proceeds from issuances of common stock.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">During the year ended December 31, 2021, our financing activities provided $13,401,602, including $10,615,975 in proceeds from issuances of common stock, and $2,785,627 in proceeds from warrant exercises.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Long-Term Liquidity</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have not completed the commercialization of any of our TAEUS technology platform applications. We expect to continue to incur significant expenses for the foreseeable future. We anticipate that our expenses will increase substantially as we:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">advance the engineering design and development of our NAFLD TAEUS application;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">acquire parts and build finished goods inventory of the TAEUS FLIP system;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">complete regulatory filings required for marketing approval of our NAFLD TAEUS application in the United States;&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">seek to hire a small internal marketing team to engage and support channel partners and clinical customers for our NAFLD TAEUS application;&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">expand marketing of our NAFLD TAEUS application;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">advance development of our other TAEUS applications; and</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">add operational, financial and management information systems and personnel, including personnel to support our product development, planned commercialization efforts and our operation as a public company.&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">43</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">It is possible that we will not achieve the progress that we expect because the actual costs and timing of completing the development and regulatory approvals for a new medical device are difficult to predict and are subject to substantial risks and delays. We have no committed external sources of funds except for the June 2021 ATM Agreement, the use of which may be limited due to registration statement rules relating to public float. We do not expect that our existing cash will be sufficient for us to complete the commercialization of our NAFLD TAEUS application or to complete the development of any other TAEUS application and we will need to raise substantial additional capital for those purposes. As a result, we will need to finance our future cash needs through public or private equity offerings, debt financings, corporate collaboration and licensing arrangements or other financing alternatives. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed in the Risk Factors section of this Annual Report on Form 10-K. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Until we can generate a sufficient amount of revenue from our TAEUS platform applications, if ever, we expect to finance future cash needs through public or private equity offerings, debt financings or corporate collaborations and licensing arrangements. Additional funds may not be available when we need them on terms that are acceptable to us, or at all. As described below, the COVID-19 pandemic has impacted our business operations to some extent and is expected to continue to do so and, in light of the effect of such pandemic on financial markets, these impacts may include reduced access to capital. Additionally, a recession or other unfavorable market conditions, including economic slowdowns, recessions, inflation, rising interest rates and tightening of credit markets caused by the ongoing COVID-19 pandemic, the conflict in Ukraine or otherwise, may limit our access to capital. If adequate funds are not available, we may be required to delay, reduce the scope of or eliminate one or more of our research or development programs or our commercialization efforts or perhaps even cease the operation of our business. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience additional dilution, and debt financing, if available, may involve restrictive covenants. To the extent that we raise additional funds through collaborations and licensing arrangements, it may be necessary to relinquish some rights to our technologies or applications or grant licenses on terms that may not be favorable to us. We may seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Nasdaq Capital Market Listing and Reverse Stock Split</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 5, 2022, the Company received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) notifying the Company that, because the closing bid price for the Company&#8217;s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company no longer met the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the &#8220;Minimum Bid Price Requirement&#8221;).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with Nasdaq Marketplace Rule 5810(c)(3)(A), the Company had a period of 180 calendar days from January 5, 2022, or until July 5, 2022, to regain compliance with the Minimum Bid Price Requirement. Prior to July 5, 2022, the Company applied for, and was provided, an additional 180-day period to regain compliance with the Minimum Bid Price Requirement. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 17, 2022, the Company distributed to stockholders and filed with the SEC a definitive proxy statement relating to a special meeting scheduled for November 29, 2022 at which stockholders voted on a proposal to approve an amendment to the Company&#8217;s certificate of incorporation to effect, at the discretion of the Company&#8217;s board of directors, a reverse stock split of the Company&#8217;s common stock at a stock split ratio between 1-for-2 and 1-for-30, with the ultimate ratio to be determined by the board of directors in its sole discretion, and the implementation and timing of which shall be subject to the discretion of the board of directors (the &#8220;Reverse Split Proposal&#8221;). On November 29, 2022, the Company held a special meeting of stockholders at which the Company&#8217;s stockholders approved the Reverse Split Proposal. Following the special meeting, the board of directors determined to effect the reverse stock split at a ratio of 1-for-20.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 8, 2022, the Company filed a Certificate of Amendment (the &#8220;Certificate of Amendment&#8221;) to the Company&#8217;s Fourth Amended and Restated Certificate of Incorporation (the &#8220;Certificate of Incorporation&#8221;) with the Secretary of State of Delaware to effect a 1-for-20 reverse stock split of the shares of the Company&#8217;s Common Stock, effective as of December 9, 2022 (the &#8220;Reverse Stock Split&#8221;). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As a result of the Reverse Stock Split, every 20 shares of issued and outstanding Common Stock was automatically combined into one issued and outstanding share of Common Stock, without any change in the par value per share. No fractional shares were issued as a result of the Reverse Stock Split. Any fractional shares that would otherwise have resulted from the Reverse Stock Split were rounded up to the next whole number. The number of authorized shares of Common Stock under the Certificate of Incorporation remained unchanged at 80,000,000 shares.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Proportionate adjustments were made to the per share exercise price and the number of shares of Common Stock that may be purchased upon exercise of outstanding stock options granted by the Company and the number of shares of Common Stock reserved for future issuance under the Company&#8217;s 2016 Omnibus Incentive Plan. The Common Stock began trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market on December 9, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">44</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As a result of the Reverse Stock Split, the Company regained compliance with the Minimum Bid Price Requirement.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Off-Balance Sheet Transactions</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">At December 31, 2022, the Company did not have any transactions, obligations or relationships that could be considered off-balance sheet arrangements.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="a12">Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Not applicable.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">45</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span class="atag" style="display: inline" id="a13">I<strong>tem 8. Financial Statements and Supplementary Data.</strong></span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="TOCFS">Index to Financial Statements</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>ENDRA Life Sciences Inc.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, 2022</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Page</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#rep">Report of Independent Registered Public Accounting Firm - (Firm ID <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorFirmId">587</ix:nonNumeric>)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">F-1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#f2">Consolidated Balance Sheets as of December 31, 2022 and 2021</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">F-2</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#f3">Consolidated Statements of Operations for the years ended December 31, 2022 and 2021</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">F-3</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#f4">Consolidated Statements of Stockholders&#8217; Equity for the years ended December 31, 2022 and 2021</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">F-4</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#f5">Consolidated Statements of Cash Flows for the years ended December 31, 2022 and 2021</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">F-5</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#f6">Notes to Consolidated Financial Statements for the years ended December 31, 2022 and 2021</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">F-6</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">46</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFS">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="rep">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">To the Board of Directors and Stockholders of</p><p style="font-size:10pt;font-family:times new roman;margin:0px">ENDRA Life Sciences Inc. and Subsidiaries</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Opinion on the Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have audited the accompanying consolidated balance sheets of ENDRA Life Sciences Inc. and Subsidiaries (collectively, the &#8220;Company&#8221;) as of December 31, 2022 and 2021, the related consolidated statements of operations, shareholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2022, and the related notes and schedules (collectively referred to as the &#8220;financial statements&#8221;). &#160;In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2022 and 2021 in conformity with accounting principles generally accepted in the United States of America.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>The Company's Ability to Continue as a Going Concern</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 2 to the accompanying consolidated financial statements, the Company has suffered recurring losses from operations, generated negative cash flows from operating activities, has an accumulated deficit and has stated that substantial doubt exists about Company&#8217;s ability to continue as a going concern. Management's evaluation of the events and conditions and management&#8217;s plans in regarding these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Basis for Opinion</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Critical Audit Matters</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We determined that there are no critical audit matters.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorName">RBSM LLP</ix:nonNumeric></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We have served as the Company&#8217;s auditor since 2015.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorLocation">New York, NY</ix:nonNumeric></p><p style="font-size:10pt;font-family:times new roman;margin:0px">March 16, 2023</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-1</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFS">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="f2">ENDRA Life Sciences Inc.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Consolidated Balance Sheets</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">Assets</span></strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Current Assets</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Cash</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1" contextRef="AsOf2022-12-31" name="us-gaap:Cash" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,889,098</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2" contextRef="AsOf2021-12-31" name="us-gaap:Cash" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,461,534</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Prepaid expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3" contextRef="AsOf2022-12-31" name="us-gaap:PrepaidExpenseCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">992,875</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_4" contextRef="AsOf2021-12-31" name="us-gaap:PrepaidExpenseCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,348,003</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Inventory</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_5" contextRef="AsOf2022-12-31" name="us-gaap:InventoryNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,644,717</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_6" contextRef="AsOf2021-12-31" name="us-gaap:InventoryNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,284,578</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total Current Assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_7" contextRef="AsOf2022-12-31" name="us-gaap:AssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,526,690</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8" contextRef="AsOf2021-12-31" name="us-gaap:AssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,094,115</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Non-Current Assets</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Fixed assets, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10" contextRef="AsOf2022-12-31" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">235,655</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11" contextRef="AsOf2021-12-31" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,130</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Right of use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_12" contextRef="AsOf2022-12-31" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">505,816</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_13" contextRef="AsOf2021-12-31" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">643,413</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Other assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_14" contextRef="AsOf2022-12-31" name="us-gaap:OtherAssetsNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,986</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_15" contextRef="AsOf2021-12-31" name="us-gaap:OtherAssetsNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,986</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Total Assets</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_16" contextRef="AsOf2022-12-31" name="us-gaap:Assets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,274,147</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_17" contextRef="AsOf2021-12-31" name="us-gaap:Assets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,874,644</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">Liabilities and Stockholders&#8217; Equity</span></strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Current Liabilities</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accounts payable and accrued liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_20" contextRef="AsOf2022-12-31" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,523,012</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_21" contextRef="AsOf2021-12-31" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,411,437</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Lease liabilities, current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_22" contextRef="AsOf2022-12-31" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,228</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_23" contextRef="AsOf2021-12-31" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">132,330</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Loans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_24" contextRef="AsOf2022-12-31" name="us-gaap:LoansPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,484</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_25" contextRef="AsOf2021-12-31" name="us-gaap:LoansPayable" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total Current Liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_26" contextRef="AsOf2022-12-31" name="us-gaap:LiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,703,724</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_27" contextRef="AsOf2021-12-31" name="us-gaap:LiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,543,767</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Long Term Debt</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Loans, long term</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_29" contextRef="AsOf2022-12-31" name="us-gaap:LongTermLoansPayable" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_30" contextRef="AsOf2021-12-31" name="us-gaap:LongTermLoansPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,484</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_31" contextRef="AsOf2022-12-31" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">365,919</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_32" contextRef="AsOf2021-12-31" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">518,147</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total Long Term Debt</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_33" contextRef="AsOf2022-12-31" name="us-gaap:LongTermDebt" format="ixt:numdotdecimal" decimals="0" unitRef="USD">365,919</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_34" contextRef="AsOf2021-12-31" name="us-gaap:LongTermDebt" format="ixt:numdotdecimal" decimals="0" unitRef="USD">546,631</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Total Liabilities</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_35" contextRef="AsOf2022-12-31" name="us-gaap:Liabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,069,643</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_36" contextRef="AsOf2021-12-31" name="us-gaap:Liabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,090,398</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Stockholders&#8217; Equity</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Series A Convertible Preferred Stock, $<ix:nonFraction id="fid_66" contextRef="AsOf2022-12-31_us-gaap_PreferredClassAMember" name="us-gaap:PreferredStockParOrStatedValuePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction> par value; <ix:nonFraction id="fid_70" contextRef="AsOf2022-12-31_us-gaap_PreferredClassAMember" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,000</ix:nonFraction> shares authorized; <ix:nonFraction id="fid_74" contextRef="AsOf2022-12-31_us-gaap_PreferredClassAMember" name="us-gaap:PreferredStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">141,397</ix:nonFraction> shares issued and outstanding</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_38" contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember" name="us-gaap:PreferredStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_54" contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" name="us-gaap:PreferredStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Series B Convertible Preferred Stock, $<ix:nonFraction id="fid_67" contextRef="AsOf2022-12-31_us-gaap_PreferredClassBMember" name="us-gaap:PreferredStockParOrStatedValuePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction> par value; <ix:nonFraction id="fid_71" contextRef="AsOf2022-12-31_us-gaap_PreferredClassBMember" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,000</ix:nonFraction> shares authorized;&#160; no shares issued and outstanding</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_40" contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" name="us-gaap:PreferredStockValue" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_41" contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember" name="us-gaap:PreferredStockValue" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Common stock, $<ix:nonFraction id="fid_56" contextRef="AsOf2022-12-31" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction> par value; <ix:nonFraction id="fid_59" contextRef="AsOf2022-12-31" name="us-gaap:CommonStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">80,000,000</ix:nonFraction> shares authorized;&#160; <ix:nonFraction id="fid_60" contextRef="AsOf2022-12-31" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,169,103</ix:nonFraction> and <ix:nonFraction id="fid_61" contextRef="AsOf2021-12-31" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,127,725</ix:nonFraction> shares issued and outstanding, respectively</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_42" contextRef="AsOf2022-12-31" name="us-gaap:CommonStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">317</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_43" contextRef="AsOf2021-12-31" name="us-gaap:CommonStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">212</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Additional paid in capital</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_44" contextRef="AsOf2022-12-31" name="us-gaap:AdditionalPaidInCapital" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,068,015</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_45" contextRef="AsOf2021-12-31" name="us-gaap:AdditionalPaidInCapital" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,460,980</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Stock payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_46" contextRef="AsOf2022-12-31" name="ndra:StockPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,073</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_47" contextRef="AsOf2021-12-31" name="ndra:StockPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,863</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Accumulated deficit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_48" contextRef="AsOf2022-12-31" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">81,869,902</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_49" contextRef="AsOf2021-12-31" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">68,690,810</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Total Stockholders&#8217; Equity</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_50" contextRef="AsOf2022-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,204,504</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_51" contextRef="AsOf2021-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,784,246</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Total Liabilities and Stockholders&#8217; Equity</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_52" contextRef="AsOf2022-12-31" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,274,147</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_53" contextRef="AsOf2021-12-31" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,874,644</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">The accompanying notes are an integral part of these consolidated financial statements. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-2</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFS">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="f3">ENDRA Life Sciences Inc.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Consolidated Statements of Operations</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Year Ended </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Year Ended </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Operating Expenses</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_81" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,554,194</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_82" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,482,531</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Sales and marketing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_83" contextRef="From2022-01-01to2022-12-31" name="us-gaap:SellingAndMarketingExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,429,150</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_84" contextRef="From2021-01-01to2021-12-31" name="us-gaap:SellingAndMarketingExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,075,376</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_85" contextRef="From2022-01-01to2022-12-31" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,174,215</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_86" contextRef="From2021-01-01to2021-12-31" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,940,398</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total operating expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_87" contextRef="From2022-01-01to2022-12-31" name="us-gaap:OperatingExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,157,559</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_88" contextRef="From2021-01-01to2021-12-31" name="us-gaap:OperatingExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,498,305</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_89" contextRef="From2022-01-01to2022-12-31" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">13,157,559</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_90" contextRef="From2021-01-01to2021-12-31" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">11,498,305</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Other Expenses</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Gain on extinguishment of debt</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_92" contextRef="From2022-01-01to2022-12-31" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_93" contextRef="From2021-01-01to2021-12-31" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">308,600</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Other income (expense)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_94" contextRef="From2022-01-01to2022-12-31" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">21,533</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_95" contextRef="From2021-01-01to2021-12-31" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">41,545</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total other expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_96" contextRef="From2022-01-01to2022-12-31" name="us-gaap:NonoperatingIncomeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">21,533</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_97" contextRef="From2021-01-01to2021-12-31" name="us-gaap:NonoperatingIncomeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">267,055</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Loss from operations before income taxes</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_98" contextRef="From2022-01-01to2022-12-31" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">13,179,092</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_99" contextRef="From2021-01-01to2021-12-31" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">11,231,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Provision for income taxes</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_100" contextRef="From2022-01-01to2022-12-31" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_101" contextRef="From2021-01-01to2021-12-31" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="MARGIN: 0px 0px 0px 30px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"><strong>Net Loss</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_102" contextRef="From2022-01-01to2022-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">13,179,092</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_103" contextRef="From2021-01-01to2021-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">11,231,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Deemed dividend</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_104" contextRef="From2022-01-01to2022-12-31" name="us-gaap:Dividends" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_105" contextRef="From2021-01-01to2021-12-31" name="us-gaap:Dividends" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,071</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net Loss attributable to common stockholders</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_106" contextRef="From2022-01-01to2022-12-31" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">13,179,092</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_107" contextRef="From2021-01-01to2021-12-31" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">11,352,321</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"><strong>Net loss per share &#8211; basic and diluted</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_108" contextRef="From2022-01-01to2022-12-31" name="us-gaap:EarningsPerShareBasic" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">4.56</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_109" contextRef="From2021-01-01to2021-12-31" name="us-gaap:EarningsPerShareBasic" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">5.55</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"><strong>Weighted average common shares &#8211; basic and diluted</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_110" contextRef="From2022-01-01to2022-12-31" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,891,292</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_111" contextRef="From2021-01-01to2021-12-31" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,046,135</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-3</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFS">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="f4">ENDRA Life Sciences Inc.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Consolidated Statements of Stockholders&#8217; Equity</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Year Ended December 31, 2021 </em></strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Series A Convertible</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Series B Convertible </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Additional</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Preferred Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Preferred Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Common stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Paid in</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Accumulated</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Stockholders'</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Shares </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Shares </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Shares </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Capital</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Payable</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Deficit</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Equity</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:20%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Balance as of December 31, 2020 </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_171" contextRef="AsOf2020-12-31_ndra_PreferredsStockSeriesAMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">196</ix:nonFraction>.794</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_174" contextRef="AsOf2020-12-31_ndra_PreferredsStockSeriesAMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_175" contextRef="AsOf2020-12-31_ndra_SeriesBPreferredStocksMember" name="us-gaap:StockholdersEquity" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_173" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,702,485</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_176" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">170</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_177" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,496,845</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_178" contextRef="AsOf2020-12-31_ndra_StockPayableMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,795</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_179" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">57,338,489</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_180" contextRef="AsOf2020-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,169,322</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series A Convertible Preferred Stock converted to common stock </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_181" contextRef="From2021-01-01to2021-12-31_ndra_PreferredsStockSeriesAMember" name="ndra:SeriesAConvertiblePreferredStockConvertedToCommonStockShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares" sign="-">55</ix:nonFraction>.397</td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_184" contextRef="From2021-01-01to2021-12-31_ndra_PreferredsStockSeriesAMember" name="ndra:SeriesAConvertiblePreferredStockConvertedToCommonStockAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_185" contextRef="From2021-01-01to2021-12-31_ndra_SeriesBPreferredStocksMember" name="ndra:SeriesAConvertiblePreferredStockConvertedToCommonStockAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_183" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="ndra:SeriesAConvertiblePreferredStockConvertedToCommonStockShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,394</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_186" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="ndra:SeriesAConvertiblePreferredStockConvertedToCommonStockAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_187" contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="ndra:SeriesAConvertiblePreferredStockConvertedToCommonStockAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_188" contextRef="From2021-01-01to2021-12-31_ndra_StockPayableMember" name="ndra:SeriesAConvertiblePreferredStockConvertedToCommonStockAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_189" contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember" name="ndra:SeriesAConvertiblePreferredStockConvertedToCommonStockAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_190" contextRef="From2021-01-01to2021-12-31" name="ndra:SeriesAConvertiblePreferredStockConvertedToCommonStockAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Common stock issued for cash, net of funding costs </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_194" contextRef="From2021-01-01to2021-12-31_ndra_PreferredsStockSeriesAMember" name="ndra:CommonStockIssuedForCashNetOfFundingCostsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_195" contextRef="From2021-01-01to2021-12-31_ndra_SeriesBPreferredStocksMember" name="ndra:CommonStockIssuedForCashNetOfFundingCostsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_193" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="ndra:CommonStockIssuedForCashNetOfFundingCostsShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">229,348</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_196" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="ndra:CommonStockIssuedForCashNetOfFundingCostsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_197" contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="ndra:CommonStockIssuedForCashNetOfFundingCostsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,615,952</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_198" contextRef="From2021-01-01to2021-12-31_ndra_StockPayableMember" name="ndra:CommonStockIssuedForCashNetOfFundingCostsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_199" contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember" name="ndra:CommonStockIssuedForCashNetOfFundingCostsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_200" contextRef="From2021-01-01to2021-12-31" name="ndra:CommonStockIssuedForCashNetOfFundingCostsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,615,975</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Common stock issued for warrant exercise </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_204" contextRef="From2021-01-01to2021-12-31_ndra_PreferredsStockSeriesAMember" name="ndra:CommonStockIssuedForWarrantExerciseAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_205" contextRef="From2021-01-01to2021-12-31_ndra_SeriesBPreferredStocksMember" name="ndra:CommonStockIssuedForWarrantExerciseAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_203" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="ndra:CommonStockIssuedForWarrantExerciseShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">188,540</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_206" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="ndra:CommonStockIssuedForWarrantExerciseAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_207" contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="ndra:CommonStockIssuedForWarrantExerciseAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,785,608</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_208" contextRef="From2021-01-01to2021-12-31_ndra_StockPayableMember" name="ndra:CommonStockIssuedForWarrantExerciseAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_209" contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember" name="ndra:CommonStockIssuedForWarrantExerciseAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_210" contextRef="From2021-01-01to2021-12-31" name="ndra:CommonStockIssuedForWarrantExerciseAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,785,627</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Common stock issued for option exercise </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_214" contextRef="From2021-01-01to2021-12-31_ndra_PreferredsStockSeriesAMember" name="ndra:CommonStockIssuedForOptionExerciseAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_215" contextRef="From2021-01-01to2021-12-31_ndra_SeriesBPreferredStocksMember" name="ndra:CommonStockIssuedForOptionExerciseAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_213" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="ndra:CommonStockIssuedForOptionExerciseShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,192</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_216" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="ndra:CommonStockIssuedForOptionExerciseAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_217" contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="ndra:CommonStockIssuedForOptionExerciseAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_218" contextRef="From2021-01-01to2021-12-31_ndra_StockPayableMember" name="ndra:CommonStockIssuedForOptionExerciseAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_219" contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember" name="ndra:CommonStockIssuedForOptionExerciseAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_220" contextRef="From2021-01-01to2021-12-31" name="ndra:CommonStockIssuedForOptionExerciseAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fair value of vested stock options </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_221" contextRef="From2021-01-01to2021-12-31_ndra_PreferredsStockSeriesAMember" name="ndra:FairValueOfVestedStockOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_222" contextRef="From2021-01-01to2021-12-31_ndra_SeriesBPreferredStocksMember" name="ndra:FairValueOfVestedStockOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_223" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="ndra:FairValueOfVestedStockOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_224" contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="ndra:FairValueOfVestedStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,334,112</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_225" contextRef="From2021-01-01to2021-12-31_ndra_StockPayableMember" name="ndra:FairValueOfVestedStockOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_226" contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember" name="ndra:FairValueOfVestedStockOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_227" contextRef="From2021-01-01to2021-12-31" name="ndra:FairValueOfVestedStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,334,112</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock payable towards preference dividend </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_228" contextRef="From2021-01-01to2021-12-31_ndra_PreferredsStockSeriesAMember" name="us-gaap:DividendsPreferredStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_229" contextRef="From2021-01-01to2021-12-31_ndra_SeriesBPreferredStocksMember" name="us-gaap:DividendsPreferredStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_230" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="us-gaap:DividendsPreferredStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_231" contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:DividendsPreferredStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,068</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_232" contextRef="From2021-01-01to2021-12-31_ndra_StockPayableMember" name="us-gaap:DividendsPreferredStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,068</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_233" contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:DividendsPreferredStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_234" contextRef="From2021-01-01to2021-12-31" name="us-gaap:DividendsPreferredStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Common stock issued for services </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_238" contextRef="From2021-01-01to2021-12-31_ndra_PreferredsStockSeriesAMember" name="ndra:CommonStockIssuedForServicesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_239" contextRef="From2021-01-01to2021-12-31_ndra_SeriesBPreferredStocksMember" name="ndra:CommonStockIssuedForServicesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_237" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="ndra:CommonStockIssuedForServicesShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,626</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_240" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="ndra:CommonStockIssuedForServicesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_241" contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="ndra:CommonStockIssuedForServicesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_242" contextRef="From2021-01-01to2021-12-31_ndra_StockPayableMember" name="ndra:CommonStockIssuedForServicesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_243" contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember" name="ndra:CommonStockIssuedForServicesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_244" contextRef="From2021-01-01to2021-12-31" name="ndra:CommonStockIssuedForServicesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock issued for RSU </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_248" contextRef="From2021-01-01to2021-12-31_ndra_PreferredsStockSeriesAMember" name="ndra:StockIssuedForRsuAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_249" contextRef="From2021-01-01to2021-12-31_ndra_SeriesBPreferredStocksMember" name="ndra:StockIssuedForRsuAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_247" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="ndra:StockIssuedForRsuShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,141</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_250" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="ndra:StockIssuedForRsuAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_251" contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="ndra:StockIssuedForRsuAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,460</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_252" contextRef="From2021-01-01to2021-12-31_ndra_StockPayableMember" name="ndra:StockIssuedForRsuAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_253" contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember" name="ndra:StockIssuedForRsuAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_254" contextRef="From2021-01-01to2021-12-31" name="ndra:StockIssuedForRsuAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,460</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Deemed dividend </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_255" contextRef="From2021-01-01to2021-12-31_ndra_PreferredsStockSeriesAMember" name="ndra:DeemedDividend" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_256" contextRef="From2021-01-01to2021-12-31_ndra_SeriesBPreferredStocksMember" name="ndra:DeemedDividend" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_257" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="ndra:DeemedDividend" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_258" contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="ndra:DeemedDividend" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,071</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_259" contextRef="From2021-01-01to2021-12-31_ndra_StockPayableMember" name="ndra:DeemedDividend" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_260" contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember" name="ndra:DeemedDividend" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">121,071</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_261" contextRef="From2021-01-01to2021-12-31" name="ndra:DeemedDividend" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_262" contextRef="From2021-01-01to2021-12-31_ndra_PreferredsStockSeriesAMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_263" contextRef="From2021-01-01to2021-12-31_ndra_SeriesBPreferredStocksMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_264" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_265" contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_266" contextRef="From2021-01-01to2021-12-31_ndra_StockPayableMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_267" contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">11,231,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_268" contextRef="From2021-01-01to2021-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">11,231,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Balance as of December 31, 2021 </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_269" contextRef="AsOf2021-12-31_ndra_PreferredsStockSeriesAMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">141</ix:nonFraction>.397</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_272" contextRef="AsOf2021-12-31_ndra_PreferredsStockSeriesAMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_273" contextRef="AsOf2021-12-31_ndra_SeriesBPreferredStocksMember" name="us-gaap:StockholdersEquity" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_271" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,127,726</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_274" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">212</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_275" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,460,980</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_276" contextRef="AsOf2021-12-31_ndra_StockPayableMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,863</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_277" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">68,690,810</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_278" contextRef="AsOf2021-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,784,246</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Year Ended December 31, 2022 </em></strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Series A Convertible</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Series B Convertible </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Additional</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Preferred Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Preferred Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Common stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Paid in</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Accumulated</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Stockholders'</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Shares </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Shares </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Capital</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Payable</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Capital</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Payable</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Deficit</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Equity</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:20%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Balance as of December 31, 2021 </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_279" contextRef="AsOf2021-12-31_ndra_PreferredsStockSeriesAMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">141</ix:nonFraction>.397</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_282" contextRef="AsOf2021-12-31_ndra_PreferredsStockSeriesAMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_283" contextRef="AsOf2021-12-31_ndra_SeriesBPreferredStocksMember" name="us-gaap:StockholdersEquity" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_281" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,127,726</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_284" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">212</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_285" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,460,980</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_286" contextRef="AsOf2021-12-31_ndra_StockPayableMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,863</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_287" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">68,690,810</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_288" contextRef="AsOf2021-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,784,246</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Common stock issued for cash, net of funding costs </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_292" contextRef="From2022-01-01to2022-12-31_ndra_PreferredsStockSeriesAMember" name="ndra:CommonStockIssuedForCashNetOfFundingCostsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_293" contextRef="From2022-01-01to2022-12-31_ndra_SeriesBPreferredStocksMember" name="ndra:CommonStockIssuedForCashNetOfFundingCostsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_291" contextRef="From2022-01-01to2022-12-31_us-gaap_CommonStockMember" name="ndra:CommonStockIssuedForCashNetOfFundingCostsShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,041,377</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_294" contextRef="From2022-01-01to2022-12-31_us-gaap_CommonStockMember" name="ndra:CommonStockIssuedForCashNetOfFundingCostsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_295" contextRef="From2022-01-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember" name="ndra:CommonStockIssuedForCashNetOfFundingCostsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,399,407</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_296" contextRef="From2022-01-01to2022-12-31_ndra_StockPayableMember" name="ndra:CommonStockIssuedForCashNetOfFundingCostsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_297" contextRef="From2022-01-01to2022-12-31_us-gaap_RetainedEarningsMember" name="ndra:CommonStockIssuedForCashNetOfFundingCostsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_298" contextRef="From2022-01-01to2022-12-31" name="ndra:CommonStockIssuedForCashNetOfFundingCostsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,399,512</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fair value of vested stock options </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_299" contextRef="From2022-01-01to2022-12-31_ndra_PreferredsStockSeriesAMember" name="ndra:FairValueOfVestedStockOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_300" contextRef="From2022-01-01to2022-12-31_ndra_SeriesBPreferredStocksMember" name="ndra:FairValueOfVestedStockOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_301" contextRef="From2022-01-01to2022-12-31_us-gaap_CommonStockMember" name="ndra:FairValueOfVestedStockOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_302" contextRef="From2022-01-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember" name="ndra:FairValueOfVestedStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,199,838</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_303" contextRef="From2022-01-01to2022-12-31_ndra_StockPayableMember" name="ndra:FairValueOfVestedStockOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_304" contextRef="From2022-01-01to2022-12-31_us-gaap_RetainedEarningsMember" name="ndra:FairValueOfVestedStockOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_305" contextRef="From2022-01-01to2022-12-31" name="ndra:FairValueOfVestedStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,199,838</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock paid towards preference dividend </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_306" contextRef="From2022-01-01to2022-12-31_ndra_PreferredsStockSeriesAMember" name="us-gaap:DividendsPreferredStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_307" contextRef="From2022-01-01to2022-12-31_ndra_SeriesBPreferredStocksMember" name="us-gaap:DividendsPreferredStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_308" contextRef="From2022-01-01to2022-12-31_us-gaap_CommonStockMember" name="us-gaap:DividendsPreferredStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_309" contextRef="From2022-01-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:DividendsPreferredStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,790</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_310" contextRef="From2022-01-01to2022-12-31_ndra_StockPayableMember" name="us-gaap:DividendsPreferredStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,790</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_311" contextRef="From2022-01-01to2022-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:DividendsPreferredStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_312" contextRef="From2022-01-01to2022-12-31" name="us-gaap:DividendsPreferredStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_313" contextRef="From2022-01-01to2022-12-31_ndra_PreferredsStockSeriesAMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_314" contextRef="From2022-01-01to2022-12-31_ndra_SeriesBPreferredStocksMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_315" contextRef="From2022-01-01to2022-12-31_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_316" contextRef="From2022-01-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_317" contextRef="From2022-01-01to2022-12-31_ndra_StockPayableMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_318" contextRef="From2022-01-01to2022-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">13,179,092</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_319" contextRef="From2022-01-01to2022-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">13,179,092</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Balance as of December 31, 2022 </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_320" contextRef="AsOf2022-12-31_ndra_PreferredsStockSeriesAMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">141</ix:nonFraction>.397</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_323" contextRef="AsOf2022-12-31_ndra_PreferredsStockSeriesAMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_324" contextRef="AsOf2022-12-31_ndra_SeriesBPreferredStocksMember" name="us-gaap:StockholdersEquity" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_322" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,169,103</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_325" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">317</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_326" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,068,015</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_327" contextRef="AsOf2022-12-31_ndra_StockPayableMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,073</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_328" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">81,869,902</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_329" contextRef="AsOf2022-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,204,504</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-4</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFS">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="f5">ENDRA Life Sciences Inc.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Consolidated Statements of Cash Flows</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Year Ended </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Year Ended </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Cash Flows from Operating Activities</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_113" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ProfitLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,179,092</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_114" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ProfitLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,231,250</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_116" contextRef="From2022-01-01to2022-12-31" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,661</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_117" contextRef="From2021-01-01to2021-12-31" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">116,238</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fixed assets write off</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_118" contextRef="From2022-01-01to2022-12-31" name="ndra:FixedAssetsWriteOff" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,391</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_119" contextRef="From2021-01-01to2021-12-31" name="ndra:FixedAssetsWriteOff" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,874</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock compensation expense including common stock issued for RSUs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_120" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,199,838</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_121" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,444,572</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Amortization of right of use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_122" contextRef="From2022-01-01to2022-12-31" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">137,597</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_123" contextRef="From2021-01-01to2021-12-31" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">108,177</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Gain on extinguishment of debt</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_124" contextRef="From2022-01-01to2022-12-31" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_125" contextRef="From2021-01-01to2021-12-31" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">308,600</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Changes in operating assets and liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Decrease in prepaid expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_127" contextRef="From2022-01-01to2022-12-31" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">355,128</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_128" contextRef="From2021-01-01to2021-12-31" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">957,203</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Increase in inventory</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_129" contextRef="From2022-01-01to2022-12-31" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,360,139</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_130" contextRef="From2021-01-01to2021-12-31" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:numdotdecimal" decimals="0" unitRef="USD">694,958</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Increase in accounts payable and accrued liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_131" contextRef="From2022-01-01to2022-12-31" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">111,575</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_132" contextRef="From2021-01-01to2021-12-31" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">491,104</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Decrease in lease liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_133" contextRef="From2022-01-01to2022-12-31" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">132,330</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_134" contextRef="From2021-01-01to2021-12-31" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">100,338</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Net cash used in operating activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_135" contextRef="From2022-01-01to2022-12-31" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">12,769,371</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_136" contextRef="From2021-01-01to2021-12-31" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">11,122,384</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Cash Flows from Investing Activities</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Purchases of fixed assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_138" contextRef="From2022-01-01to2022-12-31" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,577</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_139" contextRef="From2021-01-01to2021-12-31" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Net cash used in investing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_140" contextRef="From2022-01-01to2022-12-31" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">202,577</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_141" contextRef="From2021-01-01to2021-12-31" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">45,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Cash Flows from Financing Activities</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Proceeds from warrant exercise</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_143" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_144" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,785,627</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Proceeds from issuance of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_145" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,399,512</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_146" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,615,975</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Net cash provided by financing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_147" contextRef="From2022-01-01to2022-12-31" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,399,512</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_148" contextRef="From2021-01-01to2021-12-31" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,401,602</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net increase (decrease) in cash</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_149" contextRef="From2022-01-01to2022-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">4,572,436</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_150" contextRef="From2021-01-01to2021-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,234,218</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash, beginning of year</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_151" contextRef="AsOf2021-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,461,534</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_152" contextRef="AsOf2020-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,227,316</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Cash, end of </strong><strong>year</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_153" contextRef="AsOf2022-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,889,098</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_154" contextRef="AsOf2021-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,461,534</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Supplemental disclosures of cash items</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Interest paid</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_156" contextRef="From2022-01-01to2022-12-31" name="us-gaap:InterestPaidNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,113</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_157" contextRef="From2021-01-01to2021-12-31" name="us-gaap:InterestPaidNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,655</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Income tax paid</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_158" contextRef="From2022-01-01to2022-12-31" name="us-gaap:IncomeTaxesPaid" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_159" contextRef="From2021-01-01to2021-12-31" name="us-gaap:IncomeTaxesPaid" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Supplemental disclosures of non-cash items</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Deemed dividend</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_161" contextRef="From2022-01-01to2022-12-31" name="us-gaap:Dividends" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_162" contextRef="From2021-01-01to2021-12-31" name="us-gaap:Dividends" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,071</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Conversion of Series A Convertible Preferred Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_163" contextRef="From2022-01-01to2022-12-31" name="ndra:ConversionOfSeriesAConvertiblePreferredStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_164" contextRef="From2021-01-01to2021-12-31" name="ndra:ConversionOfSeriesAConvertiblePreferredStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Stock dividend payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_165" contextRef="From2022-01-01to2022-12-31" name="ndra:StockDividendPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,790</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_166" contextRef="From2021-01-01to2021-12-31" name="ndra:StockDividendPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">3,068</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Right of use asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_167" contextRef="From2022-01-01to2022-12-31" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">505,816</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_168" contextRef="From2021-01-01to2021-12-31" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">643,413</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Lease liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_169" contextRef="From2022-01-01to2022-12-31" name="ndra:LeaseLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">518,147</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_170" contextRef="From2021-01-01to2021-12-31" name="ndra:LeaseLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">650,477</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-5</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFS">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="f6">ENDRA Life Sciences Inc.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>For the years ended December 31, 2022 and 2021</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_340" contextRef="From2022-01-01to2022-12-31" name="us-gaap:BusinessCombinationDisclosureTextBlock" escape="true"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Note 1 - Nature of the Business</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ENDRA Life Sciences Inc. (&#8220;ENDRA&#8221; or the &#8220;Company&#8221;) has developed and is continuing to develop technology for increasing the capabilities of clinical diagnostic ultrasound to broaden patient access to the safe diagnosis and treatment of a number of significant medical conditions in circumstances where expensive X-ray computed tomography (&#8220;CT&#8221;) and magnetic resonance imaging (&#8220;MRI&#8221;) technology is unavailable or impractical.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ENDRA was incorporated on July 18, 2007 as a Delaware corporation.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_330" contextRef="From2022-01-01to2022-12-31" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="cont_3861ec"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Note 2 - Summary of Significant Accounting Policies</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_343" contextRef="From2022-01-01to2022-12-31" name="us-gaap:UseOfEstimates" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Management makes estimates that affect certain accounts including deferred income tax assets, accrued expenses, fair value of equity instruments and reserves for any other commitments or contingencies. Any adjustments applied to estimates are recognized in the period in which such adjustments are determined.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The COVID-19 pandemic has prompted governments and regulatory bodies throughout the world to issue &#8220;stay-at-home&#8221; or similar orders, and enact restrictions on the performance of &#8220;non-essential&#8221; services, public gatherings and travel.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it continues impact worldwide macroeconomic conditions, the emergence of variants of the virus and effectiveness of vaccines, access to capital markets, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of December 31, 2022 and through the date of the filing of this Annual Report on Form 10-K. The accounting matters assessed included, but were not limited to, estimates related to the accounting for potential liabilities and accrued expenses, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and assessments of impairment related to long-lived assets. The Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in additional material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Despite the Company&#8217;s efforts, the ultimate impact of COVID-19 on the Company&#8217;s business depends on factors beyond the Company&#8217;s knowledge or control, including the duration and severity of the outbreak, as well as third-party actions taken to contain its spread and mitigate its public health effects. As a result, the Company is unable to estimate the extent to which COVID-19 will negatively impact its financial results or liquidity.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline">Principles of Consolidation</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_344" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s consolidated financial statements include all accounts of the Company and its consolidated subsidiaries and/or entities as of reporting period ending date(s) and for the reporting period(s) then ended. All inter-company balances and transactions have been eliminated.</p></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline">Basis of Presentation</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_345" contextRef="From2022-01-01to2022-12-31" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). These financial statements have been prepared using the accrual basis of accounting in accordance with Generally Accepted Accounting Principles (&#8220;GAAP&#8221;) of the United States.</p></ix:nonNumeric></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-6</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFS">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_3861ec" continuedAt="cont_80c0b8"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Cash and Cash Equivalents</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_346" contextRef="From2022-01-01to2022-12-31" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company considers all cash on hand and in banks, including accounts in book overdraft positions, certificates of deposit and other highly-liquid investments with maturities of one year or less, when purchased, to be cash. As of December 31, 2022 and 2021, the Company had no cash equivalents. The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and periodically evaluates the credit worthiness of the financial institutions and has determined the credit exposure to be negligible.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Inventory</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_347" contextRef="From2022-01-01to2022-12-31" name="us-gaap:InventoryPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s inventory is stated at the lower of cost or estimated net realizable value, with cost primarily determined on a weighted-average cost basis on the first-in, first-out method. The Company periodically determines whether a reserve should be taken for devaluation or obsolescence of inventory.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Capitalization of Fixed Assets</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_348" contextRef="From2022-01-01to2022-12-31" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than one year for: (1) assets purchased; (2) existing assets that are replaced, improved or the useful lives have been extended; or (3) all land, regardless of cost. Acquisitions of new assets, additions, replacements and improvements (other than land) costing less than the minimum rule in addition to maintenance and repair costs, including any planned major maintenance activities, are expensed as incurred.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Leases</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_349" contextRef="From2022-01-01to2022-12-31" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest period presented in the financial statements. At December 31, 2022 and 2021 the Company recorded a right of use asset of $<ix:nonFraction id="fid_371" contextRef="AsOf2022-12-31" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">505,816</ix:nonFraction> and $<ix:nonFraction id="fid_372" contextRef="AsOf2021-12-31" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">643,413</ix:nonFraction>, respectively. At December 31, 2022 and 2021 the Company recorded a lease liability of $<ix:nonFraction id="fid_365" contextRef="AsOf2022-12-31" name="us-gaap:OperatingLeaseLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">518,147</ix:nonFraction> and $<ix:nonFraction id="fid_366" contextRef="AsOf2021-12-31" name="us-gaap:OperatingLeaseLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">650,477</ix:nonFraction>, respectively. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Revenue Recognition</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_350" contextRef="From2022-01-01to2022-12-31" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ASU No. 2014-09, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;ASC Topic 606&#8221;) provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Under ASC Topic 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to perform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC Topic 606 did not have an impact on the Company&#8217;s operations or cash flows.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Research and Development Costs</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_351" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company follows FASB Accounting Standards Codification (&#8220;ASC&#8221;) Subtopic 730-10, &#8220;Research and Development&#8221;. Research and development costs are charged to the statement of operations as incurred. During the years ended December 31, 2022 and 2021, the Company incurred $<ix:nonFraction id="fid_369" contextRef="From2022-01-01to2022-12-31" name="ndra:ResearchAndDevelopmentExpense1" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,554,194</ix:nonFraction> and $<ix:nonFraction id="fid_370" contextRef="From2021-01-01to2021-12-31" name="ndra:ResearchAndDevelopmentExpense1" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,482,531</ix:nonFraction> of expenses related to research and development costs, respectively.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Net Earnings (Loss) Per Common Share</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_352" contextRef="From2022-01-01to2022-12-31" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true" continuedAt="cont_910a77"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company computes earnings per share under ASC Subtopic 260-10, &#8220;Earnings Per Share&#8221;. Basic earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders (the numerator) by the weighted average number of shares of common stock outstanding (the denominator) during the reporting periods. Diluted loss per share is computed by increasing the denominator by the weighted average number of additional shares that could have been outstanding from securities convertible into common stock (using the &#8220;treasury stock&#8221; method), unless their effect on net loss per share is anti-dilutive. There were <ix:nonFraction id="fid_375" contextRef="From2022-01-01to2022-12-31" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">410,358</ix:nonFraction> and <ix:nonFraction id="fid_374" contextRef="From2021-01-01to2021-12-31" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">392,425</ix:nonFraction> potentially dilutive shares, which include outstanding common stock options, and warrants, as of December 31, 2022 and 2021, respectively.</p></ix:nonNumeric></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-7</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFS">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_80c0b8" continuedAt="cont_39a310"><ix:continuation id="cont_910a77"><ix:nonNumeric id="fid_357" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Options to purchase common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_384" contextRef="From2022-01-01to2022-12-31_ndra_OptionsToPurchaseCommonStockMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">391,902</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_385" contextRef="From2021-01-01to2021-12-31_ndra_OptionsToPurchaseCommonStockMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">262,481</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Warrants to purchase common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_386" contextRef="From2022-01-01to2022-12-31_ndra_WarrantsToPurchaseCommonStockMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,330</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_387" contextRef="From2021-01-01to2021-12-31_ndra_WarrantsToPurchaseCommonStockMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">121,818</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Shares issuable upon conversion of Series A Convertible Preferred Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_388" contextRef="From2022-01-01to2022-12-31_ndra_SharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">8,126</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_389" contextRef="From2021-01-01to2021-12-31_ndra_SharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">8,126</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Potential equivalent shares excluded</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_390" contextRef="From2022-01-01to2022-12-31" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">410,358</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_383" contextRef="From2021-01-01to2021-12-31" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">392,425</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation></ix:continuation><ix:continuation id="cont_39a310" continuedAt="cont_a386ba"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline">Fair Value Measurements</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_353" contextRef="From2022-01-01to2022-12-31" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Disclosures about fair value of financial instruments require disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with ASC Topic 820, &#8220;Fair Value Measurements and Disclosures,&#8221; the Company measures certain financial instruments at fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance with accounting principles generally accepted in the United States, and expands disclosures about fair value measurements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The carrying amounts of the Company&#8217;s financial assets and liabilities, including cash, accounts receivable, prepaid expenses, accounts payable, accrued expenses, and other current liabilities, approximate their fair values because of the short maturity of these instruments. The fair value of notes payable and convertible notes approximates their fair values since the current interest rates and terms on these obligations are the same as prevailing market rates.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Share-based Compensation</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_354" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s 2016 Omnibus Incentive Plan (the &#8220;Omnibus Plan&#8221;) permits the grant of stock options and other share-based awards to its employees, consultants and non-employee members of the board of directors. Each January 1 the pool of shares available for issuance under the Omnibus Plan automatically increases by an amount equal to the lesser of (i) the number of shares necessary such that the aggregate number of shares available under the Omnibus Plan equals 25% of the number of fully-diluted outstanding shares on the increase date (assuming the conversion of all outstanding shares of preferred stock and other outstanding convertible securities and exercise of all outstanding options and warrants to purchase shares) and (ii) if the board of directors takes action to set a lower amount, the amount determined by the board. <ix:nonNumeric id="fid_381" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">On January 1, 2023, the pool of shares issuable under the Omnibus Plan automatically increased by 867,966 shares from 454,204 shares to 1,322,169 shares</ix:nonNumeric>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company records share-based compensation in accordance with the provisions of the Share-based Compensation Topic of the FASB Codification. The guidance requires the use of option-pricing models that require the input of highly subjective assumptions, including the option&#8217;s expected life and the price volatility of the underlying stock. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option valuation model, and the resulting charge is expensed using the straight-line attribution method over the vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Stock compensation expense recognized during the period is based on the value of share-based awards that were expected to vest during the period adjusted for estimated forfeitures. The estimated fair value of grants of stock options and warrants to non-employees of the Company is charged to expense, if applicable, in the financial statements. These options vest in the same manner as the employee options granted under the stock incentive plan as described above.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-8</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFS">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_a386ba"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Going Concern</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_355" contextRef="From2022-01-01to2022-12-31" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s financial statements are prepared using accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has limited commercial experience and had a cumulative net loss from inception to December 31, 2022 of $<ix:nonFraction id="fid_379" contextRef="AsOf2022-12-31" name="us-gaap:CumulativeDividends" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,869,902</ix:nonFraction>. The Company had working capital of $<ix:nonFraction id="fid_380" contextRef="AsOf2022-12-31" name="ndra:WorkingCapital" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,822,966</ix:nonFraction> as of December 31, 2022. The Company has not established an ongoing source of revenue sufficient to cover its operating costs and to allow it to continue as a going concern and will require additional financing to fund its future planned operations, including research and development and commercialization of its products. The accompanying financial statements for the year ended December 31, 2022 have been prepared assuming the Company will continue as a going concern, but the ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it establishes a revenue stream and becomes profitable. Management&#8217;s plans to continue as a going concern include raising additional capital through sales of equity securities and borrowing. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. If the Company is not able to obtain the necessary additional financing on a timely basis, the Company will be required to delay, reduce the scope of, or eliminate one or more of the Company&#8217;s research and development activities or commercialization efforts or perhaps even cease the operation of its business. The ability of the Company to continue as a going concern is dependent upon its ability to successfully secure other sources of financing and attain profitable operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Recent Accounting Pronouncements</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_356" contextRef="From2022-01-01to2022-12-31" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company considered recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC, did not or in management&#8217;s opinion will not have a material impact on the Company&#8217;s present or future consolidated financial statements.</p></ix:nonNumeric></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_331" contextRef="From2022-01-01to2022-12-31" name="us-gaap:InventoryDisclosureTextBlock" escape="true"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Note 3 - Inventory</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2022 and 2021, inventory consisted of raw materials, subassemblies to be used in the assembly of TAEUS systems, and finished goods. As of December 31, 2022, the Company had no orders pending for the sale of a TAEUS system. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2022 and 2021, the Company had inventory valued at $<ix:nonFraction id="fid_391" contextRef="AsOf2022-12-31" name="us-gaap:InventoryNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,644,717</ix:nonFraction> and $<ix:nonFraction id="fid_392" contextRef="AsOf2021-12-31" name="us-gaap:InventoryNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,284,578</ix:nonFraction>, respectively.</p></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_332" contextRef="From2022-01-01to2022-12-31" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Note 4 - Fixed Assets</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2022 and 2021, fixed assets consisted of the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_358" contextRef="From2022-01-01to2022-12-31" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Property, leasehold and capitalized software</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_393" contextRef="AsOf2022-12-31" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">738,720</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_394" contextRef="AsOf2021-12-31" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">605,248</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">TAEUS development and testing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_395" contextRef="AsOf2022-12-31" name="us-gaap:DevelopmentInProcess" format="ixt:numdotdecimal" decimals="0" unitRef="USD">140,617</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_396" contextRef="AsOf2021-12-31" name="us-gaap:DevelopmentInProcess" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,682</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accumulated depreciation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_397" contextRef="AsOf2022-12-31" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">643,682</ix:nonFraction> </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_398" contextRef="AsOf2021-12-31" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">581,800</ix:nonFraction> </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Fixed assets, net</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_399" contextRef="AsOf2022-12-31" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">235,655</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_400" contextRef="AsOf2021-12-31" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,130</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Depreciation expense for the year ended December 31, 2022 and 2021 was $<ix:nonFraction id="fid_403" contextRef="From2022-01-01to2022-12-31" name="us-gaap:Depreciation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,661</ix:nonFraction> and $<ix:nonFraction id="fid_404" contextRef="From2021-01-01to2021-12-31" name="us-gaap:Depreciation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">116,238</ix:nonFraction>, respectively.</p></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_333" contextRef="From2022-01-01to2022-12-31" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Note 5 - Accounts Payable and Accrued Liabilities</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2022 and 2021, current liabilities consisted of the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_359" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_405" contextRef="AsOf2022-12-31" name="us-gaap:AccountsPayableCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">613,961</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_406" contextRef="AsOf2021-12-31" name="us-gaap:AccountsPayableCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">791,052</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued payroll</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_407" contextRef="AsOf2022-12-31" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,638</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_408" contextRef="AsOf2021-12-31" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,459</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued bonuses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_409" contextRef="AsOf2022-12-31" name="us-gaap:AccruedBonusesCurrentAndNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">683,738</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_410" contextRef="AsOf2021-12-31" name="us-gaap:AccruedBonusesCurrentAndNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">396,043</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued employee benefits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_411" contextRef="AsOf2022-12-31" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,750</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_412" contextRef="AsOf2021-12-31" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,750</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Insurance premium financing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_413" contextRef="AsOf2022-12-31" name="us-gaap:AccruedInsuranceCurrentAndNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,925</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_414" contextRef="AsOf2021-12-31" name="us-gaap:AccruedInsuranceCurrentAndNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,133</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Total</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_415" contextRef="AsOf2022-12-31" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,523,012</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_416" contextRef="AsOf2021-12-31" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,411,437</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-9</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFS">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_334" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ShortTermDebtTextBlock" escape="true"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Note 6 - Bank Loans</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>U.S. SBA Paycheck Protection Program</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In April 2020, the Company issued a U.S. Small Business Administration (&#8220;SBA&#8221;) Paycheck Protection Program Note (the &#8220;SBA Note&#8221;) to First Republic Bank (the &#8220;Lender&#8221;) for a loan in the principal amount of $<ix:nonFraction id="fid_422" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ProceedsFromCollectionOfNotesReceivable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">308,600</ix:nonFraction> (the &#8220;SBA Loan&#8221;) under the Paycheck Protection Program (&#8220;PPP&#8221;) promulgated under the Coronavirus Aid, Relief and Economic Security Act of 2020, as modified by the Paycheck Protection Program Flexibility Act of 2020.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 10, 2021 received notice that the SBA Loan had been forgiven in full in accordance with the terms and provisions of the PPP.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company did not provide any collateral or personal guarantees for the SBA Loan, nor did the Company pay any facility charge to the government or to the Lender.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Toronto-Dominion Bank Loan</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 27, 2020, the Company entered into a commitment loan with TD Bank under the Canadian Emergency Business Account, in the principal aggregate amount of CAD <ix:nonFraction id="fid_418" contextRef="AsOf2020-04-27_ndra_TDBankLoanMember" name="ndra:PrincipalAggregateAmount" format="ixt:numdotdecimal" decimals="0" unitRef="CAD">40,000</ix:nonFraction>, due and payable upon the expiration of the initial term on <ix:nonNumeric id="fid_419" contextRef="From2020-04-01to2020-04-27_ndra_TDBankLoanMember" name="us-gaap:LineOfCreditFacilityInitiationDate1" format="ixt:datemonthdayyearen">December 31, 2022</ix:nonNumeric>, which was later extended to December 31, 2023. This note bears interest on the unpaid balance at the rate of zero percent (<ix:nonFraction id="fid_420" contextRef="AsOf2020-04-27_ndra_TDBankLoanMember" name="ndra:InitialTermInterestRate" decimals="INF" unitRef="Pure" scale="-2">0</ix:nonFraction>%) per annum during the initial term. <ix:nonNumeric id="fid_421" contextRef="From2020-04-01to2020-04-27_ndra_TDBankLoanMember" name="ndra:BankLoanDescription">Under this note no interest payments are due until January 1, 2024. Under the conditions of the loan, twenty-five percent (25%) of the loan will be forgiven if seventy-five percent (75%) is repaid prior to the initial term date</ix:nonNumeric>.</p></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_335" contextRef="From2022-01-01to2022-12-31" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="cont_b97ae2"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Note 7 - Capital Stock</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Reverse Stock Split</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 7, 2022, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment (the &#8220;Certificate of Amendment&#8221;) to its certificate of incorporation, which Certificate of Amendment effectuated as of December 19, 2022 at 12:01 a.m. Eastern Time (the &#8220;Effective Time&#8221;) a reverse split&#160;of the Company&#8217;s common stock by a ratio of one-for-20 (the &#8220;Reverse Split&#8221;). All per share amounts and number of shares in the consolidated financial statements and related notes have been retroactively restated to reflect the Reverse Split. No fractional shares were, or shall be, issued in connection with the&#160;Reverse Split. A stockholder who would otherwise be entitled to receive a fractional share of common stock is entitled to receive the fractional share rounded up to the next whole share. The&#160;Reverse Split&#160;did not change the number of shares of common or preferred stock that the Company is authorized to issue, or the par value of the Company&#8217;s common or preferred stock.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The&#160;Reverse Split&#160;resulted in a proportionate adjustment to the per share conversion or exercise price and the number of shares of common stock issuable upon the conversion or exercise of outstanding preferred stock, stock options and warrants, as well as the number of shares of common stock eligible for issuance under the Company&#8217;s 2016 Omnibus Incentive Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Capital Stock</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">At December 31, 2022, the authorized capital of the Company consisted of <ix:nonFraction id="fid_431" contextRef="AsOf2022-12-31" name="us-gaap:CapitalUnitsAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">90,000,000</ix:nonFraction> shares of capital stock, comprised of <ix:nonFraction id="fid_430" contextRef="AsOf2022-12-31" name="us-gaap:CommonStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">80,000,000</ix:nonFraction> shares of common stock with a par value of $<ix:nonFraction id="fid_424" contextRef="AsOf2022-12-31" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction> per share, and <ix:nonFraction id="fid_480" contextRef="AsOf2022-12-31" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,000,000</ix:nonFraction> shares of preferred stock with a par value of $<ix:nonFraction id="fid_470" contextRef="AsOf2022-12-31" name="us-gaap:PreferredStockParOrStatedValuePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction> per share. The Company has designated <ix:nonFraction id="fid_428" contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,000</ix:nonFraction> shares of its preferred stock as Series A Convertible Preferred Stock (&#8220;Series A Preferred Stock&#8221;), <ix:nonFraction id="fid_427" contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,000</ix:nonFraction> shares of its preferred stock as Series B Convertible Preferred Stock (&#8220;Series B Preferred Stock&#8221;), <ix:nonFraction id="fid_474" contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">100,000</ix:nonFraction> shares of its preferred stock as Series C Preferred Stock, and the remainder of the&#160;<ix:nonFraction id="fid_479" contextRef="AsOf2022-12-31" name="ndra:PreferredStockSharesUndesignated" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">9,889,000</ix:nonFraction> preferred shares remain authorized but undesignated.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2022, there were <ix:nonFraction id="fid_432" contextRef="AsOf2022-12-31" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,169,103</ix:nonFraction> shares of common stock, <ix:nonFraction id="fid_482" contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember" name="us-gaap:PreferredStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">141</ix:nonFraction>.397 shares of Series A Preferred Stock, and no shares of Series B Preferred Stock or Series C Preferred Stock&#160;issued and outstanding, and a stock payable balance of $<ix:nonFraction id="fid_435" contextRef="AsOf2022-12-31" name="ndra:StockPayableShare" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,073</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 26, 2022, the board of directors declared a dividend of one one-thousandth of a share of Series C Preferred Stock for each outstanding share of the Company&#8217;s common stock and 1.359 shares of Series C Preferred Stock for each outstanding share of Series A Preferred Stock, to stockholders of record at 5:00 p.m. Eastern Time on October 7, 2022. Each whole share of Series C Preferred Stock (other than shares held by the Company&#8217;s directors and named executive officers) entitled the holder thereof to 1,000,000 votes on the proposal to adopt an amendment to the Company&#8217;s certificate of incorporation to reclassify the outstanding shares of common stock into a smaller number of shares of common stock. Shares of Series C Preferred Stock were eligible to vote at the special meeting of the Company&#8217;s stockholders held on November 29, 2022, at which the Company&#8217;s stockholders approved a reverse stock split of its common stock. All shares of Series C Preferred Stock were automatically redeemed in connection with the special meeting and no shares of Series C Preferred Stock remained outstanding as of December 31, 2022.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-10</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFS">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_b97ae2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2022, the Company issued a total of <ix:nonFraction id="fid_616" contextRef="From2022-01-01to2022-12-31" name="ndra:TotalCommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,041,377</ix:nonFraction> shares of its common stock in return for aggregate net proceeds of $<ix:nonFraction id="fid_448" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,399,512</ix:nonFraction> under the June 2021 ATM Agreement (as described below). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2021, the Company issued a total of <ix:nonFraction id="fid_617" contextRef="From2021-01-01to2021-12-31" name="ndra:TotalCommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">425,241</ix:nonFraction> shares of its common stock, as follows:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><ix:nonFraction id="fid_495" contextRef="From2021-01-01to2021-12-31_us-gaap_SeriesAPreferredStockMember" name="us-gaap:ConversionOfStockSharesIssued1" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,394</ix:nonFraction> shares upon the conversion of <ix:nonFraction id="fid_496" contextRef="From2021-01-01to2021-12-31_us-gaap_SeriesAPreferredStockMember" name="ndra:ConversionOfCommonStockIntoPreferredStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">55</ix:nonFraction>.397 shares of its Series A Preferred Stock;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><ix:nonFraction id="fid_447" contextRef="From2021-01-01to2021-12-31" name="ndra:SharesInReturn" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,348</ix:nonFraction> shares in return for aggregate net proceeds of $<ix:nonFraction id="fid_449" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,615,975</ix:nonFraction> from sales of common stock;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><ix:nonFraction id="fid_439" contextRef="From2021-01-01to2021-12-31" name="ndra:CommonStockSharesUponWarratExerciseShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">178,395</ix:nonFraction> shares upon warrant exercises for an aggregate exercise price of $<ix:nonFraction id="fid_440" contextRef="From2021-01-01to2021-12-31" name="ndra:CommonStockSharesUponWarrantExerciseAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,785,627</ix:nonFraction>;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><ix:nonFraction id="fid_441" contextRef="From2021-01-01to2021-12-31" name="ndra:CommonStockSharesUponCashlessWarrantExercise" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,145</ix:nonFraction> shares upon cashless warrant exercises;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><ix:nonFraction id="fid_442" contextRef="From2021-01-01to2021-12-31" name="ndra:CommonStockSharesUponCashlessOptionExercise" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,192</ix:nonFraction> shares upon cashless option exercise; </p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><ix:nonFraction id="fid_443" contextRef="From2021-01-01to2021-12-31" name="ndra:SharesForServicesValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,626</ix:nonFraction> shares for services valued at $<ix:nonFraction id="fid_445" contextRef="From2021-01-01to2021-12-31" name="ndra:CommonStockServicesValued" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,000</ix:nonFraction>; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><ix:nonFraction id="fid_444" contextRef="From2021-01-01to2021-12-31" name="ndra:CommonStockSharesUponVestingOfRestrictedUnits" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,141</ix:nonFraction> shares for RSUs valued at $<ix:nonFraction id="fid_446" contextRef="From2021-01-01to2021-12-31" name="ndra:RestictedStockUnitsValued" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,460</ix:nonFraction>.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>At-the-Market Equity Offering Program</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 21, 2021, the Company entered into the At-The-Market Issuance Sales Agreement with Ascendiant (the &#8220;June 2021 ATM Agreement&#8221;) to sell shares of common stock for aggregate gross proceeds of up to $<ix:nonFraction id="fid_454" contextRef="From2021-06-01to2021-06-21_ndra_JuneTwentyTwentyOneATMAgreementMember" name="ndra:GrossProceedsFromSalesOfCommonStock" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">20.0</ix:nonFraction> million, from time to time, through an &#8220;at-the-market&#8221; equity offering program under which Ascendiant acts as sales agent. As of December 31, 2022, under the June 2021 ATM Agreement the Company has issued an aggregate of <ix:nonFraction id="fid_434" contextRef="AsOf2022-12-31_ndra_JuneTwentyTwentyOneATMAgreementMember" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,064,634</ix:nonFraction> shares of common stock in return for net proceeds of $<ix:nonFraction id="fid_452" contextRef="From2022-01-01to2022-12-31_ndra_JuneTwentyTwentyOneATMAgreementMember" name="ndra:NetProceedsFromSalesOfCommonStock3" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,216,618</ix:nonFraction>, resulting in approximately $<ix:nonFraction id="fid_450" contextRef="From2021-06-01to2021-06-21_ndra_JuneTwentyTwentyOneATMAgreementMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">286,289</ix:nonFraction> of compensation paid to Ascendiant. During the year ended December 31, 2022, under the June 2021 ATM Agreement the Company issued an aggregate of <ix:nonFraction id="fid_437" contextRef="From2022-01-01to2022-12-31_ndra_JuneTwentyTwentyOneATMAgreementMember" name="ndra:TotalCommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,041,377</ix:nonFraction> shares of common stock in return for net proceeds of $<ix:nonFraction id="fid_453" contextRef="From2021-06-01to2021-06-21_ndra_JuneTwentyTwentyOneATMAgreementMember" name="ndra:NetProceedsFromSalesOfCommonStock3" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,398,936</ix:nonFraction>, resulting in $<ix:nonFraction id="fid_451" contextRef="From2022-01-01to2022-12-31_ndra_JuneTwentyTwentyOneATMAgreementMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">260,776</ix:nonFraction> of compensation paid to Ascendiant.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_336" contextRef="From2022-01-01to2022-12-31" name="ndra:ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock" escape="true"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Note 8 - Common Stock Options and Restricted Stock Units (RSUs)</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Common Stock Options</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Stock options are awarded to the Company&#8217;s employees, consultants and non-employee members of the board of directors under the Omnibus Plan and are generally granted with an exercise price equal to the market price of the Company&#8217;s common stock at the date of grant. The aggregate fair value of these stock options granted by the Company during the year ended December 31, 2022 was determined to be $<ix:nonFraction id="fid_523" contextRef="From2022-01-01to2022-12-31" name="ndra:AggregateFairValueOfStockOptionsGranted" format="ixt:numdotdecimal" decimals="0" unitRef="USD">919,915</ix:nonFraction> using the Black-Scholes-Merton option-pricing model based on the following assumptions: (i) volatility rate of <ix:nonFraction id="fid_526" contextRef="From2022-01-01to2022-12-31_srt_MinimumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" decimals="INF" unitRef="Pure" scale="-2">74</ix:nonFraction>% to <ix:nonFraction id="fid_532" contextRef="From2022-01-01to2022-12-31_srt_MaximumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" decimals="INF" unitRef="Pure" scale="-2">99</ix:nonFraction>%, (ii) discount rate of <ix:nonFraction id="fid_524" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" decimals="INF" unitRef="Pure" scale="-2">0</ix:nonFraction>%, (iii) zero expected dividend yield, (iv) risk free rate of <ix:nonFraction id="fid_528" contextRef="From2022-01-01to2022-12-31_srt_MinimumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" decimals="INF" unitRef="Pure" scale="-2">1.37</ix:nonFraction>% to <ix:nonFraction id="fid_529" contextRef="From2022-01-01to2022-12-31_srt_MaximumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" decimals="INF" unitRef="Pure" scale="-2">4.36</ix:nonFraction>%, and (v) expected life of <ix:nonNumeric id="fid_530" contextRef="From2022-01-01to2022-12-31_srt_MinimumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear">8</ix:nonNumeric>-<ix:nonNumeric id="fid_531" contextRef="From2022-01-01to2022-12-31_srt_MaximumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear">10</ix:nonNumeric> years. A summary of option activity under the Company&#8217;s Omnibus Plan as of December 31, 2022, and changes during the year then ended, is presented below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_360" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Average</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercise</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Price</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Average </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Remaining </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Contractual </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Term (Years)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance outstanding at December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_497" contextRef="AsOf2021-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">262,481</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_506" contextRef="AsOf2021-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">44.17</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_515" contextRef="From2022-01-01to2022-12-31" name="ndra:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear">7.42</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_499" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">141,975</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_508" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.08</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_516" contextRef="From2022-01-01to2022-12-31" name="ndra:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear">9.05</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_509" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_501" contextRef="From2022-01-01to2022-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_510" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cancelled or expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_502" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">12,554</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_511" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance outstanding at December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_619" contextRef="AsOf2022-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">391,902</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_521" contextRef="AsOf2022-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">31.47</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_517" contextRef="From2022-01-01to2022-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear">7.41</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercisable at December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_520" contextRef="AsOf2022-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">180,742</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_522" contextRef="AsOf2022-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">41.21</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_518" contextRef="From2022-01-01to2022-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear">5.69</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-11</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFS">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_337" contextRef="From2022-01-01to2022-12-31" name="ndra:ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock" escape="true"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Note 9 - Common Stock Warrants</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The following table summarizes all stock warrant activity of the Company for the year ended December 31, 2022:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_361" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Warrants</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Average</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercise </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Price</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Average </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Contractual </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Term (Years)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance outstanding at December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_533" contextRef="AsOf2021-12-31_ndra_WarrantsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">121,818</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_537" contextRef="AsOf2021-12-31_ndra_WarrantsMember" name="ndra:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">110.80</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_544" contextRef="From2022-01-01to2022-12-31_ndra_WarrantsMember" name="ndra:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" format="ixt-sec:duryear">0.58</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_538" contextRef="From2022-01-01to2022-12-31_ndra_WarrantsMember" name="ndra:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_539" contextRef="From2022-01-01to2022-12-31_ndra_WarrantsMember" name="ndra:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_540" contextRef="From2022-01-01to2022-12-31_ndra_WarrantsMember" name="ndra:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_534" contextRef="From2022-01-01to2022-12-31_ndra_WarrantsMember" name="ndra:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">111,488</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_541" contextRef="From2022-01-01to2022-12-31_ndra_WarrantsMember" name="ndra:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">118.86</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance outstanding at December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_536" contextRef="From2022-01-01to2022-12-31_ndra_WarrantsMember" name="ndra:NumberOfWarrantsEndingBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,330</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_543" contextRef="From2022-01-01to2022-12-31_ndra_WarrantsMember" name="ndra:WeightedAverageExercisableAtJune302022" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.01</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_545" contextRef="From2022-01-01to2022-12-31_ndra_WarrantsMember" name="ndra:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" format="ixt-sec:duryear">1.78</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercisable at December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_535" contextRef="From2022-01-01to2022-12-31_ndra_WarrantsMember" name="ndra:NumberOfWarrantsExercisable" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,330</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_542" contextRef="From2022-01-01to2022-12-31_ndra_WarrantsMember" name="ndra:WeightedAverageExercisePriceOutstanding" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.01</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_546" contextRef="From2022-01-01to2022-12-31_ndra_WarrantsMember" name="ndra:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermExercisable" format="ixt-sec:duryear">1.78</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_338" contextRef="From2022-01-01to2022-12-31" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="cont_7720a6"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Note 10 - Commitments and Contingencies</strong> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Effective January 1, 2015, the Company entered into an office lease agreement with Green Court, LLC, a Michigan limited liability company, for approximately <ix:nonFraction id="fid_572" contextRef="From2022-01-01to2022-12-31_ndra_JanuaryOneTwentyFifteenMember" name="ndra:RentSpace" format="ixt:numdotdecimal" decimals="INF" unitRef="sqft">3,657</ix:nonFraction> rentable square feet of space, for the initial monthly rent of $<ix:nonFraction id="fid_575" contextRef="From2022-01-01to2022-12-31_ndra_JanuaryOneTwentyFifteenMember" name="ndra:MonthlyRent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,986</ix:nonFraction>, which commenced on January 1, 2015 for an initial term of <ix:nonNumeric id="fid_577" contextRef="From2022-01-01to2022-12-31_ndra_JanuaryOneTwentyFifteenMember" name="ndra:RentTerm" format="ixt-sec:durmonth">60</ix:nonNumeric> months. <ix:nonNumeric id="fid_578" contextRef="From2017-10-01to2017-10-10_ndra_JanuaryOneTwentyFifteenMember" name="us-gaap:LesseeOperatingLeaseDescription">On October 10, 2017 this lease was amended increasing the rentable square feet of space to 3,950 and the monthly rent to $7,798. On July 16, 2019, the Company exercised its option to extend the lease for an additional <ix:nonNumeric id="fid_590" contextRef="From2017-10-01to2017-10-10_ndra_JanuaryOneTwentyFifteenMember" name="ndra:RentTerm" format="ixt-sec:durmonth">5</ix:nonNumeric> years past the initial term originally expiring on December 31, 2019</ix:nonNumeric>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><ix:nonNumeric id="fid_579" contextRef="From2021-03-01to2021-03-15_ndra_JanuaryOneTwentyFifteenMember" name="us-gaap:LesseeOperatingLeaseDescription">On March 15, 2021, the Company entered into an amendment to the lease, adding approximately 3,248 rentable square feet, increasing the initial monthly rent to $15,452 effective May 2021, and extending the term of the lease to December 31, 2025</ix:nonNumeric>. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company records the lease asset and lease liability at the present value of lease payments over the lease term. The lease typically does not provide an implicit rate; therefore, the Company uses its estimated incremental borrowing rate at the time of lease commencement to discount the present value of lease payments. The Company&#8217;s discount rate for operating leases at December 31, 2022 was <ix:nonFraction id="fid_582" contextRef="From2022-01-01to2022-12-31_ndra_JanuaryOneTwentyFifteenMember" name="ndra:OperatingLeaseDiscountRate" decimals="INF" unitRef="Pure" scale="-2">10</ix:nonFraction>%. Lease expense is recognized on a straight-line basis over the lease term to the extent that collection is considered probable. As a result, the Company has been recognizing rents as they become payable based on the adoption of ASC Topic 842. The weighted-average remaining lease term is 3.00 years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2022, the maturities of operating lease liabilities are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_362" contextRef="From2022-01-01to2022-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Operating</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Lease</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_547" contextRef="AsOf2022-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:numdotdecimal" decimals="0" unitRef="USD">196,721</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_548" contextRef="AsOf2022-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,624</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025 and beyond</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_550" contextRef="AsOf2022-12-31" name="ndra:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,624</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_551" contextRef="AsOf2022-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">601,969</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: amount representing interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_552" contextRef="AsOf2022-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,822</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Present value of future minimum lease payments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_553" contextRef="AsOf2022-12-31" name="us-gaap:OperatingLeaseLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">518,147</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: current obligations under leases</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_555" contextRef="AsOf2022-12-31" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,228</ix:nonFraction> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Long-term lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_557" contextRef="AsOf2022-12-31" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">365,919</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">For the years ended December 31, 2022 and 2021, the Company incurred rent expenses of $<ix:nonFraction id="fid_560" contextRef="From2022-01-01to2022-12-31" name="ndra:RentExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">213,912</ix:nonFraction> and $<ix:nonFraction id="fid_561" contextRef="From2021-01-01to2021-12-31" name="ndra:RentExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">178,620</ix:nonFraction>, respectively.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Employment and Consulting Agreements</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Francois Michelon</em></strong> - The Company has an employment agreement with Francois Michelon, the Company&#8217;s Chief Executive Officer and Chairman of the board of directors, dated May 12, 2017 and amended on December 27, 2019.&#160; Effective January 1, 2021, the Compensation Committee increased Mr. Michelon&#8217;s annual salary to $<ix:nonFraction id="fid_585" contextRef="From2017-05-01to2017-05-12_ndra_EmploymentAgreementsMember_ndra_FrancoisMichelonMember" name="us-gaap:SalariesAndWages" format="ixt:numdotdecimal" decimals="0" unitRef="USD">376,991</ix:nonFraction> and, effective January 1, 2022, it increased Mr. Michelon&#8217;s annual salary to $<ix:nonFraction id="fid_584" contextRef="From2022-01-01to2022-12-31_ndra_EmploymentAgreementsMember_ndra_FrancoisMichelonMember" name="us-gaap:SalariesAndWages" format="ixt:numdotdecimal" decimals="0" unitRef="USD">423,000</ix:nonFraction>. Mr. Michelon is also eligible for an annual cash bonus based upon achievement of performance-based objectives established by the Board of Directors. Under the employment agreement, Mr. Michelon is eligible for an annual cash bonus based upon achievement of performance-based objectives established by the board of directors. Upon termination without cause, any portion of Mr. Michelon&#8217;s option award scheduled to <ix:nonNumeric id="fid_568" contextRef="From2017-05-01to2017-05-12_ndra_EmploymentAgreementsMember_ndra_FrancoisMichelonMember" name="ndra:EmploymentAgreementDescription">vest within 12 months will automatically vest, and upon termination without cause within 12 months</ix:nonNumeric> following a change of control, the entire unvested portion of the option award will automatically vest. Upon termination for any other reason, the entire unvested portion of the option award will terminate.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If Mr. Michelon&#8217;s employment is terminated by the Company without cause or Mr. Michelon terminates his employment for good reason, Mr. Michelon will be entitled <ix:nonNumeric id="fid_565" contextRef="From2017-05-01to2017-05-12_ndra_EmploymentAgreementsMember_ndra_FrancoisMichelonMember" name="ndra:DescriptionOfEmploymentTerminationTerm">to receive 12 months&#8217; continuation of his current base salary and a lump sum payment equal to 12 months of continued healthcare coverage (or 24 months&#8217; continuation of his current base salary and a lump sum payment equal to 24 months</ix:nonNumeric> of continued healthcare coverage if such termination occurs within one year following a change in control).</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-12</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFS">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_7720a6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Under his employment agreement, Mr. Michelon is eligible to receive benefits that are substantially similar to those of the Company&#8217;s other senior executive officers.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Michael Thornton</em></strong> - The Company has an employment agreement with Michael Thornton, the Company&#8217;s Chief Technology Officer, dated May 12, 2017 and on December 27, 2019. The employment agreement provides for an annual base salary that is subject to adjustment at the board of directors&#8217; discretion. Effective January 1, 2021, the Compensation Committee increased Mr. Thornton&#8217;s annual salary to $<ix:nonFraction id="fid_562" contextRef="From2017-05-01to2017-05-12_ndra_EmploymentAgreementsMember_ndra_MichaelThorntonMember" name="us-gaap:SalariesAndWages" format="ixt:numdotdecimal" decimals="0" unitRef="USD">289,963</ix:nonFraction> and, effective January 1, 2022, it increased Mr. Thornton&#8217;s annual salary to $<ix:nonFraction id="fid_583" contextRef="From2022-01-01to2022-12-31_ndra_EmploymentAgreementsMember_ndra_MichaelThorntonMember" name="us-gaap:SalariesAndWages" format="ixt:numdotdecimal" decimals="0" unitRef="USD">324,000</ix:nonFraction>. Under the employment agreement, Mr. Thornton is eligible for an annual cash bonus based upon achievement of performance-based objectives established by the board of directors. Upon termination without cause, any portion of Mr. Thornton&#8217;s option award scheduled <ix:nonNumeric id="fid_569" contextRef="From2017-05-01to2017-05-12_ndra_EmploymentAgreementsMember_ndra_MichaelThorntonMember" name="ndra:EmploymentAgreementDescription">to vest within 12 months will automatically vest, and upon termination without cause within 12 months</ix:nonNumeric> following a change of control, the entire unvested portion of the option award will automatically vest. Upon termination for any other reason, the entire unvested portion of the option award will terminate.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If Mr. Thornton&#8217;s employment is terminated by the Company without cause or Mr. Thornton terminates his employment for good reason, <ix:nonNumeric id="fid_564" contextRef="From2019-04-01to2019-04-15_ndra_EmploymentAgreementsMember_ndra_MichaelThorntonMember" name="ndra:DescriptionOfEmploymentTerminationTerm">Mr. Thornton will be entitled to receive 12 months&#8217; continuation of his current base salary and a lump sum payment equal to 12 months</ix:nonNumeric> of continued healthcare coverage (or 24 months&#8217; continuation of his current base salary and a lump sum payment equal to 24 months of continued healthcare coverage if such termination occurs within one year following a change in control). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Under his employment agreement, Mr. Thornton is eligible to receive benefits that are substantially similar to those of the Company&#8217;s other senior executive officers.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Renaud Maloberti </em></strong>- The Company had&#160;an employment agreement with Renaud Maloberti, dated April 15, 2019, that provided&#160;for an annual base salary of $<ix:nonFraction id="fid_563" contextRef="From2019-04-01to2019-04-15_ndra_EmploymentgreementsMember_ndra_RenaudMalobertiMember" name="us-gaap:SalariesAndWages" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction> and eligibility for an annual cash bonus to be paid based on attainment of Company and individual performance objectives to be established by the Board of Directors. Effective January 1, 2021, the Compensation Committee increased Mr. Maloberti&#8217;s annual salary to $<ix:nonFraction id="fid_586" contextRef="From2022-01-01to2022-12-31_ndra_EmploymentgreementsMember_ndra_RenaudMalobertiMember" name="us-gaap:SalariesAndWages" format="ixt:numdotdecimal" decimals="0" unitRef="USD">266,255</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 21, 2022, Mr.&#160;Maloberti notified the Company of his resignation as the Company&#8217;s Chief Commercial Officer, effective January 13, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to his employment agreement, on April 28, 2019, Mr. Maloberti was granted stock options to purchase <ix:nonFraction id="fid_587" contextRef="From2019-04-01to2019-04-28_ndra_EmploymentgreementsMember_ndra_RenaudMalobertiMember" name="ndra:StockOptionGranted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">35,000</ix:nonFraction> shares of the Company&#8217;s common stock. The stock options have an exercise price of $<ix:nonFraction id="fid_589" contextRef="AsOf2019-04-28_ndra_EmploymentgreementsMember_ndra_RenaudMalobertiMember" name="ndra:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.04</ix:nonFraction> per share, and vest in three equal annual installments beginning on the first anniversary of the grant date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Litigation</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">From time to time the Company may become a party to litigation in the normal course of business. As of December 31, 2022, there were no legal matters that management believes would have a material effect on the Company&#8217;s financial position or results of operations.</p></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_342" contextRef="From2022-01-01to2022-12-31" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="cont_d92344"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Note 11 - Income Taxes</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets as of December 31, 2022 and 2021 are summarized below.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_363" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net operating loss carryforward</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_592" contextRef="AsOf2022-12-31" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,251,804</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_593" contextRef="AsOf2021-12-31" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,200,629</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_594" contextRef="AsOf2022-12-31" name="ndra:StockBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_595" contextRef="AsOf2021-12-31" name="ndra:StockBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,720</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fair value of options</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_596" contextRef="AsOf2022-12-31" name="ndra:FairValueOfOptions" format="ixt:numdotdecimal" decimals="0" unitRef="USD">311,958</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_597" contextRef="AsOf2021-12-31" name="ndra:FairValueOfOptions" format="ixt:numdotdecimal" decimals="0" unitRef="USD">346,869</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total deferred tax assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_598" contextRef="AsOf2022-12-31" name="us-gaap:DeferredTaxAssetsGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,939,846</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_599" contextRef="AsOf2021-12-31" name="us-gaap:DeferredTaxAssetsGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,825,040</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_600" contextRef="AsOf2022-12-31" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,939,846</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_601" contextRef="AsOf2021-12-31" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,825,040</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net deferred tax asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_602" contextRef="AsOf2022-12-31" name="us-gaap:DeferredTaxAssetsNet" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_603" contextRef="AsOf2021-12-31" name="us-gaap:DeferredTaxAssetsNet" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In assessing the potential realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the Company attaining future taxable income during the periods in which those temporary differences become deductible. As of December 31, 2022 and 2021, management was unable to determine if it is more likely than not that the Company&#8217;s deferred tax assets will be realized, and has therefore recorded an appropriate valuation allowance against deferred tax assets at such dates.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-13</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFS">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_d92344"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has not completed its evaluation of net operating loss (&#8220;NOL&#8221;) utilization limitations under Internal Revenue Code, as amended (the &#8220;Code&#8221;), Section 382/383, change of ownership rules. If the Company has had a change in ownership, the NOL&#8217;s would be limited as to the amount that could be utilized each year, or possibly eliminated, based on the Code, as amended.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">No federal or state/local tax provision has been provided for the years ended December 31, 2022 and 2021 due to the losses incurred during such periods. Reconciled below is the difference between the income tax rate computed by applying the U.S. federal statutory rate and the effective tax rate for the years ended December 31, 2021 and 2020.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_364" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">U.S. federal statutory income tax</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-<ix:nonFraction id="fid_604" contextRef="From2022-01-01to2022-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" decimals="INF" unitRef="Pure" scale="-2">21.00</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-<ix:nonFraction id="fid_605" contextRef="From2021-01-01to2021-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" decimals="INF" unitRef="Pure" scale="-2">21.00</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">State tax, net of federal tax benefit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-<ix:nonFraction id="fid_606" contextRef="From2022-01-01to2022-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" decimals="INF" unitRef="Pure" sign="-" scale="-2">5.80</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-<ix:nonFraction id="fid_607" contextRef="From2021-01-01to2021-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" decimals="INF" unitRef="Pure" sign="-" scale="-2">5.80</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_608" contextRef="From2022-01-01to2022-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" decimals="INF" unitRef="Pure" scale="-2">0.00</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_609" contextRef="From2021-01-01to2021-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" decimals="INF" unitRef="Pure" scale="-2">0.00</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Change in valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_610" contextRef="From2022-01-01to2022-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" decimals="INF" unitRef="Pure" scale="-2">26.80</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_611" contextRef="From2021-01-01to2021-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" decimals="INF" unitRef="Pure" scale="-2">26.80</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Effective tax rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_612" contextRef="From2022-01-01to2022-12-31" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" decimals="INF" unitRef="Pure" scale="-2">0.00</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_613" contextRef="From2021-01-01to2021-12-31" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" decimals="INF" unitRef="Pure" scale="-2">0.00</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">At December 31, 2022, the Company has available net operating loss carryforwards for federal and state income tax purposes of approximately $<ix:nonFraction id="fid_614" contextRef="AsOf2022-12-31" name="us-gaap:OperatingLossCarryforwards" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">65.2</ix:nonFraction> million, of which $<ix:nonFraction id="fid_615" contextRef="AsOf2022-12-31" name="ndra:NetOperatingLossCarryforwardBegainToExpire" format="ixt:numdotdecimal" decimals="-6" unitRef="USD" scale="6">16</ix:nonFraction> million will begin to expire in 2028 through 2038.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ENDRA Life Sciences Canada Inc., the Company&#8217;s wholly-owned subsidiary which was incorporated in 2017, is subject to income taxes in the jurisdictions in which it operates,&#160;Canada, at a current rate of approximately 26.6 percent for 2022. Significant judgment is required in determining the provision for income tax. There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. The Company recognizes liabilities for anticipated tax audit issues based on its current understanding of the tax law. Where the final tax outcome of these matters is different from the carrying amounts, such differences will impact the current and deferred tax provisions in the period in which such determination is made.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ENDRA Life Sciences Canada Inc.&#8217;s operations were not material for tax purposes as of December 31, 2022 and 2021 and therefore the entity had no significant impact on the year-end 2022 and 2021 tax provision. Generally, all expenses relating to research &amp; development that are incurred in Canada are the responsibility and owned by the United States parent company, since it is the owner of all of the Company&#8217;s intangibles.</p></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-14</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="a14">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">None.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="a15">Item 9A. Controls and Procedures.</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Evaluation of Disclosure Controls and Procedures</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">As of the end of the period covered by this report, management performed, with the participation of our principal executive and principal financial officers, an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosures. Based on the evaluation, our principal executive and principal financial officers concluded that, as of December 31, 2022, our disclosure controls and procedures were not effective due to a material weakness in internal control over financial reporting, as described below.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Management&#8217;s Report on Internal Control Over Financial Reporting</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Our management is responsible for establishing and maintaining effective internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act. Internal control over financial reporting is a process designed to provide reasonable assurance to the Company&#8217;s management and board of directors regarding the reliability of our financial reporting for external purposes in accordance with accounting principles generally accepted in the United States of America.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Because of its inherent limitations, internal control over financial reporting is not intended to provide absolute assurance that a misstatement of our consolidated financial statements would be prevented or detected. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Therefore, even those systems determined to be effective can only provide reasonable assurance with respect to financial statement preparation and presentation.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in <em>Internal Control - Integrated Framework (2013) </em>issued by the Committee of Sponsoring Organizations of the Treadway Commission.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Management identified the following material weakness as of December 31, 2022: insufficient personnel resources within the accounting function to segregate the duties over financial transaction processing and reporting. Because of this material weakness, management concluded that the Company&#8217;s internal control over financial reporting was not effective as of December 31, 2022.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Continuing Remediation Efforts</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">During the year ended December 31, 2022, the Company undertook the following remediation measures to correct the material weakness in its internal control over financial reporting:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">hired a Senior Director of Operations in October 2022 to assist with implementing operating procedures and policies expected to improve the Company&#8217;s disclosure controls and procedures, including with respect to segregation of duties; and</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">engaged on a contract basis a controller with expertise in the area of proper controls and procedures. Although this controller subsequently resigned due to unforeseen circumstances beyond her control, the Company intends to again fill the position.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="font-size:10pt;font-family:times new roman;margin:0px">To remediate its internal control weakness, management intends to implement the following measures during 2023, as the Company&#8217;s financial means allow:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Add additional accounting personnel or outside consultants, such as a new controller, to properly segregate duties and to effect timely, accurate preparation of the financial statements; and</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Complete the development of and maintain adequate written accounting policies and procedures.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; &#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">47</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">As we are not an &#8220;accelerated filer&#8221; under SEC rules, we are not required to provide an auditor&#8217;s attestation of management&#8217;s assessment of internal control over financial reporting as of December 31, 2022. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Changes in Internal Control of Financial Reporting</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">During the quarter ended December 31, 2022, except as described above under &#8220;Continuing Remediation Efforts,&#8221; there were no changes that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="a16">Item 9B. Other Information.</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Not applicable.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="a17">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Not applicable.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">48</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="a18">PART III</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span class="atag" style="display: inline" id="a19"><strong>Item 10. Directors, Executive Officers and Corporate Governance.</strong>&#160;</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The following table sets forth the names and ages of all of our executive officers and directors.&#160; Our officers are appointed by, and serve at the pleasure of, the board of directors.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:35%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Name</strong></p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:10%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Age</strong></p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Position</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Francois Michelon</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">57</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Executive Officer and Chairman</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Michael Thornton</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">54</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Technology Officer</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Irina Pestrikova </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">37</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Senior Director of Finance </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Louis J. Basenese</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">45</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Anthony DiGiandomenico</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">56</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Michael Harsh</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">68</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Alexander Tokman</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">61</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Biographical information with respect to our executive officers and directors is provided below.&#160;&#160;There are no family relationships between any of our executive officers or directors.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;"><strong>Francois Michelon</strong> joined ENDRA as Chief Executive Officer and Chairman of our board of directors in 2015. He has over 20 years of healthcare technology experience in general management, operations, strategy and marketing across the diagnostic imaging, surgical instrument and dental sectors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">From 2012 to 2014, Mr. Michelon served as Vice President of Global Marketing for the 3i division of Biomet, Inc. (now Zimmer Biomet Holdings, Inc.), a provider of oral reconstruction technologies, where he was responsible for the upstream and downstream development of the division&#8217;s global portfolio. From 2004 to 2011, Mr. Michelon served as Group Director of Global Services and Visualization for Smith &amp; Nephew plc&#8217;s Advanced Surgical Devices division, where he led in the B2B service and capital equipment sectors, and had responsibility over the financial performance of these as well. From 1997 to 2004, Mr. Michelon worked at GE Healthcare in a variety of global upstream and downstream marketing roles.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Mr. Michelon received an MBA from Carnegie-Mellon University and a BA in Economics from the University of Chicago. He has also earned his Six Sigma Black Belt certification.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Mr. Michelon&#8217;s extensive industry and executive experience and his intimate understanding of our business as our Chief Executive Officer position him well to serve as a member of our Board of Directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;"><strong>Michael Thornton</strong> joined ENDRA as Chief Technology Officer in 2007. Prior to that, Mr. Thornton was a founder and President of Enhanced Vision Systems Corp., or EVS, a developer and supplier of medical imaging equipment to the pharmaceutical, biotech, and academic sectors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">In 2002, EVS was acquired by General Electric Company and was integrated into the Functional and Molecular Imaging business unit of GE Medical Systems (now GE Healthcare, a subsidiary of General Electric Company). Following the acquisition of EVS by GE Medical Systems, Mr. Thornton held a number of positions at GE Healthcare, including Sales Manager, Global Product Manager, and Site Leader. He was a member of the leadership team that expanded the pre-clinical imaging business to include: computed tomography, optical, and positron emission tomography imaging technologies, with global market reach. He is also a founder of Volumetrics Medical Corp., a developer and manufacturer of quality assurance devices for diagnostic imaging.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Prior to founding EVS, Mr. Thornton developed medical imaging related technologies at the Robarts Research Institute (London, Ontario, Canada) for which he obtained an MSc in Electrical Engineering from the University of Western Ontario. Mr. Thornton also holds a BASc in Electrical Engineering from the University of Toronto and is a member of the American Association of Physicists in Medicine.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;"><strong>Irina Pestrikova</strong> joined ENDRA as Senior Director of Finance in June 2021. From 2014 to 2021, Ms. Pestrikova was the Director of Operations of Wells Compliance Group. Wells Compliance Group is a technology-based services firm supporting the financial reporting needs of publicly traded companies and privately held firms whose investor or shareholder base requires timely GAAP-compliant financial reporting. In her role as Director of Operations, Ms. Pestrikova provided accounting and bookkeeping services to a number of public companies, including ENDRA. Ms. Pestrikova has also been the Director of Finance &amp; Operations of Atlas Bookkeeping, Inc., a provider of financial reporting, modeling and analysis, since 2020. She holds an MBA in Finance from Pepperdine University. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">49</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;"><strong>Louis J. Basenese</strong>, joined our Board of Directors in April 2020. Mr. Basenese is the President, Chief Market Strategist at Public Ventures, LLC, a registered broker-dealer, Member FINRA/SIPC. Previously, he was Founder and Chief Analyst of Disruptive Tech Research, LLC, an independent equity research and advisory firm focused exclusively on disruptive technology companies that has served the investment management community from June 2014 through September 2022. Since 2005, Mr. Basenese has also managed The Basenese Group, LLC, a consulting business focused on communications and business development for private and public small and microcap businesses.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Mr. Basenese holds an M.B.A. in Finance from the Crummer Graduate School of Business at Rollins College and a Bachelor of Arts from the University of Florida. He is also a former Series 7 and Series 66 license holder.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Mr. Basenese&#8217;s experience with investor relations and business development of technology-focused companies, as well as financing and strategic planning, provides him with the qualifications and skills necessary to serve as a member of our Board of Directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;"><strong>Anthony DiGiandomenico</strong> joined our Board of Directors in 2013. A co-founder of MDB Capital Group LLC, Mr. DiGiandomenico focuses on corporate finance and capital formation for growth-oriented companies. He has participated in all areas of corporate finance including private capital, public offerings, PIPEs, business consulting and strategic planning, and mergers and acquisitions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Mr. DiGiandomenico has also worked on a wide range of transactions for growth-oriented companies in biotechnology, nutritional supplements, manufacturing and entertainment industries. Prior to forming MDB Capital Group LLC in 1997, Mr. DiGiandomenico served as President and CEO of the Digian Company, a real estate development company. Mr. DiGiandomenico has also served on the board of directors of Cue Biopharma, Inc., an immunotherapy company, and currently serves on the board of directors of Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Mr. DiGiandomenico holds an MBA from the Haas School of Business at the University of California, Berkeley and a BS in Finance from the University of Colorado.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Mr. DiGiandomenico&#8217;s financial expertise, general business acumen and significant executive leadership experience position him well to make valuable contributions to our Board of Directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;"><strong>Michael Harsh</strong> joined our Board of Directors in 2015. He is a Portfolio Executive for the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) COVID-19 Response Program and a co-founder and Chief Product Officer of Terapede Systems, a digital Xray startup that focuses on developing an ultra-high resolution medical flat panel X-ray detector. He co-founded Terapede in 2015. Prior to Terapede, Mr. Harsh had a 36-year career with General Electric (&#8220;GE&#8221;). He held numerous positions within GE and served as Vice President and Chief Technology Officer of GE Healthcare, a multi-billion dollar division of GE, where he led its global science and technology organization and research and development teams in diagnostics, healthcare IT and life sciences. In 2004, Mr. Harsh was named Global Technology Leader - Imaging Technologies at the GE Global Research Center, where he led the research for imaging technologies across the company as well as the research associated with computer visualization and superconducting systems.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Additionally, Mr. Harsh is a member of the boards of directors of Compute Health Acquisition Corp. (NYSE: CPUH), Imagion Biosystems (ASX: IBX.AX), and EmOpti, Inc., as well as a member of the Radiological Society of North America (RSNA), Research &amp; Education Foundation Board of Trustees. He had previously served as a director for FloDesign Sonics until its acquisition by MilliporeSigma, a division of the Merck Group. He is also a McKinsey Senior Advisor and a consultant in the medical device industry.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Mr. Harsh is a graduate of Marquette University, where he earned a bachelor&#8217;s degree in Electrical Engineering. He holds numerous U.S. patents in the field of medical imaging and instrumentation. In 2008, Mr. Harsh was elected to the American Institute for Medical and Biological Engineering College of Fellows for his significant contributions to the medical and biological engineering field.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Mr. Harsh&#8217;s extensive industry, executive and board experience position him well to serve on our Board of Directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>Alexander Tokman </strong>joined our Board of Directors in 2008. He currently serves as a President of iUNU, a privately held AI/Computer Vision SaaS company and&#160;recently was a CEO-in-Residence at the Allen Institute for Artificial Intelligence (AI2), from 2019 to 2020. Mr. Tokman also serves as an independent board director for Izotropic Corporation (CSE: IZO), a company commercializing a dedicated breast CT imaging platform, and on the board of the American Academy of Thermography, a non-profit organization focused on bringing novel infrared imaging applications for disease diagnosis.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">50</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Mr. Tokman served as President, Chief Executive Officer, and a director of Microvision, Inc., a publicly traded laser beam scanning display and imaging company, from January 2006 to December 2017.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Previously, Mr. Tokman completed a 10+ year tenure as an executive with GE Healthcare, where he led several global businesses, the latest being its Global Molecular Imaging and Radiopharmacy multi-technology business unit, of which he was General Manager from 2003 to 2005.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Between 1995 and 2003, Mr. Tokman served in various leadership roles at GE Healthcare, where he led the definition and successful commercialization of several product segments, including PET/CT&#160;&#160;&#160;&#160; .</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Mr. Tokman is a certified Six Sigma and Design for Six Sigma (DFSS) Black Belt and Master Black Belt and as one of General Electric Company&#8217;s Six Sigma pioneers, he drove the quality culture change across GE Healthcare in the late 1990s. From 1989 to 1995, Mr. Tokman served as development programs lead and a head of Industry and Regional Development at Tracor Applied Sciences (BAE Systems). Mr. Tokman has both an MS and BS in Electrical Engineering from the University of Massachusetts, Dartmouth.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Mr. Tokman&#8217;s industry expertise and significant executive leadership and director experience position him well to make valuable contributions to our Board of Directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Board Independence</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Board of Directors has determined that each of Mr. Basenese, Mr. DiGiandomenico, Mr. Harsh and Mr. Tokman is an independent director within the meaning of the director independence standards of The Nasdaq Stock Market (&#8220;Nasdaq&#8221;). Furthermore, the Board has determined that all of the members of the Audit Committee, Compensation Committee and Corporate Governance and Nominating Committee are independent within the meaning of the director independence standards of Nasdaq and the rules of the SEC applicable to each such committee.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Committees</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;"><em>Audit Committee</em>. Our Audit Committee consists of Mr. Basenese, Mr. DiGiandomenico, and Mr. Harsh. The Board of Directors has determined that each member of the Audit Committee is independent within the meaning of the Nasdaq director independence standards and applicable rules of the SEC for audit committee members. The Board of Directors has elected Mr. DiGiandomenico as Chairperson of the Audit Committee and has determined that he qualifies as an &#8220;audit committee financial expert&#8221; under the rules of the SEC. The Audit Committee is responsible for assisting the Board of Directors in fulfilling its oversight responsibilities with respect to financial reports and other financial information. The Audit Committee (1) reviews, monitors and reports to the Board of Directors on the adequacy of the Company&#8217;s financial reporting process and system of internal controls over financial reporting, (2) has the ultimate authority to select, evaluate and replace the independent auditor and is the ultimate authority to which the independent auditors are accountable, (3) in consultation with management, periodically reviews the adequacy of the Company&#8217;s disclosure controls and procedures and approves any significant changes thereto, (4) provides the audit committee report for inclusion in our proxy statement for our annual meeting of stockholders and (5) recommends, establishes and monitors procedures for the receipt, retention and treatment of complaints relating to accounting, internal accounting controls or auditing matters and the receipt of confidential, anonymous submissions by employees of concerns regarding questionable accounting or auditing matters. The Audit Committee met twice &#160;&#160;&#160;&#160;&#160;in 2022 as well as acted by written consent.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:33.75pt"><em>Compensation Committee</em>. Our Compensation Committee presently consists of Mr. Basenese, Mr. DiGiandomenico, Mr. Harsh and Mr. Tokman, each of whom is a non-employee director as defined in Rule 16b-3 of the Exchange Act. The Board has also determined that each member of the Compensation Committee is also an independent director within the meaning of Nasdaq&#8217;s director independence standards. Mr. Tokman serves as Chairperson of the Compensation Committee. Effective as of the 2022 Annual Meeting, Mr. Basenese will assume the Chairperson position. The Compensation Committee (1) discharges the responsibilities of the Board of Directors relating to the compensation of our directors and executive officers, (2) oversees the Company&#8217;s procedures for consideration and determination of executive and director compensation, and reviews and approves all executive compensation, and (3) administers and implements the Company&#8217;s incentive compensation plans and equity-based plans. The Compensation Committee did not meet separately from&#160;the board of directors&#160;in 2022 but acted by unanimous written consent.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;"><em>Corporate Governance and Nominating Committee</em>. Our Corporate Governance and Nominating Committee consists of Mr. Harsh and Mr. Tokman. The Board of Directors has determined that each member of the Corporate Governance and Nominating Committee is an independent director within the meaning of the Nasdaq director independence standards and applicable rules of the SEC. Mr. Harsh serves as Chairperson of the Corporate Governance and Nominating Committee. The Corporate Governance and Nominating Committee (1) recommends to the Board of Directors persons to serve as members of the Board of Directors and as members of and chairpersons for the committees of the Board of Directors, (2) considers the recommendation of candidates to serve as directors submitted from the stockholders of the Company, (3) assists the Board of Directors in evaluating the performance of the Board of Directors and the Board committees, (4) advises the Board of Directors regarding the appropriate board leadership structure for the Company, (5) reviews and makes recommendations to the Board of Directors on corporate governance and (6) reviews the size and composition of the Board of Directors and recommends to the Board of Directors any changes it deems advisable. The Corporate Governance and Nominating Committee did not meet separately from the Board of Directors in 2022 but acted by written consent.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">51</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Delinquent Section 16(a) Reports </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Section 16(a) of the Exchange Act requires our directors, executive officers and persons who own more than ten percent of a registered class of our equity securities to file reports of ownership and changes in ownership with the SEC. Such persons are required by SEC regulations to furnish us with copies of all such filings. Based solely on our review of the copies of the reports that we received and written representations that no other reports were required, we believe that our executive officers, directors and greater than 10% stockholders complied with all applicable filing requirements on a timely basis during 2022, except for one Form 4 for Michael Thornton related to a purchase of shares May 18, 2022, which was reported on May 23, 2022. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Code of Business Conduct and Ethics</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">We have in place a Code of Business Conduct and Ethics (the &#8220;Code of Ethics&#8221;) that applies to all of our directors, officers and employees. The Code of Ethics is designed to deter wrongdoing and to promote:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">full, fair, accurate, timely and understandable disclosure in reports and documents that we file with, or submit to, the SEC and in other public communications that we make;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">compliance with applicable governmental laws, rules and regulations;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">the prompt internal reporting of violations of the Code of Ethics to an appropriate person identified in the Code of Ethics; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">accountability for adherence to the Code of Ethics.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">A current copy of the Code of Ethics is available at www.endrainc.com. A copy may also be obtained, free of charge, from us upon a request directed to ENDRA Life Sciences, Inc., 3600 Green Court, Suite 350, Ann Arbor, Michigan 48105, attention: Investor Relations. We intend to disclose any amendments to or waivers of a provision of the Code of Ethics required to be disclosed by applicable SEC rules by posting such information on our website available at www.endrainc.com and/or in our public filings with the SEC.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="a20">Item 11. Executive Compensation</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Our compensation philosophy is to offer our executive officers compensation and benefits that are competitive and meet our goals of attracting, retaining and motivating highly skilled management, which is necessary to achieve our financial and strategic objectives and create long-term value for our stockholders. We believe the levels of compensation we provide should be competitive, reasonable and appropriate for our business needs and circumstances. Our board of directors uses benchmark compensation studies in determining compensation elements and levels. The principal elements of our executive compensation program have to date included base salary, annual bonus opportunity and long-term equity compensation in the form of stock options. We believe successful long-term Company performance is more critical to enhancing stockholder value than short-term results. For this reason and to conserve cash and better align the interests of management and our stockholders, we emphasize long-term performance-based equity compensation over base annual salaries.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">52</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The following table sets forth information concerning the compensation earned by the individual that served as our principal executive officer during 2022 and our two most highly compensated executive officers other than the individual who served as our principal executive officer during 2022 (collectively, the &#8220;named executive officers&#8221;):</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>2022 Summary Compensation Table</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Name and </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Principal</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Position</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Year</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Salary ($)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Option </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Awards ($) (1)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Non-equity </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Incentive Plan Compensation ($)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>All Other </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Compensation ($)(2)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total ($)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Francois Michelon&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">423,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">212,609</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">587</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>636,196</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Chief Executive Officer</em></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">374,035</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">812,391</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">137,605</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">587</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>1,324,618</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Michael Thornton</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">301,278</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">208,128</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">392</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>509,798</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Chief Technology Officer</em></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">286,168</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">812,391</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">72,582</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">392</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>1,171,533</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Renaud Maloberti</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">296,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">55,581</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">365</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>351,946</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Former Chief Commercial Officer</em></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">263,272</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">608,766</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">58,254</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">365</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>930,657</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">______________</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(1) </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The amounts shown in this column indicate the grant date fair value of option awards granted in the subject year computed in accordance with FASB ASC Topic 718. For additional information regarding the assumptions made in calculating these amounts, see notes 2 and 8 to the financial statements included in Part II, Item 8 of this Annual Report. The shares underlying these option awards vest and become exercisable in three equal annual installments beginning on the first anniversary of their respective grant dates.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(2) </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Represents insurance premiums paid by the Company with respect to life insurance for the benefit of the named executive officer.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Employment Agreements and Change of Control Arrangements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The following is a summary of the employment arrangements with our named executive officers.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><strong><em>Francois Michelon</em></strong>. Effective May 12, 2017, the Company entered into an amended and restated employment agreement with Francois Michelon, our Chief Executive Officer and Chairman of the Board of Directors, which agreement was amended on December 27, 2019. Mr. Michelon&#8217;s employment with the Company is &#8220;at will&#8221; and may be terminated by him or the Company at any time and for any reason. Pursuant to the employment agreement, Mr. Michelon receives an annual base salary that is subject to adjustment at the Board of Directors&#8217; discretion. Effective January 1, 2021, the Compensation Committee increased Mr. Michelon&#8217;s annual salary to $376,991 and, effective January 1, 2022, it increased Mr. Michelon&#8217;s annual salary to $423,000. Mr. Michelon is also eligible for an annual cash bonus based upon achievement of performance-based objectives established by the Board of Directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">If Mr. Michelon&#8217;s employment is terminated by the Company without cause (as defined in the 2016 Plan) or if Mr. Michelon resigns for good reason (as defined in the employment agreement), Mr. Michelon will be entitled to receive, subject to his execution of a standard release agreement, 12 months&#8217; continuation of his current base salary and a lump sum payment equal to 12 months of continued healthcare coverage (or 24 months&#8217; continuation of his current base salary and a lump sum payment equal to 24 months of continued healthcare coverage if such termination occurs within one year following a change in control).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Under his employment agreement, Mr. Michelon is eligible to receive benefits that are substantially similar to those of the Company&#8217;s other senior executive officers.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><strong><em>Michael Thornton</em></strong>. Effective May 12, 2017, the Company entered into an amended and restated employment agreement with Michael Thornton, our Chief Technology Officer, which agreement was amended on December 27, 2019. The employment agreement provides that Mr. Thornton&#8217;s employment with the Company is &#8220;at will&#8221; and may be terminated by him or the Company at any time and for any reason. Pursuant to the employment agreement, Mr. Thornton receives an annual base salary that is subject to adjustment at the Board of Directors&#8217; discretion. Effective January 1, 2021, the Compensation Committee increased Mr. Thornton&#8217;s annual salary to $289,963 and, effective January 1, 2022, it increased Mr. Thornton&#8217;s annual salary to $324,000.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">If Mr. Thornton&#8217;s employment is terminated by the Company without cause (as defined in the 2016 Plan) or if Mr. Thornton resigns for good reason (as defined in the employment agreement), Mr. Thornton will be entitled to receive, subject to his execution of a standard release agreement, 12 months&#8217; continuation of his current base salary and a lump sum payment equal to 12 months of continued healthcare coverage (or 24 months&#8217; continuation of his current base salary and a lump sum payment equal to 24 months of continued healthcare coverage if such termination occurs within one year following a change in control).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">53</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Under his employment agreement, Mr. Thornton is eligible to receive benefits that are substantially similar to those of the Company&#8217;s other senior executive officers.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><strong><em>Renaud Maloberti. </em></strong>On April 15, 2019, the Company entered into an employment agreement with Renaud Maloberti that provides for an annual base salary of $250,000 and eligibility for an annual cash bonus to be paid based on attainment of Company and individual performance objectives to be established by the Board of Directors. Effective January 1, 2021, the Compensation Committee increased Mr. Maloberti&#8217;s annual salary to $266,255 and, effective January 1, 2022, it increased Mr. Maloberti&#8217;s annual salary to $296,000. The employment agreement also provides for eligibility to receive benefits substantially similar to those of the Company&#8217;s other senior executive officers.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">&#160;On December 21, 2022, Renaud Maloberti notified the Company of his resignation as the Company&#8217;s Chief Commercial Officer, effective January 13, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Pursuant to his employment agreement, on May 28, 2019, Mr. Maloberti was granted stock options to purchase 1,750 shares of the Company&#8217;s common stock. The stock options have an exercise price of $20.80 per share, and vested in three equal annual installments beginning on the first anniversary of the grant date. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Additionally, our named executive officers are eligible to participate in our health and welfare programs and 401(k) plan, and other benefit programs on the same basis as other employees.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Outstanding Equity Awards at 2022 Fiscal Year End</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The following table provides information regarding equity awards held by the named executive officers as of December 31, 2022. The number of securities underlying the equity awards and option exercise prices reflect the reverse stock split of our common stock at a ratio of 1-for-20, which was effective as of December 9, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="13"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Option Awards</strong></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Securities Underlying Unexercised Options (#) Exercisable</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Securities Underlying Unexercised Options (#) Unexercisable</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Option Exercise </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Price ($)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Option </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Expiration Date</strong></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Francois Michelon&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,366</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">100.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">5/12/25</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Chief Executive Officer</em></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,598</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">91.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">5/12/25</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">45.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">12/13/26</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,600</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">12/11/29</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">833</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,667</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">(1)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">53.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4/5/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">(2)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">53.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4/5/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">35,657</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">(3)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3/28/32</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Michael Thornton</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,667</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">100.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">5/12/25</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Chief Technology Officer</em></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,598</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">91.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">5/12/25</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">45.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">12/13/26</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28,796</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">12/11/29</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">833</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,667</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">(1)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">53.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4/5/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">(2)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">53.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4/5/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">34,906</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">(3)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3/28/32</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Renaud Maloberti</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,750</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">5/28/29</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Former Chief Commercial Officer</em></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,143</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">12/11/29</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">667</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">333</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">(4)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">35.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1/24/30</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">417</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">833</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">(1)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">53.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4/5/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,500</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">(2)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">53.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4/5/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">(2)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">47.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">6/10/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,322</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">(3)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">8.00</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3/28/32</p></td><td style="width:1%;">&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">54</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">(1)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Represents unvested portion of stock option award which vests in three equal annual installments beginning on April 5, 2022.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">(2)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Represents unvested portion of stock option award which vests as follows: (i) 25% vests upon the Company&#8217;s earning $5 million or more of revenue with a gross margin of 10% or greater, (ii) 25% vests upon the Company&#8217;s earning $10 million or more of revenue with a gross margin of 35% or greater, (iii) 25% vests upon the Company&#8217;s earning $15 million or more of revenue with a gross margin of 40% or greater, and (iv) 25% vests upon the Company&#8217;s earning $20 million or more of revenue with a gross margin of 50% or greater.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">(3)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Represents unvested portion of stock option award which vests in three equal annual installments beginning on March 28, 2023.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">(4)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Represents unvested portion of stock option award which vests in three equal annual installments beginning on January 25, 2021.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Equity Compensation Plan Table</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The following table presents information on the Company&#8217;s equity compensation plans as of December 31, 2022. All outstanding awards relate to our common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Plan Category</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Securities to Be Issued upon Exercise of Outstanding Options, Warrants and Rights</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(a)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(b)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Securities Remaining Available for Future Issuance under Equity Compensation Plans (Excluding Securities Reflected in Column (a))</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(c)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity compensation plans approved by security holders</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">402,232</td><td style="width:1%;vertical-align:top;white-space: nowrap;"><sup style="vertical-align:super">(1)</sup></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">31.47</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">51,972</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><sup style="vertical-align:super">(2)</sup></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity compensation plans not approved by security holders</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Total</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">402,232</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">31.47</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">51,972</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">_________________</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(1) </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Consists of outstanding stock options exercisable for shares of common stock issued under the 2016 Plan&#160;&#160;&#160;&#160; .</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(2) </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">As of January 1, 2023, as a result of an automatic increase to the pool of shares available for issuance under the 2016 Plan on such date, the number of shares available for future issuance under the 2016 Plan was 919,937 shares.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Director Compensation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Effective April 9, 2020, the Company adopted a non-employee director compensation policy (the &#8220;<span style="text-decoration:underline">Compensation Policy</span>&#8221;) pursuant to which each of our non-employee directors receives, upon his or her initial election to the Board of Directors, a stock option exercisable for 2,500 shares of common stock with a per share exercise price equal to the closing price of the common stock on the Nasdaq on the grant date. All such stock options vest in three equal annual installments beginning on the one-year anniversary of the grant date. Under the Compensation Policy, on the first trading day of each calendar year, each non-employee director is awarded a stock option exercisable for 600 shares of common stock, with a per share exercise price equal to the closing price of the common stock on the Nasdaq on the grant date, which becomes exercisable on the first anniversary of its grant date. Additionally, pursuant to the Compensation Policy, each non-employee director is paid an annual cash retainer of $40,000, prorated for partial years of service and paid quarterly in arrears. Effective January 30, 2023, the Board of Directors adopted a revised Compensation Policy, pursuant to which each annual option grant will become exercisable in three equal annual installments beginning on the first anniversary of the grant date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">55</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The following table sets forth information with respect to compensation earned by or awarded to each of our non-employee directors who served on the Board of Directors during the fiscal year ended December 31, 2022:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Name</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fees Earned or </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Paid in Cash ($)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Option </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Awards ($)<sup style="vertical-align:super">(1)</sup></strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total ($)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Louis Basenese</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,120</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>70,120</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Anthony DiGiandomenico</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,502</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>80,502</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Michael Harsh</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,552</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>80,552</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Alexander Tokman</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,502</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>80,502</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(1) </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The amounts shown in this column indicate the grant date fair value of option awards granted in the subject year computed in accordance with FASB ASC Topic 718. For additional information regarding the assumptions made in calculating these amounts, see Notes 2 and 8 to the audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022. The following table shows the number of shares subject to outstanding option awards held by each non-employee director as of December 31, 2022:</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Name</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares Subject to Outstanding Option </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Awards (#)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Louis Basenese</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,175</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Anthony DiGiandomenico</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,401</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Michael Harsh</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,426</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Alexander Tokman</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,401</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="a21">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholders Matters.</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The following tables set forth certain information regarding beneficial ownership of our voting stock as of March 16, 2023 by:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">each person or group of affiliated persons known by us to be the beneficial owner of more than 5% of any class of our voting stock;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">each named executive officer included in the Summary Compensation Table below;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">each of our directors;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">each person nominated to become director; and</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">all executive officers, directors and nominees as a group.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Unless otherwise noted below, the address of each person listed in the tables is c/o ENDRA Life Sciences Inc. at 3600 Green Court, Suite 350, Ann Arbor, Michigan 48105. To our knowledge, each person listed below has sole voting and investment power over the shares shown as beneficially owned except to the extent jointly owned with spouses or otherwise noted below.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Beneficial ownership is determined in accordance with the rules of the SEC. The information does not necessarily indicate ownership for any other purpose. Under these rules, shares of stock which a person has the right to acquire (<em>i.e.</em>, by the exercise of any option or warrant) within 60 days after March 16, 2023 are deemed to be beneficially owned and outstanding for purposes of calculating the number of shares and the percentage beneficially owned by that person. However, these shares are not deemed to be beneficially owned and outstanding for purposes of computing the percentage beneficially owned by any other person. The applicable percentages of stock outstanding as of March 16, 2023 is based upon 3,169,103 shares of common stock and 141.397 shares of Series A Preferred Stock outstanding on that date. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">56</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Beneficial Ownership</strong>&#160;&#160;&#160;&#160; </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Name of</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Beneficial</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Owner</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares of</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Common</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Stock</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Beneficially</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Owned</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Percentage</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>of Common</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Stock</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Beneficially</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Owned</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares of</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Series A</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Preferred</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Stock</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Beneficially</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Owned</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Percentage</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>of Series A</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Preferred</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Stock</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Beneficially</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Owned</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Francois Michelon</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">72,333</p></td><td style="width:1%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><sup style="vertical-align:super">(1)</sup><sup style="vertical-align:super"></sup></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"/><td style="width:9%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2.2</p></td><td style="width:1%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Michael Thornton</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">85,964</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><sup style="vertical-align:super">(2)</sup><sup style="vertical-align:super"></sup></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2.7</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Renaud Maloberti</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8,913</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><sup style="vertical-align:super">(3)</sup><sup style="vertical-align:super"></sup></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">*</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Irina Pestrikova</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2,208</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><sup style="vertical-align:super">(4)</sup><sup style="vertical-align:super"></sup></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">*</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Louis Basenese</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">9,896</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><sup style="vertical-align:super">(5)</sup><sup style="vertical-align:super"></sup></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">*</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Anthony DiGiandomenico</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">31,441</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><sup style="vertical-align:super">(6)</sup><sup style="vertical-align:super"></sup></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">*</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Michael Harsh</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">16,118</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><sup style="vertical-align:super">(7)</sup><sup style="vertical-align:super"></sup></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">*</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Alexander Tokman</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">20,483</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><sup style="vertical-align:super">(8)</sup><sup style="vertical-align:super"></sup></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">*</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">All directors and executive officers as a group (8 persons)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">247,356</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7.4</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>5% Stockholders</em></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Michael Bryan, Sr.<sup style="vertical-align:super">(9)</sup></em></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">192,500</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6.1</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Mark R. Busch<sup style="vertical-align:super">(10)</sup></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">17.488</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12.4</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Donald Kendall<sup style="vertical-align:super">(11)</sup></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">106.421</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">75.3</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Juan R. Rivero<sup style="vertical-align:super">(12)</sup></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">17.488</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12.4</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%</p></td><td/></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">* Less than one percent.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">(1) Consists of 4,860 shares of common stock, 67,366 shares of common stock issuable upon the exercise of options that are presently exercisable or becoming exercisable within 60 days of March 16, 2023 and 107 shares of common stock issuable upon the exercise of restricted warrants.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">(2) Consists of 19,139 shares of common stock, 65,613 shares of common stock issuable upon the exercise of options that are presently exercisable or becoming exercisable within 60 days of March 16, 2023 and 1,212 shares of common stock issuable upon the exercise of restricted warrants.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">(3) Consists of 79 shares of common stock and 8,834 shares of common stock issuable upon the exercise of options that are presently exercisable or becoming exercisable within 60 days of March 16, 2023.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">(4) Consists of 2,208 shares of common stock issuable upon the exercise of options that are presently exercisable or becoming exercisable within 60 days of March 16, 2023.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">(5) Consists of 2,454 shares of common stock and 7,442 shares of common stock issuable upon the exercise of options that are presently exercisable or becoming exercisable within 60 days of March 16, 2023.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">(6) Consists of 19,101 shares of common stock, 12,340 shares of common stock issuable upon the exercise of options that are presently exercisable or becoming exercisable within 60 days of March 16, 2023 and 23,944 shares of common stock issuable upon the exercise of restricted warrants.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">(7) Consists of 3,457 shares of common stock, 12,359 shares of common stock issuable upon the exercise of options that are presently exercisable or becoming exercisable within 60 days of March 16, 2023 and 302 shares of common stock issuable upon the exercise of restricted warrants.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">(8) Consists of 8,143 shares of common stock and 12,340 shares of common stock issuable upon the exercise of options that are presently exercisable or becoming exercisable within 60 days of March 16, 2023.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">(9) According to the Schedule 13G filed on March 10, 2023 by Michael Bryan, Sr., Mr. Bryan beneficially owns 192,500 shares of common stock. The address of Mr. Bryan is 51 Wentworth Rd., Rye, New Hampshire 03870.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">(10) Shares jointly owned with spouse. Mr. Busch&#8217;s address is 300 S. Tryon St., Suite 1000, Charlotte, NC 28202.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">(11) Mr. Kendall&#8217;s address is 2000 Edwards Street, Suite B-100, Houston, TX 77007. Shares jointly owned with spouse. Mr. Busch&#8217;s address is 300 S. Tryon St., Suite 1000, Charlotte, NC 28202.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">(12) Mr. Rivero&#8217;s address is 14521 Jockey Circle, N. Davie, FL 33330.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">57</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="a22">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Policy for Review of Related Person Transactions</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Board of Directors has adopted a written policy with regard to related person transactions, which sets forth our procedures and standards for the review, approval or ratification of any transaction required to be reported in our filings with the SEC or in which one of our executive officers or directors has a direct or indirect material financial interest, with limited exceptions. Our policy is that the Corporate Governance and Nominating Committee shall review the material facts of all related person transactions (as defined in the related person transaction approval policy) and either approve or disapprove of the entry into any related person transaction. In the event that obtaining the advance approval of the Corporate Governance and Nominating Committee is not feasible, the Corporate Governance and Nominating Committee shall consider the related person transaction and, if the Corporate Governance and Nominating Committee determines it to be appropriate, may ratify the related person transaction. In determining whether to approve or ratify a related person transaction, the Corporate Governance and Nominating Committee will take into account, among other factors it deems appropriate, whether the related person transaction is on terms comparable to those available from an unaffiliated third-party under the same or similar circumstances and the extent of the related person's interest in the transaction.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Related Person Transactions</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">SEC regulations define the related person transactions that require disclosure to include any transaction, arrangement or relationship in which the amount involved exceeds the lesser of (a) $120,000 or (b) one percent of the average of the Company&#8217;s total assets at year-end for the last two completed fiscal years in which it was or is to be a participant and in which a related person had or will have a direct or indirect material interest. A related person is: (i) an executive officer, director or director nominee of the Company, (ii) a beneficial owner of more than 5% of any class of the Company&#8217;s voting securities, (iii) an immediate family member of an executive officer, director or director nominee or beneficial owner of more than 5% of any class of the Company&#8217;s voting securities, or (iv) any entity that is owned or controlled by any of the foregoing persons or in which any of the foregoing persons has a substantial ownership interest or control.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Since January 1, 2021, the Company has not participated in any such related party transaction.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="a23">Item 14. Principal Accountant Fees and Services</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">RBSM audited our financial statements for the year ended December 31, 2022. The following table sets forth the aggregate fees billed or expected to be billed by RBSM for audit and non-audit services in 2022 and 2021, including &#8220;out-of-pocket&#8221; expenses incurred in rendering these services. The nature of the services provided for each category is described following the table.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fee Category</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Audit Fees (1)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">146,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">112,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Audit-Related Fees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#8210; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Tax Fees (2)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">176,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">125,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">_________________ </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(1) </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Audit fees include fees for professional services rendered for the audit of our annual statements, quarterly reviews, consents and assistance with and review of documents filed with the SEC.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(2) </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Tax fees include fees (or, for 2022, estimated fees) for professional services rendered for tax compliance, tax advice and tax planning.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">58</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="a24">PART IV</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="a25">Item 15. Exhibits, Financial Statements and Schedules</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">(a) List of documents filed as part of this report:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">1. Financial Statements (see &#8220;Financial Statements and Supplementary Data&#8221; at Item 8 and incorporated herein by reference)</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">2. Financial Statement Schedules (Schedules to the Financial Statements have been omitted because the information required to be set forth therein is not applicable or is shown in the accompanying Financial Statements or notes thereto)</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">3. Exhibits</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The following is a list of exhibits filed as part of this Annual Report:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Exhibit </strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td style="BORDER-BOTTOM: #000000 1px solid;" colspan="3"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Incorporated by Reference</strong></p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:8%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Number</strong></p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Exhibit Description</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Filed&#160;Herewith</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Form</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exhibit</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Filing Date</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495417004582/ndra_ex32.htm">3.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495417004582/ndra_ex32.htm">Fourth Amended and Restated Certificate of Incorporation of the Company</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3.2</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">05/12/17</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495422016272/endra_ex31.htm">3.2</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495422016272/endra_ex31.htm">Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3.1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">12/08/22</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495416004599/end_ex34.htm">3.3</a></span></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495416004599/end_ex34.htm">Amended and Restated Bylaws of the Company</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">S-1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3.4</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">12/06/16</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495416004197/end_ex41.htm">4.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495416004197/end_ex41.htm">Specimen Certificate representing shares of common stock of the Company</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">S-1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4.1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">11/21/16</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495416004197/end_ex44.htm">4.2</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495416004197/end_ex44.htm">Form of Warrant Agreement and Warrant comprising a part of the Company&#8217;s units issued in its 2017 initial public offering</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">S-1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4.2</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">11/21/16</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495416004197/end_ex45.htm">4.3</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495416004197/end_ex45.htm">Form of Underwriters&#8217; Warrant issued to certain designees of the underwriters in the Company&#8217;s 2017 initial public offering</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">S-1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4.3</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">11/21/16</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495418012009/ndra_ex46.htm">4.5</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495418012009/ndra_ex46.htm">Form of Underwriters&#8217; Warrant issued to certain designees of the underwriters in the Company&#8217;s October 2018 offering</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-Q </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4.6 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">11/05/18 </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495419008564/ndra_ex4-2.htm">4.7</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495419008564/ndra_ex4-2.htm">Form of Warrant issued in July 2019 Private Placement</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4.2</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">07/29/19</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495419013822/ndra_ex41.htm">4.8</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495419013822/ndra_ex41.htm">Certificate of Designations of Series A Convertible Preferred Stock</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4.1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">12/11/19</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495419013822/ndra_ex42.htm">4.9</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495419013822/ndra_ex42.htm">Form of Warrant issued in December 2019 Series A Convertible Preferred Stock Offering</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4.2</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">12/11/19</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495419014235/ndra_ex41.htm">4.10</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495419014235/ndra_ex41.htm">Certificate of Designations of Series B Convertible Preferred Stock</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4.1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">12/26/19</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495419014235/ndra_ex42.htm">4.11</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495419014235/ndra_ex42.htm">Form of Warrant issued in December 2019 Series B Convertible Preferred Stock Offering</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4.2</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">12/26/19</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495422012997/ndra_ex31.htm">4.12</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495422012997/ndra_ex31.htm">Certificate of Designations of Series C Preferred Stock</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3.1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">09/27/22</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495422004172/ndra_ex412.htm">4.13</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495422004172/ndra_ex412.htm">Description of Securities</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4.12</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">03/30/22&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495416004599/end_ex104.htm">10.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495416004599/end_ex104.htm">ENDRA Life Sciences Inc. 2016 Omnibus Incentive Plan *</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">S-1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10.4</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">12/06/16</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000121390018005842/def14a061218_endralife.htm">10.2</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000121390018005842/def14a061218_endralife.htm">First Amendment to ENDRA Life Sciences Inc. 2016 Omnibus Incentive Plan*</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">DEF 14A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Appx. A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">05/10/18</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495416004599/end_ex105.htm">10.3</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495416004599/end_ex105.htm">Form of Stock Option Award under 2016 Omnibus Incentive Plan*</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">S-1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10.5</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">12/06/16</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495416004599/end_ex106.htm">10.4</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495416004599/end_ex106.htm">Form of Restricted Stock Unit Award under 2016 Omnibus Incentive Plan*</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">S-1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10.6</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">12/06/16</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495420009164/ndra_ex102.htm">10.5</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495420009164/ndra_ex102.htm">Non-Employee Director Compensation Policy, effective April 9, 2020*</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-Q</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10.2</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">08/14/20</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ndra_ex106.htm">10.6</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ndra_ex106.htm">Non-Employee Director Compensation Policy, effective January 30,&#160; 2023*</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">x</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495416004197/end_ex108.htm">10.6</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495416004197/end_ex108.htm">Form of Indemnification Agreement by and between the Company and each of its directors and executive officers*</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">S-1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10.8</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">11/21/16</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495417004582/ndra_ex101.htm">10.7</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495417004582/ndra_ex101.htm">Amended and Restated Employment Agreement, dated May 12, 2017, by and between the Company and Francois Michelon*</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10.1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">05/12/17</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495419014269/ndra_ex101.htm">10.8</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495419014269/ndra_ex101.htm">First Amendment to Employment Agreement, dated December 27, 2019, by and between the Company and Francois Michelon*</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10.1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">12/27/19</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495417004582/ndra_ex102.htm">10.9</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495417004582/ndra_ex102.htm">Amended and Restated Employment Agreement, dated May 12, 2017, by and between the Company and Michael Thornton*</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10.2</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">05/12/17</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">59</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="width:8%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495419014269/ndra_ex102.htm">10.10</a></p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495419014269/ndra_ex102.htm">First Amendment to Employment Agreement, dated December 27, 2019, by and between the Company and Michael Thornton*</a></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:8%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:8%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:8%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10.2</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:8%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">12/27/19</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495416004197/end_ex1017.htm">10.11</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495416004197/end_ex1017.htm">Collaborative Research Agreement, dated April 22, 2016, by and between the Company and General Electric Company</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">S-1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10.17</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">11/21/16</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495417003973/end_ex1021.htm">10.12</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495417003973/end_ex1021.htm">Amendment to Collaborative Research Agreement, dated April 21, 2017, by and between the Company and General Electric Company</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">S-1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10.21</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">05/03/17</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495418001062/ndra_ex101.htm">10.13</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495418001062/ndra_ex101.htm">Amendment 2 to Collaborative Research Agreement, dated January 30, 2018, by and between the Company and General Electric Company</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10.1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">01/30/18</p></td></tr></tbody></table><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="width:8%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495420000453/ndra_ex101.htm">10.14</a></p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495420000453/ndra_ex101.htm">Amendment 3 to Collaborative Research Agreement, dated January 13, 2020, by and between the Company and General Electric Company</a></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:8%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:8%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:8%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10.1</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:8%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">01/15/20</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495420013801/ndra_ex101.htm">10.15</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495420013801/ndra_ex101.htm">Amendment 4 to Collaborative Research Agreement, dated December 16, 2020, by and between the Company and General Electric Company</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10.1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">12/21/20</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495422016650/endra_ex101.htm">10.16</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495422016650/endra_ex101.htm">Amendment 5 to Collaborative Research Agreement, dated December 16, 2022, by and between the Company and General Electric Company</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10,1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">12/19/22</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495416004197/end_ex1018.htm">10.17</a></span></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495416004197/end_ex1018.htm">Gross Lease, dated January 1, 2015, between the Company and Green Court LLC</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">S-1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10.18</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">11/21/16</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495418005414/ndra_ex10-2.htm">10.18</a></span></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495418005414/ndra_ex10-2.htm">Amendment to Gross Lease, dated October 10, 2017, by and between the Company and Green Court LLC</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-Q</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10.2</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">05/15/18</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495421003302/ndra_ex1018.htm">10.19</a></span></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495421003302/ndra_ex1018.htm">Second Amendment to Lease, dated March 15, 2021, by and between the Company and Green Court LLC</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10.18</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">03/25/21</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495418002829/ndra_ex1019.htm"><span style="text-decoration:underline">10.2</span><span style="text-decoration:underline">0</span></a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495418002829/ndra_ex1019.htm">Consulting Agreement, dated October 31, 2017, by and between the Company and StarFish Product Engineering, Inc.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10.16</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">03/20/18</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495419009079/ndra_ex102.htm"><span style="text-decoration:underline">10.2</span><span style="text-decoration:underline">1</span></a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1681682/000165495419009079/ndra_ex102.htm">Employment Agreement, dated April 20, 2019, by and between the Company and Renaud Maloberti*</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-Q</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10.2</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">08/08/19</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ndra_ex211.htm">21.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ndra_ex211.htm">Subsidiaries of the Company</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">21.1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;03/30/22</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ndra_ex231.htm">23.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ndra_ex231.htm">Consent of RBSM LLP, Independent Registered Public Accounting Firm (with respect to Form S-3)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">x</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ndra_ex232.htm">23.2</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ndra_ex232.htm">Consent of RBSM LLP, Independent Registered Public Accounting Firm (with respect to Form S-8)</a> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">x</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#POA">24.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#POA">Power of Attorney (included on signature page)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">x</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ndra_ex311.htm">31.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ndra_ex311.htm">Certification Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">x</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ndra_ex312.htm">31.2</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ndra_ex312.htm">Certification Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">x</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ndra_ex321.htm">32.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ndra_ex321.htm">Certification Pursuant to 18 U.S.C Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">x</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.INS </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">XBRL Instance Document</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">x</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.SCH</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">XBRL Taxonomy Schema</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">x</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.CAL</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">XBRL Taxonomy Extension Calculation Linkbase</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">x</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.DEF</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">XBRL Taxonomy Extension Definition Linkbase</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">x</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.LAB</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">XBRL Taxonomy Extension Label Linkbase</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">x</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.PRE</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">XBRL Taxonomy Extension Presentation Linkbase</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">x</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">________________</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>* </strong>Indicates management compensatory plan, contract or arrangement.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="a26">Item 16. Form 10-K Summary</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">None.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">60</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOCMF">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SIGNATURES</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">ENDRA Life Sciences Inc.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="width:50%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:35%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Dated: March 16, 2023</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Francois Michelon</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Francois Michelon</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Executive Officer and Director</p><p style="font-size:10pt;font-family:times new roman;margin:0px">(Principal Executive Officer)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="POA">POWER OF ATTORNEY AND SIGNATURES</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We, the undersigned officers and directors of ENDRA Life Sciences Inc., hereby severally constitute and appoint Francois Michelon our true and lawful attorney, with full power to him to sign for us and in our names in the capacities indicated below, any amendments to this Annual Report on Form 10-K, and generally to do all things in our names and on our behalf in such capacities to enable ENDRA Life Sciences Inc. to comply with the provisions of the Securities Exchange Act of 1934, as amended, and all the requirements of the Securities Exchange Commission.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:35%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Signatures</strong></p></td><td style="width:5%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Title</strong></p></td><td style="width:5%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:15%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Date</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Francois Michelon</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Executive Officer and Director (Principal Executive Officer)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">March 16, 2023</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Francois Michelon</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Irina Pestrikova</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Senior Director, Finance (Principal Financial and Accounting Officer)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">March 16, 2023</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Irina Pestrikova</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Louis J. Basenese</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">March 16, 2023</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Louis J. Basenese</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Anthony DiGiandomenico</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">March 16, 2023</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Anthony DiGiandomenico</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Michael Harsh</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">March 16, 2023</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Michael Harsh</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Alexander Tokman</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">March 16, 2023</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Alexander Tokman</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">61</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>2
<FILENAME>ndra_ex106.htm
<DESCRIPTION>NON-EMPLOYEE DIRECTOR COMPENSATION POLICY
<TEXT>
<html><head><title>ndra_ex106.htm</title><!--Document created using EDGARMaster--></head><body style="COLOR: #000000; TEXT-ALIGN: justify; FONT: 10pt Times New Roman"><p style="MARGIN: 0px; text-align:right;"><strong>EXHIBIT 10.6</strong></p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:center;"><strong>&nbsp;</strong><strong>ENDRA Life Sciences Inc.</strong></p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:center;"><strong>&nbsp;</strong><strong>Non-Employee Director Compensation Policy</strong></p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:center;"><strong>&nbsp;</strong><strong>(Adopted by the ENDRA Life Sciences Inc. Board of Directors, effective January 30, 2023)</strong></p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">Members of the Board of Directors (the &#8220;<u>Board</u>&#8221;) of ENDRA Life Sciences Inc. (the &#8220;<u>Company</u>&#8221;) who are not employees of the Company or any subsidiary of the Company (&#8220;<u>Directors</u>&#8221;) shall be paid the following amounts in consideration for their services on the Board. </p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><u>Initial Option Grant</u></strong></p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">Upon his or her initial election to the Board (the &#8220;<u>Appointment Date</u>&#8221;), each new Director shall be awarded 2,500 Options (an &#8220;<u>Initial Option Grant</u>&#8221;) under the Company&#8217;s 2016 Omnibus Incentive Plan (the &#8220;<u>Plan</u>&#8221;). Such Options shall vest and become exercisable in three equal annual installments beginning on the one year anniversary of the Grant Date; provided, if a Director ceases to serve as a Director due to the Director&#8217;s death, or if there is a Change in Control, then any remaining unvested portion of such Options shall become fully exercisable as of the date of such death or Change in Control. If a Director ceases to serve as a Director at any time for any reason other than death or a Change in Control, then any remaining unvested portion of such Options shall be forfeited as of the date of such cessation of services. </p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><u>Annual Compensation</u></strong></p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"><strong><em>Cash Compensation</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">Each Director shall be paid an annual cash retainer of $40,000, prorated for partial years of service and paid quarterly in arrears. </p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Equity Compensation</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">On the first trading day of each calendar year (each, an &#8220;<u>Option Grant Date</u>&#8221;), each Director will be awarded 600 Options (each, an &#8220;<u>Annual Option Award</u>&#8221;). Such Options shall become exercisable in three equal annual installments beginning on the one year anniversary of the Grant Date (each, an &#8220;<u>Annual Award Vesting Date</u>&#8221;). If a Director ceases to serve as a Director before the final Annual Award Vesting Date due to the Director&#8217;s death, or if there is a Change in Control prior to the final Annual Award Vesting Date, then all Annual Option Awards shall become fully exercisable as of the date of such death or Change in Control. If a Director ceases to serve as a Director at any time for any reason other than death before an Annual Award Vesting Date or a Change in Control, then the portion of any unvested Annual Option Awards that would have vested on the first Annual Award Vesting Date following such cessation of service shall become vested pro rata (based on the number of days between the Option Grant Date or prior Annual Award Vesting Date with respect to such Annual Option Award, as applicable, and the date of cessation of services divided by 365), and to the extent any Annual Option Awards are not thereby exercisable, they shall be forfeited as of the date of such cessation of services. </p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="MARGIN: 0px; text-align:center;">1</p></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><u>Equity Award Terms</u></strong><u></u></p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">Capitalized terms used in this Policy and not otherwise defined shall have the meanings given to them in the Plan, or any successor equity compensation plan under which Directors receive awards (the &#8220;<u>Plan</u>&#8221;). Any Options granted under this Policy shall be granted under and pursuant to the Plan. Any Options issued in accordance with the terms of this Policy shall have a term of ten years and shall be exercisable through the date that is 12 months following the date the Director ceases to serve as a Director unless otherwise provided in the Plan. The Board, in its sole discretion and in recognition for meritorious service, may elect to vest up to 100% of a Director&#8217;s unvested equity awards upon retirement.</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"><strong><u>Expense Reimbursement</u></strong></p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">The compensation described in this Policy is in addition to reimbursement of all reasonable out-of-pocket expenses incurred by Directors in attending meetings of the Board.</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"><strong><u>Employee Directors</u></strong></p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">An employee of the Company who serves as a director on the Board or on the board of directors of a Company subsidiary shall not receive any additional compensation for such service.</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"><strong><u>Section 409A</u></strong></p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">This Policy is intended to comply with Code Section 409A to the extent subject thereto, and, accordingly, to the maximum extent permitted, the Policy shall be interpreted and administered to be in compliance therewith.</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="MARGIN: 0px; text-align:center;">2</p></td></tr></table></p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>ndra_ex211.htm
<DESCRIPTION>SUBSIDIARIES OF THE COMPANY
<TEXT>
<html><head><title>ndra_ex211.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: left; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 21.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Subsidiaries of the Registrant</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">ENDRA Life Sciences Canada Inc. is a corporation formed under the laws of Ontario, Canada in July 2017 and is wholly owned by the Company.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">ENDRA Life Sciences Holding B.V. was organized under the laws of The Netherlands on July 27, 2020 and is wholly owned by the Company.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">ENDRA Life Sciences Ltd. was organized under the laws of the United Kingdom on August 5, 2020 and is wholly owned by ENDRA Life Sciences Holding B.V.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">ENDRA Life Sciences B.V. was organized under the laws of The Netherlands on August 11, 2020 and is wholly owned by ENDRA Life Sciences Holding B.V.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">ENDRA Life Sciences GmbH was organized under the laws of Germany on September 9, 2020 and is wholly owned by ENDRA Life Sciences Holding B.V.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">ENDRA Life Sciences S.A.R.L. was organized under the laws of France on January 26, 2021 and is wholly owned by ENDRA Life Sciences Holding B.V.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ndra_ex231.htm
<DESCRIPTION>CONSENT
<TEXT>
<html><head><title>ndra_ex231.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: left; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 23.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (File Nos. 333-235883, 333-233466, 333-226785 and 333-254711) of our report dated March 16, 2023 on the consolidated financial statements of ENDRA Life Sciences Inc. and its subsidiaries, appearing in this Annual Report on Form 10-K of ENDRA Life Sciences Inc. for the year ended December 31, 2022.&nbsp; Our report includes an explanatory paragraph expressing substantial doubt regarding the Company&#8217;s ability to continue as a going concern.&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">/s/ RBSM LLP</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">New York, New York</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">March 16, 2023</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>5
<FILENAME>ndra_ex232.htm
<DESCRIPTION>CONSENT
<TEXT>
<html><head><title>ndra_ex232.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: left; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 23.2</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (File Nos. 333-233178, 333-218894, 333-237415, 333-254713 and 333-263992) of our report dated March 16, 2023 on the consolidated financial statements of ENDRA Life Sciences Inc. and its subsidiaries, appearing in this Annual Report on Form 10-K of ENDRA Life Sciences Inc. for the year ended December 31, 2022.&nbsp; Our report includes an explanatory paragraph expressing substantial doubt regarding the Company&#8217;s ability to continue as a going concern.&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">/s/ RBSM LLP</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">New York, New York</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">March 16, 2023</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>ndra_ex311.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>ndra_ex311.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: left; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">I, Francois Michelon, certify that:</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">1.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">I have reviewed this Annual Report on Form 10-K of ENDRA Life Sciences Inc.;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">2.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">3.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">4.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">b)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">c)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">d)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">b)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Date: March 16, 2023</p> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">/s/ Francois Michelon</p></td> <td style="width:15%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Name: Francois Michelon</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Title: Chief Executive Officer</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>ndra_ex312.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>ndra_ex312.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: left; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31.2</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">I, Irina Pestrikova, certify that:</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">1.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">I have reviewed this Annual Report on Form 10-K of ENDRA Life Sciences Inc.;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px">2.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px">3.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px">4.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">b)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">c)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">d)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">b)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Date: March 16, 2023</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">/s/ Irina Pestrikova</p></td> <td style="width:15%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name: Irina Pestrikova</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Title: Senior Director, Finance</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">(Principal Financial Officer and Principal Accounting Officer)</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>ndra_ex321.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>ndra_ex321.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: left; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 32.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATION PURSUANT TO</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>18 U.S.C. SECTION 1350,</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>AS ADOPTED PURSUANT TO</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">In connection with the Annual Report on Form 10-K of ENDRA Life Sciences Inc. (the &#8220;Company&#8221;) for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), we, Francois Michelon, Chief Executive Officer of the Company, and Irina Pestrikova, Senior Director, Finance of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, to our knowledge that:</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">(1)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px">(2)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">A signed original of this written statement required by Section 906 has been provided to ENDRA Life Sciences Inc. and will be retained by ENDRA Life Sciences Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Francois Michelon</p></td> <td style="width:15%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Irina Pestrikova </p></td> <td style="width:15%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Name: Francois Michelon</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Name: Irina Pestrikova</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Title: Chief Executive Officer</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Title: Senior Director, Finance</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">(Principal Executive Officer)</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">(Principal Financial Officer and Principal Accounting Officer)</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Date: March 16, 2023</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Date: March 16, 2023</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>ndra-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 03/16/2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:srt="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ndra="http://novaworks.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://novaworks.com/20221231">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://novaworks.com/role/Cover" id="Cover">
        <link:definition>000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
        <link:definition>000002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
        <link:definition>000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
        <link:definition>000004 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity" id="ConsolidatedStatementsOfStockholdersEquity">
        <link:definition>000005 - Statement - Consolidated Statements of Stockholders Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
        <link:definition>000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/NatureOfTheBusiness" id="NatureOfTheBusiness">
        <link:definition>000007 - Disclosure - Nature of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>000008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/Inventory" id="Inventory">
        <link:definition>000009 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/FixedAssets" id="FixedAssets">
        <link:definition>000010 - Disclosure - Fixed Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/AccountsPayableAndAccruedLiabilities" id="AccountsPayableAndAccruedLiabilities">
        <link:definition>000011 - Disclosure - Accounts Payable and Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/BankLoans" id="BankLoans">
        <link:definition>000012 - Disclosure - Bank Loans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/CapitalStock" id="CapitalStock">
        <link:definition>000013 - Disclosure - Capital Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsus" id="CommonStockOptionsAndRestrictedStockUnitsRsus">
        <link:definition>000014 - Disclosure - Common Stock Options and Restricted Stock Units (RSUs)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/CommonStockWarrants" id="CommonStockWarrants">
        <link:definition>000015 - Disclosure - Common Stock Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>000016 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>000017 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>000018 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>000019 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>000020 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/FixedAssetsTables" id="FixedAssetsTables">
        <link:definition>000021 - Disclosure - Fixed Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/AccountsPayableAndAccruedLiabilitiesTables" id="AccountsPayableAndAccruedLiabilitiesTables">
        <link:definition>000022 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusTables" id="CommonStockOptionsAndRestrictedStockUnitsRsusTables">
        <link:definition>000023 - Disclosure - Common Stock Options and Restricted Stock Units (RSUs)(Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/CommonStockWarrantsTables" id="CommonStockWarrantsTables">
        <link:definition>000024 - Disclosure - Common Stock Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
        <link:definition>000025 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <link:definition>000026 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>000027 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
        <link:definition>000028 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/InventoryDetailsNarrative" id="InventoryDetailsNarrative">
        <link:definition>000029 - Disclosure - Inventory (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/FixedAssetsDetails" id="FixedAssetsDetails">
        <link:definition>000030 - Disclosure - Fixed Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/FixedAssetsDetailsNarrative" id="FixedAssetsDetailsNarrative">
        <link:definition>000031 - Disclosure - Fixed Assets (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/AccountsPayableAndAccruedLiabilitiesDetails" id="AccountsPayableAndAccruedLiabilitiesDetails">
        <link:definition>000032 - Disclosure - Accounts Payable and Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/BankLoansDetailsNarrative" id="BankLoansDetailsNarrative">
        <link:definition>000033 - Disclosure - Bank Loans (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/CapitalStockDetailsNarrative" id="CapitalStockDetailsNarrative">
        <link:definition>000034 - Disclosure - Capital Stock (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetails" id="CommonStockOptionsAndRestrictedStockUnitsRsusDetails">
        <link:definition>000035 - Disclosure - Common Stock Options and Restricted Stock Units (RSUs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetailsNarrative" id="CommonStockOptionsAndRestrictedStockUnitsRsusDetailsNarrative">
        <link:definition>000036 - Disclosure - Common Stock Options and Restricted Stock Units (RSUs) (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/CommonStockWarrantsDetails" id="CommonStockWarrantsDetails">
        <link:definition>000037 - Disclosure - Common Stock Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <link:definition>000038 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
        <link:definition>000039 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
        <link:definition>000040 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
        <link:definition>000041 - Disclosure - Income Taxes (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://novaworks.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
        <link:definition>000042 - Disclosure - Income Taxes (Details narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="ndra-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ndra-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ndra-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ndra-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
  <import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
  <import namespace="http://fasb.org/srt-roles/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd" />
  <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
  <import namespace="http://fasb.org/us-roles/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" />
  <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
  <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <element id="ndra_StockPayable" name="StockPayable" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_SeriesAConvertiblePreferredStockConvertedToCommonStockShares" name="SeriesAConvertiblePreferredStockConvertedToCommonStockShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_SeriesAConvertiblePreferredStockConvertedToCommonStockAmount" name="SeriesAConvertiblePreferredStockConvertedToCommonStockAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_CommonStockIssuedForCashNetOfFundingCostsShares" name="CommonStockIssuedForCashNetOfFundingCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_CommonStockIssuedForCashNetOfFundingCostsAmount" name="CommonStockIssuedForCashNetOfFundingCostsAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_CommonStockIssuedForWarrantExerciseShares" name="CommonStockIssuedForWarrantExerciseShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_CommonStockIssuedForWarrantExerciseAmount" name="CommonStockIssuedForWarrantExerciseAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_CommonStockIssuedForOptionExerciseShares" name="CommonStockIssuedForOptionExerciseShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_CommonStockIssuedForOptionExerciseAmount" name="CommonStockIssuedForOptionExerciseAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_FairValueOfVestedStockOptions" name="FairValueOfVestedStockOptions" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_CommonStockIssuedForServicesShares" name="CommonStockIssuedForServicesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_CommonStockIssuedForServicesAmount" name="CommonStockIssuedForServicesAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_StockIssuedForRsuShares" name="StockIssuedForRsuShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_StockIssuedForRsuAmount" name="StockIssuedForRsuAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_DeemedDividend" name="DeemedDividend" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_FixedAssetsWriteOff" name="FixedAssetsWriteOff" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_SupplementalDisclosuresOfNoncashItemsAbstract" name="SupplementalDisclosuresOfNoncashItemsAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_ConversionOfSeriesAConvertiblePreferredStock" name="ConversionOfSeriesAConvertiblePreferredStock" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_StockDividendPayable" name="StockDividendPayable" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_LeaseLiability" name="LeaseLiability" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock" name="ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock" name="ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_ResearchAndDevelopmentExpense1" name="ResearchAndDevelopmentExpense1" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_SharesAvailableForIssuanceIncreasedUnderTheOmnibusPlan" name="SharesAvailableForIssuanceIncreasedUnderTheOmnibusPlan" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_WorkingCapital" name="WorkingCapital" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_PrincipalAggregateAmount" name="PrincipalAggregateAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_InitialTermInterestRate" name="InitialTermInterestRate" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_BankLoanDescription" name="BankLoanDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_PreferredStockSharesUndesignated" name="PreferredStockSharesUndesignated" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_StockPayableShare" name="StockPayableShare" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_CommonStockSharesUponWarratExerciseShares" name="CommonStockSharesUponWarratExerciseShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_CommonStockSharesUponWarrantExerciseAmount" name="CommonStockSharesUponWarrantExerciseAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_CommonStockSharesUponCashlessWarrantExercise" name="CommonStockSharesUponCashlessWarrantExercise" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_CommonStockSharesUponCashlessOptionExercise" name="CommonStockSharesUponCashlessOptionExercise" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_SharesForServicesValue" name="SharesForServicesValue" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_CommonStockSharesUponVestingOfRestrictedUnits" name="CommonStockSharesUponVestingOfRestrictedUnits" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_CommonStockServicesValued" name="CommonStockServicesValued" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_RestictedStockUnitsValued" name="RestictedStockUnitsValued" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_SharesInReturn" name="SharesInReturn" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_ConversionOfCommonStockIntoPreferredStock" name="ConversionOfCommonStockIntoPreferredStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_TotalCommonStockSharesIssued" name="TotalCommonStockSharesIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_NetProceedsFromSalesOfCommonStock3" name="NetProceedsFromSalesOfCommonStock3" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_GrossProceedsFromSalesOfCommonStock" name="GrossProceedsFromSalesOfCommonStock" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_AggregateFairValueOfStockOptionsGranted" name="AggregateFairValueOfStockOptionsGranted" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_ExpectedDividendYield" name="ExpectedDividendYield" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_NumberOfWarrantsExercisable" name="NumberOfWarrantsExercisable" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_NumberOfWarrantsEndingBalance" name="NumberOfWarrantsEndingBalance" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_WeightedAverageExercisePriceOutstanding" name="WeightedAverageExercisePriceOutstanding" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_WeightedAverageExercisableAtJune302022" name="WeightedAverageExercisableAtJune302022" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermExercisable" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermExercisable" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_RentExpenses" name="RentExpenses" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_DescriptionOfEmploymentTerminationTerm" name="DescriptionOfEmploymentTerminationTerm" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_ExercisePrice" name="ExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_StockOptionGranted" name="StockOptionGranted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_EmploymentAgreementDescription" name="EmploymentAgreementDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_RentSpace" name="RentSpace" nillable="true" xbrli:periodType="duration" type="num:areaItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_MonthlyRent" name="MonthlyRent" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_RentTerm" name="RentTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_WeightedAverageRemainingLeaseTerm" name="WeightedAverageRemainingLeaseTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_OperatingLeaseDiscountRate" name="OperatingLeaseDiscountRate" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_StockBasedCompensation" name="StockBasedCompensation" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_FairValueOfOptions" name="FairValueOfOptions" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_NetOperatingLossCarryforwardBegainToExpire" name="NetOperatingLossCarryforwardBegainToExpire" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ndra_IncomeTaxesAbstract" name="IncomeTaxesAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element name="PreferredsStockSeriesAMember" id="ndra_PreferredsStockSeriesAMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockPayableMember" id="ndra_StockPayableMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OptionsToPurchaseCommonStockMember" id="ndra_OptionsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="WarrantsToPurchaseCommonStockMember" id="ndra_WarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember" id="ndra_SharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TDBankLoanMember" id="ndra_TDBankLoanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="JuneTwentyTwentyOneATMAgreementMember" id="ndra_JuneTwentyTwentyOneATMAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="WarrantsMember" id="ndra_WarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="EmploymentAgreementsMember" id="ndra_EmploymentAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="MichaelThorntonMember" id="ndra_MichaelThorntonMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="EmploymentgreementsMember" id="ndra_EmploymentgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="RenaudMalobertiMember" id="ndra_RenaudMalobertiMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="FrancoisMichelonMember" id="ndra_FrancoisMichelonMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="JanuaryOneTwentyFifteenMember" id="ndra_JanuaryOneTwentyFifteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesBPreferredStocksMember" id="ndra_SeriesBPreferredStocksMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>ndra-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 03/16/2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address Address Line 2</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address State Or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Security 12b Title</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm Id</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl_16de70" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl_16de70" xml:lang="en-US">Consolidated Balance Sheets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl_203f5c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl_203f5c" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl_776c9f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl_776c9f" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl_6e8fcf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl_6e8fcf" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl_738714" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl_738714" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl_7eb496" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl_7eb496" xml:lang="en-US">Series B Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl_25fd85" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl_25fd85" xml:lang="en-US">Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl_b61d2d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl_b61d2d" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl_6b3903" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl_6b3903" xml:lang="en-US">Prepaid expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl_7de35e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryNet_lbl_7de35e" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl_5" xml:lang="en-US">[Inventory, Net]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_a1dc5a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl_a1dc5a" xml:lang="en-US">Total Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl_6" xml:lang="en-US">[Assets, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrentAbstract" xlink:label="us-gaap_OtherAssetsNoncurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrentAbstract_lbl_a02487" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrentAbstract_lbl_a02487" xml:lang="en-US">Non-Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_944f51" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_944f51" xml:lang="en-US">Fixed assets, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl_e55305" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl_e55305" xml:lang="en-US">Right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl_0475b7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl_0475b7" xml:lang="en-US">Other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_010116" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl_010116" xml:lang="en-US">Total Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl_11" xml:lang="en-US">[Assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_19b095" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_19b095" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl_ecd719" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl_ecd719" xml:lang="en-US">Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl_b459c6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl_b459c6" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl_34c088" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl_34c088" xml:lang="en-US">Lease liabilities, current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl_7ea84e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayable_lbl_7ea84e" xml:lang="en-US">Loans</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_45b25c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl_45b25c" xml:lang="en-US">Total Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl_17" xml:lang="en-US">[Liabilities, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_lbl_ad7ff9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_lbl_ad7ff9" xml:lang="en-US">Long Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LongTermLoansPayable_lbl_4c8816" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLoansPayable_lbl_4c8816" xml:lang="en-US">Loans, long term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_cab7ab" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_cab7ab" xml:lang="en-US">Lease liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl_0f13a1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl_0f13a1" xml:lang="en-US">Total Long Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl_21" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl_21" xml:lang="en-US">[Long-Term Debt]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_e99c56" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl_e99c56" xml:lang="en-US">Total Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl_22" xml:lang="en-US">[Liabilities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl_8aed2d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl_8aed2d" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl_b9b21b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl_b9b21b" xml:lang="en-US">Series A Convertible Preferred Stock, $0.0001 par value; 10,000 shares authorized; 141.397 shares issued and outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl_d5ce4a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl_d5ce4a" xml:lang="en-US">Common stock, $0.0001 par value; 80,000,000 shares authorized; 3,169,103 and 2,127,725 shares issued and outstanding, respectively</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl_4550d4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl_4550d4" xml:lang="en-US">Additional paid in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_StockPayable" xlink:label="ndra_StockPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_StockPayable" xlink:to="ndra_StockPayable_lbl_752861" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_StockPayable_lbl_752861" xml:lang="en-US">Stock payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_c108e5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_c108e5" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_b67988" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl_b67988" xml:lang="en-US">Total Stockholders' Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_29" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl_29" xml:lang="en-US">[Stockholders' Equity Attributable to Parent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_a5c97f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_a5c97f" xml:lang="en-US">Total Liabilities and Stockholders' Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_30" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_30" xml:lang="en-US">[Liabilities and Equity]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredClassAMember" xlink:to="us-gaap_PreferredClassAMember_lbl_5fa424" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredClassAMember_lbl_5fa424" xml:lang="en-US">Preferred Class A</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredClassBMember" xlink:label="us-gaap_PreferredClassBMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredClassBMember" xlink:to="us-gaap_PreferredClassBMember_lbl_12e663" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredClassBMember_lbl_12e663" xml:lang="en-US">Preferred Class B</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl_1b5c52" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl_1b5c52" xml:lang="en-US">Common stock shares, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl_54ada7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl_54ada7" xml:lang="en-US">Common stock shares, authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_35504e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl_35504e" xml:lang="en-US">Common stock shares, issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl_7af6c2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl_7af6c2" xml:lang="en-US">Common stock shares, outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_b422b3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_b422b3" xml:lang="en-US">Preferred stock shares, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl_d71dd2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl_d71dd2" xml:lang="en-US">Preferred stock shares, authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl_61b5f4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl_61b5f4" xml:lang="en-US">Preferred stock shares, issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl_e38249" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl_e38249" xml:lang="en-US">Preferred stock shares, outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl_4c4510" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl_4c4510" xml:lang="en-US">Consolidated Statements of Operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl_2776d1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl_2776d1" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl_7f4cbf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl_7f4cbf" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl_2df71a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl_2df71a" xml:lang="en-US">Sales and marketing</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl_13b7d9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl_13b7d9" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_8261d3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl_8261d3" xml:lang="en-US">Total operating expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl_6" xml:lang="en-US">[Operating Expenses]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_f39dad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl_f39dad" xml:lang="en-US">Operating loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl_7" xml:lang="en-US">[Operating Income (Loss)]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl_c67ad0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl_c67ad0" xml:lang="en-US">Other Expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl_5b9881" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl_5b9881" xml:lang="en-US">Gain on extinguishment of debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl_1e485e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl_1e485e" xml:lang="en-US">Other income (expense)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl_693882" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl_693882" xml:lang="en-US">Total other expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl_11" xml:lang="en-US">[Nonoperating Income (Expense)]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl_8ba559" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl_8ba559" xml:lang="en-US">Loss from operations before income taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl_12" xml:lang="en-US">[Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl_0a8379" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl_0a8379" xml:lang="en-US">Provision for income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_427596" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_427596" xml:lang="en-US">Net Loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl_14" xml:lang="en-US">[Net Income (Loss) Attributable to Parent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Dividends" xlink:to="us-gaap_Dividends_lbl_330ca0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_Dividends_lbl_330ca0" xml:lang="en-US">Deemed dividend</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Dividends" xlink:to="us-gaap_Dividends_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Dividends_lbl_15" xml:lang="en-US">[Dividends]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_b0b32d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_b0b32d" xml:lang="en-US">Net Loss attributable to common stockholders</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_16" xml:lang="en-US">[Net Income (Loss) Available to Common Stockholders, Basic]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl_f48f67" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl_f48f67" xml:lang="en-US">Net loss per share - basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl_ff0b36" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl_ff0b36" xml:lang="en-US">Weighted average common shares - basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl_83e78a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl_83e78a" xml:lang="en-US">Consolidated Statements of Stockholders Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl_8c6e91" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl_8c6e91" xml:lang="en-US">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_PreferredsStockSeriesAMember" xlink:label="ndra_PreferredsStockSeriesAMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_PreferredsStockSeriesAMember" xlink:to="ndra_PreferredsStockSeriesAMember_lbl_1906bd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_PreferredsStockSeriesAMember_lbl_1906bd" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl_896996" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl_896996" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl_37dc26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl_37dc26" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_StockPayableMember" xlink:label="ndra_StockPayableMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_StockPayableMember" xlink:to="ndra_StockPayableMember_lbl_d7b34d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_StockPayableMember_lbl_d7b34d" xml:lang="en-US">Stock Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl_b427b6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl_b427b6" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SeriesBPreferredStocksMember" xlink:label="ndra_SeriesBPreferredStocksMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_SeriesBPreferredStocksMember" xlink:to="ndra_SeriesBPreferredStocksMember_lbl_dcc7cb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_SeriesBPreferredStocksMember_lbl_dcc7cb" xml:lang="en-US">Series B Convertible Preferred Stocks</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_8eaf45" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl_8eaf45" xml:lang="en-US">Balance, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl_2" xml:lang="en-US">[Shares, Issued]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_e03855" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl_e03855" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SeriesAConvertiblePreferredStockConvertedToCommonStockShares" xlink:label="ndra_SeriesAConvertiblePreferredStockConvertedToCommonStockShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_SeriesAConvertiblePreferredStockConvertedToCommonStockShares" xlink:to="ndra_SeriesAConvertiblePreferredStockConvertedToCommonStockShares_lbl_dcf75c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_SeriesAConvertiblePreferredStockConvertedToCommonStockShares_lbl_dcf75c" xml:lang="en-US">Series A Convertible Preferred Stock converted to common stock, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SeriesAConvertiblePreferredStockConvertedToCommonStockAmount" xlink:label="ndra_SeriesAConvertiblePreferredStockConvertedToCommonStockAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_SeriesAConvertiblePreferredStockConvertedToCommonStockAmount" xlink:to="ndra_SeriesAConvertiblePreferredStockConvertedToCommonStockAmount_lbl_2fdfc6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_SeriesAConvertiblePreferredStockConvertedToCommonStockAmount_lbl_2fdfc6" xml:lang="en-US">Series A Convertible Preferred Stock converted to common stock, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockIssuedForCashNetOfFundingCostsShares" xlink:label="ndra_CommonStockIssuedForCashNetOfFundingCostsShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_CommonStockIssuedForCashNetOfFundingCostsShares" xlink:to="ndra_CommonStockIssuedForCashNetOfFundingCostsShares_lbl_932700" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_CommonStockIssuedForCashNetOfFundingCostsShares_lbl_932700" xml:lang="en-US">Common stock issued for cash, net of funding costs, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockIssuedForCashNetOfFundingCostsAmount" xlink:label="ndra_CommonStockIssuedForCashNetOfFundingCostsAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_CommonStockIssuedForCashNetOfFundingCostsAmount" xlink:to="ndra_CommonStockIssuedForCashNetOfFundingCostsAmount_lbl_c19e9f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_CommonStockIssuedForCashNetOfFundingCostsAmount_lbl_c19e9f" xml:lang="en-US">Common stock issued for cash, net of funding costs, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockIssuedForWarrantExerciseShares" xlink:label="ndra_CommonStockIssuedForWarrantExerciseShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_CommonStockIssuedForWarrantExerciseShares" xlink:to="ndra_CommonStockIssuedForWarrantExerciseShares_lbl_f2415d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_CommonStockIssuedForWarrantExerciseShares_lbl_f2415d" xml:lang="en-US">Common stock issued for warrant exercise, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockIssuedForWarrantExerciseAmount" xlink:label="ndra_CommonStockIssuedForWarrantExerciseAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_CommonStockIssuedForWarrantExerciseAmount" xlink:to="ndra_CommonStockIssuedForWarrantExerciseAmount_lbl_52bc7b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_CommonStockIssuedForWarrantExerciseAmount_lbl_52bc7b" xml:lang="en-US">Common stock issued for warrant exercise, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockIssuedForOptionExerciseShares" xlink:label="ndra_CommonStockIssuedForOptionExerciseShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_CommonStockIssuedForOptionExerciseShares" xlink:to="ndra_CommonStockIssuedForOptionExerciseShares_lbl_5e3f27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_CommonStockIssuedForOptionExerciseShares_lbl_5e3f27" xml:lang="en-US">Common stock issued for option exercise, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockIssuedForOptionExerciseAmount" xlink:label="ndra_CommonStockIssuedForOptionExerciseAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_CommonStockIssuedForOptionExerciseAmount" xlink:to="ndra_CommonStockIssuedForOptionExerciseAmount_lbl_abfc5c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_CommonStockIssuedForOptionExerciseAmount_lbl_abfc5c" xml:lang="en-US">Common stock issued for option exercise, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_FairValueOfVestedStockOptions" xlink:label="ndra_FairValueOfVestedStockOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_FairValueOfVestedStockOptions" xlink:to="ndra_FairValueOfVestedStockOptions_lbl_9f6f6a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_FairValueOfVestedStockOptions_lbl_9f6f6a" xml:lang="en-US">Fair value of vested stock options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl_99913a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStock_lbl_99913a" xml:lang="en-US">Stock payable towards preference dividend</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockIssuedForServicesShares" xlink:label="ndra_CommonStockIssuedForServicesShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_CommonStockIssuedForServicesShares" xlink:to="ndra_CommonStockIssuedForServicesShares_lbl_91c56a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_CommonStockIssuedForServicesShares_lbl_91c56a" xml:lang="en-US">Common stock issued for services, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockIssuedForServicesAmount" xlink:label="ndra_CommonStockIssuedForServicesAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_CommonStockIssuedForServicesAmount" xlink:to="ndra_CommonStockIssuedForServicesAmount_lbl_72e653" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_CommonStockIssuedForServicesAmount_lbl_72e653" xml:lang="en-US">Common stock issued for services, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_StockIssuedForRsuShares" xlink:label="ndra_StockIssuedForRsuShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_StockIssuedForRsuShares" xlink:to="ndra_StockIssuedForRsuShares_lbl_dbacfc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_StockIssuedForRsuShares_lbl_dbacfc" xml:lang="en-US">Stock issued for RSU, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_StockIssuedForRsuAmount" xlink:label="ndra_StockIssuedForRsuAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_StockIssuedForRsuAmount" xlink:to="ndra_StockIssuedForRsuAmount_lbl_e151b0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_StockIssuedForRsuAmount_lbl_e151b0" xml:lang="en-US">Stock issued for RSU, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_DeemedDividend" xlink:to="ndra_DeemedDividend_lbl_9edc01" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ndra_DeemedDividend_lbl_9edc01" xml:lang="en-US">Deemed dividend</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_DeemedDividend" xlink:label="ndra_DeemedDividend" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_DeemedDividend" xlink:to="ndra_DeemedDividend_lbl_18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_DeemedDividend_lbl_18" xml:lang="en-US">[Deemed dividend]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_18ec8b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_18ec8b" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_bd06f9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl_bd06f9" xml:lang="en-US">Balance, shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_599a01" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl_599a01" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl_834684" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl_834684" xml:lang="en-US">Consolidated Statements of Cash Flows</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl_0f80de" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl_0f80de" xml:lang="en-US">Cash Flows from Operating Activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl_ea7693" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ProfitLoss_lbl_ea7693" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl_3" xml:lang="en-US">[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_6ba7d9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_6ba7d9" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl_2934db" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl_2934db" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_FixedAssetsWriteOff" xlink:label="ndra_FixedAssetsWriteOff" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_FixedAssetsWriteOff" xlink:to="ndra_FixedAssetsWriteOff_lbl_6ba82e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_FixedAssetsWriteOff_lbl_6ba82e" xml:lang="en-US">Fixed assets write off</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_2824a3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl_2824a3" xml:lang="en-US">Stock compensation expense including common stock issued for RSUs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl_27ca9d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl_27ca9d" xml:lang="en-US">Amortization of right of use assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl_d8bc97" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl_d8bc97" xml:lang="en-US">Gain on extinguishment of debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl_50ae14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl_50ae14" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_4cbedc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_4cbedc" xml:lang="en-US">Decrease in prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_11" xml:lang="en-US">[Increase (Decrease) in Prepaid Expense]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl_463541" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl_463541" xml:lang="en-US">Increase in inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl_12" xml:lang="en-US">[Increase (Decrease) in Inventories]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl_5a677b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl_5a677b" xml:lang="en-US">Increase in accounts payable and accrued liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl_c75a42" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl_c75a42" xml:lang="en-US">Decrease in lease liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_134f82" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_134f82" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_15" xml:lang="en-US">[Net Cash Provided by (Used in) Operating Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_ead756" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_ead756" xml:lang="en-US">Cash Flows from Investing Activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_b08636" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_b08636" xml:lang="en-US">Purchases of fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_17" xml:lang="en-US">[Payments to Acquire Property, Plant, and Equipment]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_69ae90" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_69ae90" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_18" xml:lang="en-US">[Net Cash Provided by (Used in) Investing Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_b70504" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_b70504" xml:lang="en-US">Cash Flows from Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl_716c26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl_716c26" xml:lang="en-US">Proceeds from warrant exercise</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_1da79f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_1da79f" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_2d5c1c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_2d5c1c" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_22" xml:lang="en-US">[Net Cash Provided by (Used in) Financing Activities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_0ffc38" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_0ffc38" xml:lang="en-US">Net increase (decrease) in cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_23" xml:lang="en-US">[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_23529d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_23529d" xml:lang="en-US">Cash, beginning of year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_24" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_24" xml:lang="en-US">[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_b55b40" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_b55b40" xml:lang="en-US">Cash, end of year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl_66fba9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl_66fba9" xml:lang="en-US">Supplemental disclosures of cash items</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl_7817b7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl_7817b7" xml:lang="en-US">Interest paid</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl_74070b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl_74070b" xml:lang="en-US">Income tax paid</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SupplementalDisclosuresOfNoncashItemsAbstract" xlink:label="ndra_SupplementalDisclosuresOfNoncashItemsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_SupplementalDisclosuresOfNoncashItemsAbstract" xlink:to="ndra_SupplementalDisclosuresOfNoncashItemsAbstract_lbl_678dc5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_SupplementalDisclosuresOfNoncashItemsAbstract_lbl_678dc5" xml:lang="en-US">Supplemental disclosures of non-cash items</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Dividends" xlink:to="us-gaap_Dividends_lbl_fd0ca5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Dividends_lbl_fd0ca5" xml:lang="en-US">Deemed dividend</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ConversionOfSeriesAConvertiblePreferredStock" xlink:label="ndra_ConversionOfSeriesAConvertiblePreferredStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_ConversionOfSeriesAConvertiblePreferredStock" xlink:to="ndra_ConversionOfSeriesAConvertiblePreferredStock_lbl_731470" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_ConversionOfSeriesAConvertiblePreferredStock_lbl_731470" xml:lang="en-US">Conversion of Series A Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_StockDividendPayable" xlink:label="ndra_StockDividendPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_StockDividendPayable" xlink:to="ndra_StockDividendPayable_lbl_d74688" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_StockDividendPayable_lbl_d74688" xml:lang="en-US">Stock dividend payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl_277540" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl_277540" xml:lang="en-US">Right of use asset</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_LeaseLiability" xlink:label="ndra_LeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_LeaseLiability" xlink:to="ndra_LeaseLiability_lbl_0fc894" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_LeaseLiability_lbl_0fc894" xml:lang="en-US">Lease liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl_30cd04" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl_30cd04" xml:lang="en-US">Nature of the Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl_c3a0c1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl_c3a0c1" xml:lang="en-US">Nature Of The Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl_5458ac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl_5458ac" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_059c26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_059c26" xml:lang="en-US">Summary Of Significant Accounting Policies</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl_612eea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl_612eea" xml:lang="en-US">Inventory</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl_81e3ec" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl_81e3ec" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl_2" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl_78186a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl_78186a" xml:lang="en-US">Fixed Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl_27280e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl_27280e" xml:lang="en-US">Fixed Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl_2" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl_7e359f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl_7e359f" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl_2c5478" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl_2c5478" xml:lang="en-US">Accounts Payable And Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl_3eef47" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl_3eef47" xml:lang="en-US">Bank Loans</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTextBlock" xlink:to="us-gaap_ShortTermDebtTextBlock_lbl_5e7c28" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShortTermDebtTextBlock_lbl_5e7c28" xml:lang="en-US">Bank Loans</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="us-gaap_ShortTermDebtTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTextBlock" xlink:to="us-gaap_ShortTermDebtTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTextBlock_lbl_2" xml:lang="en-US">Short-Term Debt [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_9877c8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_9877c8" xml:lang="en-US">Capital Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_2" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl_d7559b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl_d7559b" xml:lang="en-US">Common Stock Options and Restricted Stock Units (RSUs)</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock" xlink:label="ndra_ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock" xlink:to="ndra_ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock_lbl_c888fd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock_lbl_c888fd" xml:lang="en-US">Common Stock Options and Restricted Stock Units (RSU's)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock" xlink:to="ndra_ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock_lbl_961813" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ndra_ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock_lbl_961813" xml:lang="en-US">Common Stock Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock" xlink:label="ndra_ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock" xlink:to="ndra_ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock_lbl_2" xml:lang="en-US">[Common Stock Warrants]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_6bdc3a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_6bdc3a" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_d4d8be" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_d4d8be" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_2" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_IncomeTaxesAbstract" xlink:label="ndra_IncomeTaxesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_IncomeTaxesAbstract" xlink:to="ndra_IncomeTaxesAbstract_lbl_28a204" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_IncomeTaxesAbstract_lbl_28a204" xml:lang="en-US">Income Taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl_a33539" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl_a33539" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl_2" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl_468259" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl_468259" xml:lang="en-US">Subsequent Events</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_9c003d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_9c003d" xml:lang="en-US">Subsequent Events</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_2" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl_699fd4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl_699fd4" xml:lang="en-US">Use Of Estimates</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl_1d5b23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl_1d5b23" xml:lang="en-US">Principles Of Consolidation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl_ffa3a6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl_ffa3a6" xml:lang="en-US">Basis Of Presentation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_004332" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_004332" xml:lang="en-US">Cash And Cash Equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl_f7c3c0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl_f7c3c0" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl_6" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_41111b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_41111b" xml:lang="en-US">Capitalization Of Fixed Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl_b91982" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl_b91982" xml:lang="en-US">Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl_cb1414" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl_cb1414" xml:lang="en-US">Revenue Recognition</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_e4970c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_e4970c" xml:lang="en-US">Research And Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl_eb6bda" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl_eb6bda" xml:lang="en-US">Net Earnings (loss) Per Common Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl_ade88c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl_ade88c" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl_60e0b0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl_60e0b0" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl_a1ba0a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl_a1ba0a" xml:lang="en-US">Going Concern</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_f054a2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_f054a2" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl_1dc787" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl_1dc787" xml:lang="en-US">Schedule Of Anti-dilutive Shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl_dfdb36" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl_dfdb36" xml:lang="en-US">Schedule Fixed Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl_a1f22a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl_a1f22a" xml:lang="en-US">Schedule Of Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl_d2d783" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl_d2d783" xml:lang="en-US">Summary Of Stock Option Activity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl_6ed646" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl_6ed646" xml:lang="en-US">Schedule Of Warrant Activity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl_285164" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl_285164" xml:lang="en-US">Schedule Of Operating Lease Liabilities Maturities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl_e2e010" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl_e2e010" xml:lang="en-US">Schedule of deferred tax assests and liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl_e02707" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl_e02707" xml:lang="en-US">Schedule of U.S. federal statutory rate and the effective tax rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl_859288" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl_859288" xml:lang="en-US">Financial Instrument Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_OptionsToPurchaseCommonStockMember" xlink:label="ndra_OptionsToPurchaseCommonStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_OptionsToPurchaseCommonStockMember" xlink:to="ndra_OptionsToPurchaseCommonStockMember_lbl_634aed" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_OptionsToPurchaseCommonStockMember_lbl_634aed" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_WarrantsToPurchaseCommonStockMember" xlink:label="ndra_WarrantsToPurchaseCommonStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_WarrantsToPurchaseCommonStockMember" xlink:to="ndra_WarrantsToPurchaseCommonStockMember_lbl_7761fe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_WarrantsToPurchaseCommonStockMember_lbl_7761fe" xml:lang="en-US">Warrants To Purchase Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember" xlink:label="ndra_SharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_SharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember" xlink:to="ndra_SharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember_lbl_7229fd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_SharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember_lbl_7229fd" xml:lang="en-US">Shares Issuable upon Conversion of Series A Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_2e14df" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_2e14df" xml:lang="en-US">Potential Equivalent Shares Excluded</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl_a181a3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl_a181a3" xml:lang="en-US">Lease liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl_2" xml:lang="en-US">[Operating Lease, Liability]</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ResearchAndDevelopmentExpense1" xlink:label="ndra_ResearchAndDevelopmentExpense1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_ResearchAndDevelopmentExpense1" xlink:to="ndra_ResearchAndDevelopmentExpense1_lbl_3ed21a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_ResearchAndDevelopmentExpense1_lbl_3ed21a" xml:lang="en-US">Research And Development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl_d6c614" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl_d6c614" xml:lang="en-US">Right Of Use Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_66fd3f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_66fd3f" xml:lang="en-US">Potential Equivalent Shares Excluded</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SharesAvailableForIssuanceIncreasedUnderTheOmnibusPlan" xlink:label="ndra_SharesAvailableForIssuanceIncreasedUnderTheOmnibusPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_SharesAvailableForIssuanceIncreasedUnderTheOmnibusPlan" xlink:to="ndra_SharesAvailableForIssuanceIncreasedUnderTheOmnibusPlan_lbl_ff6b2e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_SharesAvailableForIssuanceIncreasedUnderTheOmnibusPlan_lbl_ff6b2e" xml:lang="en-US">Shares Available For Issuance Increased Under The Omnibus Plan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CumulativeDividends" xlink:label="us-gaap_CumulativeDividends" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeDividends" xlink:to="us-gaap_CumulativeDividends_lbl_111fc1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CumulativeDividends_lbl_111fc1" xml:lang="en-US">Cumulative Net Loss</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_WorkingCapital" xlink:label="ndra_WorkingCapital" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_WorkingCapital" xlink:to="ndra_WorkingCapital_lbl_fa981c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_WorkingCapital_lbl_fa981c" xml:lang="en-US">Working Capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl_3ad540" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl_3ad540" xml:lang="en-US">Share based compensation, description</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl_183a56" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl_183a56" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl_2e7c77" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl_2e7c77" xml:lang="en-US">Property, Leasehold And Capitalized Software</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopmentInProcess" xlink:label="us-gaap_DevelopmentInProcess" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopmentInProcess" xlink:to="us-gaap_DevelopmentInProcess_lbl_66f72c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DevelopmentInProcess_lbl_66f72c" xml:lang="en-US">Taeus Development And Testing</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_8a3858" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_8a3858" xml:lang="en-US">Accumulated Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_4" xml:lang="en-US">[Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_7b8017" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_7b8017" xml:lang="en-US">Fixed Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl_ce508e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl_ce508e" xml:lang="en-US">Depreciation Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl_20965e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl_20965e" xml:lang="en-US">Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl_654846" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl_654846" xml:lang="en-US">Accrued Payroll</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedBonusesCurrentAndNoncurrent_lbl_a3f32c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent_lbl_a3f32c" xml:lang="en-US">Accrued Bonuses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl_d06685" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl_d06685" xml:lang="en-US">Accrued Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInsuranceCurrentAndNoncurrent" xlink:label="us-gaap_AccruedInsuranceCurrentAndNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedInsuranceCurrentAndNoncurrent" xlink:to="us-gaap_AccruedInsuranceCurrentAndNoncurrent_lbl_62215c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedInsuranceCurrentAndNoncurrent_lbl_62215c" xml:lang="en-US">Insurance Premium Financing</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl_46f31a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl_46f31a" xml:lang="en-US">Total Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl_7" xml:lang="en-US">[Accounts Payable and Accrued Liabilities, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl_5db86c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl_5db86c" xml:lang="en-US">Plan Name Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_TDBankLoanMember" xlink:label="ndra_TDBankLoanMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_TDBankLoanMember" xlink:to="ndra_TDBankLoanMember_lbl_0726f7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_TDBankLoanMember_lbl_0726f7" xml:lang="en-US">TD Bank Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:label="us-gaap_ProceedsFromCollectionOfNotesReceivable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:to="us-gaap_ProceedsFromCollectionOfNotesReceivable_lbl_6a200c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromCollectionOfNotesReceivable_lbl_6a200c" xml:lang="en-US">Paycheck protection program note to first republic bank</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_PrincipalAggregateAmount" xlink:label="ndra_PrincipalAggregateAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_PrincipalAggregateAmount" xlink:to="ndra_PrincipalAggregateAmount_lbl_6f9660" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_PrincipalAggregateAmount_lbl_6f9660" xml:lang="en-US">Principal Aggregate Amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInitiationDate1" xlink:label="us-gaap_LineOfCreditFacilityInitiationDate1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInitiationDate1" xlink:to="us-gaap_LineOfCreditFacilityInitiationDate1_lbl_b66dac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityInitiationDate1_lbl_b66dac" xml:lang="en-US">Expiration Initial Term</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_InitialTermInterestRate" xlink:label="ndra_InitialTermInterestRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_InitialTermInterestRate" xlink:to="ndra_InitialTermInterestRate_lbl_441666" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_InitialTermInterestRate_lbl_441666" xml:lang="en-US">Initial Term Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_BankLoanDescription" xlink:label="ndra_BankLoanDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_BankLoanDescription" xlink:to="ndra_BankLoanDescription_lbl_e9371e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_BankLoanDescription_lbl_e9371e" xml:lang="en-US">Bank Loan, Description</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_JuneTwentyTwentyOneATMAgreementMember" xlink:label="ndra_JuneTwentyTwentyOneATMAgreementMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_JuneTwentyTwentyOneATMAgreementMember" xlink:to="ndra_JuneTwentyTwentyOneATMAgreementMember_lbl_917fb5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_JuneTwentyTwentyOneATMAgreementMember_lbl_917fb5" xml:lang="en-US">June 2021 ATM Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl_9ab28b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl_9ab28b" xml:lang="en-US">Series C Convertible Preferred Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsAuthorized" xlink:to="us-gaap_CapitalUnitsAuthorized_lbl_d050a4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalUnitsAuthorized_lbl_d050a4" xml:lang="en-US">Capital Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="us-gaap_CapitalUnitsAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsAuthorized" xlink:to="us-gaap_CapitalUnitsAuthorized_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalUnitsAuthorized_lbl_2" xml:lang="en-US">[Capital Units, Authorized]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl_27d3ce" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl_27d3ce" xml:lang="en-US">Common Stock Shares, Authorized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl_fba1ba" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl_fba1ba" xml:lang="en-US">Common Stock Shares, Par Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl_a99349" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl_a99349" xml:lang="en-US">Preferred stock authorized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_b73587" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl_b73587" xml:lang="en-US">Common Stock Shares, Issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_35bef7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_35bef7" xml:lang="en-US">Preferred Stock Shares, Par Value</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_PreferredStockSharesUndesignated" xlink:label="ndra_PreferredStockSharesUndesignated" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_PreferredStockSharesUndesignated" xlink:to="ndra_PreferredStockSharesUndesignated_lbl_3edf54" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_PreferredStockSharesUndesignated_lbl_3edf54" xml:lang="en-US">Preferred stock shares, undesignated</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_StockPayableShare" xlink:label="ndra_StockPayableShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_StockPayableShare" xlink:to="ndra_StockPayableShare_lbl_850d36" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_StockPayableShare_lbl_850d36" xml:lang="en-US">Stock Payable</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockSharesUponWarratExerciseShares" xlink:label="ndra_CommonStockSharesUponWarratExerciseShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_CommonStockSharesUponWarratExerciseShares" xlink:to="ndra_CommonStockSharesUponWarratExerciseShares_lbl_d419f1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_CommonStockSharesUponWarratExerciseShares_lbl_d419f1" xml:lang="en-US">Common Stock Shares Upon Warrant Exercise, Shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockSharesUponWarrantExerciseAmount" xlink:label="ndra_CommonStockSharesUponWarrantExerciseAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_CommonStockSharesUponWarrantExerciseAmount" xlink:to="ndra_CommonStockSharesUponWarrantExerciseAmount_lbl_268028" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_CommonStockSharesUponWarrantExerciseAmount_lbl_268028" xml:lang="en-US">Common Stock Shares Upon Warrant Exercise, Amount</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockSharesUponCashlessWarrantExercise" xlink:label="ndra_CommonStockSharesUponCashlessWarrantExercise" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_CommonStockSharesUponCashlessWarrantExercise" xlink:to="ndra_CommonStockSharesUponCashlessWarrantExercise_lbl_a754a4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_CommonStockSharesUponCashlessWarrantExercise_lbl_a754a4" xml:lang="en-US">Common stock shares upon cashless warrant exercise</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockSharesUponCashlessOptionExercise" xlink:label="ndra_CommonStockSharesUponCashlessOptionExercise" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_CommonStockSharesUponCashlessOptionExercise" xlink:to="ndra_CommonStockSharesUponCashlessOptionExercise_lbl_7cb6d8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_CommonStockSharesUponCashlessOptionExercise_lbl_7cb6d8" xml:lang="en-US">Common Stock Shares Upon Cashless Option Exercise</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SharesForServicesValue" xlink:label="ndra_SharesForServicesValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_SharesForServicesValue" xlink:to="ndra_SharesForServicesValue_lbl_aa7400" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_SharesForServicesValue_lbl_aa7400" xml:lang="en-US">Shares For Services Value</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockSharesUponVestingOfRestrictedUnits" xlink:label="ndra_CommonStockSharesUponVestingOfRestrictedUnits" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_CommonStockSharesUponVestingOfRestrictedUnits" xlink:to="ndra_CommonStockSharesUponVestingOfRestrictedUnits_lbl_38ee96" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_CommonStockSharesUponVestingOfRestrictedUnits_lbl_38ee96" xml:lang="en-US">Common stock shares upon vesting of restricted units</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockServicesValued" xlink:label="ndra_CommonStockServicesValued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_CommonStockServicesValued" xlink:to="ndra_CommonStockServicesValued_lbl_887e38" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_CommonStockServicesValued_lbl_887e38" xml:lang="en-US">Common stock services valued</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_RestictedStockUnitsValued" xlink:label="ndra_RestictedStockUnitsValued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_RestictedStockUnitsValued" xlink:to="ndra_RestictedStockUnitsValued_lbl_963099" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_RestictedStockUnitsValued_lbl_963099" xml:lang="en-US">Resticted stock units valued</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SharesInReturn" xlink:label="ndra_SharesInReturn" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_SharesInReturn" xlink:to="ndra_SharesInReturn_lbl_eca535" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_SharesInReturn_lbl_eca535" xml:lang="en-US">Shares in return</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_d2f6a9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_d2f6a9" xml:lang="en-US">Net proceeds from sale of common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl_668f75" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl_668f75" xml:lang="en-US">Preferred stock shares, outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl_c712bb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl_c712bb" xml:lang="en-US">Conversion Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ConversionOfCommonStockIntoPreferredStock" xlink:label="ndra_ConversionOfCommonStockIntoPreferredStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_ConversionOfCommonStockIntoPreferredStock" xlink:to="ndra_ConversionOfCommonStockIntoPreferredStock_lbl_871752" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_ConversionOfCommonStockIntoPreferredStock_lbl_871752" xml:lang="en-US">Conversion Of Common Stock Into Preferred Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl_ed6e58" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl_ed6e58" xml:lang="en-US">Preferred Stock Shares, issued</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_TotalCommonStockSharesIssued" xlink:label="ndra_TotalCommonStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_TotalCommonStockSharesIssued" xlink:to="ndra_TotalCommonStockSharesIssued_lbl_9b17cd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_TotalCommonStockSharesIssued_lbl_9b17cd" xml:lang="en-US">Total Common Stock Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl_858f6b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl_858f6b" xml:lang="en-US">Stock Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_NetProceedsFromSalesOfCommonStock3" xlink:label="ndra_NetProceedsFromSalesOfCommonStock3" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_NetProceedsFromSalesOfCommonStock3" xlink:to="ndra_NetProceedsFromSalesOfCommonStock3_lbl_2a5f61" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_NetProceedsFromSalesOfCommonStock3_lbl_2a5f61" xml:lang="en-US">Net Proceeds From Sales Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_GrossProceedsFromSalesOfCommonStock" xlink:label="ndra_GrossProceedsFromSalesOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_GrossProceedsFromSalesOfCommonStock" xlink:to="ndra_GrossProceedsFromSalesOfCommonStock_lbl_2b47e7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_GrossProceedsFromSalesOfCommonStock_lbl_2b47e7" xml:lang="en-US">Gross Proceeds From Sales Of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_6e13c0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_6e13c0" xml:lang="en-US">Number Of Options Outstanding, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_2" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_cd5278" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_cd5278" xml:lang="en-US">Number Of Options Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_caa4b6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_caa4b6" xml:lang="en-US">Number Of Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl_7d76be" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl_7d76be" xml:lang="en-US">Number Of Options, Forfeited</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_d32f3d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_d32f3d" xml:lang="en-US">Number Of Options Cancelled Or Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_6" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_ce9863" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_ce9863" xml:lang="en-US">Number Of Options Outstanding, Ending</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl_5ab4ae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl_5ab4ae" xml:lang="en-US">Number Of Options Outstanding, Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl_8" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_b53911" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_b53911" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_9" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_b96942" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_b96942" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_7f5ea4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_7f5ea4" xml:lang="en-US">Weighted Average Exercise Price Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl_76012d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl_76012d" xml:lang="en-US">Weighted Average Exercise Price Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl_d01807" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl_d01807" xml:lang="en-US">Weighted Average Exercise Price Cancelled Or Expired</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_deaf27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_deaf27" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Ending</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl_9b45cf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl_9b45cf" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl_15" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price]</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl_ab1b09" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl_ab1b09" xml:lang="en-US">Weighted Average Remaining Contractual Term Outstanding, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl_7f6e35" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl_7f6e35" xml:lang="en-US">Weighted Average Remaining Contractual Term Outstanding, Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl_a8ca52" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl_a8ca52" xml:lang="en-US">Weighted Average Remaining Contractual Term Outstanding, Ending</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl_80852c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl_80852c" xml:lang="en-US">Weighted Average Remaining Contractual Term Outstanding, Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl_08affb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl_08affb" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl_1d4f37" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl_1d4f37" xml:lang="en-US">Minimum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl_50dda1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl_50dda1" xml:lang="en-US">Maximum</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_AggregateFairValueOfStockOptionsGranted" xlink:label="ndra_AggregateFairValueOfStockOptionsGranted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_AggregateFairValueOfStockOptionsGranted" xlink:to="ndra_AggregateFairValueOfStockOptionsGranted_lbl_b76709" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_AggregateFairValueOfStockOptionsGranted_lbl_b76709" xml:lang="en-US">Aggregate Fair Value Of Stock Options Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl_b9252f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl_b9252f" xml:lang="en-US">Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ExpectedDividendYield" xlink:label="ndra_ExpectedDividendYield" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_ExpectedDividendYield" xlink:to="ndra_ExpectedDividendYield_lbl_e36172" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_ExpectedDividendYield_lbl_e36172" xml:lang="en-US">Expected Dividend Yield</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl_a8dd49" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl_a8dd49" xml:lang="en-US">Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl_1bf7bb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl_1bf7bb" xml:lang="en-US">Risk Free Rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl_0f7627" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl_0f7627" xml:lang="en-US">Expected Life</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl_fec2a9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl_fec2a9" xml:lang="en-US">Award Type Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_WarrantsMember" xlink:label="ndra_WarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_WarrantsMember" xlink:to="ndra_WarrantsMember_lbl_909401" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_WarrantsMember_lbl_909401" xml:lang="en-US">Warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl_e90994" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl_e90994" xml:lang="en-US">Balance Outstanding, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl_2" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl_df56bf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl_df56bf" xml:lang="en-US">Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:label="ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl_3" xml:lang="en-US">[Expired]</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_NumberOfWarrantsExercisable" xlink:label="ndra_NumberOfWarrantsExercisable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_NumberOfWarrantsExercisable" xlink:to="ndra_NumberOfWarrantsExercisable_lbl_d57db7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_NumberOfWarrantsExercisable_lbl_d57db7" xml:lang="en-US">Number of Warrants exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_NumberOfWarrantsEndingBalance" xlink:label="ndra_NumberOfWarrantsEndingBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_NumberOfWarrantsEndingBalance" xlink:to="ndra_NumberOfWarrantsEndingBalance_lbl_663f04" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_NumberOfWarrantsEndingBalance_lbl_663f04" xml:lang="en-US">Number of Warrants ending balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl_32a370" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl_32a370" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl_6" xml:lang="en-US">[Weighted Average Exercise Price Outstanding, Beginning]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_e8a997" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_e8a997" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_7" xml:lang="en-US">[Weighted Average Exercise Price Granted]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl_3e3018" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl_3e3018" xml:lang="en-US">Weighted Average Exercise Price Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl_8" xml:lang="en-US">[Weighted Average Exercise Price Exercised]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice" xlink:to="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice_lbl_dd7b91" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice_lbl_dd7b91" xml:lang="en-US">Weighted Average Exercise Price Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice" xlink:to="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice_lbl_9" xml:lang="en-US">[Weighted Average Exercise Price Forfeited]</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice_lbl_39c46b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice_lbl_39c46b" xml:lang="en-US">Weighted Average Exercise Price Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_WeightedAverageExercisePriceOutstanding" xlink:label="ndra_WeightedAverageExercisePriceOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_WeightedAverageExercisePriceOutstanding" xlink:to="ndra_WeightedAverageExercisePriceOutstanding_lbl_1e5994" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_WeightedAverageExercisePriceOutstanding_lbl_1e5994" xml:lang="en-US">Weighted Average Exercise Price outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_WeightedAverageExercisableAtJune302022" xlink:label="ndra_WeightedAverageExercisableAtJune302022" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_WeightedAverageExercisableAtJune302022" xlink:to="ndra_WeightedAverageExercisableAtJune302022_lbl_31c4ae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_WeightedAverageExercisableAtJune302022_lbl_31c4ae" xml:lang="en-US">Weighted Average Exercisable at June 30, 2022</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" xlink:to="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_lbl_375790" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_lbl_375790" xml:lang="en-US">Weighted Average Remaining Contractual Term Outstanding, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" xlink:label="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" xlink:to="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_lbl_13" xml:lang="en-US">[Weighted Average Remaining Contractual Term Outstanding, Beginning]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:to="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_lbl_8f8a8d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_lbl_8f8a8d" xml:lang="en-US">Weighted Average Remaining Contractual Term Outstanding, Ending</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:label="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:to="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_lbl_14" xml:lang="en-US">[Weighted Average Remaining Contractual Term Outstanding, Ending]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermExercisable" xlink:to="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermExercisable_lbl_2b6918" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermExercisable_lbl_2b6918" xml:lang="en-US">Weighted Average Remaining Contractual Term Outstanding, Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermExercisable" xlink:label="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermExercisable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermExercisable" xlink:to="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermExercisable_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermExercisable_lbl_15" xml:lang="en-US">[Weighted Average Remaining Contractual Term Outstanding, Exercisable]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_d8eb80" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_d8eb80" xml:lang="en-US">2023</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_ac1309" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_ac1309" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="ndra_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="ndra_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl_1b2838" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl_1b2838" xml:lang="en-US">2025 And Beyond</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl_6e94b8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl_6e94b8" xml:lang="en-US">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl_5" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_5efba6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_5efba6" xml:lang="en-US">Less: Amount Representing Interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_6" xml:lang="en-US">[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl_bae81c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl_bae81c" xml:lang="en-US">Present Value Of Future Minimum Lease Payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl_806324" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl_806324" xml:lang="en-US">Less: Current Obligations Under Lease</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_307062" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_307062" xml:lang="en-US">Long-term Lease Obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl_d70bd3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl_d70bd3" xml:lang="en-US">Related Party Transaction Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl_f88a92" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl_f88a92" xml:lang="en-US">Award Date Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_EmploymentAgreementsMember" xlink:label="ndra_EmploymentAgreementsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_EmploymentAgreementsMember" xlink:to="ndra_EmploymentAgreementsMember_lbl_a153c5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_EmploymentAgreementsMember_lbl_a153c5" xml:lang="en-US">Employment Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_MichaelThorntonMember" xlink:label="ndra_MichaelThorntonMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_MichaelThorntonMember" xlink:to="ndra_MichaelThorntonMember_lbl_64bf2f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_MichaelThorntonMember_lbl_64bf2f" xml:lang="en-US">Michael Thornton [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_EmploymentgreementsMember" xlink:to="ndra_EmploymentgreementsMember_lbl_5ce76e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ndra_EmploymentgreementsMember_lbl_5ce76e" xml:lang="en-US">Employment Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_EmploymentgreementsMember" xlink:label="ndra_EmploymentgreementsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_EmploymentgreementsMember" xlink:to="ndra_EmploymentgreementsMember_lbl_54" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_EmploymentgreementsMember_lbl_54" xml:lang="en-US">[Employment Agreements [Member]]</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_RenaudMalobertiMember" xlink:label="ndra_RenaudMalobertiMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_RenaudMalobertiMember" xlink:to="ndra_RenaudMalobertiMember_lbl_728492" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_RenaudMalobertiMember_lbl_728492" xml:lang="en-US">Renaud Maloberti [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_FrancoisMichelonMember" xlink:label="ndra_FrancoisMichelonMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_FrancoisMichelonMember" xlink:to="ndra_FrancoisMichelonMember_lbl_5840e9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_FrancoisMichelonMember_lbl_5840e9" xml:lang="en-US">Francois Michelon [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_JanuaryOneTwentyFifteenMember" xlink:label="ndra_JanuaryOneTwentyFifteenMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_JanuaryOneTwentyFifteenMember" xlink:to="ndra_JanuaryOneTwentyFifteenMember_lbl_006cc3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_JanuaryOneTwentyFifteenMember_lbl_006cc3" xml:lang="en-US">January 1, 2015 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_RentExpenses" xlink:label="ndra_RentExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_RentExpenses" xlink:to="ndra_RentExpenses_lbl_3ef7d2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_RentExpenses_lbl_3ef7d2" xml:lang="en-US">Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages" xlink:label="us-gaap_SalariesAndWages" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl_5f2c7b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesAndWages_lbl_5f2c7b" xml:lang="en-US">Annual Basic Salary</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_DescriptionOfEmploymentTerminationTerm" xlink:label="ndra_DescriptionOfEmploymentTerminationTerm" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_DescriptionOfEmploymentTerminationTerm" xlink:to="ndra_DescriptionOfEmploymentTerminationTerm_lbl_7cb266" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_DescriptionOfEmploymentTerminationTerm_lbl_7cb266" xml:lang="en-US">Description Of Employment Termination Term</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ExercisePrice" xlink:label="ndra_ExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_ExercisePrice" xlink:to="ndra_ExercisePrice_lbl_f8407f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_ExercisePrice_lbl_f8407f" xml:lang="en-US">Exercise price</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_StockOptionGranted" xlink:label="ndra_StockOptionGranted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_StockOptionGranted" xlink:to="ndra_StockOptionGranted_lbl_76452e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_StockOptionGranted_lbl_76452e" xml:lang="en-US">Stock option granted</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_EmploymentAgreementDescription" xlink:label="ndra_EmploymentAgreementDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_EmploymentAgreementDescription" xlink:to="ndra_EmploymentAgreementDescription_lbl_c11644" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_EmploymentAgreementDescription_lbl_c11644" xml:lang="en-US">Employment Agreement, Description</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_RentSpace" xlink:label="ndra_RentSpace" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_RentSpace" xlink:to="ndra_RentSpace_lbl_4bb5c0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_RentSpace_lbl_4bb5c0" xml:lang="en-US">Rent Space</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_MonthlyRent" xlink:label="ndra_MonthlyRent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_MonthlyRent" xlink:to="ndra_MonthlyRent_lbl_2ae033" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_MonthlyRent_lbl_2ae033" xml:lang="en-US">Monthly Rent</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_RentTerm" xlink:label="ndra_RentTerm" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_RentTerm" xlink:to="ndra_RentTerm_lbl_1da50f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_RentTerm_lbl_1da50f" xml:lang="en-US">Rent Term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl_e9716a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl_e9716a" xml:lang="en-US">Office Lease, Description</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl_f37caa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl_f37caa" xml:lang="en-US">Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_WeightedAverageRemainingLeaseTerm" xlink:label="ndra_WeightedAverageRemainingLeaseTerm" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_WeightedAverageRemainingLeaseTerm" xlink:to="ndra_WeightedAverageRemainingLeaseTerm_lbl_c74394" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_WeightedAverageRemainingLeaseTerm_lbl_c74394" xml:lang="en-US">Weighted-average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_OperatingLeaseDiscountRate" xlink:label="ndra_OperatingLeaseDiscountRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_OperatingLeaseDiscountRate" xlink:to="ndra_OperatingLeaseDiscountRate_lbl_e32191" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_OperatingLeaseDiscountRate_lbl_e32191" xml:lang="en-US">Operating Lease Discount Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl_e32e68" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl_e32e68" xml:lang="en-US">Net operating loss carryforward</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl_2" xml:lang="en-US">[Deferred Tax Assets, Operating Loss Carryforwards]</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_StockBasedCompensation" xlink:label="ndra_StockBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_StockBasedCompensation" xlink:to="ndra_StockBasedCompensation_lbl_93702a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_StockBasedCompensation_lbl_93702a" xml:lang="en-US">Stock based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_FairValueOfOptions" xlink:label="ndra_FairValueOfOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_FairValueOfOptions" xlink:to="ndra_FairValueOfOptions_lbl_8ae895" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_FairValueOfOptions_lbl_8ae895" xml:lang="en-US">Fair value of options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl_5ef429" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl_5ef429" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl_5" xml:lang="en-US">[Deferred Tax Assets, Gross]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl_c24578" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl_c24578" xml:lang="en-US">Valuation allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl_2d301c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl_2d301c" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl_4be1b7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl_4be1b7" xml:lang="en-US">U.S. federal statutory income tax</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl_2" xml:lang="en-US">[Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl_e286a9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl_e286a9" xml:lang="en-US">State tax, net of federal tax benefit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl_f27926" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl_f27926" xml:lang="en-US">Stock based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl_4" xml:lang="en-US">[Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl_8b04e7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl_8b04e7" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl_8549da" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl_8549da" xml:lang="en-US">Effective tax rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl_ba6462" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl_ba6462" xml:lang="en-US">Net operating loss carryforward</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl_2" xml:lang="en-US">[Operating Loss Carryforwards]</link:label>
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_NetOperatingLossCarryforwardBegainToExpire" xlink:label="ndra_NetOperatingLossCarryforwardBegainToExpire" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ndra_NetOperatingLossCarryforwardBegainToExpire" xlink:to="ndra_NetOperatingLossCarryforwardBegainToExpire_lbl_9047f4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ndra_NetOperatingLossCarryforwardBegainToExpire_lbl_9047f4" xml:lang="en-US">Net operating loss carryforward begain to expire</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="ndra_StockDividendPayable" xlink:to="ndra_StockDividendPayable_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="ndra_StockDividendPayable_d">Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>ndra-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 03/16/2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://novaworks.com/role/Cover" xlink:href="ndra-20221231.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/ConsolidatedBalanceSheets" xlink:href="ndra-20221231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="ndra-20221231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/ConsolidatedStatementsOfOperations" xlink:href="ndra-20221231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="ndra-20221231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="ndra-20221231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/NatureOfTheBusiness" xlink:href="ndra-20221231.xsd#NatureOfTheBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ndra-20221231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/Inventory" xlink:href="ndra-20221231.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/FixedAssets" xlink:href="ndra-20221231.xsd#FixedAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/AccountsPayableAndAccruedLiabilities" xlink:href="ndra-20221231.xsd#AccountsPayableAndAccruedLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/BankLoans" xlink:href="ndra-20221231.xsd#BankLoans" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CapitalStock" xlink:href="ndra-20221231.xsd#CapitalStock" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsus" xlink:href="ndra-20221231.xsd#CommonStockOptionsAndRestrictedStockUnitsRsus" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommonStockWarrants" xlink:href="ndra-20221231.xsd#CommonStockWarrants" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommitmentsAndContingencies" xlink:href="ndra-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/IncomeTaxes" xlink:href="ndra-20221231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/SubsequentEvents" xlink:href="ndra-20221231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ndra-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="ndra-20221231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/FixedAssetsTables" xlink:href="ndra-20221231.xsd#FixedAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:href="ndra-20221231.xsd#AccountsPayableAndAccruedLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusTables" xlink:href="ndra-20221231.xsd#CommonStockOptionsAndRestrictedStockUnitsRsusTables" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommonStockWarrantsTables" xlink:href="ndra-20221231.xsd#CommonStockWarrantsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommitmentsAndContingenciesTables" xlink:href="ndra-20221231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/IncomeTaxesTables" xlink:href="ndra-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="ndra-20221231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ndra-20221231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/InventoryDetailsNarrative" xlink:href="ndra-20221231.xsd#InventoryDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/FixedAssetsDetails" xlink:href="ndra-20221231.xsd#FixedAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/FixedAssetsDetailsNarrative" xlink:href="ndra-20221231.xsd#FixedAssetsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:href="ndra-20221231.xsd#AccountsPayableAndAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/BankLoansDetailsNarrative" xlink:href="ndra-20221231.xsd#BankLoansDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CapitalStockDetailsNarrative" xlink:href="ndra-20221231.xsd#CapitalStockDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetails" xlink:href="ndra-20221231.xsd#CommonStockOptionsAndRestrictedStockUnitsRsusDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetailsNarrative" xlink:href="ndra-20221231.xsd#CommonStockOptionsAndRestrictedStockUnitsRsusDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommonStockWarrantsDetails" xlink:href="ndra-20221231.xsd#CommonStockWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommitmentsAndContingenciesDetails" xlink:href="ndra-20221231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="ndra-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/IncomeTaxesDetails" xlink:href="ndra-20221231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/IncomeTaxesDetails1" xlink:href="ndra-20221231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/IncomeTaxesDetailsNarrative" xlink:href="ndra-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/ConsolidatedBalanceSheets" xlink:title="000002 - Statement - Consolidated Balance Sheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLoansPayable" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaapLongTermLoansPayable" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapLongTermLoansPayable" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_StockPayable" xlink:label="loc_ndraStockPayable" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_ndraStockPayable" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/ConsolidatedStatementsOfOperations" xlink:title="000004 - Statement - Consolidated Statements of Operations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends" xlink:label="loc_us-gaapDividends" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapDividends" xlink:type="arc" weight="-1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:title="000005 - Statement - Consolidated Statements of Stockholders Equity" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="000006 - Statement - Consolidated Statements of Cash Flows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_FixedAssetsWriteOff" xlink:label="loc_ndraFixedAssetsWriteOff" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ndraFixedAssetsWriteOff" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/NatureOfTheBusiness" xlink:title="000007 - Disclosure - Nature of the Business" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="000008 - Disclosure - Summary of Significant Accounting Policies" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/Inventory" xlink:title="000009 - Disclosure - Inventory" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/FixedAssets" xlink:title="000010 - Disclosure - Fixed Assets" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/AccountsPayableAndAccruedLiabilities" xlink:title="000011 - Disclosure - Accounts Payable and Accrued Liabilities" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/BankLoans" xlink:title="000012 - Disclosure - Bank Loans" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/CapitalStock" xlink:title="000013 - Disclosure - Capital Stock" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsus" xlink:title="000014 - Disclosure - Common Stock Options and Restricted Stock Units (RSUs)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommonStockWarrants" xlink:title="000015 - Disclosure - Common Stock Warrants" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommitmentsAndContingencies" xlink:title="000016 - Disclosure - Commitments and Contingencies" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/IncomeTaxes" xlink:title="000017 - Disclosure - Income Taxes" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/SubsequentEvents" xlink:title="000018 - Disclosure - Subsequent Events" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000019 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="000020 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/FixedAssetsTables" xlink:title="000021 - Disclosure - Fixed Assets (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:title="000022 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusTables" xlink:title="000023 - Disclosure - Common Stock Options and Restricted Stock Units (RSUs)(Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommonStockWarrantsTables" xlink:title="000024 - Disclosure - Common Stock Warrants (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommitmentsAndContingenciesTables" xlink:title="000025 - Disclosure - Commitments and Contingencies (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/IncomeTaxesTables" xlink:title="000026 - Disclosure - Income Taxes (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="000027 - Disclosure - Summary of Significant Accounting Policies (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000028 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/InventoryDetailsNarrative" xlink:title="000029 - Disclosure - Inventory (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/FixedAssetsDetails" xlink:title="000030 - Disclosure - Fixed Assets (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/FixedAssetsDetailsNarrative" xlink:title="000031 - Disclosure - Fixed Assets (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:title="000032 - Disclosure - Accounts Payable and Accrued Liabilities (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/BankLoansDetailsNarrative" xlink:title="000033 - Disclosure - Bank Loans (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/CapitalStockDetailsNarrative" xlink:title="000034 - Disclosure - Capital Stock (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetails" xlink:title="000035 - Disclosure - Common Stock Options and Restricted Stock Units (RSUs) (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetailsNarrative" xlink:title="000036 - Disclosure - Common Stock Options and Restricted Stock Units (RSUs) (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommonStockWarrantsDetails" xlink:title="000037 - Disclosure - Common Stock Warrants (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommitmentsAndContingenciesDetails" xlink:title="000038 - Disclosure - Commitments and Contingencies (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000039 - Disclosure - Commitments and Contingencies (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/IncomeTaxesDetails" xlink:title="000040 - Disclosure - Income Taxes (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/IncomeTaxesDetails1" xlink:title="000041 - Disclosure - Income Taxes (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://novaworks.com/role/IncomeTaxesDetailsNarrative" xlink:title="000042 - Disclosure - Income Taxes (Details narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>ndra-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 03/16/2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://novaworks.com/role/Cover" xlink:href="ndra-20221231.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/ConsolidatedBalanceSheets" xlink:href="ndra-20221231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="ndra-20221231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/ConsolidatedStatementsOfOperations" xlink:href="ndra-20221231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="ndra-20221231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="ndra-20221231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/NatureOfTheBusiness" xlink:href="ndra-20221231.xsd#NatureOfTheBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ndra-20221231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/Inventory" xlink:href="ndra-20221231.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/FixedAssets" xlink:href="ndra-20221231.xsd#FixedAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/AccountsPayableAndAccruedLiabilities" xlink:href="ndra-20221231.xsd#AccountsPayableAndAccruedLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/BankLoans" xlink:href="ndra-20221231.xsd#BankLoans" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CapitalStock" xlink:href="ndra-20221231.xsd#CapitalStock" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsus" xlink:href="ndra-20221231.xsd#CommonStockOptionsAndRestrictedStockUnitsRsus" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommonStockWarrants" xlink:href="ndra-20221231.xsd#CommonStockWarrants" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommitmentsAndContingencies" xlink:href="ndra-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/IncomeTaxes" xlink:href="ndra-20221231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/SubsequentEvents" xlink:href="ndra-20221231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ndra-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="ndra-20221231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/FixedAssetsTables" xlink:href="ndra-20221231.xsd#FixedAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:href="ndra-20221231.xsd#AccountsPayableAndAccruedLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusTables" xlink:href="ndra-20221231.xsd#CommonStockOptionsAndRestrictedStockUnitsRsusTables" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommonStockWarrantsTables" xlink:href="ndra-20221231.xsd#CommonStockWarrantsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommitmentsAndContingenciesTables" xlink:href="ndra-20221231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/IncomeTaxesTables" xlink:href="ndra-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="ndra-20221231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ndra-20221231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/InventoryDetailsNarrative" xlink:href="ndra-20221231.xsd#InventoryDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/FixedAssetsDetails" xlink:href="ndra-20221231.xsd#FixedAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/FixedAssetsDetailsNarrative" xlink:href="ndra-20221231.xsd#FixedAssetsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:href="ndra-20221231.xsd#AccountsPayableAndAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/BankLoansDetailsNarrative" xlink:href="ndra-20221231.xsd#BankLoansDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CapitalStockDetailsNarrative" xlink:href="ndra-20221231.xsd#CapitalStockDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetails" xlink:href="ndra-20221231.xsd#CommonStockOptionsAndRestrictedStockUnitsRsusDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetailsNarrative" xlink:href="ndra-20221231.xsd#CommonStockOptionsAndRestrictedStockUnitsRsusDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommonStockWarrantsDetails" xlink:href="ndra-20221231.xsd#CommonStockWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommitmentsAndContingenciesDetails" xlink:href="ndra-20221231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="ndra-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/IncomeTaxesDetails" xlink:href="ndra-20221231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/IncomeTaxesDetails1" xlink:href="ndra-20221231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/IncomeTaxesDetailsNarrative" xlink:href="ndra-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
    <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/ConsolidatedBalanceSheets" xlink:title="000002 - Statement - Consolidated Balance Sheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_1eb5f4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_e8e8ed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_1eb5f4" xlink:to="loc_us-gaapStatementTable_e8e8ed" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_ec2273" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_e8e8ed" xlink:to="loc_us-gaapStatementLineItems_ec2273" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis_8c586c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_e8e8ed" xlink:to="loc_us-gaapStatementClassOfStockAxis_8c586c" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_b371e2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis_8c586c" xlink:to="loc_us-gaapClassOfStockDomain_b371e2" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_80007a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_b371e2" xlink:to="loc_us-gaapSeriesAPreferredStockMember_80007a" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_6f7126" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_b371e2" xlink:to="loc_us-gaapSeriesBPreferredStockMember_6f7126" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_250126" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ec2273" xlink:to="loc_us-gaapAssetsCurrentAbstract_250126" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_9ea7a8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_250126" xlink:to="loc_us-gaapCash_9ea7a8" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_895049" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_250126" xlink:to="loc_us-gaapPrepaidExpenseCurrent_895049" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet_17ab61" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_250126" xlink:to="loc_us-gaapInventoryNet_17ab61" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_2b3227" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_250126" xlink:to="loc_us-gaapAssetsCurrent_2b3227" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrentAbstract" xlink:label="loc_us-gaapOtherAssetsNoncurrentAbstract_51d554" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_250126" xlink:to="loc_us-gaapOtherAssetsNoncurrentAbstract_51d554" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_e04de9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsNoncurrentAbstract_51d554" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_e04de9" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_4109e5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsNoncurrentAbstract_51d554" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_4109e5" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent_647015" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsNoncurrentAbstract_51d554" xlink:to="loc_us-gaapOtherAssetsNoncurrent_647015" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_3863df" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsNoncurrentAbstract_51d554" xlink:to="loc_us-gaapAssets_3863df" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_3932c0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsNoncurrentAbstract_51d554" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_3932c0" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_fc1da4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_3932c0" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_fc1da4" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_73bb3c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_fc1da4" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_73bb3c" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_a23f07" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_fc1da4" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_a23f07" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable_6d8e97" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_fc1da4" xlink:to="loc_us-gaapLoansPayable_6d8e97" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_b8f1c7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_fc1da4" xlink:to="loc_us-gaapLiabilitiesCurrent_b8f1c7" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesOtherThanLongTermDebtNoncurrentAbstract_fc012f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_fc1da4" xlink:to="loc_us-gaapLiabilitiesOtherThanLongTermDebtNoncurrentAbstract_fc012f" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaapLongTermLoansPayable_64b538" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesOtherThanLongTermDebtNoncurrentAbstract_fc012f" xlink:to="loc_us-gaapLongTermLoansPayable_64b538" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_6ec90c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesOtherThanLongTermDebtNoncurrentAbstract_fc012f" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_6ec90c" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt_10448f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesOtherThanLongTermDebtNoncurrentAbstract_fc012f" xlink:to="loc_us-gaapLongTermDebt_10448f" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_529c50" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesOtherThanLongTermDebtNoncurrentAbstract_fc012f" xlink:to="loc_us-gaapLiabilities_529c50" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_2afe47" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesOtherThanLongTermDebtNoncurrentAbstract_fc012f" xlink:to="loc_us-gaapStockholdersEquityAbstract_2afe47" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_201d99" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_2afe47" xlink:to="loc_us-gaapPreferredStockValue_201d99" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_1f7be7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_2afe47" xlink:to="loc_us-gaapCommonStockValue_1f7be7" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_0ec40f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_2afe47" xlink:to="loc_us-gaapAdditionalPaidInCapital_0ec40f" order="25" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_StockPayable" xlink:label="loc_ndraStockPayable_202900" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_2afe47" xlink:to="loc_ndraStockPayable_202900" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_fbe605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_2afe47" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_fbe605" order="27" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_e26b95" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_2afe47" xlink:to="loc_us-gaapStockholdersEquity_e26b95" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_11e274" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_2afe47" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_11e274" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_3d7ff3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_12e25f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3d7ff3" xlink:to="loc_us-gaapStatementTable_12e25f" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_cb0974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_12e25f" xlink:to="loc_us-gaapStatementLineItems_cb0974" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis_c970a9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_12e25f" xlink:to="loc_us-gaapStatementClassOfStockAxis_c970a9" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_767969" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis_c970a9" xlink:to="loc_us-gaapClassOfStockDomain_767969" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaapPreferredClassAMember_5f1415" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_767969" xlink:to="loc_us-gaapPreferredClassAMember_5f1415" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredClassBMember" xlink:label="loc_us-gaapPreferredClassBMember_b7c147" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_767969" xlink:to="loc_us-gaapPreferredClassBMember_b7c147" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_640a4f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_cb0974" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_640a4f" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_7c7b9f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_cb0974" xlink:to="loc_us-gaapCommonStockSharesAuthorized_7c7b9f" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_f28f31" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_cb0974" xlink:to="loc_us-gaapCommonStockSharesIssued_f28f31" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_a61c1e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_cb0974" xlink:to="loc_us-gaapCommonStockSharesOutstanding_a61c1e" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_2de810" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_cb0974" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_2de810" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_741dab" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_cb0974" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_741dab" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_8ff5a0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_cb0974" xlink:to="loc_us-gaapPreferredStockSharesIssued_8ff5a0" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_1f9dad" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_cb0974" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_1f9dad" order="8" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/ConsolidatedStatementsOfOperations" xlink:title="000004 - Statement - Consolidated Statements of Operations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract_5ea9e9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_e8f864" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_5ea9e9" xlink:to="loc_us-gaapOperatingExpensesAbstract_e8f864" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_995f05" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_e8f864" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_995f05" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense_9ba64f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_e8f864" xlink:to="loc_us-gaapSellingAndMarketingExpense_9ba64f" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_6c10c7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_e8f864" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_6c10c7" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_201710" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_e8f864" xlink:to="loc_us-gaapOperatingExpenses_201710" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_0700f0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_e8f864" xlink:to="loc_us-gaapOperatingIncomeLoss_0700f0" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_e5f93e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_e8f864" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_e5f93e" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_633240" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_e5f93e" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_633240" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_555659" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_e5f93e" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_555659" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_9cce7d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_e5f93e" xlink:to="loc_us-gaapNonoperatingIncomeExpense_9cce7d" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_064d8b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_e5f93e" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_064d8b" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_d9ef2b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_e5f93e" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_d9ef2b" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_c046ce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_e5f93e" xlink:to="loc_us-gaapNetIncomeLoss_c046ce" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends" xlink:label="loc_us-gaapDividends_43764e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_e5f93e" xlink:to="loc_us-gaapDividends_43764e" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_5b8d74" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_e5f93e" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_5b8d74" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_7ba5ba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_e5f93e" xlink:to="loc_us-gaapEarningsPerShareBasic_7ba5ba" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesIssuedBasic_4c235b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_e5f93e" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesIssuedBasic_4c235b" order="17" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:title="000005 - Statement - Consolidated Statements of Stockholders Equity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract_0460be" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_270008" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract_0460be" xlink:to="loc_us-gaapStatementTable_270008" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_eb6130" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_270008" xlink:to="loc_us-gaapStatementLineItems_eb6130" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis_377bfd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_270008" xlink:to="loc_us-gaapStatementEquityComponentsAxis_377bfd" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_a489fe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis_377bfd" xlink:to="loc_us-gaapEquityComponentDomain_a489fe" order="20" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_PreferredsStockSeriesAMember" xlink:label="loc_ndraPreferredsStockSeriesAMember_1924fe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_a489fe" xlink:to="loc_ndraPreferredsStockSeriesAMember_1924fe" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_166d72" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_a489fe" xlink:to="loc_us-gaapCommonStockMember_166d72" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_11688a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_a489fe" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_11688a" order="23" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_StockPayableMember" xlink:label="loc_ndraStockPayableMember_695db2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_a489fe" xlink:to="loc_ndraStockPayableMember_695db2" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_226cc3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_a489fe" xlink:to="loc_us-gaapRetainedEarningsMember_226cc3" order="25" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SeriesBPreferredStocksMember" xlink:label="loc_ndraSeriesBPreferredStocksMember_cc4c83" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_a489fe" xlink:to="loc_ndraSeriesBPreferredStocksMember_cc4c83" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_7fb2b7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eb6130" xlink:to="loc_us-gaapSharesIssued_7fb2b7" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_9645c2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eb6130" xlink:to="loc_us-gaapStockholdersEquity_9645c2" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SeriesAConvertiblePreferredStockConvertedToCommonStockShares" xlink:label="loc_ndraSeriesAConvertiblePreferredStockConvertedToCommonStockShares_b71bf7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eb6130" xlink:to="loc_ndraSeriesAConvertiblePreferredStockConvertedToCommonStockShares_b71bf7" order="3" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SeriesAConvertiblePreferredStockConvertedToCommonStockAmount" xlink:label="loc_ndraSeriesAConvertiblePreferredStockConvertedToCommonStockAmount_cb1f1d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eb6130" xlink:to="loc_ndraSeriesAConvertiblePreferredStockConvertedToCommonStockAmount_cb1f1d" order="4" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockIssuedForCashNetOfFundingCostsShares" xlink:label="loc_ndraCommonStockIssuedForCashNetOfFundingCostsShares_79caf3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eb6130" xlink:to="loc_ndraCommonStockIssuedForCashNetOfFundingCostsShares_79caf3" order="5" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockIssuedForCashNetOfFundingCostsAmount" xlink:label="loc_ndraCommonStockIssuedForCashNetOfFundingCostsAmount_7a899d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eb6130" xlink:to="loc_ndraCommonStockIssuedForCashNetOfFundingCostsAmount_7a899d" order="6" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockIssuedForWarrantExerciseShares" xlink:label="loc_ndraCommonStockIssuedForWarrantExerciseShares_1475f6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eb6130" xlink:to="loc_ndraCommonStockIssuedForWarrantExerciseShares_1475f6" order="7" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockIssuedForWarrantExerciseAmount" xlink:label="loc_ndraCommonStockIssuedForWarrantExerciseAmount_d311a3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eb6130" xlink:to="loc_ndraCommonStockIssuedForWarrantExerciseAmount_d311a3" order="8" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockIssuedForOptionExerciseShares" xlink:label="loc_ndraCommonStockIssuedForOptionExerciseShares_2b8194" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eb6130" xlink:to="loc_ndraCommonStockIssuedForOptionExerciseShares_2b8194" order="9" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockIssuedForOptionExerciseAmount" xlink:label="loc_ndraCommonStockIssuedForOptionExerciseAmount_192d6b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eb6130" xlink:to="loc_ndraCommonStockIssuedForOptionExerciseAmount_192d6b" order="10" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_FairValueOfVestedStockOptions" xlink:label="loc_ndraFairValueOfVestedStockOptions_c3160b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eb6130" xlink:to="loc_ndraFairValueOfVestedStockOptions_c3160b" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock_aca404" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eb6130" xlink:to="loc_us-gaapDividendsPreferredStock_aca404" order="12" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockIssuedForServicesShares" xlink:label="loc_ndraCommonStockIssuedForServicesShares_0e354c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eb6130" xlink:to="loc_ndraCommonStockIssuedForServicesShares_0e354c" order="13" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockIssuedForServicesAmount" xlink:label="loc_ndraCommonStockIssuedForServicesAmount_3b4541" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eb6130" xlink:to="loc_ndraCommonStockIssuedForServicesAmount_3b4541" order="14" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_StockIssuedForRsuShares" xlink:label="loc_ndraStockIssuedForRsuShares_16d4c4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eb6130" xlink:to="loc_ndraStockIssuedForRsuShares_16d4c4" order="15" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_StockIssuedForRsuAmount" xlink:label="loc_ndraStockIssuedForRsuAmount_239f85" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eb6130" xlink:to="loc_ndraStockIssuedForRsuAmount_239f85" order="16" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_DeemedDividend" xlink:label="loc_ndraDeemedDividend_db1375" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eb6130" xlink:to="loc_ndraDeemedDividend_db1375" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_f0833c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eb6130" xlink:to="loc_us-gaapNetIncomeLoss_f0833c" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_a02e06" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eb6130" xlink:to="loc_us-gaapSharesIssued_a02e06" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_c42467" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eb6130" xlink:to="loc_us-gaapStockholdersEquity_c42467" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="000006 - Statement - Consolidated Statements of Cash Flows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract_92ab85" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_0be897" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_92ab85" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_0be897" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_55e7f5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_0be897" xlink:to="loc_us-gaapProfitLoss_55e7f5" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_adf2b5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_0be897" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_adf2b5" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization_1b16fb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_adf2b5" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization_1b16fb" order="4" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_FixedAssetsWriteOff" xlink:label="loc_ndraFixedAssetsWriteOff_5cf18c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_adf2b5" xlink:to="loc_ndraFixedAssetsWriteOff_5cf18c" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_0359cc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_adf2b5" xlink:to="loc_us-gaapShareBasedCompensation_0359cc" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense_f8be1e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_adf2b5" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense_f8be1e" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_f3b81f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_adf2b5" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_f3b81f" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_0fb8f2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_adf2b5" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_0fb8f2" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense_3f9260" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_0fb8f2" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense_3f9260" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories_f104ed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_0fb8f2" xlink:to="loc_us-gaapIncreaseDecreaseInInventories_f104ed" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c91d31" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_0fb8f2" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c91d31" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability_e4c03a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_0fb8f2" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability_e4c03a" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_b9929a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_0fb8f2" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_b9929a" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_8bbd27" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_0fb8f2" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_8bbd27" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_c27ade" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_8bbd27" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_c27ade" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_06ecb8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_8bbd27" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_06ecb8" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_69e6d4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_8bbd27" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_69e6d4" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_d4295a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_69e6d4" xlink:to="loc_us-gaapProceedsFromWarrantExercises_d4295a" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_b9d103" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_69e6d4" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_b9d103" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_706314" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_69e6d4" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_706314" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_b48719" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_69e6d4" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_b48719" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_63018d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_69e6d4" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_63018d" order="23" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8bae18" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_69e6d4" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8bae18" order="24" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract_9a8976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_69e6d4" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract_9a8976" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet_426a53" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract_9a8976" xlink:to="loc_us-gaapInterestPaidNet_426a53" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid_221406" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract_9a8976" xlink:to="loc_us-gaapIncomeTaxesPaid_221406" order="27" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SupplementalDisclosuresOfNoncashItemsAbstract" xlink:label="loc_ndraSupplementalDisclosuresOfNoncashItemsAbstract_e64516" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract_9a8976" xlink:to="loc_ndraSupplementalDisclosuresOfNoncashItemsAbstract_e64516" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends" xlink:label="loc_us-gaapDividends_7c5731" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ndraSupplementalDisclosuresOfNoncashItemsAbstract_e64516" xlink:to="loc_us-gaapDividends_7c5731" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ConversionOfSeriesAConvertiblePreferredStock" xlink:label="loc_ndraConversionOfSeriesAConvertiblePreferredStock_8b39af" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ndraSupplementalDisclosuresOfNoncashItemsAbstract_e64516" xlink:to="loc_ndraConversionOfSeriesAConvertiblePreferredStock_8b39af" order="30" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_StockDividendPayable" xlink:label="loc_ndraStockDividendPayable_7ecad9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ndraSupplementalDisclosuresOfNoncashItemsAbstract_e64516" xlink:to="loc_ndraStockDividendPayable_7ecad9" order="31" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization_3ab1f1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ndraSupplementalDisclosuresOfNoncashItemsAbstract_e64516" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization_3ab1f1" order="32" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_LeaseLiability" xlink:label="loc_ndraLeaseLiability_fd225d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ndraSupplementalDisclosuresOfNoncashItemsAbstract_e64516" xlink:to="loc_ndraLeaseLiability_fd225d" order="33" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/NatureOfTheBusiness" xlink:title="000007 - Disclosure - Nature of the Business">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_da0d69" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaapBusinessCombinationDisclosureTextBlock_afa9d4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_da0d69" xlink:to="loc_us-gaapBusinessCombinationDisclosureTextBlock_afa9d4" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="000008 - Disclosure - Summary of Significant Accounting Policies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_bf9627" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock_7aa91c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_bf9627" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock_7aa91c" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/Inventory" xlink:title="000009 - Disclosure - Inventory">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract_aaca21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock_a9c1a6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract_aaca21" xlink:to="loc_us-gaapInventoryDisclosureTextBlock_a9c1a6" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/FixedAssets" xlink:title="000010 - Disclosure - Fixed Assets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_6d0d44" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock_5928db" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_6d0d44" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock_5928db" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/AccountsPayableAndAccruedLiabilities" xlink:title="000011 - Disclosure - Accounts Payable and Accrued Liabilities">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract_be6649" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_bef5aa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_be6649" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_bef5aa" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/BankLoans" xlink:title="000012 - Disclosure - Bank Loans">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract_70d7b3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="loc_us-gaapShortTermDebtTextBlock_7fb617" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract_70d7b3" xlink:to="loc_us-gaapShortTermDebtTextBlock_7fb617" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/CapitalStock" xlink:title="000013 - Disclosure - Capital Stock">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_a87662" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_ee0e16" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_a87662" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_ee0e16" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsus" xlink:title="000014 - Disclosure - Common Stock Options and Restricted Stock Units (RSUs)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5f3cc" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock" xlink:label="loc_ndraScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock_fc82fd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5f3cc" xlink:to="loc_ndraScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock_fc82fd" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommonStockWarrants" xlink:title="000015 - Disclosure - Common Stock Warrants">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8b5fdc" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock" xlink:label="loc_ndraScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock_5ce367" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8b5fdc" xlink:to="loc_ndraScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock_5ce367" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommitmentsAndContingencies" xlink:title="000016 - Disclosure - Commitments and Contingencies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_027609" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_4754ff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_027609" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_4754ff" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/IncomeTaxes" xlink:title="000017 - Disclosure - Income Taxes">
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_IncomeTaxesAbstract" xlink:label="loc_ndraIncomeTaxesAbstract_0d0e61" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock_69409e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ndraIncomeTaxesAbstract_0d0e61" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock_69409e" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/SubsequentEvents" xlink:title="000018 - Disclosure - Subsequent Events">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_134219" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock_56d97a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_134219" xlink:to="loc_us-gaapSubsequentEventsTextBlock_56d97a" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000019 - Disclosure - Summary of Significant Accounting Policies (Policies)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_3bffab" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates_43f809" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_3bffab" xlink:to="loc_us-gaapUseOfEstimates_43f809" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock_3ea5f4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_3bffab" xlink:to="loc_us-gaapConsolidationPolicyTextBlock_3ea5f4" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock_c9d5d2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_3bffab" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock_c9d5d2" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_245873" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_3bffab" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_245873" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock_fa466d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_3bffab" xlink:to="loc_us-gaapInventoryPolicyTextBlock_fa466d" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_b5dc43" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_3bffab" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_b5dc43" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock_9d869b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_3bffab" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock_9d869b" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock_ce9fed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_3bffab" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock_ce9fed" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy_09b9b3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_3bffab" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy_09b9b3" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock_c0cb7c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_3bffab" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock_c0cb7c" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock_a21921" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_3bffab" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock_a21921" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy_7914d3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_3bffab" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy_7914d3" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock_1c24b0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_3bffab" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock_1c24b0" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_15a0ce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_3bffab" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_15a0ce" order="14" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="000020 - Disclosure - Summary of Significant Accounting Policies (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_18df6b" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f77695" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_18df6b" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f77695" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/FixedAssetsTables" xlink:title="000021 - Disclosure - Fixed Assets (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_35a82a" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock_5a92d6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_35a82a" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock_5a92d6" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:title="000022 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract_ecc600" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_39fc42" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_ecc600" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_39fc42" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusTables" xlink:title="000023 - Disclosure - Common Stock Options and Restricted Stock Units (RSUs)(Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6bf71a" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_efa844" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6bf71a" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_efa844" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommonStockWarrantsTables" xlink:title="000024 - Disclosure - Common Stock Warrants (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a71a76" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock_b8a6be" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a71a76" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock_b8a6be" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommitmentsAndContingenciesTables" xlink:title="000025 - Disclosure - Commitments and Contingencies (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_c236e7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock_141aa1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_c236e7" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock_141aa1" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/IncomeTaxesTables" xlink:title="000026 - Disclosure - Income Taxes (Tables)">
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_IncomeTaxesAbstract" xlink:label="loc_ndraIncomeTaxesAbstract_9035a7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_a9d13d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ndraIncomeTaxesAbstract_9035a7" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_a9d13d" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0a636d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ndraIncomeTaxesAbstract_9035a7" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0a636d" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="000027 - Disclosure - Summary of Significant Accounting Policies (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_ada2e7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_8418a7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_ada2e7" xlink:to="loc_us-gaapStatementTable_8418a7" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_eb24c5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_8418a7" xlink:to="loc_us-gaapStatementLineItems_eb24c5" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis_233751" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_8418a7" xlink:to="loc_us-gaapStatementClassOfStockAxis_233751" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_ac5718" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis_233751" xlink:to="loc_us-gaapClassOfStockDomain_ac5718" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis_5b0b01" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_8418a7" xlink:to="loc_us-gaapFinancialInstrumentAxis_5b0b01" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2d0867" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis_5b0b01" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2d0867" order="30" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_OptionsToPurchaseCommonStockMember" xlink:label="loc_ndraOptionsToPurchaseCommonStockMember_c0050b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_ac5718" xlink:to="loc_ndraOptionsToPurchaseCommonStockMember_c0050b" order="31" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_WarrantsToPurchaseCommonStockMember" xlink:label="loc_ndraWarrantsToPurchaseCommonStockMember_c3a503" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2d0867" xlink:to="loc_ndraWarrantsToPurchaseCommonStockMember_c3a503" order="32" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember" xlink:label="loc_ndraSharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember_f0695d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2d0867" xlink:to="loc_ndraSharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember_f0695d" order="33" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_284d28" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eb24c5" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_284d28" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000028 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_4b03c0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_92f078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_4b03c0" xlink:to="loc_us-gaapOperatingLeaseLiability_92f078" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ResearchAndDevelopmentExpense1" xlink:label="loc_ndraResearchAndDevelopmentExpense1_b0771e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_4b03c0" xlink:to="loc_ndraResearchAndDevelopmentExpense1_b0771e" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_38cec3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_4b03c0" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_38cec3" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_cf619d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_4b03c0" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_cf619d" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SharesAvailableForIssuanceIncreasedUnderTheOmnibusPlan" xlink:label="loc_ndraSharesAvailableForIssuanceIncreasedUnderTheOmnibusPlan_4f5996" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_4b03c0" xlink:to="loc_ndraSharesAvailableForIssuanceIncreasedUnderTheOmnibusPlan_4f5996" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CumulativeDividends" xlink:label="loc_us-gaapCumulativeDividends_23981a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_4b03c0" xlink:to="loc_us-gaapCumulativeDividends_23981a" order="6" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_WorkingCapital" xlink:label="loc_ndraWorkingCapital_a9e568" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_4b03c0" xlink:to="loc_ndraWorkingCapital_a9e568" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_5ea07b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_4b03c0" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_5ea07b" order="8" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/InventoryDetailsNarrative" xlink:title="000029 - Disclosure - Inventory (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract_3e673d" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet_3cfaa5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract_3e673d" xlink:to="loc_us-gaapInventoryNet_3cfaa5" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/FixedAssetsDetails" xlink:title="000030 - Disclosure - Fixed Assets (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_fa6ad6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_dd6a3b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_fa6ad6" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_dd6a3b" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopmentInProcess" xlink:label="loc_us-gaapDevelopmentInProcess_ec1db1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_fa6ad6" xlink:to="loc_us-gaapDevelopmentInProcess_ec1db1" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_66e994" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_fa6ad6" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_66e994" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_3e28a4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_fa6ad6" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_3e28a4" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/FixedAssetsDetailsNarrative" xlink:title="000031 - Disclosure - Fixed Assets (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_48922d" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_044b23" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_48922d" xlink:to="loc_us-gaapDepreciation_044b23" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:title="000032 - Disclosure - Accounts Payable and Accrued Liabilities (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract_2e2949" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_f46556" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_2e2949" xlink:to="loc_us-gaapAccountsPayableCurrent_f46556" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent_2beefc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_2e2949" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent_2beefc" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedBonusesCurrentAndNoncurrent_39d084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_2e2949" xlink:to="loc_us-gaapAccruedBonusesCurrentAndNoncurrent_39d084" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaapAccruedEmployeeBenefitsCurrent_092267" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_2e2949" xlink:to="loc_us-gaapAccruedEmployeeBenefitsCurrent_092267" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInsuranceCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedInsuranceCurrentAndNoncurrent_19f416" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_2e2949" xlink:to="loc_us-gaapAccruedInsuranceCurrentAndNoncurrent_19f416" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent_c81a72" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_2e2949" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent_c81a72" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/BankLoansDetailsNarrative" xlink:title="000033 - Disclosure - Bank Loans (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract_8fe2cb" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_953e4b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract_8fe2cb" xlink:to="loc_us-gaapStatementTable_953e4b" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_9c559c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_953e4b" xlink:to="loc_us-gaapStatementLineItems_9c559c" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_0dcf9d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_953e4b" xlink:to="loc_us-gaapPlanNameAxis_0dcf9d" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_403401" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_0dcf9d" xlink:to="loc_us-gaapPlanNameDomain_403401" order="20" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_TDBankLoanMember" xlink:label="loc_ndraTDBankLoanMember_a912c3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_403401" xlink:to="loc_ndraTDBankLoanMember_a912c3" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:label="loc_us-gaapProceedsFromCollectionOfNotesReceivable_3998e7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9c559c" xlink:to="loc_us-gaapProceedsFromCollectionOfNotesReceivable_3998e7" order="1" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_PrincipalAggregateAmount" xlink:label="loc_ndraPrincipalAggregateAmount_254dd9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9c559c" xlink:to="loc_ndraPrincipalAggregateAmount_254dd9" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInitiationDate1" xlink:label="loc_us-gaapLineOfCreditFacilityInitiationDate1_590e31" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9c559c" xlink:to="loc_us-gaapLineOfCreditFacilityInitiationDate1_590e31" order="3" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_InitialTermInterestRate" xlink:label="loc_ndraInitialTermInterestRate_754871" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9c559c" xlink:to="loc_ndraInitialTermInterestRate_754871" order="4" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_BankLoanDescription" xlink:label="loc_ndraBankLoanDescription_8965d2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9c559c" xlink:to="loc_ndraBankLoanDescription_8965d2" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/CapitalStockDetailsNarrative" xlink:title="000034 - Disclosure - Capital Stock (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_2223a1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_3cf86f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_2223a1" xlink:to="loc_us-gaapStatementTable_3cf86f" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_279739" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_3cf86f" xlink:to="loc_us-gaapStatementLineItems_279739" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis_dc4b51" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_3cf86f" xlink:to="loc_us-gaapStatementClassOfStockAxis_dc4b51" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_617021" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis_dc4b51" xlink:to="loc_us-gaapClassOfStockDomain_617021" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_b95485" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_3cf86f" xlink:to="loc_us-gaapPlanNameAxis_b95485" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_1aa907" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_b95485" xlink:to="loc_us-gaapPlanNameDomain_1aa907" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_798677" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_617021" xlink:to="loc_us-gaapSeriesAPreferredStockMember_798677" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_cda921" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_617021" xlink:to="loc_us-gaapSeriesBPreferredStockMember_cda921" order="22" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_JuneTwentyTwentyOneATMAgreementMember" xlink:label="loc_ndraJuneTwentyTwentyOneATMAgreementMember_bbe6a0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_1aa907" xlink:to="loc_ndraJuneTwentyTwentyOneATMAgreementMember_bbe6a0" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_3c8245" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_617021" xlink:to="loc_us-gaapSeriesCPreferredStockMember_3c8245" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="loc_us-gaapCapitalUnitsAuthorized_805503" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_279739" xlink:to="loc_us-gaapCapitalUnitsAuthorized_805503" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_9fe648" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_279739" xlink:to="loc_us-gaapCommonStockSharesAuthorized_9fe648" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_37c679" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_279739" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_37c679" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_110b9c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_279739" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_110b9c" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_13f062" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_279739" xlink:to="loc_us-gaapCommonStockSharesIssued_13f062" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_e6163b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_279739" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_e6163b" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_PreferredStockSharesUndesignated" xlink:label="loc_ndraPreferredStockSharesUndesignated_44d809" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_279739" xlink:to="loc_ndraPreferredStockSharesUndesignated_44d809" order="7" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_StockPayableShare" xlink:label="loc_ndraStockPayableShare_94e9ec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_279739" xlink:to="loc_ndraStockPayableShare_94e9ec" order="8" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockSharesUponWarratExerciseShares" xlink:label="loc_ndraCommonStockSharesUponWarratExerciseShares_1bfabb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_279739" xlink:to="loc_ndraCommonStockSharesUponWarratExerciseShares_1bfabb" order="9" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockSharesUponWarrantExerciseAmount" xlink:label="loc_ndraCommonStockSharesUponWarrantExerciseAmount_ff5dfe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_279739" xlink:to="loc_ndraCommonStockSharesUponWarrantExerciseAmount_ff5dfe" order="10" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockSharesUponCashlessWarrantExercise" xlink:label="loc_ndraCommonStockSharesUponCashlessWarrantExercise_e037b0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_279739" xlink:to="loc_ndraCommonStockSharesUponCashlessWarrantExercise_e037b0" order="11" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockSharesUponCashlessOptionExercise" xlink:label="loc_ndraCommonStockSharesUponCashlessOptionExercise_72eb3e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_279739" xlink:to="loc_ndraCommonStockSharesUponCashlessOptionExercise_72eb3e" order="12" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SharesForServicesValue" xlink:label="loc_ndraSharesForServicesValue_5e2f81" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_279739" xlink:to="loc_ndraSharesForServicesValue_5e2f81" order="13" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockSharesUponVestingOfRestrictedUnits" xlink:label="loc_ndraCommonStockSharesUponVestingOfRestrictedUnits_459b67" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_279739" xlink:to="loc_ndraCommonStockSharesUponVestingOfRestrictedUnits_459b67" order="14" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockServicesValued" xlink:label="loc_ndraCommonStockServicesValued_1a8af5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_279739" xlink:to="loc_ndraCommonStockServicesValued_1a8af5" order="15" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_RestictedStockUnitsValued" xlink:label="loc_ndraRestictedStockUnitsValued_f7894e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_279739" xlink:to="loc_ndraRestictedStockUnitsValued_f7894e" order="16" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SharesInReturn" xlink:label="loc_ndraSharesInReturn_f01abd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_279739" xlink:to="loc_ndraSharesInReturn_f01abd" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_6f5f88" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_279739" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_6f5f88" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_b88ad1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_279739" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_b88ad1" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_7b2242" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_279739" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_7b2242" order="20" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ConversionOfCommonStockIntoPreferredStock" xlink:label="loc_ndraConversionOfCommonStockIntoPreferredStock_a4fb06" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_279739" xlink:to="loc_ndraConversionOfCommonStockIntoPreferredStock_a4fb06" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_87ed5a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_279739" xlink:to="loc_us-gaapPreferredStockSharesIssued_87ed5a" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_TotalCommonStockSharesIssued" xlink:label="loc_ndraTotalCommonStockSharesIssued_936514" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_279739" xlink:to="loc_ndraTotalCommonStockSharesIssued_936514" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_ce1a16" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_279739" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_ce1a16" order="24" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_NetProceedsFromSalesOfCommonStock3" xlink:label="loc_ndraNetProceedsFromSalesOfCommonStock3_21c402" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_279739" xlink:to="loc_ndraNetProceedsFromSalesOfCommonStock3_21c402" order="25" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_GrossProceedsFromSalesOfCommonStock" xlink:label="loc_ndraGrossProceedsFromSalesOfCommonStock_7f37d2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_279739" xlink:to="loc_ndraGrossProceedsFromSalesOfCommonStock_7f37d2" order="26" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetails" xlink:title="000035 - Disclosure - Common Stock Options and Restricted Stock Units (RSUs) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_471c5b" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cd3762" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_471c5b" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cd3762" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ba3575" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_471c5b" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ba3575" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_da4e14" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_471c5b" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_da4e14" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_4257ce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_471c5b" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_4257ce" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_61c06a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_471c5b" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_61c06a" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_819d71" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_471c5b" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_819d71" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_beff3e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_471c5b" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_beff3e" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_54a661" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_471c5b" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_54a661" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_66dc4f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_471c5b" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_66dc4f" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ecd59b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_471c5b" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ecd59b" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_60bc57" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_471c5b" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_60bc57" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6f6ff9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_471c5b" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6f6ff9" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a4de38" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_471c5b" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a4de38" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50b65a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_471c5b" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50b65a" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_ndraSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_47fb8d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_471c5b" xlink:to="loc_ndraSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_47fb8d" order="15" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_ndraSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_61ce5a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_471c5b" xlink:to="loc_ndraSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_61ce5a" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c287ca" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_471c5b" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c287ca" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d259b5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_471c5b" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d259b5" order="18" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetailsNarrative" xlink:title="000036 - Disclosure - Common Stock Options and Restricted Stock Units (RSUs) (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_716e1a" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_a6110d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_716e1a" xlink:to="loc_us-gaapStatementTable_a6110d" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_15834f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_a6110d" xlink:to="loc_us-gaapStatementLineItems_15834f" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis_01fba1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_a6110d" xlink:to="loc_srtRangeAxis_01fba1" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_5dbeb6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis_01fba1" xlink:to="loc_srtRangeMember_5dbeb6" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_031786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_5dbeb6" xlink:to="loc_srtMinimumMember_031786" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_0177a1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_5dbeb6" xlink:to="loc_srtMaximumMember_0177a1" order="22" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_AggregateFairValueOfStockOptionsGranted" xlink:label="loc_ndraAggregateFairValueOfStockOptionsGranted_1a5d84" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_15834f" xlink:to="loc_ndraAggregateFairValueOfStockOptionsGranted_1a5d84" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_287a34" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_15834f" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_287a34" order="2" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ExpectedDividendYield" xlink:label="loc_ndraExpectedDividendYield_c1c190" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_15834f" xlink:to="loc_ndraExpectedDividendYield_c1c190" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5071be" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_15834f" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5071be" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b1faac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_15834f" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b1faac" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fd20e5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_15834f" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fd20e5" order="6" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommonStockWarrantsDetails" xlink:title="000037 - Disclosure - Common Stock Warrants (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bbdbe0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_260abc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bbdbe0" xlink:to="loc_us-gaapStatementTable_260abc" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_a38fe9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_260abc" xlink:to="loc_us-gaapStatementLineItems_a38fe9" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_956d31" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_260abc" xlink:to="loc_us-gaapAwardTypeAxis_956d31" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6106c6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_956d31" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6106c6" order="20" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_WarrantsMember" xlink:label="loc_ndraWarrantsMember_8ffef1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6106c6" xlink:to="loc_ndraWarrantsMember_8ffef1" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_75d57c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a38fe9" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_75d57c" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:label="loc_ndraShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_87b1aa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a38fe9" xlink:to="loc_ndraShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_87b1aa" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_NumberOfWarrantsExercisable" xlink:label="loc_ndraNumberOfWarrantsExercisable_e53e40" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a38fe9" xlink:to="loc_ndraNumberOfWarrantsExercisable_e53e40" order="3" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_NumberOfWarrantsEndingBalance" xlink:label="loc_ndraNumberOfWarrantsEndingBalance_27ccc7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a38fe9" xlink:to="loc_ndraNumberOfWarrantsEndingBalance_27ccc7" order="4" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_ndraShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_6712fc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a38fe9" xlink:to="loc_ndraShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_6712fc" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_ndraShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_56967d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a38fe9" xlink:to="loc_ndraShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_56967d" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_ndraShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_37ae78" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a38fe9" xlink:to="loc_ndraShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_37ae78" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="loc_ndraShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice_4e041c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a38fe9" xlink:to="loc_ndraShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice_4e041c" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_ndraShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice_9688bb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a38fe9" xlink:to="loc_ndraShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice_9688bb" order="9" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_WeightedAverageExercisePriceOutstanding" xlink:label="loc_ndraWeightedAverageExercisePriceOutstanding_8a3e26" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a38fe9" xlink:to="loc_ndraWeightedAverageExercisePriceOutstanding_8a3e26" order="10" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_WeightedAverageExercisableAtJune302022" xlink:label="loc_ndraWeightedAverageExercisableAtJune302022_f8e87a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a38fe9" xlink:to="loc_ndraWeightedAverageExercisableAtJune302022_f8e87a" order="11" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" xlink:label="loc_ndraSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_aee2e4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a38fe9" xlink:to="loc_ndraSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_aee2e4" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:label="loc_ndraSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_c90f24" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a38fe9" xlink:to="loc_ndraSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_c90f24" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermExercisable" xlink:label="loc_ndraSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermExercisable_895473" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a38fe9" xlink:to="loc_ndraSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermExercisable_895473" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommitmentsAndContingenciesDetails" xlink:title="000038 - Disclosure - Commitments and Contingencies (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_8c1cdf" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0ec271" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_8c1cdf" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0ec271" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c50a68" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_8c1cdf" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c50a68" order="2" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="loc_ndraLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_d0a7c2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_8c1cdf" xlink:to="loc_ndraLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_d0a7c2" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_9cbd76" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_8c1cdf" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_9cbd76" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_216c23" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_8c1cdf" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_216c23" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_0afbae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_8c1cdf" xlink:to="loc_us-gaapOperatingLeaseLiability_0afbae" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_562bf4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_8c1cdf" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_562bf4" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_b44fb0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_8c1cdf" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_b44fb0" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000039 - Disclosure - Commitments and Contingencies (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_417165" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_71bb51" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_417165" xlink:to="loc_us-gaapStatementTable_71bb51" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_0fe97b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_71bb51" xlink:to="loc_us-gaapStatementLineItems_0fe97b" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_afcd8a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_71bb51" xlink:to="loc_us-gaapPlanNameAxis_afcd8a" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_ec554f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_afcd8a" xlink:to="loc_us-gaapPlanNameDomain_ec554f" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis_9b8ff6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_71bb51" xlink:to="loc_us-gaapRelatedPartyTransactionAxis_9b8ff6" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_eb5fdd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis_9b8ff6" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_eb5fdd" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis_40ad54" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_71bb51" xlink:to="loc_us-gaapAwardDateAxis_40ad54" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_6d817a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis_40ad54" xlink:to="loc_us-gaapAwardDateDomain_6d817a" order="50" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_EmploymentAgreementsMember" xlink:label="loc_ndraEmploymentAgreementsMember_8ed054" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_ec554f" xlink:to="loc_ndraEmploymentAgreementsMember_8ed054" order="51" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_MichaelThorntonMember" xlink:label="loc_ndraMichaelThorntonMember_933d62" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain_eb5fdd" xlink:to="loc_ndraMichaelThorntonMember_933d62" order="52" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_EmploymentgreementsMember" xlink:label="loc_ndraEmploymentgreementsMember_ed3fab" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_ec554f" xlink:to="loc_ndraEmploymentgreementsMember_ed3fab" order="53" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_RenaudMalobertiMember" xlink:label="loc_ndraRenaudMalobertiMember_886175" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain_eb5fdd" xlink:to="loc_ndraRenaudMalobertiMember_886175" order="54" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_FrancoisMichelonMember" xlink:label="loc_ndraFrancoisMichelonMember_4260de" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain_eb5fdd" xlink:to="loc_ndraFrancoisMichelonMember_4260de" order="55" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_JanuaryOneTwentyFifteenMember" xlink:label="loc_ndraJanuaryOneTwentyFifteenMember_accd75" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_6d817a" xlink:to="loc_ndraJanuaryOneTwentyFifteenMember_accd75" order="56" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_RentExpenses" xlink:label="loc_ndraRentExpenses_94996b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0fe97b" xlink:to="loc_ndraRentExpenses_94996b" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages_281524" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0fe97b" xlink:to="loc_us-gaapSalariesAndWages_281524" order="2" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_DescriptionOfEmploymentTerminationTerm" xlink:label="loc_ndraDescriptionOfEmploymentTerminationTerm_03e8f6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0fe97b" xlink:to="loc_ndraDescriptionOfEmploymentTerminationTerm_03e8f6" order="3" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ExercisePrice" xlink:label="loc_ndraExercisePrice_f100b4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0fe97b" xlink:to="loc_ndraExercisePrice_f100b4" order="4" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_StockOptionGranted" xlink:label="loc_ndraStockOptionGranted_dea818" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0fe97b" xlink:to="loc_ndraStockOptionGranted_dea818" order="5" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_EmploymentAgreementDescription" xlink:label="loc_ndraEmploymentAgreementDescription_a7345a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0fe97b" xlink:to="loc_ndraEmploymentAgreementDescription_a7345a" order="6" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_RentSpace" xlink:label="loc_ndraRentSpace_49da2a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0fe97b" xlink:to="loc_ndraRentSpace_49da2a" order="7" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_MonthlyRent" xlink:label="loc_ndraMonthlyRent_8f90ba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0fe97b" xlink:to="loc_ndraMonthlyRent_8f90ba" order="8" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_RentTerm" xlink:label="loc_ndraRentTerm_701ef3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0fe97b" xlink:to="loc_ndraRentTerm_701ef3" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription_18a89f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0fe97b" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription_18a89f" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_8df8f5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0fe97b" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_8df8f5" order="11" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_WeightedAverageRemainingLeaseTerm" xlink:label="loc_ndraWeightedAverageRemainingLeaseTerm_e0f732" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0fe97b" xlink:to="loc_ndraWeightedAverageRemainingLeaseTerm_e0f732" order="12" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_OperatingLeaseDiscountRate" xlink:label="loc_ndraOperatingLeaseDiscountRate_266f71" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0fe97b" xlink:to="loc_ndraOperatingLeaseDiscountRate_266f71" order="13" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/IncomeTaxesDetails" xlink:title="000040 - Disclosure - Income Taxes (Details)">
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_IncomeTaxesAbstract" xlink:label="loc_ndraIncomeTaxesAbstract_1fbcd7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_36a790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ndraIncomeTaxesAbstract_1fbcd7" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_36a790" order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_StockBasedCompensation" xlink:label="loc_ndraStockBasedCompensation_83dbf0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ndraIncomeTaxesAbstract_1fbcd7" xlink:to="loc_ndraStockBasedCompensation_83dbf0" order="2" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_FairValueOfOptions" xlink:label="loc_ndraFairValueOfOptions_4f38eb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ndraIncomeTaxesAbstract_1fbcd7" xlink:to="loc_ndraFairValueOfOptions_4f38eb" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross_3df884" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ndraIncomeTaxesAbstract_1fbcd7" xlink:to="loc_us-gaapDeferredTaxAssetsGross_3df884" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_e08b7d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ndraIncomeTaxesAbstract_1fbcd7" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_e08b7d" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet_17602a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ndraIncomeTaxesAbstract_1fbcd7" xlink:to="loc_us-gaapDeferredTaxAssetsNet_17602a" order="6" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/IncomeTaxesDetails1" xlink:title="000041 - Disclosure - Income Taxes (Details 1)">
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_IncomeTaxesAbstract" xlink:label="loc_ndraIncomeTaxesAbstract_2ff2aa" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_a19615" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ndraIncomeTaxesAbstract_2ff2aa" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_a19615" order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8556f2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ndraIncomeTaxesAbstract_2ff2aa" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8556f2" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_c53fd5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ndraIncomeTaxesAbstract_2ff2aa" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_c53fd5" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_9b4090" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ndraIncomeTaxesAbstract_2ff2aa" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_9b4090" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_9e448b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ndraIncomeTaxesAbstract_2ff2aa" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_9e448b" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://novaworks.com/role/IncomeTaxesDetailsNarrative" xlink:title="000042 - Disclosure - Income Taxes (Details narrative)">
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_IncomeTaxesAbstract" xlink:label="loc_ndraIncomeTaxesAbstract_ef15ba" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_a5b9b2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ndraIncomeTaxesAbstract_ef15ba" xlink:to="loc_us-gaapOperatingLossCarryforwards_a5b9b2" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_NetOperatingLossCarryforwardBegainToExpire" xlink:label="loc_ndraNetOperatingLossCarryforwardBegainToExpire_0d245e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ndraIncomeTaxesAbstract_ef15ba" xlink:to="loc_ndraNetOperatingLossCarryforwardBegainToExpire_0d245e" order="2" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>ndra-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 03/16/2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://novaworks.com/role/Cover" xlink:href="ndra-20221231.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/ConsolidatedBalanceSheets" xlink:href="ndra-20221231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="ndra-20221231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/ConsolidatedStatementsOfOperations" xlink:href="ndra-20221231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="ndra-20221231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="ndra-20221231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/NatureOfTheBusiness" xlink:href="ndra-20221231.xsd#NatureOfTheBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ndra-20221231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/Inventory" xlink:href="ndra-20221231.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/FixedAssets" xlink:href="ndra-20221231.xsd#FixedAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/AccountsPayableAndAccruedLiabilities" xlink:href="ndra-20221231.xsd#AccountsPayableAndAccruedLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/BankLoans" xlink:href="ndra-20221231.xsd#BankLoans" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CapitalStock" xlink:href="ndra-20221231.xsd#CapitalStock" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsus" xlink:href="ndra-20221231.xsd#CommonStockOptionsAndRestrictedStockUnitsRsus" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommonStockWarrants" xlink:href="ndra-20221231.xsd#CommonStockWarrants" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommitmentsAndContingencies" xlink:href="ndra-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/IncomeTaxes" xlink:href="ndra-20221231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/SubsequentEvents" xlink:href="ndra-20221231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ndra-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="ndra-20221231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/FixedAssetsTables" xlink:href="ndra-20221231.xsd#FixedAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:href="ndra-20221231.xsd#AccountsPayableAndAccruedLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusTables" xlink:href="ndra-20221231.xsd#CommonStockOptionsAndRestrictedStockUnitsRsusTables" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommonStockWarrantsTables" xlink:href="ndra-20221231.xsd#CommonStockWarrantsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommitmentsAndContingenciesTables" xlink:href="ndra-20221231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/IncomeTaxesTables" xlink:href="ndra-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="ndra-20221231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ndra-20221231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/InventoryDetailsNarrative" xlink:href="ndra-20221231.xsd#InventoryDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/FixedAssetsDetails" xlink:href="ndra-20221231.xsd#FixedAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/FixedAssetsDetailsNarrative" xlink:href="ndra-20221231.xsd#FixedAssetsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:href="ndra-20221231.xsd#AccountsPayableAndAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/BankLoansDetailsNarrative" xlink:href="ndra-20221231.xsd#BankLoansDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CapitalStockDetailsNarrative" xlink:href="ndra-20221231.xsd#CapitalStockDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetails" xlink:href="ndra-20221231.xsd#CommonStockOptionsAndRestrictedStockUnitsRsusDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetailsNarrative" xlink:href="ndra-20221231.xsd#CommonStockOptionsAndRestrictedStockUnitsRsusDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommonStockWarrantsDetails" xlink:href="ndra-20221231.xsd#CommonStockWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommitmentsAndContingenciesDetails" xlink:href="ndra-20221231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="ndra-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/IncomeTaxesDetails" xlink:href="ndra-20221231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/IncomeTaxesDetails1" xlink:href="ndra-20221231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://novaworks.com/role/IncomeTaxesDetailsNarrative" xlink:href="ndra-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCover" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/ConsolidatedBalanceSheets" xlink:title="000002 - Statement - Consolidated Balance Sheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrentAbstract" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCash" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseCurrent" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInventoryNet" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrent" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrentAbstract" xlink:label="loc_us-gaapOtherAssetsNoncurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherAssetsNoncurrentAbstract" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherAssetsNoncurrent" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLoansPayable" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesCurrent" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesOtherThanLongTermDebtNoncurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesOtherThanLongTermDebtNoncurrentAbstract" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaapLongTermLoansPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermLoansPayable" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermDebt" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilities" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockValue" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockValue" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital" order="25" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_StockPayable" xlink:label="loc_ndraStockPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraStockPayable" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" order="27" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" order="29" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaapPreferredClassAMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapPreferredClassAMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredClassBMember" xlink:label="loc_us-gaapPreferredClassBMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapPreferredClassBMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" order="8" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/ConsolidatedStatementsOfOperations" xlink:title="000004 - Statement - Consolidated Statements of Operations" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:title="000005 - Statement - Consolidated Statements of Stockholders Equity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_PreferredsStockSeriesAMember" xlink:label="loc_ndraPreferredsStockSeriesAMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ndraPreferredsStockSeriesAMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_StockPayableMember" xlink:label="loc_ndraStockPayableMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ndraStockPayableMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember" order="25" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SeriesBPreferredStocksMember" xlink:label="loc_ndraSeriesBPreferredStocksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ndraSeriesBPreferredStocksMember" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" order="2" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SeriesAConvertiblePreferredStockConvertedToCommonStockShares" xlink:label="loc_ndraSeriesAConvertiblePreferredStockConvertedToCommonStockShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraSeriesAConvertiblePreferredStockConvertedToCommonStockShares" order="3" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SeriesAConvertiblePreferredStockConvertedToCommonStockAmount" xlink:label="loc_ndraSeriesAConvertiblePreferredStockConvertedToCommonStockAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraSeriesAConvertiblePreferredStockConvertedToCommonStockAmount" order="4" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockIssuedForCashNetOfFundingCostsShares" xlink:label="loc_ndraCommonStockIssuedForCashNetOfFundingCostsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraCommonStockIssuedForCashNetOfFundingCostsShares" order="5" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockIssuedForCashNetOfFundingCostsAmount" xlink:label="loc_ndraCommonStockIssuedForCashNetOfFundingCostsAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraCommonStockIssuedForCashNetOfFundingCostsAmount" order="6" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockIssuedForWarrantExerciseShares" xlink:label="loc_ndraCommonStockIssuedForWarrantExerciseShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraCommonStockIssuedForWarrantExerciseShares" order="7" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockIssuedForWarrantExerciseAmount" xlink:label="loc_ndraCommonStockIssuedForWarrantExerciseAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraCommonStockIssuedForWarrantExerciseAmount" order="8" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockIssuedForOptionExerciseShares" xlink:label="loc_ndraCommonStockIssuedForOptionExerciseShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraCommonStockIssuedForOptionExerciseShares" order="9" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockIssuedForOptionExerciseAmount" xlink:label="loc_ndraCommonStockIssuedForOptionExerciseAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraCommonStockIssuedForOptionExerciseAmount" order="10" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_FairValueOfVestedStockOptions" xlink:label="loc_ndraFairValueOfVestedStockOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraFairValueOfVestedStockOptions" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividendsPreferredStock" order="12" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockIssuedForServicesShares" xlink:label="loc_ndraCommonStockIssuedForServicesShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraCommonStockIssuedForServicesShares" order="13" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockIssuedForServicesAmount" xlink:label="loc_ndraCommonStockIssuedForServicesAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraCommonStockIssuedForServicesAmount" order="14" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_StockIssuedForRsuShares" xlink:label="loc_ndraStockIssuedForRsuShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraStockIssuedForRsuShares" order="15" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_StockIssuedForRsuAmount" xlink:label="loc_ndraStockIssuedForRsuAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraStockIssuedForRsuAmount" order="16" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_DeemedDividend" xlink:label="loc_ndraDeemedDividend" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraDeemedDividend" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" order="18" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="000006 - Statement - Consolidated Statements of Cash Flows" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/NatureOfTheBusiness" xlink:title="000007 - Disclosure - Nature of the Business" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="000008 - Disclosure - Summary of Significant Accounting Policies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/Inventory" xlink:title="000009 - Disclosure - Inventory" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/FixedAssets" xlink:title="000010 - Disclosure - Fixed Assets" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/AccountsPayableAndAccruedLiabilities" xlink:title="000011 - Disclosure - Accounts Payable and Accrued Liabilities" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/BankLoans" xlink:title="000012 - Disclosure - Bank Loans" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/CapitalStock" xlink:title="000013 - Disclosure - Capital Stock" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsus" xlink:title="000014 - Disclosure - Common Stock Options and Restricted Stock Units (RSUs)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommonStockWarrants" xlink:title="000015 - Disclosure - Common Stock Warrants" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommitmentsAndContingencies" xlink:title="000016 - Disclosure - Commitments and Contingencies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/IncomeTaxes" xlink:title="000017 - Disclosure - Income Taxes" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/SubsequentEvents" xlink:title="000018 - Disclosure - Subsequent Events" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000019 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="000020 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/FixedAssetsTables" xlink:title="000021 - Disclosure - Fixed Assets (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:title="000022 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusTables" xlink:title="000023 - Disclosure - Common Stock Options and Restricted Stock Units (RSUs)(Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommonStockWarrantsTables" xlink:title="000024 - Disclosure - Common Stock Warrants (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommitmentsAndContingenciesTables" xlink:title="000025 - Disclosure - Commitments and Contingencies (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/IncomeTaxesTables" xlink:title="000026 - Disclosure - Income Taxes (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="000027 - Disclosure - Summary of Significant Accounting Policies (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_OptionsToPurchaseCommonStockMember" xlink:label="loc_ndraOptionsToPurchaseCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ndraOptionsToPurchaseCommonStockMember" order="31" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_WarrantsToPurchaseCommonStockMember" xlink:label="loc_ndraWarrantsToPurchaseCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_ndraWarrantsToPurchaseCommonStockMember" order="32" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember" xlink:label="loc_ndraSharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_ndraSharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember" order="33" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000028 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/InventoryDetailsNarrative" xlink:title="000029 - Disclosure - Inventory (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/FixedAssetsDetails" xlink:title="000030 - Disclosure - Fixed Assets (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/FixedAssetsDetailsNarrative" xlink:title="000031 - Disclosure - Fixed Assets (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:title="000032 - Disclosure - Accounts Payable and Accrued Liabilities (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/BankLoansDetailsNarrative" xlink:title="000033 - Disclosure - Bank Loans (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_TDBankLoanMember" xlink:label="loc_ndraTDBankLoanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ndraTDBankLoanMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:label="loc_us-gaapProceedsFromCollectionOfNotesReceivable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromCollectionOfNotesReceivable" order="1" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_PrincipalAggregateAmount" xlink:label="loc_ndraPrincipalAggregateAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraPrincipalAggregateAmount" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInitiationDate1" xlink:label="loc_us-gaapLineOfCreditFacilityInitiationDate1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityInitiationDate1" order="3" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_InitialTermInterestRate" xlink:label="loc_ndraInitialTermInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraInitialTermInterestRate" order="4" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_BankLoanDescription" xlink:label="loc_ndraBankLoanDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraBankLoanDescription" order="5" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/CapitalStockDetailsNarrative" xlink:title="000034 - Disclosure - Capital Stock (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_JuneTwentyTwentyOneATMAgreementMember" xlink:label="loc_ndraJuneTwentyTwentyOneATMAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ndraJuneTwentyTwentyOneATMAgreementMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="loc_us-gaapCapitalUnitsAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCapitalUnitsAuthorized" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" order="6" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_PreferredStockSharesUndesignated" xlink:label="loc_ndraPreferredStockSharesUndesignated" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraPreferredStockSharesUndesignated" order="7" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_StockPayableShare" xlink:label="loc_ndraStockPayableShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraStockPayableShare" order="8" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockSharesUponWarratExerciseShares" xlink:label="loc_ndraCommonStockSharesUponWarratExerciseShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraCommonStockSharesUponWarratExerciseShares" order="9" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockSharesUponWarrantExerciseAmount" xlink:label="loc_ndraCommonStockSharesUponWarrantExerciseAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraCommonStockSharesUponWarrantExerciseAmount" order="10" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockSharesUponCashlessWarrantExercise" xlink:label="loc_ndraCommonStockSharesUponCashlessWarrantExercise" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraCommonStockSharesUponCashlessWarrantExercise" order="11" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockSharesUponCashlessOptionExercise" xlink:label="loc_ndraCommonStockSharesUponCashlessOptionExercise" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraCommonStockSharesUponCashlessOptionExercise" order="12" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SharesForServicesValue" xlink:label="loc_ndraSharesForServicesValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraSharesForServicesValue" order="13" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockSharesUponVestingOfRestrictedUnits" xlink:label="loc_ndraCommonStockSharesUponVestingOfRestrictedUnits" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraCommonStockSharesUponVestingOfRestrictedUnits" order="14" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_CommonStockServicesValued" xlink:label="loc_ndraCommonStockServicesValued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraCommonStockServicesValued" order="15" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_RestictedStockUnitsValued" xlink:label="loc_ndraRestictedStockUnitsValued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraRestictedStockUnitsValued" order="16" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SharesInReturn" xlink:label="loc_ndraSharesInReturn" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraSharesInReturn" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" order="20" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ConversionOfCommonStockIntoPreferredStock" xlink:label="loc_ndraConversionOfCommonStockIntoPreferredStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraConversionOfCommonStockIntoPreferredStock" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" order="22" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_TotalCommonStockSharesIssued" xlink:label="loc_ndraTotalCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraTotalCommonStockSharesIssued" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" order="24" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_NetProceedsFromSalesOfCommonStock3" xlink:label="loc_ndraNetProceedsFromSalesOfCommonStock3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraNetProceedsFromSalesOfCommonStock3" order="25" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_GrossProceedsFromSalesOfCommonStock" xlink:label="loc_ndraGrossProceedsFromSalesOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraGrossProceedsFromSalesOfCommonStock" order="26" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetails" xlink:title="000035 - Disclosure - Common Stock Options and Restricted Stock Units (RSUs) (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetailsNarrative" xlink:title="000036 - Disclosure - Common Stock Options and Restricted Stock Units (RSUs) (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_AggregateFairValueOfStockOptionsGranted" xlink:label="loc_ndraAggregateFairValueOfStockOptionsGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraAggregateFairValueOfStockOptionsGranted" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" order="2" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ExpectedDividendYield" xlink:label="loc_ndraExpectedDividendYield" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraExpectedDividendYield" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="6" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommonStockWarrantsDetails" xlink:title="000037 - Disclosure - Common Stock Warrants (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_WarrantsMember" xlink:label="loc_ndraWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ndraWarrantsMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:label="loc_ndraShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" order="2" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_NumberOfWarrantsExercisable" xlink:label="loc_ndraNumberOfWarrantsExercisable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraNumberOfWarrantsExercisable" order="3" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_NumberOfWarrantsEndingBalance" xlink:label="loc_ndraNumberOfWarrantsEndingBalance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraNumberOfWarrantsEndingBalance" order="4" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_ndraShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" order="5" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_ndraShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" order="6" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_ndraShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" order="7" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="loc_ndraShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice" order="8" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_ndraShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" order="9" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_WeightedAverageExercisePriceOutstanding" xlink:label="loc_ndraWeightedAverageExercisePriceOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraWeightedAverageExercisePriceOutstanding" order="10" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_WeightedAverageExercisableAtJune302022" xlink:label="loc_ndraWeightedAverageExercisableAtJune302022" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraWeightedAverageExercisableAtJune302022" order="11" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" xlink:label="loc_ndraSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" order="12" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:label="loc_ndraSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" order="13" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermExercisable" xlink:label="loc_ndraSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermExercisable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermExercisable" order="14" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommitmentsAndContingenciesDetails" xlink:title="000038 - Disclosure - Commitments and Contingencies (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000039 - Disclosure - Commitments and Contingencies (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardDateAxis" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" order="70" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_EmploymentAgreementsMember" xlink:label="loc_ndraEmploymentAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ndraEmploymentAgreementsMember" order="51" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_MichaelThorntonMember" xlink:label="loc_ndraMichaelThorntonMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_ndraMichaelThorntonMember" order="52" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_EmploymentgreementsMember" xlink:label="loc_ndraEmploymentgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ndraEmploymentgreementsMember" order="53" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_RenaudMalobertiMember" xlink:label="loc_ndraRenaudMalobertiMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_ndraRenaudMalobertiMember" order="54" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_FrancoisMichelonMember" xlink:label="loc_ndraFrancoisMichelonMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_ndraFrancoisMichelonMember" order="55" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_JanuaryOneTwentyFifteenMember" xlink:label="loc_ndraJanuaryOneTwentyFifteenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_ndraJanuaryOneTwentyFifteenMember" order="56" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_RentExpenses" xlink:label="loc_ndraRentExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraRentExpenses" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSalariesAndWages" order="2" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_DescriptionOfEmploymentTerminationTerm" xlink:label="loc_ndraDescriptionOfEmploymentTerminationTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraDescriptionOfEmploymentTerminationTerm" order="3" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_ExercisePrice" xlink:label="loc_ndraExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraExercisePrice" order="4" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_StockOptionGranted" xlink:label="loc_ndraStockOptionGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraStockOptionGranted" order="5" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_EmploymentAgreementDescription" xlink:label="loc_ndraEmploymentAgreementDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraEmploymentAgreementDescription" order="6" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_RentSpace" xlink:label="loc_ndraRentSpace" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraRentSpace" order="7" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_MonthlyRent" xlink:label="loc_ndraMonthlyRent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraMonthlyRent" order="8" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_RentTerm" xlink:label="loc_ndraRentTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraRentTerm" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" order="11" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_WeightedAverageRemainingLeaseTerm" xlink:label="loc_ndraWeightedAverageRemainingLeaseTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraWeightedAverageRemainingLeaseTerm" order="12" />
    <link:loc xlink:type="locator" xlink:href="ndra-20221231.xsd#ndra_OperatingLeaseDiscountRate" xlink:label="loc_ndraOperatingLeaseDiscountRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ndraOperatingLeaseDiscountRate" order="13" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/IncomeTaxesDetails" xlink:title="000040 - Disclosure - Income Taxes (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/IncomeTaxesDetails1" xlink:title="000041 - Disclosure - Income Taxes (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://novaworks.com/role/IncomeTaxesDetailsNarrative" xlink:title="000042 - Disclosure - Income Taxes (Details narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ndra_10kimg6.jpg
<TEXT>
begin 644 ndra_10kimg6.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" &5 M # 2(  A$! Q$!_\0
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M/R=_6M?Q-X5@UGP1JOA_3([?3FOHB@=8P%!)!R0O6M?;1]W^DM;F?LIN]_\
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M+<1% =I<., ^F:X*UMH-.^!DKV,0MVFTLS2&/@L[1C+?4UPM]:V]GH^N6=E
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MTK7/MEG'%*;72U6)9-P9<@*2<<9&/I0![Q]LM=JM]JBPQPIWC!IQFB$GEF1
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MY$,1M][L.W0]\U'#X5TNUUBRO[&,V_V::>?RU+$-)*H5CR>!@=.G3&._444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!R-Q<J=8NT8;"7XSWQQ_2GTSQ%8F&Z%XGW)>&]FK.M[QU98Y&&P=\<T
MP-,D*,L0!ZFKN@W"S3W2JO VX:LFVL=0U7;\OEP@_?(P/_KUT=K9V>CV;LT@
M5>LDCG%(#2K@?%WQ$TGP[#<1FZ2.6$[9'?\ A/H!W/Z5TRS7M\-MFIMH/^?B
M5?F;_=4_S/ZUQ&H?!7P+JVM0ZMJ]C=ZA,C%W2XNW:.8]MZ9P<=ATJ9)O8#QC
M4O%WC+QI:W>I^&]!O[W18#FYO]O#+GG9GF3Z+P/0UW7P/U'[9KFIK;W3BV$
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M),;<G&74;HI/9U[?4?I7T1X7\=:7XA2.&1EM;QQ\J[LI+_N-_3^= ';4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH$+-,DMU"J[V4Y$BD?+(/8C]: .RHHHH **** "BBB@ HHHH **** "BBB@
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M;!I)501K\Q8XVXZU4TN$W&JV\?;=N/T'->9_%O5);4QZ-;S%!/([S!3@E0<
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MDK[9YG5CPD9V@?E0LOB>8_-<W48[?O&_QKW#PKX(\-QO,T,TI8G@.%&*Z_\
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MA:"=HV.2#VK].?@;J1U+P9Y^\OYT-O<[CW\R/.?TH ]9HHHH **** "BBB@
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M3M)8;UBC#GNM0&2*R!52"/2JEWHFK-"+O2U1UZ_NWSG\*J;K@Q;;Z,Q2#K0
M]]1FEN=B)@=LBMFVNYW@:&:U;@<-FJ-C%:SQE?.V/V)XJ:5;NS?]Y<,L?9@,
MB@"*#6&M[I[>97 SP?:M*WU:.]!BL69I/2H%N=,VAII$D/KQ6KX?DTZ/44-J
MR!2?F51N_P#U4 $;SV?S:HETR]L<BJLUW:S3!D280$\[R!7TCH>A>'=8TQ4N
M+RW\PK]UU&:\A\>> 1I.MI<0F$VV_IM^6@#(AC\+O: W$QAEQPP'.:H+XDLM
M(NUCBF>09^5XP<&O1='L='AT]3<1K]W_ )9VGF?K6%KIT6,NUGIRL_9GA\KF
MO8PV85*2Y9>\O,YJN&IU=T;6@?%+R2 D.,?Q,2*ZY/B)?:A&?)O$0?W4)S7!
M^!;6+7"]K=S0HW96 ->B:1X/O]'EGEMM/BNX\$C;QFMI8NA)\SAJ<_U6*ZG#
MZMXHNA?%9KB[1W/!.>?SKD]7C:ZD^TW\SN@Z9/%:GCJYOEUH3WEG_9_ED[%4
M;L_A7$:I<W=Q9_:&U(,B@_(QP/RJ*V.E*')32BO+<UI86G3'1WEA%J&Z$32'
M/(5L"NKAU'6)46.ST^%8B.79N:\TT[3SJ-T)DF2W;N8^2:[Q5CTZT'G7T[X'
MW5X%>*W?4["6WAGMM?2ZU*?]QW4=!7LECXM\&V6C*VWS7"]*\.L=+UKQ5>K;
MV3&*V+8\Q^#BO3[7X2:38Z4LFJ:B)'VY*[LT@/,/B!XVTJ_G>.SM8X0<_-W%
M>*7JK<,S6\DLASDDGBO7O&FF:+IC.+6Q67'H.M>67678,(?*3KL04 9:3)"'
M";I#W!H0*^U/+8%C5N0(Q#*OEO[TR0^1,FUBSXW$T 0N@@<I*0"?TI[^2L05
MD=V/=>E%S"S+YDF6W^G:B%#]G\OS5XYPXS0!S.M62V\RR1YP_)'I7Z"_LU7!
MF\"6'I_9=JO_ 'RNVOA;5--22R!A53*1D\U]R?LRV[0>!K%&ZC383^9)H ^@
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L+
M7M4:T06MN<2N,EO[HK<)"J6/05PU\LEPLFHS$CS9-L:^H%,#.KN]'6-='M_+
MZ%<GZ]ZX2N[TF/R](ME_V,_G3$9_BB7;90P]V?=^0_\ KUF6;;K1,=N*N>*O
MO6WT;^E<ZKNN=K%?H:0%K4+?2WNEFN=/AN+A0,.Z D?C3K+[-]OGN(X3'-.J
MAB#D';G'TZU6F=)&#J"&/WAVS6G9HJVRLO5N2:KF=K7%97N)]D4W1NF"O(8_
M*Y'!7.<4VTT^SL9)6M+:.#S,%O+4*/TJSN4L4[XSB@E8T)/"CFIN]AV1DWA_
MTQ\5W=G)YUA!)_>0?RKSYVWR,Y[G-=QH_P#R![?_ '?ZT 97BA4W6S_QG(_"
ML"VN)K6X6:%MKK^M=!XJ3Y;:3_>'\JYD=: ._P!/O%OK-+A1@GAE]#5RN;T7
M?97YMBQ:"X021MZUTE(8QT21"DBAE/!![UR>L:/):;KBW!>#N.Z?_6KKZ0@$
M$'D'M0!\P_%N,G0;N3=M A1]WIMD!/Z5Y%H.I:9>@0W6R5NF2,$5].?%;P[
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M'7M5N;K5_P#B<W4K*3\K&,8_'%<]=KIK2^3+&)8&_C7C%4[C4;^YE=;BS-C
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M/_KTP.<O(_*OYX^FUR/UJ"M/7(_+UF;T;#?F*S*!#HU+RJ@ZL0*]&1=B*HZ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX-3V^C:E(Z,L)B_B#.<8KN**+BL,4,$ 8Y;')]:?112&%%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BFACGC,<BY4U+14M
M)JS Y*?P7HL\RR,;B-U.0T<Q4CID?3C^7HN.DAABMX4@AC$<2*%55& H'058
MI*I::$1A&/PHJ+9VL:!([6)%'0!0 .<_S I_V>!;AKA84$S##.%&XCZ_A5JB
M@LH_V=88Q]A@QYGF_P"K'W_[WU]Z?]GMO-6;[/'YBYVMM&1GD\^]6Z* ,UM/
MLW41M:PL@8-M*#&0, _7  ^E.?3[*3>DEG$RNWF,#&"&;U/OR:T** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
3 **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ndra_10kimg5.jpg
<TEXT>
begin 644 ndra_10kimg5.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %? G # 2(  A$! Q$!_\0
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M*>&ZEP-L#M$JJI]]U%T%I'+WWB;QMJ&E>*?'NF>(WLM/T&^:"WTKR5:*=(F
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M;G0=;M=/7P_<WPNV"6\T4B@._P#$N/45%=>/8K>#4WETJ;.G7D-I(F]?O/\
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M:#:R0^*-.U&\-Q)8G7+F);=E.R&7^!^G=OXO:O==BJWRKMSW%-\I?[BKWZ4
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M,UNQD^#>K>'E:9M2BMYI6A\EU.UI?EYV^]>Y"-5^ZNWZ"F>3&/\ ED/]W:M
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445 TT:_>8+]6%
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M1110 4444 %%%% !1110 4444 %%%% !1110 54NK:*\M7@F^9'_ +O6K=%
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M+>IJ>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** ,K7+9KC37V]4^:OG;Q(NW4F
MB5BTK-M7_>9MO_LU?3,R>9 \?][CFO(M0^'VNWGBJ&^C6V6U6X65MS_-M5O2
MB]@/1?"^F?V-X4TW3?XXH1O_ -X_,WZFMVF*>OUZ4Z@!:*** "BBB@ HHHH
M2HV16#;OF!Z@]*EI* .(N/AGX(NKIKF7PU;*[G<53<B,W^TJMM/Y5T]G86>G
M6D5KI]M%:6\2[4BB0*JCV"UH8I:-Q6&[%I/+Y^\:?10,9LW?>:EVKMVTZB@!
M@3^]S3?+Q3MS9I^: &X_VJ,?[5.S1F@!GEK3MM+FC- ";:;Y?^T:?FC- #/+
MYSN.:-G/WJ?FB@!GE_[1J#R(?.\[RDWA<;]HW?G5JL^XOH+6XAAF;8TQV1Y4
M_,WIF@"Z(UPOM0R\?WO:G?PUB"]GL8PFKW$*>;-Y4,B*55@?NJ?[K4 :0FA-
MQY/FKYN-VW/S8J?;_M&J$UA:O?1:AL'VF)2J2?Q8/\/TJI9W$^(H-1:"*].[
M:B/N5P&^\HZ^GR]J -KR_>CR_>G*=PI: (6A5F5F^\O1N]3444 -QBA45:=1
M0 BC:*:J;:?10 BC:*6BB@ HHHH **** "BBB@ HHK@])N_&6M:>VH07^F6T
M322HB/;.QPKLO)W>U '>9HS7*?9?'7_0:TG_ ,!7_P#BJ/L_CK_H,:3_ . K
M_P#Q5 '5YHS7*?9_'1_YC&D_^ K_ /Q5)]F\=?\ 0:TG_P !7_\ BJ .LS1F
MN3^S>.O^@UI/_@*__P 51]F\=?\ 0:TG_P !7_\ BJ .LS1FN4^R^.O^@UI/
M_@*__P 51]E\=?\ 08TG_P !'_\ BJ .KS1FN5^R^.O^@QI7_@*__P 51]G\
M=?\ 08TG_P !7_\ BJ0'59HS7*_9?'?_ $%])_\  5__ (JD^R^/-W_(8TG_
M ,!7_P#BJ8'5T5P6M3^-M&TBZU2;4=)F2W569!;.I;YAWW5VT;;D1O[R@F@"
M>BBB@ HHHH **** "BBB@!C-M:N.AN?$UK<7K26IN4=BMNOR_+UVMPW3UKLB
M,^].Q0!Q=O>>+I)MMQ:I$I_B9%95VYW?=;=EOEV_6H8[WQA]Z332OLJKM5=Q
M#-][YCC;M6NX(KF-0?5/[9\O3_E"PAOF'R?>;=^/W1GW- $$%UXB^R3/=VB;
M]G[E%QN5E(^]SR6SG'M4,-OX@NK&>:ZNKF&=KE&1(MJ%8OE5A_%]Y<MM_A:E
MMY/%3M*MS'Y41A=4"HF$E^\O?E1]U?[W\52VDGBC[%=M+;[9EAS"L@7=O_X"
M=K9^;_QV@#/,GBJ;465X9TA+.Z,KK\F5VHIVM^/S>M6I)/$4NHPR+#=+"NQ&
M3Y57=\N]F^;IU_O4Z2Z\7/%NBT\>;N7*'9C;[-NZ_P J=ITWB-;^WCU:/RT\
MXJNSYMZ[6^\?^^?^!4 +]O\ $D]Y=K;V\?V>)WV/+']_:VU57YOXO6JW]H>-
MD$S1Z?YK-MV!T5=HX5F^]_P+;7;A?E_O?[U/H JVS2-:Q-.NV78"X]ZM444
M%%%% !1110 4444 %%%% !1110!XK^T!JUUH_P ,[:XM=;NM&#:I;QS7EHQW
MI$=VYL*?F]=O\6VO$=:T?QZM_I^E>#/BIKWB;4[VQ34OL[.UJJ6SK\KM*[[?
M[OR_>^:OHGXR> ]3^(W@ ^&])N[>TN?M44^^XW;-JY_N]Z\TD^#OQ,DNY9OM
MWAU7DT%?#_#S?ZH*OSCY?O\ R_[M 'D<FG_M 0VOVN34/$2IYBP[5U#<^YFV
M+\N[=][Y=WW?NUU*^"?C-]BL8Y/'FK1:M>+N^R->;HK=O.V*KRJ^W;_%\JLW
M\->I:3X)^+&C>%=/T.VN?#$DM@D2+=N\V]]C[U9EV[=S-N#-_%2OX!^)<-M!
M::5;^$M-MK>198HHI+A]C"X\YOO+_$Q;\ZH#Q&31?C<J0P6GB;7+N^:XF21$
MU%?)1$V_/YWF[?F9E^5MNW[M4;G3_C]8Z7=ZE=:EK\=K9LZW#?V@NY=C;795
MW;F5=R_,OR[6KW>3X=^/;BS?2?['\%QZ+,DR36$1N427S6#,VX?-NW+G=WJ/
M5/AW\5-6U--0N;CPNKI:7-HL2^=L5+C;NXV_PJBB@D\7BTOXTV\%]/KGBK6]
M+AM]/N+^.7[=YRSM$JLT7RLVUMK*WS5#I<GC_4K7P3<_\+,UF)?%=Y-:K_I#
MM]EV,J[F^;YMVZO>M=\%?%77--FT^;_A%8(IX)K=VCDN/E\U54L%*_P[%VBL
M;PQ\(_'WAO1='T^2'PIJLVASR7&FW=R]PKV[O][A556_O<K0!YMX@\,?&+2=
M#36M-^(6I:E9,L2MNOV@?>^[Y55F^;[NWY6W,S?*ORUEOX?_ &B4O&M6U#7E
ME5-^UM47[NYE7:V[:S;EV[?O5[;_ ,*_^)4UA%9W]OX/U!8OL[PO,LS>5+$K
M*)0-OWB"W^RO\-5?#_@?XK>%_$VKWT']@7QUJ[;4&9I)E2U?=]Q<?-M;<S8_
MO"@H\1^P_'[[+8W/]IZ^JW[JENO]H?.S-N5=R[MR[L-\S+M^6F7EG\>;&ZM[
M:ZU77EEN)DMX=NI*ZRRON9%5E9E;=M;YOX=M?1*^%?BS;V-K:Q_\(HWV=T<O
M*\S[U5CN4!E^3=N^9A5#2?!OC^WN(M.M=(\)+8Z#);_8;1WN=EO*BEU=7^\_
M^M/WOXJD#PK^S_V@&L+6^CU+7Y+>Z9$C9-05FW.VU=R[MRJS;OF^[NKT.W^*
MOC;X46_A_3?B(J>)+?4K4W#A61KBSVNR[=ZLRR_=S_L_=KK;7P!\5-&O9=6C
MO/"\3)80VK,[3;=D+E]S?+_%N*M_LUT6F_!WPOJ":%?>(=-LKR72;8Q6MG:E
MVM$5W+[L.<O\S'[WR_[-!)TG@?QCI'BS1X]2TW5_MR3EY8U>%HI?*#;=K*P^
M8JQQN7[W%;VH6/VB);B"))+N ,UN[_,J/M/_ *%T:I+J/[,MC]ABLX$BD6)M
MZA-L3?>5/[IZ<5LKNW-_=H**EG(\UHDDJHLW_+5$8,J/_$N?]ZM"LVVLX+.2
MX\B)8_/D,S[?XG*\G]!6E0 4444 %%!I.: %HI*3F@!U%':B@ HHHH ****
M"BBB@!K5YC]MNM,^"&MZA8SM!=6MO>2PRK\Q1@SD,-WO7IS5Y3J'_)OOB/\
MZ\]0_P#0GH@KS0/8^/T^.7Q7V*W_  G-^WR[B=L7_P 37L?PJ\>>-O$GA>]O
M-8\27EW<17;(K95?EVAMORK7RM&O[A-W]U:Z#0?$6IZ3.EO%KE[I^FO)OF^Q
MMN;=_>56^\U?4PP]'^4\O$0J5%:#/LG^W-?V_P#(8O?^^U_^)IW]N:__ -!J
M]_-?_B:^7[GQ)?"PNI[/QUXBGF1-Z*]OM3=_#EONKN6L_1_%GB"ZWMJOB_6+
M9%954VR[VW-_#MK?V.'M?E.+V.(_G/KB/5-8DB5F\17D+\_*?F_7;3UU/5<K
M_P 55=;?7_*U\:7GC7Q?#?W$47BC4VB1SM,K[6V_P[A_"W^S4/\ PG7C/_H9
M-0_[^5/U2DR>3$+[1]F3:MK"(K)XBO)6_B4-M_\ 9:A_MG7O^@Y>_P#?:_\
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M*I/-\OP3,VQMK_,WRMUVGY:Y'3;VULHO%?FZ?J5W#>2(UO"-\4LX5V9F#XW
M_-WK>\2^)+.;2WBL]/GU1GG5Q%Y4R-"/*5=V5 W$-Q\WI5>Y?1%J=1*[9-'\
M6]<N/L_E>%1(MPY2)EE9M[+]Y1\O451N/BEJK746IS>'GB6S9X6_TAEBWMMW
M*WR_,1M^6L_PEJT6F>'[A=0L[G[;93-=:?$UN_SNR,NW[O\ >K=N-3T"XU.T
M3[._V*59KN?S;5V3[2ZJJJ=RL-P^;^%J'[-/82G6:W(/^%V7V[_D PX_Z[G_
M .)JK#\8M21[B672XYUEEW1@S%5B7:J[?N_-RK&KEQ/X06XN98]%\UH'9(8H
MK-U6='V[G^[U5E:K+7'@Q=3\UM/LEB6-E\U;-E10SKMW?)M5MN[[R_\  JK]
MWV,KU^YG3?&2\FMGB_X1^!MZLNUYBR_\"7;]W;74>%_B?H>JK%8WP&EW6%5$
M<_NF_A&UOZ&O&M8LVDUZ^DT^SG:R:9FA9;=E7;N^7:NWY5K:\._#OQ!K^V>2
M Z?8_>::96W-_NI][=_M5I.G1Y+W'3J5^>Q[YJ"K=/IT/]GB\A:Y5RV[ @VJ
MS*__ 'UM&/>MG^&N0\(:!!I.G131OJ+,T>Q8KV7<R+N[#HN[KBNAU"_MK%8O
M/DVO-((HP%+;G/3BO->CT/8@VU[PZUOH[JYNXDBD7[+)Y3,5^5FVJW'_ 'U6
ME6?IL$]II\4%U=-=S*OSS,NTN?I6A4F@444TF@!K'Y>NVN&USXE^%]#F>VDN
MOM-POWHK==VWZGI7*_%CQU<:?_Q3FE2^7<2KFXE0_,BG[JCW->&M_P"/?Q,?
M[U8.IRGI8;!\_O2/>?\ A>6AM*O_ !*[S9_?^6MJQ^+?@Z\95DO)+0M_SV1E
M7\Z^:"RJNYF"K_>;[M(+BV8LJRHS-_#NK/VDCK>!IL^Q[+6]*U! UCJ4,^?[
MDBM5_P R/^_7Q=&[PONCD>)O[R-M:M!=>UR--D>L7BK_ '?.:M/:&+P'9GV"
MTT"K\T@_$U&+RS8[5NHV/IN6OCJ35-2N/];J%S)_>5I&JNMQ)&QE\UU9?FW;
MV5O^^J/:$_4/,^UE.:=7E7P9U[5=<\'2MJDKS_9YVBAF?[S(/X6/JM>J=JU6
MIYDX<DN4=1115$B5Y3J/_)OGB+_KSO\ _P!">O5FZ5Y3?#=^S_XC7[N;6_7_
M ,>>JI_&B6?!T?AW4UM8=WD1[XT?:TRJVUEW+_X[4J^&]59?^7;;_>^T+6[Y
MGF.[?>VNR+_NK\O_ ++5N-=UJS?=9:_0,/1C.*.1Z>\3:'X%UK7-)NXK:Y2T
M959W\V\9HI6V_*NQ?E_NTZ'X;ZYIOAZ75=0EA9%D_P"/2*Z9'W?PNS+_ '6_
MAW5Z=\.;?S(KA=OS-\W_ ([6_P".--:W\*&/;MRR_P /^U43I4X3]F<,L7R.
MUCYMF\)^()F>Z:*-D;[SO<*S?[S5$OA+6G3=''"R_P!Y;A:]UCT96\/L^W<-
MOWJX?3VW3RVW]QMM>O#!TY:1,*>-Y[GGS>&=55MK>0K?W?.6E;PKK"JK-' J
MM_TV6O0+BQ_XF,2[?O-4^I6_DSPQM'M1OXMM:?V?8W6,BVHGFK>&]57[WD?]
M_EJKJ&DZAI]NDMTL:Q.VU6B?=\W^U7HEU;Q+ W]Y?FKF/%"[= M/[S7#?^@K
M7%6PWLSK3YCF8YI(U=8Y#&KJJLH;[P7^]_P*IKK5-1OHDBOM0FN8D;<JRMN_
MAV_]];?EJI17#)(TN?;?PI_Y-1M?^N4O_HXU[M;_ /'K%_NK_P"@UX/\*_\
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MV:OJ3]D.QGL?$?B56CF:'[+%ME>-D7=O^[\R]:<E9!=7/LKM10**P-0HHHH
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MSV>U4W1,Z[5W;OF5=OS;?O;J /JG_A:WPW_Z';1__ I:/^%K?#?_ *';1_\
MP*6ODR3X ^3>_9;GQ1Y3W5PUOI^[3V9;AUA\YM[*S*B[?E5MS;JKV/P)EN=2
MOK6Y\0I;0V;0JUPUBS*ZO:M<,R_-\VU49=M 'UW_ ,+6^&__ $.VC_\ @4M7
M=%\9>%_$EU+::!XAL=4GB&]TMIE=D7[N?SKY'\+_  5T&;Q#I-YJ?B$WWA^]
MN+9+58K%U>\69&=5?:W[I=JM\VYJZ#]E^"*W^*WBV"&(1Q16K(@_N@3;57/^
MZM 'U^IW"EHHH **** "BBB@ [50NH5N+*X@;I+&4_[Z7%7STIC4#1\6WEL]
MG>W5K(I5X)&1E;^\K;:P=6?=<11_W5^:O2OBK9PZ3\0=0D5MJ3JLY7W9?FKR
M>XF::=Y6_B^;;_LUQ-6D?10GS4T1UI:+HFI>(=9M]*TJ SW4[;=JK\NW^)F;
M^%5JWX:\*:UXLU1;'1[,R?-^\F;=Y40_O%J^KO OP_TGP/I?E6J^?>N/W]VX
M^:3_ .M6B5V<U>OR>[$K^!_ASI?@_2T_<1W.H%=TMRXRV?[JY^Z*[U455%/'
M2G5NHV/(E.4MQN%%.Q115$"*N*6BB@ HHHH ;WKRN_7_ (Q]\1^OV.__ /0G
MKU:O+6L[N_\ @;KUC8P//<SVU]%%$GWG<LZJH_X%0M)<P'P#I]Q%'9"*6*:1
MMZ2H\3+N5E7Y?O5T6J^,9=8\1OXAU&.2YU)X4MV?<B+M"A?NJOWMHJ['\)?B
MAY2?\4%JWW5^7R5_^*I__"I?B?\ ]"%J_P#WY7_XJO4^NMD<AFPZY=?\(9<>
M&8+6X71[BZ^U.C>5N9QM7[[+N4?[*US]^\DFHRR>48F^5=C-N9=J[:]#M?A?
M\2FLEMF\"ZM&R[OO0KMV_P#?54;GX5_$R:Z9U\!:PJ_*J[H?_LJ<<PG%^Z/V
M1P\=G<R1+)'$63=MW*U121R1R-')&RNOS-7I=K\+_B5]B6*3P+JT;*6;YH?X
M?^^JHW/PK^)<UPTD?@+657:J_-;_ #?^A5I_:<R?9Q.2L5D^QRK+9S2Q,ZNK
MQ,JLK+_#\WWOO5M:SXMO-8UY=7U6&:?4HK=+56^1%V!?EW*J_>V_W:Z&U^%_
MQ*:R6VD\"ZM&R[MS-"NW;_WU5&Z^%?Q+FNFDC\!:QMVJNYH=K?\ H59?7Y2E
MS6'[-(Q8_$GD>$[OPK%%<1Z9=7(NID^1G9PNU<.RY4>PK+^T?:M>AN?+,:LZ
M*J,VYMJ[5_\ 9:ZG_A4OQ1_Z$'6/^_/_ -E4]G\*?B6E_;M)X%U9564,S?9U
M^[N_WJI8]H7(==H>I:99Q11WEM!)*E\)E::%F79L964LOS,N[;\M6KB^\/+I
M>L10,));B1GMV:WVO\RKMVM_#M96^7^)66NCT_X2ZK<M_IUKJMIN^]ML]W_L
MU:#?"66SGEDCM=0U!/+=566U95W,ORM\K;MRM\U#S!7*ITVSO_!)_P",:U_W
M'_\ 1U>SVW_'M%_N+_*O)/#^EW6B_ &73KZ"2"6!'W),OS?ZW^):];@_X]8/
M]Q?Y5YE1WES%-6+%%%%0 4444 %%%% !1110 5A^(=2N-*T[[9;1K(J.!(.^
MVMRJ]S:P74#P7$8DB?[RFI YR*ZN=22*ZBEW(5^5E;;_ ..UF7D-U?.ZM.(F
M1OF^16KI5T/2HU"Q0-#[(S+6!J 6SUW[.GW)8]RLS[FW+5(:^(\.^)GB+P/H
M>HS>'O%%S-)?/;K.J+IJNKJRMM^=5_O?>KRNQ^('ARSM[73XY'CL4;<R16+,
MZ+_$JLR_-_NM\M>F_M#>&VU30]*\311?Z182-:W#+][RG^96;_=;_P!"KR?P
MGX/O-:OX;&SMC/<.RJB*O\7\6[_97^*M$VD9M7/>OACXYT'Q,VH:;X<:99;.
M-7;[;:JK;6;:K*&[;OE:O8]%NIQ*UG?74<CSC=%LV_W?FXKC/#O@'3/!_AZ&
MYMHA)J:8:ZN%7:SHR[61?]E?O+_M+57Q]\5-,^$^GZ?<:IH%UJ37KNMO/;*@
M7Y<<,Y;Y<[N*F_,-1MJ?+UY^T9\7-"\6ZM:2>((KR*WNIK=89K9-J[79>JKN
M_AKUG]GGXT>./B!\1]0T7Q5J$,]K]A:XMXHK=4V$.O=?]D_Q5X]X5^&]M\7O
MBAXFUB/4$T72EO?M4MB9!+<LDN6;81\N/]K^'(XKZ0^$OP)T#P+XJF\4Z;>:
MP)D#VD<-XZ,DL3;?F^5:-@6I] T445)04444 %%%% "-TJ$(GVCS58YV[<=J
MF8;A6#<L]GK%M=SZD(+)T^S_ &=Q]^5CN5L^O!% &U(S*F[;N/I6%H$<<.CV
MJI8O8_*S?9G;<R$L6;)]6;FMPNI_VOXJ\N\5>*M0\)6LVGZ9I]Y=LA:5KVY7
M,40=F8?-_%CG[U5"$IRY49U)JG'F8GC+X<^$]3NO[<BLTTWQ#&I6*]M+@6DK
MJ?E=68<,-I/WEK#A^"7P]LYM,EM=?UF*72586+)JO-JK-N94X^4$FO-M3U74
MM:NFO-3O'GF;^)V^5?HOW56NG7P_H%YIVB_V;%?QW>K3-#'YLBLL6UOF9OE^
M9=NZN^6$]G%<S/*^O<\N6*.K'P]T.#Q%YT/Q&U^)KBVVR*-47>X5OE;=MQM
M9EQ[U9M_A;X5M=ZV_C;Q'"KH(F":QM^56W*O3MN_6N?D\!Z/'J\VV6Y?3_L+
M7$;/*L3,ZOL=2S?*J_=-9-UX7TI9=%:+SHQ?Z@;1T:X67Y>/NLORYYK/V,'U
M*>*J+H=99_#KPG=6MWIZ^-/$OV>&^9VB?5-J^8I#[E^7IN.<^M2V7PM\)Z=)
M_H/C'Q!!]]ODU4#YG;>[8V]2PW9_O5@7O@G0X;&X^RRW5W-!"\I9+A-R%6*J
MK1?>V\#YEJEX?\)Z/JF@VMU*T\]W/OWI%,B,F/F7:C?,^[_9:A4(6O<'C)WM
M8W]0^"?P[U.:UN=2\1:U=W%JQ>WEEU7YHF9LLRG'!+?-]:TM0^&_AG4#"U]X
MX\27)3>J;]87Y0RLK=NX8C_@5<-'\/=5FW1QZA8*R*K3Q-(VZW5EW+O^7^[2
MKX"O'L)G6XM69"CK>+,RP^24+[V&W/;[U/ZO#N1]=J=CL[WX2>#=4T<:3J7B
MW7KO3?+2+[++JJF+8K95<;>U6!\-O#RQVZKX[\1[;/:T*G5EVIA=J_P_W>.:
M\VTOPU!=:]<Z//<)/<?8S-:RVS[HG8+N7;N7[I7BNBNOAW8V,4-S)-(UO!9.
M]YM?[EPJHRHK?P[F:AX>">XUC*DNATO_  K;P[NO?^*Z\1_Z:NRXVZP/G7;M
MZ;?EXX^6D7X9^%VTZ'3V\;>(OLEJGE0Q-JPVHNTIM^[_ '69?H:X:X^'.N06
M_G^;:RMLW>4C-NR-NY55EZ[3FGW/PVURVMVE:ZLV8';M61E^7=MW9VX^\U;?
M5:7\X_K-7L=GI_PP\+Z0%72O&7B&S38D.V+50J[$W;5^[T4,=M:/@'X8>"/
M^O7VJ^&[RZFO;R-DN/M%YYNY=VYCMQ_>KR+Q%X;O/#=U#!?2QRM.K,K1;E^Z
MVUOO+77?!P;?&5[]Y?\ 0^_^\M34PBC3YXL*.,E.IR21]!+TI:1>E+7FGL!1
M110 4444 %(U+24 >(?$CX5ZYXN\1KJ&F7EO'%*JK*)F;Y&5=O\ ".:3P]\
M]"LMDVOWDFI3?W$^2+_=]:]PII_VJCD-_;3Y>5&;I>CZ;HUFMGIEG#:0+]V*
M)-JUJ=J**LR;;W%HHHH)"BBB@ HHHH **** #M7 :/'XOT/3UTV/0K.[1))7
M64WNPMN=FZ;?>N_HH Y3^U/&W_0KV?\ X'C_ .)H_M3QM_T*]G_X'C_XFNKH
MH Y3^U/&W_0KV?\ X'C_ .)JAJ?B3Q;I-@]]=>&;7RE9%^6]RV68+_=]Z[JN
M=\5Z;=:KX:N;&Q6-KABC)O.U6VN&VY_"@"M_:7CC_H6;+_P/_P#L:/[2\<?]
M"S9?^!__ -C2_:O'/_0#TO\ \#&_^(IWVSQU_P! /2O_  -?_P"(H 9_:7CC
M_H6;+_P/_P#L:0ZEXXQ_R+=BO_;_ /\ V-2?;/'7_0#TK_P-?_XBF-=>.MOR
MZ/I7_ KQ_P#XF@"EIOB3Q5JEO+-:^&K1D29X6W7W\2M@_P -7?[4\;?]"O9_
M^!X_^)J;PKIM_IFD31:DL:7$]U+<,L;;E^9MW6NEH Y3^TO&W_0KV?\ X'__
M &-']I>-/^A7M/\ P/\ _L:ZNB@#SW6E\8:UHMSI;:!:P"X&SS5O=S*-P.[&
MWFN[A#+$BM]Y5"FIZ* "BBB@ HHHH **** "BBB@ II./PIU96L;AHU\T<IB
M=8'8.HY7Y3\U '@'[3'BK4K'X>P_V!>7-NDMR;>:[MPR_P )*HI]6Z9K(_9^
MT:QT:P235=:O+O6M:MUN(8KF9G7Y%W,J+N^9E5ANKT/Q9X8L_'/P.;1IW,?V
MC:Z3+]Y)=NY7_P"^J\Q\"Z#9KX>M=/L[46GQ"\*[]RW<C/YJ-]YX=S;=K+_=
M7_9K16>@'I'C37/#-KX4U.6\T.\UNW>/Y[*VW;I55E;Y?EW*VZJ7@F/3;;2[
M?7M TJ32(KUX91#+;;IH(6^]"[,WWF9=VY:X3^VO'5_*T=M]MW*S-MAMOXF^
M]\RK39-#\>7B;KJ6ZC5OE9KFZ6)?E^[]YOEVULJ:74CVGD>KW^M7D<ZV<<^L
M:A<2VURS2V]LJQ?Q,JN_S*K*JJJ_WMVZJ\FN7.N>"K**^\(S7S:C&D+6[.CL
MK-N5F9F7;N554[ON_-7GWALZCX4U,W=SXLT:*WE^2ZM);YI5E'\60N[YE_A:
MN]N/BOX7L+2X_LK[?KKHHW16EO\ ,J*O\.[;N7_=^:LFK"3ON<#X6^'ND> ?
MB1>W7AR5)[K4;9DM[:YC>)756W2K$^UEW?+]W<OW:^DM'U*WU*PB:)?*=%"O
M"WWHCM^Z:^9[K]H31[V?[&OA&:"%T\I;FXNMK1,WW67Y=J?[RUO1^,/$-O=6
M\=S=:/9/N7<L4CW]ZZ[?E^9?XO\ :H8SZ3S17-^&]4N+[0;6:_A>VNV3+12<
M/CLS+_"Q'.VNDK(L**** "BBB@ K/N(8YXL/"C<C;E=P5AT./9JT*1AN% &)
M8W,MOY6GZG=6S:CL9MD7R[US]X#^E2:A8M>I%''=&#9(KL H8.O=&'H:GDMH
MY763RQYR;MDK*I9,_P 0J.PAO([)$OYTGG7K*B;58=FQZT$_$>:WGPW\.Z_=
M7$^G_;-*E25DDA6/:F1Z*WKUW+QS5^W^'DVGP6C:?KMQOLA*UJK0INRZ\C=M
M_P#'J[Y[5)?+WL?D;<,<<C^GM5WRU]ZW]O-JUSF^K0OS6/.])\)ZM_9B)+XA
MOMK[@\-];13.,]5+,#QTJU;^"[ZU)\C7PH\SS=GV"+;&VW&Y!CY3BNZ6/;4E
M9^TF:>Q@<!_P@NH?8?L[>))I,Q-"9FM8O-V-U7?C.*K:;\/[K2K"*SL_$,RQ
M0;O*9[6)WBS][:S#<N?:O1J7FE[20>P@SS]_!VI_9A$WB2;;L\MR+6+?*-NW
MYVQEL!C2V_@C4K6)(HO$TWEQ*B!&M8F5E52@4C;_ '6KT#;2;:KVD@]A \O;
MX9R_V]%K2^(KB.^AV[&6!%1<?+MQC&W;_#5J3X?WDD-]:2>*KOR=1F^T7 \A
M-Q?Y>AQ\H^5?EKT:EH]HV3[""V.#/A'59;JWNO\ A*IA);,71EM8@68KM9CQ
M\V13%\$ZDMM]E_X2JY9,LP=K:)GY;<5W;?N[OX:[ZEVU/M)%>QB>8ZW\-Y-<
M,#:EK]P_D9V+' B*NYOFX4=ZM^$?A[!X5U674(M2FN6>,Q,DJJ%^\&W"O0L4
M5K[>?)R7T)CAH*7,.%%%%8'2%%%% !1110 4444 %%%% !1110 4444 %%%%
M !110: "BDW4N:D HHS15 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 53N(5N()+=^C@@_B"M7** /$O!_B*+4/!\WAZ-D
M:]LY'M725MNR5'.U6_WEVFO-O%'@WXA:EJUIJ5KJMAI&L63-*MS:JS?+N^52
MW]WYFW+5GQCH=]X'^)VH^+K.<R^']4O-MXB_*UJS-][_ '=WS;J]4M6DO@DL
MF&E6%59U^ZZ[MRLO^\K4;%6N>+WWQ \:.JZ5XV\ "^:W^;[=IE^T$4O^UM_O
M-6?<>(-':#[3'\-WE5OXKO5F?_T&O3O$VFM>02QJP7<K*WRUYS8:')'*VFRJ
MZLGS1LOR[T_^*6I<B>4BL?$T4C)'%X7T3296^ZTJM/\ \!W-\M6[?Q!XJDU>
MUT^6Y&GQ.K[Q:1I$K+M^5HF5?F_NLK?-5+Q#X1N9K6U:SC\N59/FE9ONC;_>
M;Y:GDOO!VC:0NFZ]XXM?M#[=D,3[Y4?^%EV[F5MU4F1[Q27P7X5T_4IM2U#1
MQJ[7#;F:[D9F1F;[RK]UO7;7O'@6^\-7&D_9M%CM8)K5V21(D57^]_WU_=KR
M73;C^TEM;FZ4K+;S*CKM^5W7;\R_Y_BK'DD\G4KB^MI7MKAKAV2:)MK;5;;_
M .RU*;;+^R?4L:[O^6@;_:7^]6C!=30K\TGF#T->0^$O'T[00VVO1F3=M5;F
M)?\ T):]+74+58E;S3)N7=\J_P -%X@D=%%=12?>S&W]UJL[JXY]:7_EE;.W
M^TWRK5O2=1NKK4$@^58L%F447B5:QT_>BBN.\5^))=!@M;73[7[?K.H3>396
MA;:K,%W,SM_"BK\S&J1FW8["EKR.9M875(]/U7XKPV>O2\I8VMO"L2D_=78V
MYF_%ANK9\.Z_K$6O2^%?%<</]I"'[1;7=OQ%>H&PS*K?<=6QE?QIM6)Y[GH?
M\-"KBN<U[Q#!X<T[[==6=[<P+N9S9P-*R*%W%F%8<GQ$T.R\*Q>)=0BU"SL)
M9HX(UFM6$KL^"& _B&TYSZ*QJ$:'H%%<E>>+K.UUF72(-/U34+B-$E<V-J94
M0/G;N;[O.TFK \5:0WAZ?Q"LDGV&WD:%SY9W;@^QAM_WJH#I:*X6'Q[I-Q>P
M6T5OJ7V::Y-HE\UFWV=I=S+M#_[P(W8Q5O4_&5GI>L7&E_V=J=[<6\*S3&SM
M#*J*<XRV?]EJ .OHKA;;Q]I>H7OV?3+'4]03]TS36UJSQ()5W+EOI][^[78/
M<1Q[/-E$>\[5R1\QH M455^T1;O+\X;]OW ?F_+K3?/@VLRSHRI\K$,,+]:
M+E%5?M$7'[]/F^[\Z_-]*<LJL^WS VY=W#?RH L452^U1%Y56=-R??&5RO\
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M<0K'O:>-4^]N+#&* +5%5?.C*%E==BX^;=\N/K42S6Y\S_24W)]]58?)]?\
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MAF4[@\3+_=7Y6/\ O5UL/C3PO<:O=Z8NL6WVJUV,_P"\7;AUW*RG[I^\.?\
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M>E\VN6:VSNT2R^:NW>/F9?J!S3Y/%'AN&_AL9-<L5N)PK1Q^>NY@>5_B[_\
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MKU[PRNH?\(OI/]L9;4/LJ>=O^]OV_-N_VO[W^U0!T/E\_>-"QX;=N+?6GT4
M%%%% !1110 4T_=]:=2-TH YS5K;11<K>:G<(@+HFV5UV;E9F7(_%JPQX(T%
M6F5;Z9O/9=^94^95PRK]WC[JG</FJ[K'@F#5K][N:^F5&9G6$(I57*A=W_CH
MJ*Y\"V5U#;JUW-')$SL[HBJT^YMQS^>V@"+_ (0C09"474+AM\7E!5D1OW1;
M[J_+T]Z6^\'^&W?[9-?2VZ6JJQ5)E5$VKM5L;:=;^!X+>1'CU2;*-O1C&NY6
M'W<'^ZO]W[M,/@&Q:R%LMY-YOSL\IC5M[/\ >9E/WL?P_P!W/% ';1R1R6ZR
M(VY&&<CTKQGQ_/;>//$MWX-7R8-!T)4O==U-UYB=6#Q0H?[W&YF_A7_>KV&W
MA6WM8H%;Y8D";C[+BOFCQ=IMYH?A[2/ NL2_9G\8>*KB74[EC_Q\0[V?;GT9
M51?]WY:EE(\NN?@MKFM>+=0\0>');9K#5+HOIDLS,J['^97/][;N^7^]7L'@
M/]ES0?#OFS>)M5DUF:ZMGM9X85\J+#;=V#NW=L5ZSH.D^?=P3>5Y=O9-MB &
MU<#[J@+\O%=Q0IMHEI(P/#OAGP_X7TF'3/#VF0V-M"NU5C3#?B>OYUHW5K:7
MEK+:7EO'/;S*4DB=0RNK=5(K1%%4!FZ;IFFZ38)8Z5I\%E;)TA@0(J_@M:+=
M*6FOTH XS4CX=C\3-'>23"\<Q,^UV6+</F3=S_LU =#\$QK<;+Q(K>X7S;B%
M;PK%(I9OO+GIN)IVJ:7X?U#7)(KZ[G%W+L1EB^[GG9\V-P;'^U52X\'^%=\-
ML^H.KKE47[2%.X;F)8?Q;=W0T 2W5AX435#%/IKLT]JSB9 RQ>4JCYMP.T%0
MJ_-][[M:=OXHTJX4>4\Q1E0^9L8!=[856YW;NF:EN-,T.[LX;.2Y7RE@%JJI
M,%^0LOR_+_>VBJ(\$Z=;RWDUM)<Q_:FWE5D5MK;@P96(W##+G;G% &HFOZ7)
MK+Z7$TTEQ%)Y3[(VVHQY^8_\!ZUT0KDH_"EG%J,5\MQ=R3)+Y[,[JV^3GYCQ
MG_@*[5KJU^4!: '4444 <;XS748O"M[?:/K4FEW%A ]QN2%'63:I*JVY>F?2
MN1U'6O%EIX3T.STW7A>>(-53^T/.N+=%"0I$LLJ8&T?,Q5%;MO\ ]FO3-2LH
MM4TNYTZYW>3=1M%(J'YMK+M.#^-8/_"#^'FO[6\O-/2_DM;-+*$785UB0-V&
M.K=SWVK0!QY\8:AK/B3=8ZKJUMI\MC9W$,6G:>MPJF3=NWMM;;RNW'LU::^)
M=87X:ZCKDDP:^M[J:%9=B[<+<;%X^[]T?-_M5=M/AUH^EW4SZ+JNK:2L^U6A
MMKE0FU6+*H5E;@;FX]&J23P#IKO+$U]J2V$]R+N33UG7[.[[MYW+MW89N67=
MMH YNWU[Q';^(;9=:UBZT^9]2\HVTVG+]AEB9R$5)E5FW,,;69OO?+M6NSU#
MQ9::;<:S%+;3.VE)#(^-OSB5L#'T]ZSXO .DI=0M]NU.2S@N_M:6#W&ZW67>
M77Y<;MJLV57=MJQK?@G3]>NYKJ:ZOH'N%C2=+:?8LZHV4WC;_"?2@#F=)^(6
MN)>:Q%J>D_:[3389KAKN*14.U9I55=OT3%6[CXBW%G913WWAFZLFG#.$NKJ)
M%9%175E;=M9FSMPOW6^]5^\^'.@7A;S)+^-)A+YR0S[5EWNS\\?-M9F(^O\
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M.QS2T4 -(I-OU_.GT4 1;6W5)MI:* &%?JWXTY5Q2T4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
4 !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653470723984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 16, 2023</div></th>
<th class="th"><div>Mar. 10, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ENDRA Life Sciences Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001681682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well Known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,169,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,628,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-0579295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">Icfr Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">3600 Green Court<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line 2</a></td>
<td class="text">Suite 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Ann Arbor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">MI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">48105-1570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">335-0468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NDRA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm Id</a></td>
<td class="text">587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">RBSM LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">New York, NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653470801552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 4,889,098<span></span>
</td>
<td class="nump">$ 9,461,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">992,875<span></span>
</td>
<td class="nump">1,348,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">2,644,717<span></span>
</td>
<td class="nump">1,284,578<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">8,526,690<span></span>
</td>
<td class="nump">12,094,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrentAbstract', window );"><strong>Non-Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">235,655<span></span>
</td>
<td class="nump">131,130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets</a></td>
<td class="nump">505,816<span></span>
</td>
<td class="nump">643,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">5,986<span></span>
</td>
<td class="nump">5,986<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">9,274,147<span></span>
</td>
<td class="nump">12,874,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">1,523,012<span></span>
</td>
<td class="nump">1,411,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, current portion</a></td>
<td class="nump">152,228<span></span>
</td>
<td class="nump">132,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loans</a></td>
<td class="nump">28,484<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">1,703,724<span></span>
</td>
<td class="nump">1,543,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract', window );"><strong>Long Term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Loans, long term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">28,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities</a></td>
<td class="nump">365,919<span></span>
</td>
<td class="nump">518,147<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total Long Term Debt</a></td>
<td class="nump">365,919<span></span>
</td>
<td class="nump">546,631<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">2,069,643<span></span>
</td>
<td class="nump">2,090,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 80,000,000 shares authorized; 3,169,103 and 2,127,725 shares issued and outstanding, respectively</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">89,068,015<span></span>
</td>
<td class="nump">79,460,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_StockPayable', window );">Stock payable</a></td>
<td class="nump">6,073<span></span>
</td>
<td class="nump">13,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(81,869,902)<span></span>
</td>
<td class="num">(68,690,810)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">7,204,504<span></span>
</td>
<td class="nump">10,784,246<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">9,274,147<span></span>
</td>
<td class="nump">12,874,644<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series A Convertible Preferred Stock, $0.0001 par value; 10,000 shares authorized; 141.397 shares issued and outstanding</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series A Convertible Preferred Stock, $0.0001 par value; 10,000 shares authorized; 141.397 shares issued and outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_StockPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_StockPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(1),(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653470358160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock shares, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares, authorized</a></td>
<td class="nump">80,000,000<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares, issued</a></td>
<td class="nump">3,169,103<span></span>
</td>
<td class="nump">2,127,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares, outstanding</a></td>
<td class="nump">3,169,103<span></span>
</td>
<td class="nump">2,127,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock shares, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares, authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember', window );">Preferred Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock shares, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares, authorized</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares, issued</a></td>
<td class="nump">141,397<span></span>
</td>
<td class="nump">141,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares, outstanding</a></td>
<td class="nump">141,397<span></span>
</td>
<td class="nump">141,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember', window );">Preferred Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock shares, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares, authorized</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653470784880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 6,554,194<span></span>
</td>
<td class="nump">$ 5,482,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">1,429,150<span></span>
</td>
<td class="nump">1,075,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,174,215<span></span>
</td>
<td class="nump">4,940,398<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">13,157,559<span></span>
</td>
<td class="nump">11,498,305<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(13,157,559)<span></span>
</td>
<td class="num">(11,498,305)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(308,600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="num">(21,533)<span></span>
</td>
<td class="num">(41,545)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expenses</a></td>
<td class="num">(21,533)<span></span>
</td>
<td class="nump">267,055<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from operations before income taxes</a></td>
<td class="num">(13,179,092)<span></span>
</td>
<td class="num">(11,231,250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(13,179,092)<span></span>
</td>
<td class="num">(11,231,250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Deemed dividend</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(121,071)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net Loss attributable to common stockholders</a></td>
<td class="num">$ (13,179,092)<span></span>
</td>
<td class="num">$ (11,352,321)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic and diluted</a></td>
<td class="num">$ (4.56)<span></span>
</td>
<td class="num">$ (5.55)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted average common shares - basic and diluted</a></td>
<td class="nump">2,891,292<span></span>
</td>
<td class="nump">2,046,135<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653467856368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series A Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Stock Payable [Member]</div></th>
<th class="th"><div>Retained Earnings (Accumulated Deficit)</div></th>
<th class="th"><div>Series B Convertible Preferred Stocks</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="nump">1,702,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2020</a></td>
<td class="nump">$ 7,169,322<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
<td class="nump">$ 64,496,845<span></span>
</td>
<td class="nump">$ 10,795<span></span>
</td>
<td class="num">$ (57,338,489)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_SeriesAConvertiblePreferredStockConvertedToCommonStockShares', window );">Series A Convertible Preferred Stock converted to common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="nump">3,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_SeriesAConvertiblePreferredStockConvertedToCommonStockAmount', window );">Series A Convertible Preferred Stock converted to common stock, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_CommonStockIssuedForCashNetOfFundingCostsShares', window );">Common stock issued for cash, net of funding costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_CommonStockIssuedForCashNetOfFundingCostsAmount', window );">Common stock issued for cash, net of funding costs, amount</a></td>
<td class="nump">10,615,975<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">10,615,952<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_CommonStockIssuedForWarrantExerciseShares', window );">Common stock issued for warrant exercise, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_CommonStockIssuedForWarrantExerciseAmount', window );">Common stock issued for warrant exercise, amount</a></td>
<td class="nump">2,785,627<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">2,785,608<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_CommonStockIssuedForOptionExerciseShares', window );">Common stock issued for option exercise, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_CommonStockIssuedForOptionExerciseAmount', window );">Common stock issued for option exercise, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_FairValueOfVestedStockOptions', window );">Fair value of vested stock options</a></td>
<td class="nump">1,334,112<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,334,112<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Stock payable towards preference dividend</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,068<span></span>
</td>
<td class="nump">3,068<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_CommonStockIssuedForServicesShares', window );">Common stock issued for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_CommonStockIssuedForServicesAmount', window );">Common stock issued for services, amount</a></td>
<td class="nump">74,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">74,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_StockIssuedForRsuShares', window );">Stock issued for RSU, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_StockIssuedForRsuAmount', window );">Stock issued for RSU, amount</a></td>
<td class="nump">36,460<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">36,460<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_DeemedDividend', window );">Deemed dividend</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">121,071<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(121,071)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(11,231,250)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,231,250)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="nump">2,127,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2021</a></td>
<td class="nump">10,784,246<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 212<span></span>
</td>
<td class="nump">79,460,980<span></span>
</td>
<td class="nump">13,863<span></span>
</td>
<td class="num">(68,690,810)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_CommonStockIssuedForCashNetOfFundingCostsShares', window );">Common stock issued for cash, net of funding costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,041,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_CommonStockIssuedForCashNetOfFundingCostsAmount', window );">Common stock issued for cash, net of funding costs, amount</a></td>
<td class="nump">8,399,512<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">8,399,407<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_FairValueOfVestedStockOptions', window );">Fair value of vested stock options</a></td>
<td class="nump">1,199,838<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,199,838<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Stock payable towards preference dividend</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,790<span></span>
</td>
<td class="nump">7,790<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(13,179,092)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,179,092)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="nump">3,169,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2022</a></td>
<td class="nump">$ 7,204,504<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 317<span></span>
</td>
<td class="nump">$ 89,068,015<span></span>
</td>
<td class="nump">$ 6,073<span></span>
</td>
<td class="num">$ (81,869,902)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_CommonStockIssuedForCashNetOfFundingCostsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_CommonStockIssuedForCashNetOfFundingCostsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_CommonStockIssuedForCashNetOfFundingCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_CommonStockIssuedForCashNetOfFundingCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_CommonStockIssuedForOptionExerciseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_CommonStockIssuedForOptionExerciseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_CommonStockIssuedForOptionExerciseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_CommonStockIssuedForOptionExerciseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_CommonStockIssuedForServicesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_CommonStockIssuedForServicesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_CommonStockIssuedForServicesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_CommonStockIssuedForServicesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_CommonStockIssuedForWarrantExerciseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_CommonStockIssuedForWarrantExerciseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_CommonStockIssuedForWarrantExerciseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_CommonStockIssuedForWarrantExerciseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_FairValueOfVestedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_FairValueOfVestedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_SeriesAConvertiblePreferredStockConvertedToCommonStockAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_SeriesAConvertiblePreferredStockConvertedToCommonStockAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_SeriesAConvertiblePreferredStockConvertedToCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_SeriesAConvertiblePreferredStockConvertedToCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_StockIssuedForRsuAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_StockIssuedForRsuAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_StockIssuedForRsuShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_StockIssuedForRsuShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653472729408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (13,179,092)<span></span>
</td>
<td class="num">$ (11,231,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">96,661<span></span>
</td>
<td class="nump">116,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_FixedAssetsWriteOff', window );">Fixed assets write off</a></td>
<td class="nump">1,391<span></span>
</td>
<td class="nump">9,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation expense including common stock issued for RSUs</a></td>
<td class="nump">1,199,838<span></span>
</td>
<td class="nump">1,444,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right of use assets</a></td>
<td class="nump">137,597<span></span>
</td>
<td class="nump">108,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(308,600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Decrease in prepaid expenses</a></td>
<td class="nump">355,128<span></span>
</td>
<td class="num">(957,203)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventory</a></td>
<td class="num">(1,360,139)<span></span>
</td>
<td class="num">(694,958)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase in accounts payable and accrued liabilities</a></td>
<td class="nump">111,575<span></span>
</td>
<td class="nump">491,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Decrease in lease liability</a></td>
<td class="num">(132,330)<span></span>
</td>
<td class="num">(100,338)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(12,769,371)<span></span>
</td>
<td class="num">(11,122,384)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of fixed assets</a></td>
<td class="num">(202,577)<span></span>
</td>
<td class="num">(45,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(202,577)<span></span>
</td>
<td class="num">(45,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercise</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,785,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">8,399,512<span></span>
</td>
<td class="nump">10,615,975<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">8,399,512<span></span>
</td>
<td class="nump">13,401,602<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash</a></td>
<td class="num">(4,572,436)<span></span>
</td>
<td class="nump">2,234,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, beginning of year</a></td>
<td class="nump">9,461,534<span></span>
</td>
<td class="nump">7,227,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, end of year</a></td>
<td class="nump">4,889,098<span></span>
</td>
<td class="nump">9,461,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">59,113<span></span>
</td>
<td class="nump">57,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income tax paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_SupplementalDisclosuresOfNoncashItemsAbstract', window );"><strong>Supplemental disclosures of non-cash items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Deemed dividend</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">121,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_ConversionOfSeriesAConvertiblePreferredStock', window );">Conversion of Series A Convertible Preferred Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_StockDividendPayable', window );">Stock dividend payable</a></td>
<td class="nump">7,790<span></span>
</td>
<td class="num">(3,068)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Right of use asset</a></td>
<td class="nump">505,816<span></span>
</td>
<td class="nump">643,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_LeaseLiability', window );">Lease liability</a></td>
<td class="nump">$ 518,147<span></span>
</td>
<td class="nump">$ 650,477<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_ConversionOfSeriesAConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_ConversionOfSeriesAConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_FixedAssetsWriteOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_FixedAssetsWriteOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_StockDividendPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_StockDividendPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_SupplementalDisclosuresOfNoncashItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_SupplementalDisclosuresOfNoncashItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653476895456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of the Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Nature Of The Business</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Note 1 - Nature of the Business</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ENDRA Life Sciences Inc. (&#8220;ENDRA&#8221; or the &#8220;Company&#8221;) has developed and is continuing to develop technology for increasing the capabilities of clinical diagnostic ultrasound to broaden patient access to the safe diagnosis and treatment of a number of significant medical conditions in circumstances where expensive X-ray computed tomography (&#8220;CT&#8221;) and magnetic resonance imaging (&#8220;MRI&#8221;) technology is unavailable or impractical.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ENDRA was incorporated on July 18, 2007 as a Delaware corporation.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653470953184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary Of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Note 2 - Summary of Significant Accounting Policies</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Management makes estimates that affect certain accounts including deferred income tax assets, accrued expenses, fair value of equity instruments and reserves for any other commitments or contingencies. Any adjustments applied to estimates are recognized in the period in which such adjustments are determined.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The COVID-19 pandemic has prompted governments and regulatory bodies throughout the world to issue &#8220;stay-at-home&#8221; or similar orders, and enact restrictions on the performance of &#8220;non-essential&#8221; services, public gatherings and travel.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it continues impact worldwide macroeconomic conditions, the emergence of variants of the virus and effectiveness of vaccines, access to capital markets, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of December 31, 2022 and through the date of the filing of this Annual Report on Form 10-K. The accounting matters assessed included, but were not limited to, estimates related to the accounting for potential liabilities and accrued expenses, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and assessments of impairment related to long-lived assets. The Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in additional material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Despite the Company&#8217;s efforts, the ultimate impact of COVID-19 on the Company&#8217;s business depends on factors beyond the Company&#8217;s knowledge or control, including the duration and severity of the outbreak, as well as third-party actions taken to contain its spread and mitigate its public health effects. As a result, the Company is unable to estimate the extent to which COVID-19 will negatively impact its financial results or liquidity.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline">Principles of Consolidation</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s consolidated financial statements include all accounts of the Company and its consolidated subsidiaries and/or entities as of reporting period ending date(s) and for the reporting period(s) then ended. All inter-company balances and transactions have been eliminated.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline">Basis of Presentation</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). These financial statements have been prepared using the accrual basis of accounting in accordance with Generally Accepted Accounting Principles (&#8220;GAAP&#8221;) of the United States.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Cash and Cash Equivalents</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company considers all cash on hand and in banks, including accounts in book overdraft positions, certificates of deposit and other highly-liquid investments with maturities of one year or less, when purchased, to be cash. As of December 31, 2022 and 2021, the Company had no cash equivalents. The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and periodically evaluates the credit worthiness of the financial institutions and has determined the credit exposure to be negligible.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Inventory</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s inventory is stated at the lower of cost or estimated net realizable value, with cost primarily determined on a weighted-average cost basis on the first-in, first-out method. The Company periodically determines whether a reserve should be taken for devaluation or obsolescence of inventory.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Capitalization of Fixed Assets</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than one year for: (1) assets purchased; (2) existing assets that are replaced, improved or the useful lives have been extended; or (3) all land, regardless of cost. Acquisitions of new assets, additions, replacements and improvements (other than land) costing less than the minimum rule in addition to maintenance and repair costs, including any planned major maintenance activities, are expensed as incurred.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Leases</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest period presented in the financial statements. At December 31, 2022 and 2021 the Company recorded a right of use asset of $505,816 and $643,413, respectively. At December 31, 2022 and 2021 the Company recorded a lease liability of $518,147 and $650,477, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Revenue Recognition</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ASU No. 2014-09, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;ASC Topic 606&#8221;) provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Under ASC Topic 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to perform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC Topic 606 did not have an impact on the Company&#8217;s operations or cash flows.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Research and Development Costs</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company follows FASB Accounting Standards Codification (&#8220;ASC&#8221;) Subtopic 730-10, &#8220;Research and Development&#8221;. Research and development costs are charged to the statement of operations as incurred. During the years ended December 31, 2022 and 2021, the Company incurred $6,554,194 and $5,482,531 of expenses related to research and development costs, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Net Earnings (Loss) Per Common Share</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company computes earnings per share under ASC Subtopic 260-10, &#8220;Earnings Per Share&#8221;. Basic earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders (the numerator) by the weighted average number of shares of common stock outstanding (the denominator) during the reporting periods. Diluted loss per share is computed by increasing the denominator by the weighted average number of additional shares that could have been outstanding from securities convertible into common stock (using the &#8220;treasury stock&#8221; method), unless their effect on net loss per share is anti-dilutive. There were 410,358 and 392,425 potentially dilutive shares, which include outstanding common stock options, and warrants, as of December 31, 2022 and 2021, respectively.</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Options to purchase common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">391,902</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">262,481</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Warrants to purchase common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,330</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">121,818</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Shares issuable upon conversion of Series A Convertible Preferred Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,126</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,126</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Potential equivalent shares excluded</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>410,358</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>392,425</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline">Fair Value Measurements</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Disclosures about fair value of financial instruments require disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with ASC Topic 820, &#8220;Fair Value Measurements and Disclosures,&#8221; the Company measures certain financial instruments at fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance with accounting principles generally accepted in the United States, and expands disclosures about fair value measurements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The carrying amounts of the Company&#8217;s financial assets and liabilities, including cash, accounts receivable, prepaid expenses, accounts payable, accrued expenses, and other current liabilities, approximate their fair values because of the short maturity of these instruments. The fair value of notes payable and convertible notes approximates their fair values since the current interest rates and terms on these obligations are the same as prevailing market rates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Share-based Compensation</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s 2016 Omnibus Incentive Plan (the &#8220;Omnibus Plan&#8221;) permits the grant of stock options and other share-based awards to its employees, consultants and non-employee members of the board of directors. Each January 1 the pool of shares available for issuance under the Omnibus Plan automatically increases by an amount equal to the lesser of (i) the number of shares necessary such that the aggregate number of shares available under the Omnibus Plan equals 25% of the number of fully-diluted outstanding shares on the increase date (assuming the conversion of all outstanding shares of preferred stock and other outstanding convertible securities and exercise of all outstanding options and warrants to purchase shares) and (ii) if the board of directors takes action to set a lower amount, the amount determined by the board. On January 1, 2023, the pool of shares issuable under the Omnibus Plan automatically increased by 867,966 shares from 454,204 shares to 1,322,169 shares.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company records share-based compensation in accordance with the provisions of the Share-based Compensation Topic of the FASB Codification. The guidance requires the use of option-pricing models that require the input of highly subjective assumptions, including the option&#8217;s expected life and the price volatility of the underlying stock. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option valuation model, and the resulting charge is expensed using the straight-line attribution method over the vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Stock compensation expense recognized during the period is based on the value of share-based awards that were expected to vest during the period adjusted for estimated forfeitures. The estimated fair value of grants of stock options and warrants to non-employees of the Company is charged to expense, if applicable, in the financial statements. These options vest in the same manner as the employee options granted under the stock incentive plan as described above.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Going Concern</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s financial statements are prepared using accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has limited commercial experience and had a cumulative net loss from inception to December 31, 2022 of $81,869,902. The Company had working capital of $6,822,966 as of December 31, 2022. The Company has not established an ongoing source of revenue sufficient to cover its operating costs and to allow it to continue as a going concern and will require additional financing to fund its future planned operations, including research and development and commercialization of its products. The accompanying financial statements for the year ended December 31, 2022 have been prepared assuming the Company will continue as a going concern, but the ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it establishes a revenue stream and becomes profitable. Management&#8217;s plans to continue as a going concern include raising additional capital through sales of equity securities and borrowing. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. If the Company is not able to obtain the necessary additional financing on a timely basis, the Company will be required to delay, reduce the scope of, or eliminate one or more of the Company&#8217;s research and development activities or commercialization efforts or perhaps even cease the operation of its business. The ability of the Company to continue as a going concern is dependent upon its ability to successfully secure other sources of financing and attain profitable operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Recent Accounting Pronouncements</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company considered recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC, did not or in management&#8217;s opinion will not have a material impact on the Company&#8217;s present or future consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653470713264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Note 3 - Inventory</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2022 and 2021, inventory consisted of raw materials, subassemblies to be used in the assembly of TAEUS systems, and finished goods. As of December 31, 2022, the Company had no orders pending for the sale of a TAEUS system. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2022 and 2021, the Company had inventory valued at $2,644,717 and $1,284,578, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653562271440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Fixed Assets</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Note 4 - Fixed Assets</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2022 and 2021, fixed assets consisted of the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Property, leasehold and capitalized software</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">738,720</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">605,248</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">TAEUS development and testing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">140,617</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">107,682</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accumulated depreciation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(643,682 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(581,800 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Fixed assets, net</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>235,655</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>131,130</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Depreciation expense for the year ended December 31, 2022 and 2021 was $96,661 and $116,238, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653474162496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accounts Payable and Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable And Accrued Liabilities</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Note 5 - Accounts Payable and Accrued Liabilities</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2022 and 2021, current liabilities consisted of the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">613,961</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">791,052</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued payroll</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">60,638</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">101,459</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued bonuses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">683,738</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">396,043</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued employee benefits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,750</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,750</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Insurance premium financing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">158,925</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">117,133</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Total</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>1,523,012</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>1,411,437</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653562271440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bank Loans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Bank Loans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTextBlock', window );">Bank Loans</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Note 6 - Bank Loans</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>U.S. SBA Paycheck Protection Program</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In April 2020, the Company issued a U.S. Small Business Administration (&#8220;SBA&#8221;) Paycheck Protection Program Note (the &#8220;SBA Note&#8221;) to First Republic Bank (the &#8220;Lender&#8221;) for a loan in the principal amount of $308,600 (the &#8220;SBA Loan&#8221;) under the Paycheck Protection Program (&#8220;PPP&#8221;) promulgated under the Coronavirus Aid, Relief and Economic Security Act of 2020, as modified by the Paycheck Protection Program Flexibility Act of 2020.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 10, 2021 received notice that the SBA Loan had been forgiven in full in accordance with the terms and provisions of the PPP.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company did not provide any collateral or personal guarantees for the SBA Loan, nor did the Company pay any facility charge to the government or to the Lender.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Toronto-Dominion Bank Loan</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 27, 2020, the Company entered into a commitment loan with TD Bank under the Canadian Emergency Business Account, in the principal aggregate amount of CAD 40,000, due and payable upon the expiration of the initial term on December 31, 2022, which was later extended to December 31, 2023. This note bears interest on the unpaid balance at the rate of zero percent (0%) per annum during the initial term. Under this note no interest payments are due until January 1, 2024. Under the conditions of the loan, twenty-five percent (25%) of the loan will be forgiven if seventy-five percent (75%) is repaid prior to the initial term date.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653476724368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capital Stock</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Note 7 - Capital Stock</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Reverse Stock Split</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 7, 2022, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment (the &#8220;Certificate of Amendment&#8221;) to its certificate of incorporation, which Certificate of Amendment effectuated as of December 19, 2022 at 12:01 a.m. Eastern Time (the &#8220;Effective Time&#8221;) a reverse split&#160;of the Company&#8217;s common stock by a ratio of one-for-20 (the &#8220;Reverse Split&#8221;). All per share amounts and number of shares in the consolidated financial statements and related notes have been retroactively restated to reflect the Reverse Split. No fractional shares were, or shall be, issued in connection with the&#160;Reverse Split. A stockholder who would otherwise be entitled to receive a fractional share of common stock is entitled to receive the fractional share rounded up to the next whole share. The&#160;Reverse Split&#160;did not change the number of shares of common or preferred stock that the Company is authorized to issue, or the par value of the Company&#8217;s common or preferred stock.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The&#160;Reverse Split&#160;resulted in a proportionate adjustment to the per share conversion or exercise price and the number of shares of common stock issuable upon the conversion or exercise of outstanding preferred stock, stock options and warrants, as well as the number of shares of common stock eligible for issuance under the Company&#8217;s 2016 Omnibus Incentive Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Capital Stock</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">At December 31, 2022, the authorized capital of the Company consisted of 90,000,000 shares of capital stock, comprised of 80,000,000 shares of common stock with a par value of $0.0001 per share, and 10,000,000 shares of preferred stock with a par value of $0.0001 per share. The Company has designated 10,000 shares of its preferred stock as Series A Convertible Preferred Stock (&#8220;Series A Preferred Stock&#8221;), 1,000 shares of its preferred stock as Series B Convertible Preferred Stock (&#8220;Series B Preferred Stock&#8221;), 100,000 shares of its preferred stock as Series C Preferred Stock, and the remainder of the&#160;9,889,000 preferred shares remain authorized but undesignated.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2022, there were 3,169,103 shares of common stock, 141.397 shares of Series A Preferred Stock, and no shares of Series B Preferred Stock or Series C Preferred Stock&#160;issued and outstanding, and a stock payable balance of $6,073.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 26, 2022, the board of directors declared a dividend of one one-thousandth of a share of Series C Preferred Stock for each outstanding share of the Company&#8217;s common stock and 1.359 shares of Series C Preferred Stock for each outstanding share of Series A Preferred Stock, to stockholders of record at 5:00 p.m. Eastern Time on October 7, 2022. Each whole share of Series C Preferred Stock (other than shares held by the Company&#8217;s directors and named executive officers) entitled the holder thereof to 1,000,000 votes on the proposal to adopt an amendment to the Company&#8217;s certificate of incorporation to reclassify the outstanding shares of common stock into a smaller number of shares of common stock. Shares of Series C Preferred Stock were eligible to vote at the special meeting of the Company&#8217;s stockholders held on November 29, 2022, at which the Company&#8217;s stockholders approved a reverse stock split of its common stock. All shares of Series C Preferred Stock were automatically redeemed in connection with the special meeting and no shares of Series C Preferred Stock remained outstanding as of December 31, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2022, the Company issued a total of 1,041,377 shares of its common stock in return for aggregate net proceeds of $8,399,512 under the June 2021 ATM Agreement (as described below). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2021, the Company issued a total of 425,241 shares of its common stock, as follows:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">3,394 shares upon the conversion of 55.397 shares of its Series A Preferred Stock;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">229,348 shares in return for aggregate net proceeds of $10,615,975 from sales of common stock;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">178,395 shares upon warrant exercises for an aggregate exercise price of $2,785,627;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">10,145 shares upon cashless warrant exercises;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">1,192 shares upon cashless option exercise; </p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">1,626 shares for services valued at $74,000; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">1,141 shares for RSUs valued at $36,460.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>At-the-Market Equity Offering Program</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 21, 2021, the Company entered into the At-The-Market Issuance Sales Agreement with Ascendiant (the &#8220;June 2021 ATM Agreement&#8221;) to sell shares of common stock for aggregate gross proceeds of up to $20.0 million, from time to time, through an &#8220;at-the-market&#8221; equity offering program under which Ascendiant acts as sales agent. As of December 31, 2022, under the June 2021 ATM Agreement the Company has issued an aggregate of 1,064,634 shares of common stock in return for net proceeds of $9,216,618, resulting in approximately $286,289 of compensation paid to Ascendiant. During the year ended December 31, 2022, under the June 2021 ATM Agreement the Company issued an aggregate of 1,041,377 shares of common stock in return for net proceeds of $8,398,936, resulting in $260,776 of compensation paid to Ascendiant.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653473885392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Options and Restricted Stock Units (RSUs)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Common Stock Options and Restricted Stock Units (RSUs)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock', window );">Common Stock Options and Restricted Stock Units (RSU's)</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Note 8 - Common Stock Options and Restricted Stock Units (RSUs)</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Common Stock Options</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Stock options are awarded to the Company&#8217;s employees, consultants and non-employee members of the board of directors under the Omnibus Plan and are generally granted with an exercise price equal to the market price of the Company&#8217;s common stock at the date of grant. The aggregate fair value of these stock options granted by the Company during the year ended December 31, 2022 was determined to be $919,915 using the Black-Scholes-Merton option-pricing model based on the following assumptions: (i) volatility rate of 74% to 99%, (ii) discount rate of 0%, (iii) zero expected dividend yield, (iv) risk free rate of 1.37% to 4.36%, and (v) expected life of 8-10 years. A summary of option activity under the Company&#8217;s Omnibus Plan as of December 31, 2022, and changes during the year then ended, is presented below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Average</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercise</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Price</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Average </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Remaining </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Contractual </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Term (Years)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance outstanding at December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">262,481</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">44.17</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7.42</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">141,975</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.08</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.05</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cancelled or expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(12,554 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance outstanding at December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">391,902</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">31.47</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7.41</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercisable at December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">180,742</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">41.21</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.69</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653476891216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Common Stock Options and Restricted Stock Units (RSUs)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock', window );">Common Stock Warrants</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Note 9 - Common Stock Warrants</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The following table summarizes all stock warrant activity of the Company for the year ended December 31, 2022:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Warrants</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Average</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercise </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Price</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Average </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Contractual </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Term (Years)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance outstanding at December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">121,818</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">110.80</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.58</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(111,488 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">118.86</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance outstanding at December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,330</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25.01</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.78</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercisable at December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,330</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25.01</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.78</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653473885392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Note 10 - Commitments and Contingencies</strong> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Effective January 1, 2015, the Company entered into an office lease agreement with Green Court, LLC, a Michigan limited liability company, for approximately 3,657 rentable square feet of space, for the initial monthly rent of $5,986, which commenced on January 1, 2015 for an initial term of 60 months. On October 10, 2017 this lease was amended increasing the rentable square feet of space to 3,950 and the monthly rent to $7,798. On July 16, 2019, the Company exercised its option to extend the lease for an additional 5 years past the initial term originally expiring on December 31, 2019.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On March 15, 2021, the Company entered into an amendment to the lease, adding approximately 3,248 rentable square feet, increasing the initial monthly rent to $15,452 effective May 2021, and extending the term of the lease to December 31, 2025. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company records the lease asset and lease liability at the present value of lease payments over the lease term. The lease typically does not provide an implicit rate; therefore, the Company uses its estimated incremental borrowing rate at the time of lease commencement to discount the present value of lease payments. The Company&#8217;s discount rate for operating leases at December 31, 2022 was 10%. Lease expense is recognized on a straight-line basis over the lease term to the extent that collection is considered probable. As a result, the Company has been recognizing rents as they become payable based on the adoption of ASC Topic 842. The weighted-average remaining lease term is 3.00 years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2022, the maturities of operating lease liabilities are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Operating</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Lease</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">196,721</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">202,624</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025 and beyond</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">202,624</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">601,969</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: amount representing interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(83,822 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Present value of future minimum lease payments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">518,147</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: current obligations under leases</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(152,228 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Long-term lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">365,919</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">For the years ended December 31, 2022 and 2021, the Company incurred rent expenses of $213,912 and $178,620, respectively.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Employment and Consulting Agreements</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Francois Michelon</em></strong> - The Company has an employment agreement with Francois Michelon, the Company&#8217;s Chief Executive Officer and Chairman of the board of directors, dated May 12, 2017 and amended on December 27, 2019.&#160; Effective January 1, 2021, the Compensation Committee increased Mr. Michelon&#8217;s annual salary to $376,991 and, effective January 1, 2022, it increased Mr. Michelon&#8217;s annual salary to $423,000. Mr. Michelon is also eligible for an annual cash bonus based upon achievement of performance-based objectives established by the Board of Directors. Under the employment agreement, Mr. Michelon is eligible for an annual cash bonus based upon achievement of performance-based objectives established by the board of directors. Upon termination without cause, any portion of Mr. Michelon&#8217;s option award scheduled to vest within 12 months will automatically vest, and upon termination without cause within 12 months following a change of control, the entire unvested portion of the option award will automatically vest. Upon termination for any other reason, the entire unvested portion of the option award will terminate.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If Mr. Michelon&#8217;s employment is terminated by the Company without cause or Mr. Michelon terminates his employment for good reason, Mr. Michelon will be entitled to receive 12 months&#8217; continuation of his current base salary and a lump sum payment equal to 12 months of continued healthcare coverage (or 24 months&#8217; continuation of his current base salary and a lump sum payment equal to 24 months of continued healthcare coverage if such termination occurs within one year following a change in control).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Under his employment agreement, Mr. Michelon is eligible to receive benefits that are substantially similar to those of the Company&#8217;s other senior executive officers.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Michael Thornton</em></strong> - The Company has an employment agreement with Michael Thornton, the Company&#8217;s Chief Technology Officer, dated May 12, 2017 and on December 27, 2019. The employment agreement provides for an annual base salary that is subject to adjustment at the board of directors&#8217; discretion. Effective January 1, 2021, the Compensation Committee increased Mr. Thornton&#8217;s annual salary to $289,963 and, effective January 1, 2022, it increased Mr. Thornton&#8217;s annual salary to $324,000. Under the employment agreement, Mr. Thornton is eligible for an annual cash bonus based upon achievement of performance-based objectives established by the board of directors. Upon termination without cause, any portion of Mr. Thornton&#8217;s option award scheduled to vest within 12 months will automatically vest, and upon termination without cause within 12 months following a change of control, the entire unvested portion of the option award will automatically vest. Upon termination for any other reason, the entire unvested portion of the option award will terminate.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If Mr. Thornton&#8217;s employment is terminated by the Company without cause or Mr. Thornton terminates his employment for good reason, Mr. Thornton will be entitled to receive 12 months&#8217; continuation of his current base salary and a lump sum payment equal to 12 months of continued healthcare coverage (or 24 months&#8217; continuation of his current base salary and a lump sum payment equal to 24 months of continued healthcare coverage if such termination occurs within one year following a change in control). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Under his employment agreement, Mr. Thornton is eligible to receive benefits that are substantially similar to those of the Company&#8217;s other senior executive officers.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Renaud Maloberti </em></strong>- The Company had&#160;an employment agreement with Renaud Maloberti, dated April 15, 2019, that provided&#160;for an annual base salary of $250,000 and eligibility for an annual cash bonus to be paid based on attainment of Company and individual performance objectives to be established by the Board of Directors. Effective January 1, 2021, the Compensation Committee increased Mr. Maloberti&#8217;s annual salary to $266,255.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 21, 2022, Mr.&#160;Maloberti notified the Company of his resignation as the Company&#8217;s Chief Commercial Officer, effective January 13, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to his employment agreement, on April 28, 2019, Mr. Maloberti was granted stock options to purchase 35,000 shares of the Company&#8217;s common stock. The stock options have an exercise price of $1.04 per share, and vest in three equal annual installments beginning on the first anniversary of the grant date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Litigation</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">From time to time the Company may become a party to litigation in the normal course of business. As of December 31, 2022, there were no legal matters that management believes would have a material effect on the Company&#8217;s financial position or results of operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653473949776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_IncomeTaxesAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Note 11 - Income Taxes</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets as of December 31, 2022 and 2021 are summarized below.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net operating loss carryforward</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(17,251,804</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(14,200,629</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28,720</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fair value of options</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">311,958</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">346,869</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total deferred tax assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(16,939,846</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(13,825,040</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,939,846</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,825,040</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net deferred tax asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In assessing the potential realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the Company attaining future taxable income during the periods in which those temporary differences become deductible. As of December 31, 2022 and 2021, management was unable to determine if it is more likely than not that the Company&#8217;s deferred tax assets will be realized, and has therefore recorded an appropriate valuation allowance against deferred tax assets at such dates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has not completed its evaluation of net operating loss (&#8220;NOL&#8221;) utilization limitations under Internal Revenue Code, as amended (the &#8220;Code&#8221;), Section 382/383, change of ownership rules. If the Company has had a change in ownership, the NOL&#8217;s would be limited as to the amount that could be utilized each year, or possibly eliminated, based on the Code, as amended.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">No federal or state/local tax provision has been provided for the years ended December 31, 2022 and 2021 due to the losses incurred during such periods. Reconciled below is the difference between the income tax rate computed by applying the U.S. federal statutory rate and the effective tax rate for the years ended December 31, 2021 and 2020.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">U.S. federal statutory income tax</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-21.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-21.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">State tax, net of federal tax benefit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-5.80</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-5.80</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Change in valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26.80</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26.80</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Effective tax rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">At December 31, 2022, the Company has available net operating loss carryforwards for federal and state income tax purposes of approximately $65.2 million, of which $16 million will begin to expire in 2028 through 2038.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ENDRA Life Sciences Canada Inc., the Company&#8217;s wholly-owned subsidiary which was incorporated in 2017, is subject to income taxes in the jurisdictions in which it operates,&#160;Canada, at a current rate of approximately 26.6 percent for 2022. Significant judgment is required in determining the provision for income tax. There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. The Company recognizes liabilities for anticipated tax audit issues based on its current understanding of the tax law. Where the final tax outcome of these matters is different from the carrying amounts, such differences will impact the current and deferred tax provisions in the period in which such determination is made.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ENDRA Life Sciences Canada Inc.&#8217;s operations were not material for tax purposes as of December 31, 2022 and 2021 and therefore the entity had no significant impact on the year-end 2022 and 2021 tax provision. Generally, all expenses relating to research &amp; development that are incurred in Canada are the responsibility and owned by the United States parent company, since it is the owner of all of the Company&#8217;s intangibles.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_IncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_IncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653473099456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">[Note 12 - Subsequent Events]<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653470920112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use Of Estimates</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Management makes estimates that affect certain accounts including deferred income tax assets, accrued expenses, fair value of equity instruments and reserves for any other commitments or contingencies. Any adjustments applied to estimates are recognized in the period in which such adjustments are determined.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The COVID-19 pandemic has prompted governments and regulatory bodies throughout the world to issue &#8220;stay-at-home&#8221; or similar orders, and enact restrictions on the performance of &#8220;non-essential&#8221; services, public gatherings and travel.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it continues impact worldwide macroeconomic conditions, the emergence of variants of the virus and effectiveness of vaccines, access to capital markets, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of December 31, 2022 and through the date of the filing of this Annual Report on Form 10-K. The accounting matters assessed included, but were not limited to, estimates related to the accounting for potential liabilities and accrued expenses, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and assessments of impairment related to long-lived assets. The Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in additional material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Despite the Company&#8217;s efforts, the ultimate impact of COVID-19 on the Company&#8217;s business depends on factors beyond the Company&#8217;s knowledge or control, including the duration and severity of the outbreak, as well as third-party actions taken to contain its spread and mitigate its public health effects. As a result, the Company is unable to estimate the extent to which COVID-19 will negatively impact its financial results or liquidity.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles Of Consolidation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s consolidated financial statements include all accounts of the Company and its consolidated subsidiaries and/or entities as of reporting period ending date(s) and for the reporting period(s) then ended. All inter-company balances and transactions have been eliminated.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis Of Presentation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). These financial statements have been prepared using the accrual basis of accounting in accordance with Generally Accepted Accounting Principles (&#8220;GAAP&#8221;) of the United States.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash And Cash Equivalents</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company considers all cash on hand and in banks, including accounts in book overdraft positions, certificates of deposit and other highly-liquid investments with maturities of one year or less, when purchased, to be cash. As of December 31, 2022 and 2021, the Company had no cash equivalents. The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and periodically evaluates the credit worthiness of the financial institutions and has determined the credit exposure to be negligible.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s inventory is stated at the lower of cost or estimated net realizable value, with cost primarily determined on a weighted-average cost basis on the first-in, first-out method. The Company periodically determines whether a reserve should be taken for devaluation or obsolescence of inventory.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Capitalization Of Fixed Assets</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than one year for: (1) assets purchased; (2) existing assets that are replaced, improved or the useful lives have been extended; or (3) all land, regardless of cost. Acquisitions of new assets, additions, replacements and improvements (other than land) costing less than the minimum rule in addition to maintenance and repair costs, including any planned major maintenance activities, are expensed as incurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest period presented in the financial statements. At December 31, 2022 and 2021 the Company recorded a right of use asset of $505,816 and $643,413, respectively. At December 31, 2022 and 2021 the Company recorded a lease liability of $518,147 and $650,477, respectively. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ASU No. 2014-09, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;ASC Topic 606&#8221;) provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Under ASC Topic 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to perform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC Topic 606 did not have an impact on the Company&#8217;s operations or cash flows.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research And Development Costs</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company follows FASB Accounting Standards Codification (&#8220;ASC&#8221;) Subtopic 730-10, &#8220;Research and Development&#8221;. Research and development costs are charged to the statement of operations as incurred. During the years ended December 31, 2022 and 2021, the Company incurred $6,554,194 and $5,482,531 of expenses related to research and development costs, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Earnings (loss) Per Common Share</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company computes earnings per share under ASC Subtopic 260-10, &#8220;Earnings Per Share&#8221;. Basic earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders (the numerator) by the weighted average number of shares of common stock outstanding (the denominator) during the reporting periods. Diluted loss per share is computed by increasing the denominator by the weighted average number of additional shares that could have been outstanding from securities convertible into common stock (using the &#8220;treasury stock&#8221; method), unless their effect on net loss per share is anti-dilutive. There were 410,358 and 392,425 potentially dilutive shares, which include outstanding common stock options, and warrants, as of December 31, 2022 and 2021, respectively.</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Options to purchase common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">391,902</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">262,481</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Warrants to purchase common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,330</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">121,818</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Shares issuable upon conversion of Series A Convertible Preferred Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,126</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,126</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Potential equivalent shares excluded</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>410,358</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>392,425</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Disclosures about fair value of financial instruments require disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with ASC Topic 820, &#8220;Fair Value Measurements and Disclosures,&#8221; the Company measures certain financial instruments at fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance with accounting principles generally accepted in the United States, and expands disclosures about fair value measurements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="font-family:symbol">&#183;</span></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The carrying amounts of the Company&#8217;s financial assets and liabilities, including cash, accounts receivable, prepaid expenses, accounts payable, accrued expenses, and other current liabilities, approximate their fair values because of the short maturity of these instruments. The fair value of notes payable and convertible notes approximates their fair values since the current interest rates and terms on these obligations are the same as prevailing market rates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s 2016 Omnibus Incentive Plan (the &#8220;Omnibus Plan&#8221;) permits the grant of stock options and other share-based awards to its employees, consultants and non-employee members of the board of directors. Each January 1 the pool of shares available for issuance under the Omnibus Plan automatically increases by an amount equal to the lesser of (i) the number of shares necessary such that the aggregate number of shares available under the Omnibus Plan equals 25% of the number of fully-diluted outstanding shares on the increase date (assuming the conversion of all outstanding shares of preferred stock and other outstanding convertible securities and exercise of all outstanding options and warrants to purchase shares) and (ii) if the board of directors takes action to set a lower amount, the amount determined by the board. On January 1, 2023, the pool of shares issuable under the Omnibus Plan automatically increased by 867,966 shares from 454,204 shares to 1,322,169 shares.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company records share-based compensation in accordance with the provisions of the Share-based Compensation Topic of the FASB Codification. The guidance requires the use of option-pricing models that require the input of highly subjective assumptions, including the option&#8217;s expected life and the price volatility of the underlying stock. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option valuation model, and the resulting charge is expensed using the straight-line attribution method over the vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Stock compensation expense recognized during the period is based on the value of share-based awards that were expected to vest during the period adjusted for estimated forfeitures. The estimated fair value of grants of stock options and warrants to non-employees of the Company is charged to expense, if applicable, in the financial statements. These options vest in the same manner as the employee options granted under the stock incentive plan as described above.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Going Concern</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s financial statements are prepared using accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has limited commercial experience and had a cumulative net loss from inception to December 31, 2022 of $81,869,902. The Company had working capital of $6,822,966 as of December 31, 2022. The Company has not established an ongoing source of revenue sufficient to cover its operating costs and to allow it to continue as a going concern and will require additional financing to fund its future planned operations, including research and development and commercialization of its products. The accompanying financial statements for the year ended December 31, 2022 have been prepared assuming the Company will continue as a going concern, but the ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it establishes a revenue stream and becomes profitable. Management&#8217;s plans to continue as a going concern include raising additional capital through sales of equity securities and borrowing. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. If the Company is not able to obtain the necessary additional financing on a timely basis, the Company will be required to delay, reduce the scope of, or eliminate one or more of the Company&#8217;s research and development activities or commercialization efforts or perhaps even cease the operation of its business. The ability of the Company to continue as a going concern is dependent upon its ability to successfully secure other sources of financing and attain profitable operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company considered recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC, did not or in management&#8217;s opinion will not have a material impact on the Company&#8217;s present or future consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI https://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653476930496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule Of Anti-dilutive Shares</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Options to purchase common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">391,902</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">262,481</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Warrants to purchase common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,330</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">121,818</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Shares issuable upon conversion of Series A Convertible Preferred Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,126</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,126</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Potential equivalent shares excluded</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>410,358</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>392,425</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653473949776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule Fixed Assets</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Property, leasehold and capitalized software</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">738,720</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">605,248</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">TAEUS development and testing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">140,617</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">107,682</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accumulated depreciation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(643,682 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(581,800 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Fixed assets, net</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>235,655</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>131,130</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653473949776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accounts Payable and Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule Of Current Liabilities</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">613,961</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">791,052</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued payroll</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">60,638</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">101,459</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued bonuses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">683,738</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">396,043</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued employee benefits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,750</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,750</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Insurance premium financing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">158,925</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">117,133</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Total</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>1,523,012</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>1,411,437</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653476680848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Options and Restricted Stock Units (RSUs)(Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Common Stock Options and Restricted Stock Units (RSUs)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary Of Stock Option Activity</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Average</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercise</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Price</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Average </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Remaining </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Contractual </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Term (Years)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance outstanding at December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">262,481</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">44.17</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7.42</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">141,975</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.08</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.05</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cancelled or expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(12,554 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance outstanding at December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">391,902</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">31.47</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7.41</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercisable at December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">180,742</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">41.21</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.69</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653476975520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Common Stock Options and Restricted Stock Units (RSUs)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule Of Warrant Activity</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Warrants</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Average</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercise </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Price</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Average </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Contractual </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Term (Years)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance outstanding at December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">121,818</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">110.80</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.58</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(111,488 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">118.86</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance outstanding at December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,330</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25.01</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.78</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercisable at December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,330</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25.01</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.78</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653476680848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule Of Operating Lease Liabilities Maturities</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Operating</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Lease</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">196,721</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">202,624</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025 and beyond</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">202,624</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">601,969</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: amount representing interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(83,822 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Present value of future minimum lease payments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">518,147</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: current obligations under leases</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(152,228 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Long-term lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">365,919</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653476790720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_IncomeTaxesAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assests and liabilities</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net operating loss carryforward</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(17,251,804</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(14,200,629</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28,720</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fair value of options</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">311,958</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">346,869</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total deferred tax assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(16,939,846</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(13,825,040</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,939,846</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,825,040</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net deferred tax asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of U.S. federal statutory rate and the effective tax rate</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">U.S. federal statutory income tax</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-21.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-21.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">State tax, net of federal tax benefit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-5.80</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-5.80</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Change in valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26.80</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26.80</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Effective tax rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_IncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_IncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653470413536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential Equivalent Shares Excluded</a></td>
<td class="nump">410,358<span></span>
</td>
<td class="nump">392,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ndra_WarrantsToPurchaseCommonStockMember', window );">Warrants To Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential Equivalent Shares Excluded</a></td>
<td class="nump">10,330<span></span>
</td>
<td class="nump">121,818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ndra_SharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember', window );">Shares Issuable upon Conversion of Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential Equivalent Shares Excluded</a></td>
<td class="nump">8,126<span></span>
</td>
<td class="nump">8,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ndra_OptionsToPurchaseCommonStockMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential Equivalent Shares Excluded</a></td>
<td class="nump">391,902<span></span>
</td>
<td class="nump">262,481<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ndra_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ndra_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ndra_SharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ndra_SharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ndra_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ndra_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653470380256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">$ 518,147<span></span>
</td>
<td class="nump">$ 650,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_ResearchAndDevelopmentExpense1', window );">Research And Development</a></td>
<td class="nump">6,554,194<span></span>
</td>
<td class="nump">5,482,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right Of Use Assets</a></td>
<td class="nump">$ 505,816<span></span>
</td>
<td class="nump">$ 643,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential Equivalent Shares Excluded</a></td>
<td class="nump">410,358<span></span>
</td>
<td class="nump">392,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_SharesAvailableForIssuanceIncreasedUnderTheOmnibusPlan', window );">Shares Available For Issuance Increased Under The Omnibus Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">867,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CumulativeDividends', window );">Cumulative Net Loss</a></td>
<td class="nump">$ 81,869,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_WorkingCapital', window );">Working Capital</a></td>
<td class="nump">$ 6,822,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share based compensation, description</a></td>
<td class="text">On January 1, 2023, the pool of shares issuable under the Omnibus Plan automatically increased by 867,966 shares from 454,204 shares to 1,322,169 shares<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_ResearchAndDevelopmentExpense1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_ResearchAndDevelopmentExpense1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_SharesAvailableForIssuanceIncreasedUnderTheOmnibusPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_SharesAvailableForIssuanceIncreasedUnderTheOmnibusPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative cash dividends distributed to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653476747440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">$ 2,644,717<span></span>
</td>
<td class="nump">$ 1,284,578<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653470673216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fixed Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Leasehold And Capitalized Software</a></td>
<td class="nump">$ 738,720<span></span>
</td>
<td class="nump">$ 605,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DevelopmentInProcess', window );">Taeus Development And Testing</a></td>
<td class="nump">140,617<span></span>
</td>
<td class="nump">107,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation</a></td>
<td class="num">(643,682)<span></span>
</td>
<td class="num">(581,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed Assets, Net</a></td>
<td class="nump">$ 235,655<span></span>
</td>
<td class="nump">$ 131,130<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of expenditures for a real estate project that has not yet been completed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653476964640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation Expense</a></td>
<td class="nump">$ 96,661<span></span>
</td>
<td class="nump">$ 116,238<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653468030608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accounts Payable and Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts Payable</a></td>
<td class="nump">$ 613,961<span></span>
</td>
<td class="nump">$ 791,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued Payroll</a></td>
<td class="nump">60,638<span></span>
</td>
<td class="nump">101,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrentAndNoncurrent', window );">Accrued Bonuses</a></td>
<td class="nump">683,738<span></span>
</td>
<td class="nump">396,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued Employee Benefits</a></td>
<td class="nump">5,750<span></span>
</td>
<td class="nump">5,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedInsuranceCurrentAndNoncurrent', window );">Insurance Premium Financing</a></td>
<td class="nump">158,925<span></span>
</td>
<td class="nump">117,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">$ 1,523,012<span></span>
</td>
<td class="nump">$ 1,411,437<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInsuranceCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInsuranceCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653470640304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bank Loans (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 27, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfNotesReceivable', window );">Paycheck protection program note to first republic bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 308,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ndra_TDBankLoanMember', window );">TD Bank Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_PrincipalAggregateAmount', window );">Principal Aggregate Amount</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInitiationDate1', window );">Expiration Initial Term</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_InitialTermInterestRate', window );">Initial Term Interest Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_BankLoanDescription', window );">Bank Loan, Description</a></td>
<td class="text">Under this note no interest payments are due until January 1, 2024. Under the conditions of the loan, twenty-five percent (25%) of the loan will be forgiven if seventy-five percent (75%) is repaid prior to the initial term date<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_BankLoanDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_BankLoanDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_InitialTermInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_InitialTermInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_PrincipalAggregateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_PrincipalAggregateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInitiationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the credit facility first became available, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInitiationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ndra_TDBankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ndra_TDBankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653467385120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 21, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnitsAuthorized', window );">Capital Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock Shares, Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock Shares, Par Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,169,103<span></span>
</td>
<td class="nump">2,127,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock Shares, Par Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_PreferredStockSharesUndesignated', window );">Preferred stock shares, undesignated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,889,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_StockPayableShare', window );">Stock Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_CommonStockSharesUponWarratExerciseShares', window );">Common Stock Shares Upon Warrant Exercise, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_CommonStockSharesUponWarrantExerciseAmount', window );">Common Stock Shares Upon Warrant Exercise, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,785,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_CommonStockSharesUponCashlessWarrantExercise', window );">Common stock shares upon cashless warrant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_CommonStockSharesUponCashlessOptionExercise', window );">Common Stock Shares Upon Cashless Option Exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_SharesForServicesValue', window );">Shares For Services Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_CommonStockSharesUponVestingOfRestrictedUnits', window );">Common stock shares upon vesting of restricted units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_CommonStockServicesValued', window );">Common stock services valued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_RestictedStockUnitsValued', window );">Resticted stock units valued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_SharesInReturn', window );">Shares in return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,399,512<span></span>
</td>
<td class="nump">$ 10,615,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_TotalCommonStockSharesIssued', window );">Total Common Stock Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,041,377<span></span>
</td>
<td class="nump">425,241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ndra_JuneTwentyTwentyOneATMAgreementMember', window );">June 2021 ATM Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,064,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_TotalCommonStockSharesIssued', window );">Total Common Stock Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,041,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock Based Compensation</a></td>
<td class="nump">$ 286,289<span></span>
</td>
<td class="nump">$ 260,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_NetProceedsFromSalesOfCommonStock3', window );">Net Proceeds From Sales Of Common Stock</a></td>
<td class="nump">8,398,936<span></span>
</td>
<td class="nump">$ 9,216,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_GrossProceedsFromSalesOfCommonStock', window );">Gross Proceeds From Sales Of Common Stock</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock Shares, Par Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion Of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_ConversionOfCommonStockIntoPreferredStock', window );">Conversion Of Common Stock Into Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock Shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock Shares, Par Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock Shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock Shares, Par Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock Shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_CommonStockServicesValued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_CommonStockServicesValued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_CommonStockSharesUponCashlessOptionExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_CommonStockSharesUponCashlessOptionExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_CommonStockSharesUponCashlessWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_CommonStockSharesUponCashlessWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_CommonStockSharesUponVestingOfRestrictedUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_CommonStockSharesUponVestingOfRestrictedUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_CommonStockSharesUponWarrantExerciseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_CommonStockSharesUponWarrantExerciseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_CommonStockSharesUponWarratExerciseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_CommonStockSharesUponWarratExerciseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_ConversionOfCommonStockIntoPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_ConversionOfCommonStockIntoPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_GrossProceedsFromSalesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_GrossProceedsFromSalesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_NetProceedsFromSalesOfCommonStock3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_NetProceedsFromSalesOfCommonStock3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_PreferredStockSharesUndesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_PreferredStockSharesUndesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_RestictedStockUnitsValued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_RestictedStockUnitsValued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_SharesForServicesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_SharesForServicesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_SharesInReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_SharesInReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_StockPayableShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_StockPayableShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_TotalCommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_TotalCommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.16(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ndra_JuneTwentyTwentyOneATMAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ndra_JuneTwentyTwentyOneATMAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653467811040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Options and Restricted Stock Units (RSUs) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Common Stock Options and Restricted Stock Units (RSUs)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number Of Options Outstanding, Beginning | shares</a></td>
<td class="nump">262,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number Of Options Granted | shares</a></td>
<td class="nump">141,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Number Of Options, Forfeited | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number Of Options Cancelled Or Expired | shares</a></td>
<td class="num">(12,554)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number Of Options Outstanding, Ending | shares</a></td>
<td class="nump">391,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Of Options Outstanding, Exercisable | shares</a></td>
<td class="nump">180,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Beginning</a></td>
<td class="nump">$ 44.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">8.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeited</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Cancelled Or Expired</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Ending</a></td>
<td class="nump">31.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Exercisable</a></td>
<td class="nump">$ 41.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term Outstanding, Beginning</a></td>
<td class="text">7 years 5 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term Outstanding, Granted</a></td>
<td class="text">9 years 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term Outstanding, Ending</a></td>
<td class="text">7 years 4 months 28 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term Outstanding, Exercisable</a></td>
<td class="text">5 years 8 months 8 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653467230032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Options and Restricted Stock Units (RSUs) (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_AggregateFairValueOfStockOptionsGranted', window );">Aggregate Fair Value Of Stock Options Granted</a></td>
<td class="nump">$ 919,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Discount Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_ExpectedDividendYield', window );">Expected Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility Rate</a></td>
<td class="nump">74.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Rate</a></td>
<td class="nump">1.37%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Life</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility Rate</a></td>
<td class="nump">99.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Rate</a></td>
<td class="nump">4.36%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_AggregateFairValueOfStockOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_AggregateFairValueOfStockOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_ExpectedDividendYield">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_ExpectedDividendYield</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653467356032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants (Details) - Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance Outstanding, Beginning | shares</a></td>
<td class="nump">121,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod', window );">Expired | shares</a></td>
<td class="num">(111,488)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_NumberOfWarrantsExercisable', window );">Number of Warrants exercisable | shares</a></td>
<td class="nump">10,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_NumberOfWarrantsEndingBalance', window );">Number of Warrants ending balance | shares</a></td>
<td class="nump">10,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Beginning</a></td>
<td class="nump">$ 110.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeited</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Expired</a></td>
<td class="nump">118.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_WeightedAverageExercisePriceOutstanding', window );">Weighted Average Exercise Price outstanding</a></td>
<td class="nump">25.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_WeightedAverageExercisableAtJune302022', window );">Weighted Average Exercisable at June 30, 2022</a></td>
<td class="nump">$ 25.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning', window );">Weighted Average Remaining Contractual Term Outstanding, Beginning</a></td>
<td class="text">6 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding', window );">Weighted Average Remaining Contractual Term Outstanding, Ending</a></td>
<td class="text">1 year 9 months 10 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermExercisable', window );">Weighted Average Remaining Contractual Term Outstanding, Exercisable</a></td>
<td class="text">1 year 9 months 10 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_NumberOfWarrantsEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_NumberOfWarrantsEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_NumberOfWarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_NumberOfWarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_WeightedAverageExercisableAtJune302022">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_WeightedAverageExercisableAtJune302022</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_WeightedAverageExercisePriceOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_WeightedAverageExercisePriceOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ndra_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ndra_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653468070112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 196,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">202,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">2025 And Beyond</a></td>
<td class="nump">202,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">601,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Amount Representing Interest</a></td>
<td class="num">(83,822)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present Value Of Future Minimum Lease Payments</a></td>
<td class="nump">518,147<span></span>
</td>
<td class="nump">$ 650,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current Obligations Under Lease</a></td>
<td class="num">(152,228)<span></span>
</td>
<td class="num">(132,330)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term Lease Obligations</a></td>
<td class="nump">$ 365,919<span></span>
</td>
<td class="nump">$ 518,147<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653467894544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 15, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Oct. 10, 2017 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>May 12, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 28, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 15, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_RentExpenses', window );">Rent Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213,912<span></span>
</td>
<td class="nump">$ 178,620<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=ndra_JanuaryOneTwentyFifteenMember', window );">January 1, 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_RentSpace', window );">Rent Space | ft&#178;</a></td>
<td class="nump">3,248<span></span>
</td>
<td class="nump">3,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_MonthlyRent', window );">Monthly Rent</a></td>
<td class="nump">$ 15,452<span></span>
</td>
<td class="nump">$ 7,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_RentTerm', window );">Rent Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Office Lease, Description</a></td>
<td class="text">On March 15, 2021, the Company entered into an amendment to the lease, adding approximately 3,248 rentable square feet, increasing the initial monthly rent to $15,452 effective May 2021, and extending the term of the lease to December 31, 2025<span></span>
</td>
<td class="text">On October 10, 2017 this lease was amended increasing the rentable square feet of space to 3,950 and the monthly rent to $7,798. On July 16, 2019, the Company exercised its option to extend the lease for an additional 5 years past the initial term originally expiring on December 31, 2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Expiration Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">Dec. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_WeightedAverageRemainingLeaseTerm', window );">Weighted-average Remaining Lease Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_OperatingLeaseDiscountRate', window );">Operating Lease Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ndra_EmploymentAgreementsMember', window );">Employment Agreements [Member] | Michael Thornton [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Annual Basic Salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 289,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 324,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_DescriptionOfEmploymentTerminationTerm', window );">Description Of Employment Termination Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mr. Thornton will be entitled to receive 12 months&#8217; continuation of his current base salary and a lump sum payment equal to 12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_EmploymentAgreementDescription', window );">Employment Agreement, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">to vest within 12 months will automatically vest, and upon termination without cause within 12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ndra_EmploymentAgreementsMember', window );">Employment Agreements [Member] | Francois Michelon [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Annual Basic Salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 376,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">423,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_DescriptionOfEmploymentTerminationTerm', window );">Description Of Employment Termination Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">to receive 12 months&#8217; continuation of his current base salary and a lump sum payment equal to 12 months of continued healthcare coverage (or 24 months&#8217; continuation of his current base salary and a lump sum payment equal to 24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_EmploymentAgreementDescription', window );">Employment Agreement, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vest within 12 months will automatically vest, and upon termination without cause within 12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ndra_EmploymentgreementsMember', window );">Employment Agreements [Member] | Renaud Maloberti [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Annual Basic Salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 266,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_ExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_StockOptionGranted', window );">Stock option granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_DescriptionOfEmploymentTerminationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_DescriptionOfEmploymentTerminationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_EmploymentAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_EmploymentAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_MonthlyRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_MonthlyRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_OperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_OperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_RentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_RentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_RentSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_RentSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_RentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_RentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_StockOptionGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_StockOptionGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_WeightedAverageRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_WeightedAverageRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=ndra_JanuaryOneTwentyFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=ndra_JanuaryOneTwentyFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ndra_EmploymentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ndra_EmploymentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ndra_MichaelThorntonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ndra_MichaelThorntonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ndra_FrancoisMichelonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ndra_FrancoisMichelonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ndra_EmploymentgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ndra_EmploymentgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ndra_RenaudMalobertiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ndra_RenaudMalobertiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653467648944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_IncomeTaxesAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="num">$ (17,251,804)<span></span>
</td>
<td class="num">$ (14,200,629)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_StockBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">28,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_FairValueOfOptions', window );">Fair value of options</a></td>
<td class="nump">311,958<span></span>
</td>
<td class="nump">346,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="num">(16,939,846)<span></span>
</td>
<td class="num">(13,825,040)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">16,939,846<span></span>
</td>
<td class="nump">13,825,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_FairValueOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_FairValueOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_IncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_IncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_StockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_StockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653467646704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 1)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_IncomeTaxesAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory income tax</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal tax benefit</a></td>
<td class="num">(5.80%)<span></span>
</td>
<td class="num">(5.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">26.80%<span></span>
</td>
<td class="nump">26.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_IncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_IncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139653476785136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details narrative)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_IncomeTaxesAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 65.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ndra_NetOperatingLossCarryforwardBegainToExpire', window );">Net operating loss carryforward begain to expire</a></td>
<td class="nump">$ 16.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_IncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_IncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ndra_NetOperatingLossCarryforwardBegainToExpire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ndra_NetOperatingLossCarryforwardBegainToExpire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ndra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>ndra_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:ndra="http://novaworks.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ndra-20221231.xsd" xlink:type="simple"/>
    <context id="From2022-01-01to2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_ndra_JanuaryOneTwentyFifteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ndra:JanuaryOneTwentyFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-03-01to2021-03-15_ndra_JanuaryOneTwentyFifteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ndra:JanuaryOneTwentyFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-15</endDate>
        </period>
    </context>
    <context id="From2017-10-01to2017-10-10_ndra_JanuaryOneTwentyFifteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ndra:JanuaryOneTwentyFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-10</endDate>
        </period>
    </context>
    <context id="From2019-04-01to2019-04-28_ndra_EmploymentgreementsMember_ndra_RenaudMalobertiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ndra:EmploymentgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ndra:RenaudMalobertiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-28</endDate>
        </period>
    </context>
    <context id="AsOf2019-04-28_ndra_EmploymentgreementsMember_ndra_RenaudMalobertiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ndra:EmploymentgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ndra:RenaudMalobertiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-28</instant>
        </period>
    </context>
    <context id="From2019-04-01to2019-04-15_ndra_EmploymentAgreementsMember_ndra_MichaelThorntonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ndra:EmploymentAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ndra:MichaelThorntonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-15</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_ndra_EmploymentgreementsMember_ndra_RenaudMalobertiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ndra:EmploymentgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ndra:RenaudMalobertiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2019-04-01to2019-04-15_ndra_EmploymentgreementsMember_ndra_RenaudMalobertiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ndra:EmploymentgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ndra:RenaudMalobertiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-15</endDate>
        </period>
    </context>
    <context id="From2017-05-01to2017-05-12_ndra_EmploymentAgreementsMember_ndra_FrancoisMichelonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ndra:EmploymentAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ndra:FrancoisMichelonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-12</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_ndra_EmploymentAgreementsMember_ndra_FrancoisMichelonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ndra:EmploymentAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ndra:FrancoisMichelonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_ndra_EmploymentAgreementsMember_ndra_MichaelThorntonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ndra:EmploymentAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ndra:MichaelThorntonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2017-05-01to2017-05-12_ndra_EmploymentAgreementsMember_ndra_MichaelThorntonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ndra:EmploymentAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ndra:MichaelThorntonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-12</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_ndra_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ndra:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_ndra_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ndra:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-06-01to2021-06-21_ndra_JuneTwentyTwentyOneATMAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ndra:JuneTwentyTwentyOneATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_ndra_JuneTwentyTwentyOneATMAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ndra:JuneTwentyTwentyOneATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_ndra_JuneTwentyTwentyOneATMAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ndra:JuneTwentyTwentyOneATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2020-04-01to2020-04-27_ndra_TDBankLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ndra:TDBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-27</endDate>
        </period>
    </context>
    <context id="AsOf2020-04-27_ndra_TDBankLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ndra:TDBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-27</instant>
        </period>
    </context>
    <context id="AsOf2023-01-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_ndra_SharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ndra:SharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_ndra_SharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ndra:SharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_ndra_WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ndra:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_ndra_WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ndra:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_ndra_OptionsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ndra:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_ndra_OptionsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ndra:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_ndra_StockPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:StockPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_ndra_SeriesBPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:SeriesBPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_ndra_PreferredsStockSeriesAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:PreferredsStockSeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_ndra_StockPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:StockPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_ndra_SeriesBPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:SeriesBPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_ndra_PreferredsStockSeriesAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:PreferredsStockSeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_ndra_StockPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:StockPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_ndra_SeriesBPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:SeriesBPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_ndra_PreferredsStockSeriesAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:PreferredsStockSeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_ndra_StockPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:StockPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_ndra_SeriesBPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:SeriesBPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_ndra_PreferredsStockSeriesAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:PreferredsStockSeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_ndra_StockPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:StockPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_ndra_SeriesBPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:SeriesBPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_ndra_PreferredsStockSeriesAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ndra:PreferredsStockSeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
        </entity>
        <period>
            <instant>2023-03-10</instant>
        </period>
    </context>
    <context id="AsOf2023-03-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001681682</identifier>
        </entity>
        <period>
            <instant>2023-03-16</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="CAD">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-01-01to2022-12-31">0001681682</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-01-01to2022-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-01-01to2022-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-01-01to2022-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2022-01-01to2022-12-31">2022</dei:DocumentFiscalYearFocus>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="0" unitRef="Shares">80000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="0" unitRef="Shares">3169103</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="0" unitRef="Shares">2127725</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31_us-gaap_PreferredClassAMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31_us-gaap_PreferredClassBMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2021-12-31_us-gaap_PreferredClassAMember"
      decimals="0"
      unitRef="Shares">10000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2021-12-31_us-gaap_PreferredClassBMember"
      decimals="0"
      unitRef="Shares">1000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-12-31_us-gaap_PreferredClassBMember"
      decimals="0"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_PreferredClassBMember"
      decimals="0"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-12-31_us-gaap_PreferredClassAMember"
      decimals="0"
      unitRef="Shares">141397</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredClassAMember"
      decimals="0"
      unitRef="Shares">141397</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredClassAMember"
      decimals="0"
      unitRef="Shares">141397</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredClassBMember"
      decimals="0"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredClassBMember"
      decimals="0"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2022-01-01to2022-12-31">[Note 12 - Subsequent Events]</us-gaap:SubsequentEventsTextBlock>
    <ndra:SharesAvailableForIssuanceIncreasedUnderTheOmnibusPlan contextRef="AsOf2023-01-01" decimals="0" unitRef="Shares">867966</ndra:SharesAvailableForIssuanceIncreasedUnderTheOmnibusPlan>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      unitRef="Shares">10000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="0" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      unitRef="Shares">141</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      unitRef="Shares">141</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      unitRef="Shares">141</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2021-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      unitRef="Shares">100000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      unitRef="Shares">1000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <ndra:ExpectedDividendYield
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0</ndra:ExpectedDividendYield>
    <ndra:RentSpace
      contextRef="From2017-10-01to2017-10-10_ndra_JanuaryOneTwentyFifteenMember"
      decimals="INF"
      unitRef="sqft">3950</ndra:RentSpace>
    <ndra:RentSpace
      contextRef="From2021-03-01to2021-03-15_ndra_JanuaryOneTwentyFifteenMember"
      decimals="INF"
      unitRef="sqft">3248</ndra:RentSpace>
    <ndra:MonthlyRent
      contextRef="From2017-10-01to2017-10-10_ndra_JanuaryOneTwentyFifteenMember"
      decimals="0"
      unitRef="USD">7798</ndra:MonthlyRent>
    <ndra:MonthlyRent
      contextRef="From2021-03-01to2021-03-15_ndra_JanuaryOneTwentyFifteenMember"
      decimals="0"
      unitRef="USD">15452</ndra:MonthlyRent>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2017-10-01to2017-10-10_ndra_JanuaryOneTwentyFifteenMember">2019-12-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-03-01to2021-03-15_ndra_JanuaryOneTwentyFifteenMember">2025-12-31</us-gaap:DebtInstrumentMaturityDate>
    <ndra:WeightedAverageRemainingLeaseTerm contextRef="From2022-01-01to2022-12-31_ndra_JanuaryOneTwentyFifteenMember">P3Y</ndra:WeightedAverageRemainingLeaseTerm>
    <dei:DocumentType contextRef="From2022-01-01to2022-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2022-01-01to2022-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-01-01to2022-12-31">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2022-01-01to2022-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-01-01to2022-12-31">001-37969</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-01-01to2022-12-31">ENDRA Life Sciences Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-01-01to2022-12-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-01-01to2022-12-31">26-0579295</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-01-01to2022-12-31">3600 Green Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-01-01to2022-12-31">Suite 350</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-01-01to2022-12-31">Ann Arbor</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-01-01to2022-12-31">MI</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-01-01to2022-12-31">48105-1570</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-01-01to2022-12-31">734</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-01-01to2022-12-31">335-0468</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-01-01to2022-12-31">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-01-01to2022-12-31">NDRA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-01-01to2022-12-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2022-01-01to2022-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2022-01-01to2022-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-01-01to2022-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-01-01to2022-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-01-01to2022-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2022-01-01to2022-12-31">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="From2022-01-01to2022-12-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="AsOf2023-03-16" decimals="0" unitRef="USD">15628360</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-03-10" decimals="INF" unitRef="Shares">3169103</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="From2022-01-01to2022-12-31">587</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2022-01-01to2022-12-31">RBSM LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2022-01-01to2022-12-31">New York, NY</dei:AuditorLocation>
    <us-gaap:Cash
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_1"
      unitRef="USD">4889098</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_2"
      unitRef="USD">9461534</us-gaap:Cash>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_3"
      unitRef="USD">992875</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_4"
      unitRef="USD">1348003</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:InventoryNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_5"
      unitRef="USD">2644717</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_6"
      unitRef="USD">1284578</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_7"
      unitRef="USD">8526690</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_8"
      unitRef="USD">12094115</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_10"
      unitRef="USD">235655</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_11"
      unitRef="USD">131130</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_12"
      unitRef="USD">505816</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_13"
      unitRef="USD">643413</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_14"
      unitRef="USD">5986</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_15"
      unitRef="USD">5986</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_16"
      unitRef="USD">9274147</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_17"
      unitRef="USD">12874644</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_20"
      unitRef="USD">1523012</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_21"
      unitRef="USD">1411437</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_22"
      unitRef="USD">152228</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_23"
      unitRef="USD">132330</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LoansPayable
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_24"
      unitRef="USD">28484</us-gaap:LoansPayable>
    <us-gaap:LoansPayable
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_25"
      unitRef="USD">0</us-gaap:LoansPayable>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_26"
      unitRef="USD">1703724</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_27"
      unitRef="USD">1543767</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermLoansPayable
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_29"
      unitRef="USD">0</us-gaap:LongTermLoansPayable>
    <us-gaap:LongTermLoansPayable
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_30"
      unitRef="USD">28484</us-gaap:LongTermLoansPayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_31"
      unitRef="USD">365919</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_32"
      unitRef="USD">518147</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebt
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_33"
      unitRef="USD">365919</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_34"
      unitRef="USD">546631</us-gaap:LongTermDebt>
    <us-gaap:Liabilities
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_35"
      unitRef="USD">2069643</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_36"
      unitRef="USD">2090398</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_PreferredClassAMember"
      decimals="INF"
      id="fid_66"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_PreferredClassAMember"
      decimals="0"
      id="fid_70"
      unitRef="Shares">10000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_PreferredClassAMember"
      decimals="0"
      id="fid_74"
      unitRef="Shares">141397</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="fid_38"
      unitRef="USD">1</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="fid_54"
      unitRef="USD">1</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_PreferredClassBMember"
      decimals="INF"
      id="fid_67"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_PreferredClassBMember"
      decimals="0"
      id="fid_71"
      unitRef="Shares">1000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="fid_40"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="fid_41"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="fid_56"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_59"
      unitRef="Shares">80000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_60"
      unitRef="Shares">3169103</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_61"
      unitRef="Shares">2127725</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_42"
      unitRef="USD">317</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_43"
      unitRef="USD">212</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_44"
      unitRef="USD">89068015</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_45"
      unitRef="USD">79460980</us-gaap:AdditionalPaidInCapital>
    <ndra:StockPayable
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_46"
      unitRef="USD">6073</ndra:StockPayable>
    <ndra:StockPayable
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_47"
      unitRef="USD">13863</ndra:StockPayable>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_48"
      unitRef="USD">-81869902</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_49"
      unitRef="USD">-68690810</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_50"
      unitRef="USD">7204504</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_51"
      unitRef="USD">10784246</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_52"
      unitRef="USD">9274147</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_53"
      unitRef="USD">12874644</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_81"
      unitRef="USD">6554194</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_82"
      unitRef="USD">5482531</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_83"
      unitRef="USD">1429150</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_84"
      unitRef="USD">1075376</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_85"
      unitRef="USD">5174215</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_86"
      unitRef="USD">4940398</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_87"
      unitRef="USD">13157559</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_88"
      unitRef="USD">11498305</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_89"
      unitRef="USD">-13157559</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_90"
      unitRef="USD">-11498305</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_92"
      unitRef="USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_93"
      unitRef="USD">-308600</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_94"
      unitRef="USD">-21533</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_95"
      unitRef="USD">-41545</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_96"
      unitRef="USD">-21533</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_97"
      unitRef="USD">267055</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_98"
      unitRef="USD">-13179092</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_99"
      unitRef="USD">-11231250</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_100"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_101"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_102"
      unitRef="USD">-13179092</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_103"
      unitRef="USD">-11231250</us-gaap:NetIncomeLoss>
    <us-gaap:Dividends
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_104"
      unitRef="USD">0</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_105"
      unitRef="USD">121071</us-gaap:Dividends>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_106"
      unitRef="USD">-13179092</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_107"
      unitRef="USD">-11352321</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      id="fid_108"
      unitRef="USDPShares">-4.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="fid_109"
      unitRef="USDPShares">-5.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_110"
      unitRef="Shares">2891292</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_111"
      unitRef="Shares">2046135</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:SharesIssued
      contextRef="AsOf2020-12-31_ndra_PreferredsStockSeriesAMember"
      decimals="0"
      id="fid_171"
      unitRef="Shares">196</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_ndra_PreferredsStockSeriesAMember"
      decimals="0"
      id="fid_174"
      unitRef="USD">1</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_ndra_SeriesBPreferredStocksMember"
      decimals="0"
      id="fid_175"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_173"
      unitRef="Shares">1702485</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_176"
      unitRef="USD">170</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_177"
      unitRef="USD">64496845</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_ndra_StockPayableMember"
      decimals="0"
      id="fid_178"
      unitRef="USD">10795</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_179"
      unitRef="USD">-57338489</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_180"
      unitRef="USD">7169322</us-gaap:StockholdersEquity>
    <ndra:SeriesAConvertiblePreferredStockConvertedToCommonStockShares
      contextRef="From2021-01-01to2021-12-31_ndra_PreferredsStockSeriesAMember"
      decimals="0"
      id="fid_181"
      unitRef="Shares">-55</ndra:SeriesAConvertiblePreferredStockConvertedToCommonStockShares>
    <ndra:SeriesAConvertiblePreferredStockConvertedToCommonStockAmount
      contextRef="From2021-01-01to2021-12-31_ndra_PreferredsStockSeriesAMember"
      decimals="0"
      id="fid_184"
      unitRef="USD">0</ndra:SeriesAConvertiblePreferredStockConvertedToCommonStockAmount>
    <ndra:SeriesAConvertiblePreferredStockConvertedToCommonStockAmount
      contextRef="From2021-01-01to2021-12-31_ndra_SeriesBPreferredStocksMember"
      decimals="0"
      id="fid_185"
      unitRef="USD">0</ndra:SeriesAConvertiblePreferredStockConvertedToCommonStockAmount>
    <ndra:SeriesAConvertiblePreferredStockConvertedToCommonStockShares
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_183"
      unitRef="Shares">3394</ndra:SeriesAConvertiblePreferredStockConvertedToCommonStockShares>
    <ndra:SeriesAConvertiblePreferredStockConvertedToCommonStockAmount
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_186"
      unitRef="USD">0</ndra:SeriesAConvertiblePreferredStockConvertedToCommonStockAmount>
    <ndra:SeriesAConvertiblePreferredStockConvertedToCommonStockAmount
      contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_187"
      unitRef="USD">0</ndra:SeriesAConvertiblePreferredStockConvertedToCommonStockAmount>
    <ndra:SeriesAConvertiblePreferredStockConvertedToCommonStockAmount
      contextRef="From2021-01-01to2021-12-31_ndra_StockPayableMember"
      decimals="0"
      id="fid_188"
      unitRef="USD">0</ndra:SeriesAConvertiblePreferredStockConvertedToCommonStockAmount>
    <ndra:SeriesAConvertiblePreferredStockConvertedToCommonStockAmount
      contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_189"
      unitRef="USD">0</ndra:SeriesAConvertiblePreferredStockConvertedToCommonStockAmount>
    <ndra:SeriesAConvertiblePreferredStockConvertedToCommonStockAmount
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_190"
      unitRef="USD">0</ndra:SeriesAConvertiblePreferredStockConvertedToCommonStockAmount>
    <ndra:CommonStockIssuedForCashNetOfFundingCostsAmount
      contextRef="From2021-01-01to2021-12-31_ndra_PreferredsStockSeriesAMember"
      decimals="0"
      id="fid_194"
      unitRef="USD">0</ndra:CommonStockIssuedForCashNetOfFundingCostsAmount>
    <ndra:CommonStockIssuedForCashNetOfFundingCostsAmount
      contextRef="From2021-01-01to2021-12-31_ndra_SeriesBPreferredStocksMember"
      decimals="0"
      id="fid_195"
      unitRef="USD">0</ndra:CommonStockIssuedForCashNetOfFundingCostsAmount>
    <ndra:CommonStockIssuedForCashNetOfFundingCostsShares
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_193"
      unitRef="Shares">229348</ndra:CommonStockIssuedForCashNetOfFundingCostsShares>
    <ndra:CommonStockIssuedForCashNetOfFundingCostsAmount
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_196"
      unitRef="USD">23</ndra:CommonStockIssuedForCashNetOfFundingCostsAmount>
    <ndra:CommonStockIssuedForCashNetOfFundingCostsAmount
      contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_197"
      unitRef="USD">10615952</ndra:CommonStockIssuedForCashNetOfFundingCostsAmount>
    <ndra:CommonStockIssuedForCashNetOfFundingCostsAmount
      contextRef="From2021-01-01to2021-12-31_ndra_StockPayableMember"
      decimals="0"
      id="fid_198"
      unitRef="USD">0</ndra:CommonStockIssuedForCashNetOfFundingCostsAmount>
    <ndra:CommonStockIssuedForCashNetOfFundingCostsAmount
      contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_199"
      unitRef="USD">0</ndra:CommonStockIssuedForCashNetOfFundingCostsAmount>
    <ndra:CommonStockIssuedForCashNetOfFundingCostsAmount
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_200"
      unitRef="USD">10615975</ndra:CommonStockIssuedForCashNetOfFundingCostsAmount>
    <ndra:CommonStockIssuedForWarrantExerciseAmount
      contextRef="From2021-01-01to2021-12-31_ndra_PreferredsStockSeriesAMember"
      decimals="0"
      id="fid_204"
      unitRef="USD">0</ndra:CommonStockIssuedForWarrantExerciseAmount>
    <ndra:CommonStockIssuedForWarrantExerciseAmount
      contextRef="From2021-01-01to2021-12-31_ndra_SeriesBPreferredStocksMember"
      decimals="0"
      id="fid_205"
      unitRef="USD">0</ndra:CommonStockIssuedForWarrantExerciseAmount>
    <ndra:CommonStockIssuedForWarrantExerciseShares
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_203"
      unitRef="Shares">188540</ndra:CommonStockIssuedForWarrantExerciseShares>
    <ndra:CommonStockIssuedForWarrantExerciseAmount
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_206"
      unitRef="USD">19</ndra:CommonStockIssuedForWarrantExerciseAmount>
    <ndra:CommonStockIssuedForWarrantExerciseAmount
      contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_207"
      unitRef="USD">2785608</ndra:CommonStockIssuedForWarrantExerciseAmount>
    <ndra:CommonStockIssuedForWarrantExerciseAmount
      contextRef="From2021-01-01to2021-12-31_ndra_StockPayableMember"
      decimals="0"
      id="fid_208"
      unitRef="USD">0</ndra:CommonStockIssuedForWarrantExerciseAmount>
    <ndra:CommonStockIssuedForWarrantExerciseAmount
      contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_209"
      unitRef="USD">0</ndra:CommonStockIssuedForWarrantExerciseAmount>
    <ndra:CommonStockIssuedForWarrantExerciseAmount
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_210"
      unitRef="USD">2785627</ndra:CommonStockIssuedForWarrantExerciseAmount>
    <ndra:CommonStockIssuedForOptionExerciseAmount
      contextRef="From2021-01-01to2021-12-31_ndra_PreferredsStockSeriesAMember"
      decimals="0"
      id="fid_214"
      unitRef="USD">0</ndra:CommonStockIssuedForOptionExerciseAmount>
    <ndra:CommonStockIssuedForOptionExerciseAmount
      contextRef="From2021-01-01to2021-12-31_ndra_SeriesBPreferredStocksMember"
      decimals="0"
      id="fid_215"
      unitRef="USD">0</ndra:CommonStockIssuedForOptionExerciseAmount>
    <ndra:CommonStockIssuedForOptionExerciseShares
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_213"
      unitRef="Shares">1192</ndra:CommonStockIssuedForOptionExerciseShares>
    <ndra:CommonStockIssuedForOptionExerciseAmount
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_216"
      unitRef="USD">0</ndra:CommonStockIssuedForOptionExerciseAmount>
    <ndra:CommonStockIssuedForOptionExerciseAmount
      contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_217"
      unitRef="USD">0</ndra:CommonStockIssuedForOptionExerciseAmount>
    <ndra:CommonStockIssuedForOptionExerciseAmount
      contextRef="From2021-01-01to2021-12-31_ndra_StockPayableMember"
      decimals="0"
      id="fid_218"
      unitRef="USD">0</ndra:CommonStockIssuedForOptionExerciseAmount>
    <ndra:CommonStockIssuedForOptionExerciseAmount
      contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_219"
      unitRef="USD">0</ndra:CommonStockIssuedForOptionExerciseAmount>
    <ndra:CommonStockIssuedForOptionExerciseAmount
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_220"
      unitRef="USD">0</ndra:CommonStockIssuedForOptionExerciseAmount>
    <ndra:FairValueOfVestedStockOptions
      contextRef="From2021-01-01to2021-12-31_ndra_PreferredsStockSeriesAMember"
      decimals="0"
      id="fid_221"
      unitRef="USD">0</ndra:FairValueOfVestedStockOptions>
    <ndra:FairValueOfVestedStockOptions
      contextRef="From2021-01-01to2021-12-31_ndra_SeriesBPreferredStocksMember"
      decimals="0"
      id="fid_222"
      unitRef="USD">0</ndra:FairValueOfVestedStockOptions>
    <ndra:FairValueOfVestedStockOptions
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_223"
      unitRef="USD">0</ndra:FairValueOfVestedStockOptions>
    <ndra:FairValueOfVestedStockOptions
      contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_224"
      unitRef="USD">1334112</ndra:FairValueOfVestedStockOptions>
    <ndra:FairValueOfVestedStockOptions
      contextRef="From2021-01-01to2021-12-31_ndra_StockPayableMember"
      decimals="0"
      id="fid_225"
      unitRef="USD">0</ndra:FairValueOfVestedStockOptions>
    <ndra:FairValueOfVestedStockOptions
      contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_226"
      unitRef="USD">0</ndra:FairValueOfVestedStockOptions>
    <ndra:FairValueOfVestedStockOptions
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_227"
      unitRef="USD">1334112</ndra:FairValueOfVestedStockOptions>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-01-01to2021-12-31_ndra_PreferredsStockSeriesAMember"
      decimals="0"
      id="fid_228"
      unitRef="USD">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-01-01to2021-12-31_ndra_SeriesBPreferredStocksMember"
      decimals="0"
      id="fid_229"
      unitRef="USD">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_230"
      unitRef="USD">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_231"
      unitRef="USD">3068</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-01-01to2021-12-31_ndra_StockPayableMember"
      decimals="0"
      id="fid_232"
      unitRef="USD">3068</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_233"
      unitRef="USD">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_234"
      unitRef="USD">0</us-gaap:DividendsPreferredStock>
    <ndra:CommonStockIssuedForServicesAmount
      contextRef="From2021-01-01to2021-12-31_ndra_PreferredsStockSeriesAMember"
      decimals="0"
      id="fid_238"
      unitRef="USD">0</ndra:CommonStockIssuedForServicesAmount>
    <ndra:CommonStockIssuedForServicesAmount
      contextRef="From2021-01-01to2021-12-31_ndra_SeriesBPreferredStocksMember"
      decimals="0"
      id="fid_239"
      unitRef="USD">0</ndra:CommonStockIssuedForServicesAmount>
    <ndra:CommonStockIssuedForServicesShares
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_237"
      unitRef="Shares">1626</ndra:CommonStockIssuedForServicesShares>
    <ndra:CommonStockIssuedForServicesAmount
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_240"
      unitRef="USD">0</ndra:CommonStockIssuedForServicesAmount>
    <ndra:CommonStockIssuedForServicesAmount
      contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_241"
      unitRef="USD">74000</ndra:CommonStockIssuedForServicesAmount>
    <ndra:CommonStockIssuedForServicesAmount
      contextRef="From2021-01-01to2021-12-31_ndra_StockPayableMember"
      decimals="0"
      id="fid_242"
      unitRef="USD">0</ndra:CommonStockIssuedForServicesAmount>
    <ndra:CommonStockIssuedForServicesAmount
      contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_243"
      unitRef="USD">0</ndra:CommonStockIssuedForServicesAmount>
    <ndra:CommonStockIssuedForServicesAmount
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_244"
      unitRef="USD">74000</ndra:CommonStockIssuedForServicesAmount>
    <ndra:StockIssuedForRsuAmount
      contextRef="From2021-01-01to2021-12-31_ndra_PreferredsStockSeriesAMember"
      decimals="0"
      id="fid_248"
      unitRef="USD">0</ndra:StockIssuedForRsuAmount>
    <ndra:StockIssuedForRsuAmount
      contextRef="From2021-01-01to2021-12-31_ndra_SeriesBPreferredStocksMember"
      decimals="0"
      id="fid_249"
      unitRef="USD">0</ndra:StockIssuedForRsuAmount>
    <ndra:StockIssuedForRsuShares
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_247"
      unitRef="Shares">1141</ndra:StockIssuedForRsuShares>
    <ndra:StockIssuedForRsuAmount
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_250"
      unitRef="USD">0</ndra:StockIssuedForRsuAmount>
    <ndra:StockIssuedForRsuAmount
      contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_251"
      unitRef="USD">36460</ndra:StockIssuedForRsuAmount>
    <ndra:StockIssuedForRsuAmount
      contextRef="From2021-01-01to2021-12-31_ndra_StockPayableMember"
      decimals="0"
      id="fid_252"
      unitRef="USD">0</ndra:StockIssuedForRsuAmount>
    <ndra:StockIssuedForRsuAmount
      contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_253"
      unitRef="USD">0</ndra:StockIssuedForRsuAmount>
    <ndra:StockIssuedForRsuAmount
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_254"
      unitRef="USD">36460</ndra:StockIssuedForRsuAmount>
    <ndra:DeemedDividend
      contextRef="From2021-01-01to2021-12-31_ndra_PreferredsStockSeriesAMember"
      decimals="0"
      id="fid_255"
      unitRef="USD">0</ndra:DeemedDividend>
    <ndra:DeemedDividend
      contextRef="From2021-01-01to2021-12-31_ndra_SeriesBPreferredStocksMember"
      decimals="0"
      id="fid_256"
      unitRef="USD">0</ndra:DeemedDividend>
    <ndra:DeemedDividend
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_257"
      unitRef="USD">0</ndra:DeemedDividend>
    <ndra:DeemedDividend
      contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_258"
      unitRef="USD">121071</ndra:DeemedDividend>
    <ndra:DeemedDividend
      contextRef="From2021-01-01to2021-12-31_ndra_StockPayableMember"
      decimals="0"
      id="fid_259"
      unitRef="USD">0</ndra:DeemedDividend>
    <ndra:DeemedDividend
      contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_260"
      unitRef="USD">-121071</ndra:DeemedDividend>
    <ndra:DeemedDividend
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_261"
      unitRef="USD">0</ndra:DeemedDividend>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31_ndra_PreferredsStockSeriesAMember"
      decimals="0"
      id="fid_262"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31_ndra_SeriesBPreferredStocksMember"
      decimals="0"
      id="fid_263"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_264"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_265"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31_ndra_StockPayableMember"
      decimals="0"
      id="fid_266"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_267"
      unitRef="USD">-11231250</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_268"
      unitRef="USD">-11231250</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-12-31_ndra_PreferredsStockSeriesAMember"
      decimals="0"
      id="fid_269"
      unitRef="Shares">141</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_ndra_PreferredsStockSeriesAMember"
      decimals="0"
      id="fid_272"
      unitRef="USD">1</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_ndra_SeriesBPreferredStocksMember"
      decimals="0"
      id="fid_273"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_271"
      unitRef="Shares">2127726</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_274"
      unitRef="USD">212</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_275"
      unitRef="USD">79460980</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_ndra_StockPayableMember"
      decimals="0"
      id="fid_276"
      unitRef="USD">13863</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_277"
      unitRef="USD">-68690810</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_278"
      unitRef="USD">10784246</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-12-31_ndra_PreferredsStockSeriesAMember"
      decimals="0"
      id="fid_279"
      unitRef="Shares">141</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_ndra_PreferredsStockSeriesAMember"
      decimals="0"
      id="fid_282"
      unitRef="USD">1</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_ndra_SeriesBPreferredStocksMember"
      decimals="0"
      id="fid_283"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_281"
      unitRef="Shares">2127726</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_284"
      unitRef="USD">212</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_285"
      unitRef="USD">79460980</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_ndra_StockPayableMember"
      decimals="0"
      id="fid_286"
      unitRef="USD">13863</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_287"
      unitRef="USD">-68690810</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_288"
      unitRef="USD">10784246</us-gaap:StockholdersEquity>
    <ndra:CommonStockIssuedForCashNetOfFundingCostsAmount
      contextRef="From2022-01-01to2022-12-31_ndra_PreferredsStockSeriesAMember"
      decimals="0"
      id="fid_292"
      unitRef="USD">0</ndra:CommonStockIssuedForCashNetOfFundingCostsAmount>
    <ndra:CommonStockIssuedForCashNetOfFundingCostsAmount
      contextRef="From2022-01-01to2022-12-31_ndra_SeriesBPreferredStocksMember"
      decimals="0"
      id="fid_293"
      unitRef="USD">0</ndra:CommonStockIssuedForCashNetOfFundingCostsAmount>
    <ndra:CommonStockIssuedForCashNetOfFundingCostsShares
      contextRef="From2022-01-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_291"
      unitRef="Shares">1041377</ndra:CommonStockIssuedForCashNetOfFundingCostsShares>
    <ndra:CommonStockIssuedForCashNetOfFundingCostsAmount
      contextRef="From2022-01-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_294"
      unitRef="USD">105</ndra:CommonStockIssuedForCashNetOfFundingCostsAmount>
    <ndra:CommonStockIssuedForCashNetOfFundingCostsAmount
      contextRef="From2022-01-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_295"
      unitRef="USD">8399407</ndra:CommonStockIssuedForCashNetOfFundingCostsAmount>
    <ndra:CommonStockIssuedForCashNetOfFundingCostsAmount
      contextRef="From2022-01-01to2022-12-31_ndra_StockPayableMember"
      decimals="0"
      id="fid_296"
      unitRef="USD">0</ndra:CommonStockIssuedForCashNetOfFundingCostsAmount>
    <ndra:CommonStockIssuedForCashNetOfFundingCostsAmount
      contextRef="From2022-01-01to2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_297"
      unitRef="USD">0</ndra:CommonStockIssuedForCashNetOfFundingCostsAmount>
    <ndra:CommonStockIssuedForCashNetOfFundingCostsAmount
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_298"
      unitRef="USD">8399512</ndra:CommonStockIssuedForCashNetOfFundingCostsAmount>
    <ndra:FairValueOfVestedStockOptions
      contextRef="From2022-01-01to2022-12-31_ndra_PreferredsStockSeriesAMember"
      decimals="0"
      id="fid_299"
      unitRef="USD">0</ndra:FairValueOfVestedStockOptions>
    <ndra:FairValueOfVestedStockOptions
      contextRef="From2022-01-01to2022-12-31_ndra_SeriesBPreferredStocksMember"
      decimals="0"
      id="fid_300"
      unitRef="USD">0</ndra:FairValueOfVestedStockOptions>
    <ndra:FairValueOfVestedStockOptions
      contextRef="From2022-01-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_301"
      unitRef="USD">0</ndra:FairValueOfVestedStockOptions>
    <ndra:FairValueOfVestedStockOptions
      contextRef="From2022-01-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_302"
      unitRef="USD">1199838</ndra:FairValueOfVestedStockOptions>
    <ndra:FairValueOfVestedStockOptions
      contextRef="From2022-01-01to2022-12-31_ndra_StockPayableMember"
      decimals="0"
      id="fid_303"
      unitRef="USD">0</ndra:FairValueOfVestedStockOptions>
    <ndra:FairValueOfVestedStockOptions
      contextRef="From2022-01-01to2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_304"
      unitRef="USD">0</ndra:FairValueOfVestedStockOptions>
    <ndra:FairValueOfVestedStockOptions
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_305"
      unitRef="USD">1199838</ndra:FairValueOfVestedStockOptions>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-01-01to2022-12-31_ndra_PreferredsStockSeriesAMember"
      decimals="0"
      id="fid_306"
      unitRef="USD">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-01-01to2022-12-31_ndra_SeriesBPreferredStocksMember"
      decimals="0"
      id="fid_307"
      unitRef="USD">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-01-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_308"
      unitRef="USD">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-01-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_309"
      unitRef="USD">7790</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-01-01to2022-12-31_ndra_StockPayableMember"
      decimals="0"
      id="fid_310"
      unitRef="USD">7790</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-01-01to2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_311"
      unitRef="USD">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_312"
      unitRef="USD">0</us-gaap:DividendsPreferredStock>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31_ndra_PreferredsStockSeriesAMember"
      decimals="0"
      id="fid_313"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31_ndra_SeriesBPreferredStocksMember"
      decimals="0"
      id="fid_314"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_315"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_316"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31_ndra_StockPayableMember"
      decimals="0"
      id="fid_317"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_318"
      unitRef="USD">-13179092</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_319"
      unitRef="USD">-13179092</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2022-12-31_ndra_PreferredsStockSeriesAMember"
      decimals="0"
      id="fid_320"
      unitRef="Shares">141</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_ndra_PreferredsStockSeriesAMember"
      decimals="0"
      id="fid_323"
      unitRef="USD">1</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_ndra_SeriesBPreferredStocksMember"
      decimals="0"
      id="fid_324"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_322"
      unitRef="Shares">3169103</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_325"
      unitRef="USD">317</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_326"
      unitRef="USD">89068015</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_ndra_StockPayableMember"
      decimals="0"
      id="fid_327"
      unitRef="USD">6073</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_328"
      unitRef="USD">-81869902</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_329"
      unitRef="USD">7204504</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_113"
      unitRef="USD">13179092</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_114"
      unitRef="USD">11231250</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_116"
      unitRef="USD">96661</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_117"
      unitRef="USD">116238</us-gaap:DepreciationDepletionAndAmortization>
    <ndra:FixedAssetsWriteOff
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_118"
      unitRef="USD">1391</ndra:FixedAssetsWriteOff>
    <ndra:FixedAssetsWriteOff
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_119"
      unitRef="USD">9874</ndra:FixedAssetsWriteOff>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_120"
      unitRef="USD">1199838</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_121"
      unitRef="USD">1444572</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_122"
      unitRef="USD">137597</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_123"
      unitRef="USD">108177</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_124"
      unitRef="USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_125"
      unitRef="USD">-308600</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_127"
      unitRef="USD">-355128</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_128"
      unitRef="USD">957203</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_129"
      unitRef="USD">1360139</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_130"
      unitRef="USD">694958</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_131"
      unitRef="USD">111575</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_132"
      unitRef="USD">491104</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_133"
      unitRef="USD">-132330</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_134"
      unitRef="USD">-100338</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_135"
      unitRef="USD">-12769371</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_136"
      unitRef="USD">-11122384</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_138"
      unitRef="USD">202577</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_139"
      unitRef="USD">45000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_140"
      unitRef="USD">-202577</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_141"
      unitRef="USD">-45000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_143"
      unitRef="USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_144"
      unitRef="USD">2785627</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_145"
      unitRef="USD">8399512</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_146"
      unitRef="USD">10615975</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_147"
      unitRef="USD">8399512</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_148"
      unitRef="USD">13401602</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_149"
      unitRef="USD">-4572436</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_150"
      unitRef="USD">2234218</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_151"
      unitRef="USD">9461534</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_152"
      unitRef="USD">7227316</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_153"
      unitRef="USD">4889098</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_154"
      unitRef="USD">9461534</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_156"
      unitRef="USD">59113</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_157"
      unitRef="USD">57655</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_158"
      unitRef="USD">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_159"
      unitRef="USD">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:Dividends
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_161"
      unitRef="USD">0</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_162"
      unitRef="USD">121071</us-gaap:Dividends>
    <ndra:ConversionOfSeriesAConvertiblePreferredStock
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_163"
      unitRef="USD">0</ndra:ConversionOfSeriesAConvertiblePreferredStock>
    <ndra:ConversionOfSeriesAConvertiblePreferredStock
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_164"
      unitRef="USD">-7</ndra:ConversionOfSeriesAConvertiblePreferredStock>
    <ndra:StockDividendPayable
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_165"
      unitRef="USD">7790</ndra:StockDividendPayable>
    <ndra:StockDividendPayable
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_166"
      unitRef="USD">-3068</ndra:StockDividendPayable>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_167"
      unitRef="USD">505816</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_168"
      unitRef="USD">643413</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <ndra:LeaseLiability
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_169"
      unitRef="USD">518147</ndra:LeaseLiability>
    <ndra:LeaseLiability
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_170"
      unitRef="USD">650477</ndra:LeaseLiability>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_340">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Note 1 - Nature of the Business&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;ENDRA Life Sciences Inc. (&#x201c;ENDRA&#x201d; or the &#x201c;Company&#x201d;) has developed and is continuing to develop technology for increasing the capabilities of clinical diagnostic ultrasound to broaden patient access to the safe diagnosis and treatment of a number of significant medical conditions in circumstances where expensive X-ray computed tomography (&#x201c;CT&#x201d;) and magnetic resonance imaging (&#x201c;MRI&#x201d;) technology is unavailable or impractical.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;ENDRA was incorporated on July 18, 2007 as a Delaware corporation.&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_330">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Note 2 - Summary of Significant Accounting Policies&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span style="text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Management makes estimates that affect certain accounts including deferred income tax assets, accrued expenses, fair value of equity instruments and reserves for any other commitments or contingencies. Any adjustments applied to estimates are recognized in the period in which such adjustments are determined.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The COVID-19 pandemic has prompted governments and regulatory bodies throughout the world to issue &#x201c;stay-at-home&#x201d; or similar orders, and enact restrictions on the performance of &#x201c;non-essential&#x201d; services, public gatherings and travel.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The extent to which COVID-19 impacts the Company&#x2019;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it continues impact worldwide macroeconomic conditions, the emergence of variants of the virus and effectiveness of vaccines, access to capital markets, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of December 31, 2022 and through the date of the filing of this Annual Report on Form 10-K. The accounting matters assessed included, but were not limited to, estimates related to the accounting for potential liabilities and accrued expenses, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and assessments of impairment related to long-lived assets. The Company&#x2019;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in additional material impacts to the Company&#x2019;s consolidated financial statements in future reporting periods.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Despite the Company&#x2019;s efforts, the ultimate impact of COVID-19 on the Company&#x2019;s business depends on factors beyond the Company&#x2019;s knowledge or control, including the duration and severity of the outbreak, as well as third-party actions taken to contain its spread and mitigate its public health effects. As a result, the Company is unable to estimate the extent to which COVID-19 will negatively impact its financial results or liquidity.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span style="text-decoration:underline"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s consolidated financial statements include all accounts of the Company and its consolidated subsidiaries and/or entities as of reporting period ending date(s) and for the reporting period(s) then ended. All inter-company balances and transactions have been eliminated.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span style="text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). These financial statements have been prepared using the accrual basis of accounting in accordance with Generally Accepted Accounting Principles (&#x201c;GAAP&#x201d;) of the United States.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company considers all cash on hand and in banks, including accounts in book overdraft positions, certificates of deposit and other highly-liquid investments with maturities of one year or less, when purchased, to be cash. As of December 31, 2022 and 2021, the Company had no cash equivalents. The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and periodically evaluates the credit worthiness of the financial institutions and has determined the credit exposure to be negligible.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s inventory is stated at the lower of cost or estimated net realizable value, with cost primarily determined on a weighted-average cost basis on the first-in, first-out method. The Company periodically determines whether a reserve should be taken for devaluation or obsolescence of inventory.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Capitalization of Fixed Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than one year for: (1) assets purchased; (2) existing assets that are replaced, improved or the useful lives have been extended; or (3) all land, regardless of cost. Acquisitions of new assets, additions, replacements and improvements (other than land) costing less than the minimum rule in addition to maintenance and repair costs, including any planned major maintenance activities, are expensed as incurred.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest period presented in the financial statements. At December 31, 2022 and 2021 the Company recorded a right of use asset of $505,816 and $643,413, respectively. At December 31, 2022 and 2021 the Company recorded a lease liability of $518,147 and $650,477, respectively. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;ASU No. 2014-09, &#x201c;Revenue from Contracts with Customers&#x201d; (&#x201c;ASC Topic 606&#x201d;) provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Under ASC Topic 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to perform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC Topic 606 did not have an impact on the Company&#x2019;s operations or cash flows.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company follows FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) Subtopic 730-10, &#x201c;Research and Development&#x201d;. Research and development costs are charged to the statement of operations as incurred. During the years ended December 31, 2022 and 2021, the Company incurred $6,554,194 and $5,482,531 of expenses related to research and development costs, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Net Earnings (Loss) Per Common Share&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company computes earnings per share under ASC Subtopic 260-10, &#x201c;Earnings Per Share&#x201d;. Basic earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders (the numerator) by the weighted average number of shares of common stock outstanding (the denominator) during the reporting periods. Diluted loss per share is computed by increasing the denominator by the weighted average number of additional shares that could have been outstanding from securities convertible into common stock (using the &#x201c;treasury stock&#x201d; method), unless their effect on net loss per share is anti-dilutive. There were 410,358 and 392,425 potentially dilutive shares, which include outstanding common stock options, and warrants, as of December 31, 2022 and 2021, respectively.&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;391,902&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;262,481&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,330&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;121,818&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Shares issuable upon conversion of Series A Convertible Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;8,126&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;8,126&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Potential equivalent shares excluded&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;410,358&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;392,425&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span style="text-decoration:underline"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Disclosures about fair value of financial instruments require disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In accordance with ASC Topic 820, &#x201c;Fair Value Measurements and Disclosures,&#x201d; the Company measures certain financial instruments at fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance with accounting principles generally accepted in the United States, and expands disclosures about fair value measurements.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The carrying amounts of the Company&#x2019;s financial assets and liabilities, including cash, accounts receivable, prepaid expenses, accounts payable, accrued expenses, and other current liabilities, approximate their fair values because of the short maturity of these instruments. The fair value of notes payable and convertible notes approximates their fair values since the current interest rates and terms on these obligations are the same as prevailing market rates.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Share-based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s 2016 Omnibus Incentive Plan (the &#x201c;Omnibus Plan&#x201d;) permits the grant of stock options and other share-based awards to its employees, consultants and non-employee members of the board of directors. Each January 1 the pool of shares available for issuance under the Omnibus Plan automatically increases by an amount equal to the lesser of (i) the number of shares necessary such that the aggregate number of shares available under the Omnibus Plan equals 25% of the number of fully-diluted outstanding shares on the increase date (assuming the conversion of all outstanding shares of preferred stock and other outstanding convertible securities and exercise of all outstanding options and warrants to purchase shares) and (ii) if the board of directors takes action to set a lower amount, the amount determined by the board. On January 1, 2023, the pool of shares issuable under the Omnibus Plan automatically increased by 867,966 shares from 454,204 shares to 1,322,169 shares.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company records share-based compensation in accordance with the provisions of the Share-based Compensation Topic of the FASB Codification. The guidance requires the use of option-pricing models that require the input of highly subjective assumptions, including the option&#x2019;s expected life and the price volatility of the underlying stock. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option valuation model, and the resulting charge is expensed using the straight-line attribution method over the vesting period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Stock compensation expense recognized during the period is based on the value of share-based awards that were expected to vest during the period adjusted for estimated forfeitures. The estimated fair value of grants of stock options and warrants to non-employees of the Company is charged to expense, if applicable, in the financial statements. These options vest in the same manner as the employee options granted under the stock incentive plan as described above.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Going Concern&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s financial statements are prepared using accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has limited commercial experience and had a cumulative net loss from inception to December 31, 2022 of $81,869,902. The Company had working capital of $6,822,966 as of December 31, 2022. The Company has not established an ongoing source of revenue sufficient to cover its operating costs and to allow it to continue as a going concern and will require additional financing to fund its future planned operations, including research and development and commercialization of its products. The accompanying financial statements for the year ended December 31, 2022 have been prepared assuming the Company will continue as a going concern, but the ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it establishes a revenue stream and becomes profitable. Management&#x2019;s plans to continue as a going concern include raising additional capital through sales of equity securities and borrowing. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. If the Company is not able to obtain the necessary additional financing on a timely basis, the Company will be required to delay, reduce the scope of, or eliminate one or more of the Company&#x2019;s research and development activities or commercialization efforts or perhaps even cease the operation of its business. The ability of the Company to continue as a going concern is dependent upon its ability to successfully secure other sources of financing and attain profitable operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company considered recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC, did not or in management&#x2019;s opinion will not have a material impact on the Company&#x2019;s present or future consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2022-01-01to2022-12-31" id="fid_343">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Management makes estimates that affect certain accounts including deferred income tax assets, accrued expenses, fair value of equity instruments and reserves for any other commitments or contingencies. Any adjustments applied to estimates are recognized in the period in which such adjustments are determined.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The COVID-19 pandemic has prompted governments and regulatory bodies throughout the world to issue &#x201c;stay-at-home&#x201d; or similar orders, and enact restrictions on the performance of &#x201c;non-essential&#x201d; services, public gatherings and travel.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The extent to which COVID-19 impacts the Company&#x2019;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it continues impact worldwide macroeconomic conditions, the emergence of variants of the virus and effectiveness of vaccines, access to capital markets, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of December 31, 2022 and through the date of the filing of this Annual Report on Form 10-K. The accounting matters assessed included, but were not limited to, estimates related to the accounting for potential liabilities and accrued expenses, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and assessments of impairment related to long-lived assets. The Company&#x2019;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in additional material impacts to the Company&#x2019;s consolidated financial statements in future reporting periods.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Despite the Company&#x2019;s efforts, the ultimate impact of COVID-19 on the Company&#x2019;s business depends on factors beyond the Company&#x2019;s knowledge or control, including the duration and severity of the outbreak, as well as third-party actions taken to contain its spread and mitigate its public health effects. As a result, the Company is unable to estimate the extent to which COVID-19 will negatively impact its financial results or liquidity.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_344">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s consolidated financial statements include all accounts of the Company and its consolidated subsidiaries and/or entities as of reporting period ending date(s) and for the reporting period(s) then ended. All inter-company balances and transactions have been eliminated.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_345">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). These financial statements have been prepared using the accrual basis of accounting in accordance with Generally Accepted Accounting Principles (&#x201c;GAAP&#x201d;) of the United States.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_346">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company considers all cash on hand and in banks, including accounts in book overdraft positions, certificates of deposit and other highly-liquid investments with maturities of one year or less, when purchased, to be cash. As of December 31, 2022 and 2021, the Company had no cash equivalents. The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and periodically evaluates the credit worthiness of the financial institutions and has determined the credit exposure to be negligible.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_347">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s inventory is stated at the lower of cost or estimated net realizable value, with cost primarily determined on a weighted-average cost basis on the first-in, first-out method. The Company periodically determines whether a reserve should be taken for devaluation or obsolescence of inventory.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_348">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than one year for: (1) assets purchased; (2) existing assets that are replaced, improved or the useful lives have been extended; or (3) all land, regardless of cost. Acquisitions of new assets, additions, replacements and improvements (other than land) costing less than the minimum rule in addition to maintenance and repair costs, including any planned major maintenance activities, are expensed as incurred.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_349">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest period presented in the financial statements. At December 31, 2022 and 2021 the Company recorded a right of use asset of $505,816 and $643,413, respectively. At December 31, 2022 and 2021 the Company recorded a lease liability of $518,147 and $650,477, respectively. &lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_371"
      unitRef="USD">505816</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_372"
      unitRef="USD">643413</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_365"
      unitRef="USD">518147</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_366"
      unitRef="USD">650477</us-gaap:OperatingLeaseLiability>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_350">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;ASU No. 2014-09, &#x201c;Revenue from Contracts with Customers&#x201d; (&#x201c;ASC Topic 606&#x201d;) provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Under ASC Topic 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to perform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC Topic 606 did not have an impact on the Company&#x2019;s operations or cash flows.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2022-01-01to2022-12-31" id="fid_351">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company follows FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) Subtopic 730-10, &#x201c;Research and Development&#x201d;. Research and development costs are charged to the statement of operations as incurred. During the years ended December 31, 2022 and 2021, the Company incurred $6,554,194 and $5,482,531 of expenses related to research and development costs, respectively.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <ndra:ResearchAndDevelopmentExpense1
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_369"
      unitRef="USD">6554194</ndra:ResearchAndDevelopmentExpense1>
    <ndra:ResearchAndDevelopmentExpense1
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_370"
      unitRef="USD">5482531</ndra:ResearchAndDevelopmentExpense1>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_352">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company computes earnings per share under ASC Subtopic 260-10, &#x201c;Earnings Per Share&#x201d;. Basic earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders (the numerator) by the weighted average number of shares of common stock outstanding (the denominator) during the reporting periods. Diluted loss per share is computed by increasing the denominator by the weighted average number of additional shares that could have been outstanding from securities convertible into common stock (using the &#x201c;treasury stock&#x201d; method), unless their effect on net loss per share is anti-dilutive. There were 410,358 and 392,425 potentially dilutive shares, which include outstanding common stock options, and warrants, as of December 31, 2022 and 2021, respectively.&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;391,902&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;262,481&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,330&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;121,818&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Shares issuable upon conversion of Series A Convertible Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;8,126&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;8,126&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Potential equivalent shares excluded&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;410,358&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;392,425&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_375"
      unitRef="Shares">410358</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_374"
      unitRef="Shares">392425</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_357">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;391,902&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;262,481&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,330&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;121,818&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Shares issuable upon conversion of Series A Convertible Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;8,126&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;8,126&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Potential equivalent shares excluded&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;410,358&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;392,425&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-01to2022-12-31_ndra_OptionsToPurchaseCommonStockMember"
      decimals="0"
      id="fid_384"
      unitRef="Shares">391902</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-01to2021-12-31_ndra_OptionsToPurchaseCommonStockMember"
      decimals="0"
      id="fid_385"
      unitRef="Shares">262481</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-01to2022-12-31_ndra_WarrantsToPurchaseCommonStockMember"
      decimals="0"
      id="fid_386"
      unitRef="Shares">10330</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-01to2021-12-31_ndra_WarrantsToPurchaseCommonStockMember"
      decimals="0"
      id="fid_387"
      unitRef="Shares">121818</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-01to2022-12-31_ndra_SharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_388"
      unitRef="Shares">8126</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-01to2021-12-31_ndra_SharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_389"
      unitRef="Shares">8126</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_390"
      unitRef="Shares">410358</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_383"
      unitRef="Shares">392425</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_353">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Disclosures about fair value of financial instruments require disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In accordance with ASC Topic 820, &#x201c;Fair Value Measurements and Disclosures,&#x201d; the Company measures certain financial instruments at fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance with accounting principles generally accepted in the United States, and expands disclosures about fair value measurements.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The carrying amounts of the Company&#x2019;s financial assets and liabilities, including cash, accounts receivable, prepaid expenses, accounts payable, accrued expenses, and other current liabilities, approximate their fair values because of the short maturity of these instruments. The fair value of notes payable and convertible notes approximates their fair values since the current interest rates and terms on these obligations are the same as prevailing market rates.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2022-01-01to2022-12-31" id="fid_354">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s 2016 Omnibus Incentive Plan (the &#x201c;Omnibus Plan&#x201d;) permits the grant of stock options and other share-based awards to its employees, consultants and non-employee members of the board of directors. Each January 1 the pool of shares available for issuance under the Omnibus Plan automatically increases by an amount equal to the lesser of (i) the number of shares necessary such that the aggregate number of shares available under the Omnibus Plan equals 25% of the number of fully-diluted outstanding shares on the increase date (assuming the conversion of all outstanding shares of preferred stock and other outstanding convertible securities and exercise of all outstanding options and warrants to purchase shares) and (ii) if the board of directors takes action to set a lower amount, the amount determined by the board. On January 1, 2023, the pool of shares issuable under the Omnibus Plan automatically increased by 867,966 shares from 454,204 shares to 1,322,169 shares.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company records share-based compensation in accordance with the provisions of the Share-based Compensation Topic of the FASB Codification. The guidance requires the use of option-pricing models that require the input of highly subjective assumptions, including the option&#x2019;s expected life and the price volatility of the underlying stock. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option valuation model, and the resulting charge is expensed using the straight-line attribution method over the vesting period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Stock compensation expense recognized during the period is based on the value of share-based awards that were expected to vest during the period adjusted for estimated forfeitures. The estimated fair value of grants of stock options and warrants to non-employees of the Company is charged to expense, if applicable, in the financial statements. These options vest in the same manner as the employee options granted under the stock incentive plan as described above.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2022-01-01to2022-12-31" id="fid_381">On January 1, 2023, the pool of shares issuable under the Omnibus Plan automatically increased by 867,966 shares from 454,204 shares to 1,322,169 shares</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_355">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s financial statements are prepared using accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has limited commercial experience and had a cumulative net loss from inception to December 31, 2022 of $81,869,902. The Company had working capital of $6,822,966 as of December 31, 2022. The Company has not established an ongoing source of revenue sufficient to cover its operating costs and to allow it to continue as a going concern and will require additional financing to fund its future planned operations, including research and development and commercialization of its products. The accompanying financial statements for the year ended December 31, 2022 have been prepared assuming the Company will continue as a going concern, but the ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it establishes a revenue stream and becomes profitable. Management&#x2019;s plans to continue as a going concern include raising additional capital through sales of equity securities and borrowing. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. If the Company is not able to obtain the necessary additional financing on a timely basis, the Company will be required to delay, reduce the scope of, or eliminate one or more of the Company&#x2019;s research and development activities or commercialization efforts or perhaps even cease the operation of its business. The ability of the Company to continue as a going concern is dependent upon its ability to successfully secure other sources of financing and attain profitable operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.&lt;/p&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:CumulativeDividends
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_379"
      unitRef="USD">81869902</us-gaap:CumulativeDividends>
    <ndra:WorkingCapital
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_380"
      unitRef="USD">6822966</ndra:WorkingCapital>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_356">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company considered recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC, did not or in management&#x2019;s opinion will not have a material impact on the Company&#x2019;s present or future consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_331">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Note 3 - Inventory&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;As of December 31, 2022 and 2021, inventory consisted of raw materials, subassemblies to be used in the assembly of TAEUS systems, and finished goods. As of December 31, 2022, the Company had no orders pending for the sale of a TAEUS system. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;As of December 31, 2022 and 2021, the Company had inventory valued at $2,644,717 and $1,284,578, respectively.&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_391"
      unitRef="USD">2644717</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_392"
      unitRef="USD">1284578</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_332">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Note 4 - Fixed Assets&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;As of December 31, 2022 and 2021, fixed assets consisted of the following:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Property, leasehold and capitalized software&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;738,720&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;605,248&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;TAEUS development and testing&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;140,617&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;107,682&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(643,682 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(581,800 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Fixed assets, net&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;235,655&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;131,130&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Depreciation expense for the year ended December 31, 2022 and 2021 was $96,661 and $116,238, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_358">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Property, leasehold and capitalized software&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;738,720&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;605,248&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;TAEUS development and testing&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;140,617&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;107,682&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(643,682 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(581,800 &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Fixed assets, net&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;235,655&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;131,130&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_393"
      unitRef="USD">738720</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_394"
      unitRef="USD">605248</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:DevelopmentInProcess
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_395"
      unitRef="USD">140617</us-gaap:DevelopmentInProcess>
    <us-gaap:DevelopmentInProcess
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_396"
      unitRef="USD">107682</us-gaap:DevelopmentInProcess>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_397"
      unitRef="USD">643682</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_398"
      unitRef="USD">581800</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_399"
      unitRef="USD">235655</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_400"
      unitRef="USD">131130</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_403"
      unitRef="USD">96661</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_404"
      unitRef="USD">116238</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_333">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Note 5 - Accounts Payable and Accrued Liabilities&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;As of December 31, 2022 and 2021, current liabilities consisted of the following:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;613,961&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;791,052&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Accrued payroll&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;60,638&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;101,459&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Accrued bonuses&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;683,738&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;396,043&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Accrued employee benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,750&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,750&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Insurance premium financing&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;158,925&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;117,133&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Total&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;1,523,012&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;1,411,437&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_359">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;613,961&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;791,052&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Accrued payroll&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;60,638&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;101,459&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Accrued bonuses&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;683,738&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;396,043&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Accrued employee benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,750&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,750&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Insurance premium financing&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;158,925&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;117,133&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Total&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;1,523,012&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;1,411,437&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_405"
      unitRef="USD">613961</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_406"
      unitRef="USD">791052</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_407"
      unitRef="USD">60638</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_408"
      unitRef="USD">101459</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedBonusesCurrentAndNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_409"
      unitRef="USD">683738</us-gaap:AccruedBonusesCurrentAndNoncurrent>
    <us-gaap:AccruedBonusesCurrentAndNoncurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_410"
      unitRef="USD">396043</us-gaap:AccruedBonusesCurrentAndNoncurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_411"
      unitRef="USD">5750</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_412"
      unitRef="USD">5750</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedInsuranceCurrentAndNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_413"
      unitRef="USD">158925</us-gaap:AccruedInsuranceCurrentAndNoncurrent>
    <us-gaap:AccruedInsuranceCurrentAndNoncurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_414"
      unitRef="USD">117133</us-gaap:AccruedInsuranceCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_415"
      unitRef="USD">1523012</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_416"
      unitRef="USD">1411437</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:ShortTermDebtTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_334">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Note 6 - Bank Loans&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;U.S. SBA Paycheck Protection Program&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In April 2020, the Company issued a U.S. Small Business Administration (&#x201c;SBA&#x201d;) Paycheck Protection Program Note (the &#x201c;SBA Note&#x201d;) to First Republic Bank (the &#x201c;Lender&#x201d;) for a loan in the principal amount of $308,600 (the &#x201c;SBA Loan&#x201d;) under the Paycheck Protection Program (&#x201c;PPP&#x201d;) promulgated under the Coronavirus Aid, Relief and Economic Security Act of 2020, as modified by the Paycheck Protection Program Flexibility Act of 2020.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On May 10, 2021 received notice that the SBA Loan had been forgiven in full in accordance with the terms and provisions of the PPP.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company did not provide any collateral or personal guarantees for the SBA Loan, nor did the Company pay any facility charge to the government or to the Lender.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Toronto-Dominion Bank Loan&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On April 27, 2020, the Company entered into a commitment loan with TD Bank under the Canadian Emergency Business Account, in the principal aggregate amount of CAD 40,000, due and payable upon the expiration of the initial term on December 31, 2022, which was later extended to December 31, 2023. This note bears interest on the unpaid balance at the rate of zero percent (0%) per annum during the initial term. Under this note no interest payments are due until January 1, 2024. Under the conditions of the loan, twenty-five percent (25%) of the loan will be forgiven if seventy-five percent (75%) is repaid prior to the initial term date.&lt;/p&gt;</us-gaap:ShortTermDebtTextBlock>
    <us-gaap:ProceedsFromCollectionOfNotesReceivable
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_422"
      unitRef="USD">308600</us-gaap:ProceedsFromCollectionOfNotesReceivable>
    <ndra:PrincipalAggregateAmount
      contextRef="AsOf2020-04-27_ndra_TDBankLoanMember"
      decimals="0"
      id="fid_418"
      unitRef="CAD">40000</ndra:PrincipalAggregateAmount>
    <us-gaap:LineOfCreditFacilityInitiationDate1
      contextRef="From2020-04-01to2020-04-27_ndra_TDBankLoanMember"
      id="fid_419">2022-12-31</us-gaap:LineOfCreditFacilityInitiationDate1>
    <ndra:InitialTermInterestRate
      contextRef="AsOf2020-04-27_ndra_TDBankLoanMember"
      decimals="INF"
      id="fid_420"
      unitRef="Pure">0</ndra:InitialTermInterestRate>
    <ndra:BankLoanDescription
      contextRef="From2020-04-01to2020-04-27_ndra_TDBankLoanMember"
      id="fid_421">Under this note no interest payments are due until January 1, 2024. Under the conditions of the loan, twenty-five percent (25%) of the loan will be forgiven if seventy-five percent (75%) is repaid prior to the initial term date</ndra:BankLoanDescription>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_335">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Note 7 - Capital Stock&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Reverse Stock Split&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On December 7, 2022, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment (the &#x201c;Certificate of Amendment&#x201d;) to its certificate of incorporation, which Certificate of Amendment effectuated as of December 19, 2022 at 12:01 a.m. Eastern Time (the &#x201c;Effective Time&#x201d;) a reverse split&#160;of the Company&#x2019;s common stock by a ratio of one-for-20 (the &#x201c;Reverse Split&#x201d;). All per share amounts and number of shares in the consolidated financial statements and related notes have been retroactively restated to reflect the Reverse Split. No fractional shares were, or shall be, issued in connection with the&#160;Reverse Split. A stockholder who would otherwise be entitled to receive a fractional share of common stock is entitled to receive the fractional share rounded up to the next whole share. The&#160;Reverse Split&#160;did not change the number of shares of common or preferred stock that the Company is authorized to issue, or the par value of the Company&#x2019;s common or preferred stock.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The&#160;Reverse Split&#160;resulted in a proportionate adjustment to the per share conversion or exercise price and the number of shares of common stock issuable upon the conversion or exercise of outstanding preferred stock, stock options and warrants, as well as the number of shares of common stock eligible for issuance under the Company&#x2019;s 2016 Omnibus Incentive Plan.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Capital Stock&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;At December 31, 2022, the authorized capital of the Company consisted of 90,000,000 shares of capital stock, comprised of 80,000,000 shares of common stock with a par value of $0.0001 per share, and 10,000,000 shares of preferred stock with a par value of $0.0001 per share. The Company has designated 10,000 shares of its preferred stock as Series A Convertible Preferred Stock (&#x201c;Series A Preferred Stock&#x201d;), 1,000 shares of its preferred stock as Series B Convertible Preferred Stock (&#x201c;Series B Preferred Stock&#x201d;), 100,000 shares of its preferred stock as Series C Preferred Stock, and the remainder of the&#160;9,889,000 preferred shares remain authorized but undesignated.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;As of December 31, 2022, there were 3,169,103 shares of common stock, 141.397 shares of Series A Preferred Stock, and no shares of Series B Preferred Stock or Series C Preferred Stock&#160;issued and outstanding, and a stock payable balance of $6,073.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On September 26, 2022, the board of directors declared a dividend of one one-thousandth of a share of Series C Preferred Stock for each outstanding share of the Company&#x2019;s common stock and 1.359 shares of Series C Preferred Stock for each outstanding share of Series A Preferred Stock, to stockholders of record at 5:00 p.m. Eastern Time on October 7, 2022. Each whole share of Series C Preferred Stock (other than shares held by the Company&#x2019;s directors and named executive officers) entitled the holder thereof to 1,000,000 votes on the proposal to adopt an amendment to the Company&#x2019;s certificate of incorporation to reclassify the outstanding shares of common stock into a smaller number of shares of common stock. Shares of Series C Preferred Stock were eligible to vote at the special meeting of the Company&#x2019;s stockholders held on November 29, 2022, at which the Company&#x2019;s stockholders approved a reverse stock split of its common stock. All shares of Series C Preferred Stock were automatically redeemed in connection with the special meeting and no shares of Series C Preferred Stock remained outstanding as of December 31, 2022.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the year ended December 31, 2022, the Company issued a total of 1,041,377 shares of its common stock in return for aggregate net proceeds of $8,399,512 under the June 2021 ATM Agreement (as described below). &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the year ended December 31, 2021, the Company issued a total of 425,241 shares of its common stock, as follows:&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;3,394 shares upon the conversion of 55.397 shares of its Series A Preferred Stock;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;229,348 shares in return for aggregate net proceeds of $10,615,975 from sales of common stock;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;178,395 shares upon warrant exercises for an aggregate exercise price of $2,785,627;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;10,145 shares upon cashless warrant exercises;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;1,192 shares upon cashless option exercise; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;1,626 shares for services valued at $74,000; and&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;1,141 shares for RSUs valued at $36,460.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&lt;em&gt;At-the-Market Equity Offering Program&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On June 21, 2021, the Company entered into the At-The-Market Issuance Sales Agreement with Ascendiant (the &#x201c;June 2021 ATM Agreement&#x201d;) to sell shares of common stock for aggregate gross proceeds of up to $20.0 million, from time to time, through an &#x201c;at-the-market&#x201d; equity offering program under which Ascendiant acts as sales agent. As of December 31, 2022, under the June 2021 ATM Agreement the Company has issued an aggregate of 1,064,634 shares of common stock in return for net proceeds of $9,216,618, resulting in approximately $286,289 of compensation paid to Ascendiant. During the year ended December 31, 2022, under the June 2021 ATM Agreement the Company issued an aggregate of 1,041,377 shares of common stock in return for net proceeds of $8,398,936, resulting in $260,776 of compensation paid to Ascendiant.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CapitalUnitsAuthorized
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_431"
      unitRef="Shares">90000000</us-gaap:CapitalUnitsAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_430"
      unitRef="Shares">80000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="fid_424"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_480"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="fid_470"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="fid_428"
      unitRef="Shares">10000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="fid_427"
      unitRef="Shares">1000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="fid_474"
      unitRef="Shares">100000</us-gaap:PreferredStockSharesAuthorized>
    <ndra:PreferredStockSharesUndesignated
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_479"
      unitRef="Shares">9889000</ndra:PreferredStockSharesUndesignated>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_432"
      unitRef="Shares">3169103</us-gaap:CommonStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="fid_482"
      unitRef="Shares">141</us-gaap:PreferredStockSharesIssued>
    <ndra:StockPayableShare
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_435"
      unitRef="USD">6073</ndra:StockPayableShare>
    <ndra:TotalCommonStockSharesIssued
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_616"
      unitRef="Shares">1041377</ndra:TotalCommonStockSharesIssued>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_448"
      unitRef="USD">8399512</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ndra:TotalCommonStockSharesIssued
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_617"
      unitRef="Shares">425241</ndra:TotalCommonStockSharesIssued>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2021-01-01to2021-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="fid_495"
      unitRef="Shares">3394</us-gaap:ConversionOfStockSharesIssued1>
    <ndra:ConversionOfCommonStockIntoPreferredStock
      contextRef="From2021-01-01to2021-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="fid_496"
      unitRef="Shares">55</ndra:ConversionOfCommonStockIntoPreferredStock>
    <ndra:SharesInReturn
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_447"
      unitRef="USD">229348</ndra:SharesInReturn>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_449"
      unitRef="USD">10615975</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ndra:CommonStockSharesUponWarratExerciseShares
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_439"
      unitRef="Shares">178395</ndra:CommonStockSharesUponWarratExerciseShares>
    <ndra:CommonStockSharesUponWarrantExerciseAmount
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_440"
      unitRef="USD">2785627</ndra:CommonStockSharesUponWarrantExerciseAmount>
    <ndra:CommonStockSharesUponCashlessWarrantExercise
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_441"
      unitRef="USD">10145</ndra:CommonStockSharesUponCashlessWarrantExercise>
    <ndra:CommonStockSharesUponCashlessOptionExercise
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_442"
      unitRef="Shares">1192</ndra:CommonStockSharesUponCashlessOptionExercise>
    <ndra:SharesForServicesValue
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_443"
      unitRef="USD">1626</ndra:SharesForServicesValue>
    <ndra:CommonStockServicesValued
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_445"
      unitRef="USD">74000</ndra:CommonStockServicesValued>
    <ndra:CommonStockSharesUponVestingOfRestrictedUnits
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_444"
      unitRef="USD">1141</ndra:CommonStockSharesUponVestingOfRestrictedUnits>
    <ndra:RestictedStockUnitsValued
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_446"
      unitRef="USD">36460</ndra:RestictedStockUnitsValued>
    <ndra:GrossProceedsFromSalesOfCommonStock
      contextRef="From2021-06-01to2021-06-21_ndra_JuneTwentyTwentyOneATMAgreementMember"
      decimals="-5"
      id="fid_454"
      unitRef="USD">20000000.0</ndra:GrossProceedsFromSalesOfCommonStock>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-31_ndra_JuneTwentyTwentyOneATMAgreementMember"
      decimals="0"
      id="fid_434"
      unitRef="Shares">1064634</us-gaap:CommonStockSharesIssued>
    <ndra:NetProceedsFromSalesOfCommonStock3
      contextRef="From2022-01-01to2022-12-31_ndra_JuneTwentyTwentyOneATMAgreementMember"
      decimals="0"
      id="fid_452"
      unitRef="USD">9216618</ndra:NetProceedsFromSalesOfCommonStock3>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-06-01to2021-06-21_ndra_JuneTwentyTwentyOneATMAgreementMember"
      decimals="0"
      id="fid_450"
      unitRef="USD">286289</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <ndra:TotalCommonStockSharesIssued
      contextRef="From2022-01-01to2022-12-31_ndra_JuneTwentyTwentyOneATMAgreementMember"
      decimals="0"
      id="fid_437"
      unitRef="Shares">1041377</ndra:TotalCommonStockSharesIssued>
    <ndra:NetProceedsFromSalesOfCommonStock3
      contextRef="From2021-06-01to2021-06-21_ndra_JuneTwentyTwentyOneATMAgreementMember"
      decimals="0"
      id="fid_453"
      unitRef="USD">8398936</ndra:NetProceedsFromSalesOfCommonStock3>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-01to2022-12-31_ndra_JuneTwentyTwentyOneATMAgreementMember"
      decimals="0"
      id="fid_451"
      unitRef="USD">260776</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <ndra:ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_336">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Note 8 - Common Stock Options and Restricted Stock Units (RSUs)&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Common Stock Options&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Stock options are awarded to the Company&#x2019;s employees, consultants and non-employee members of the board of directors under the Omnibus Plan and are generally granted with an exercise price equal to the market price of the Company&#x2019;s common stock at the date of grant. The aggregate fair value of these stock options granted by the Company during the year ended December 31, 2022 was determined to be $919,915 using the Black-Scholes-Merton option-pricing model based on the following assumptions: (i) volatility rate of 74% to 99%, (ii) discount rate of 0%, (iii) zero expected dividend yield, (iv) risk free rate of 1.37% to 4.36%, and (v) expected life of 8-10 years. A summary of option activity under the Company&#x2019;s Omnibus Plan as of December 31, 2022, and changes during the year then ended, is presented below:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Options&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Average&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Exercise&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Average &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Remaining &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Contractual &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Term (Years)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Balance outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;262,481&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;44.17&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7.42&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;141,975&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8.08&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9.05&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Cancelled or expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(12,554 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Balance outstanding at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;391,902&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;31.47&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7.41&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Exercisable at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;180,742&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;41.21&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5.69&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ndra:ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock>
    <ndra:AggregateFairValueOfStockOptionsGranted
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_523"
      unitRef="USD">919915</ndra:AggregateFairValueOfStockOptionsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-01to2022-12-31_srt_MinimumMember"
      decimals="INF"
      id="fid_526"
      unitRef="Pure">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-01to2022-12-31_srt_MaximumMember"
      decimals="INF"
      id="fid_532"
      unitRef="Pure">0.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      id="fid_524"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-01to2022-12-31_srt_MinimumMember"
      decimals="INF"
      id="fid_528"
      unitRef="Pure">0.0137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-01to2022-12-31_srt_MaximumMember"
      decimals="INF"
      id="fid_529"
      unitRef="Pure">0.0436</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2022-01-01to2022-12-31_srt_MinimumMember"
      id="fid_530">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2022-01-01to2022-12-31_srt_MaximumMember"
      id="fid_531">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_360">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Options&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Average&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Exercise&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Average &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Remaining &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Contractual &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Term (Years)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Balance outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;262,481&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;44.17&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7.42&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;141,975&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8.08&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9.05&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Cancelled or expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(12,554 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Balance outstanding at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;391,902&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;31.47&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7.41&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Exercisable at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;180,742&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;41.21&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5.69&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_497"
      unitRef="Shares">262481</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="fid_506"
      unitRef="USDPShares">44.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <ndra:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-01to2022-12-31" id="fid_515">P7Y5M1D</ndra:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_499"
      unitRef="Shares">141975</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      id="fid_508"
      unitRef="USDPShares">8.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <ndra:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm contextRef="From2022-01-01to2022-12-31" id="fid_516">P9Y18D</ndra:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      id="fid_509"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_501"
      unitRef="USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      id="fid_510"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_502"
      unitRef="Shares">12554</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      id="fid_511"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_619"
      unitRef="Shares">391902</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="fid_521"
      unitRef="USDPShares">31.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-01to2022-12-31" id="fid_517">P7Y4M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_520"
      unitRef="Shares">180742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="fid_522"
      unitRef="USDPShares">41.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-01to2022-12-31" id="fid_518">P5Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <ndra:ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_337">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Note 9 - Common Stock Warrants&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;The following table summarizes all stock warrant activity of the Company for the year ended December 31, 2022:&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Number of &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Warrants&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Average&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Exercise &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Average &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Contractual &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Term (Years)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Balance outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;121,818&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;110.80&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.58&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(111,488 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;118.86&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Balance outstanding at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,330&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25.01&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.78&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Exercisable at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,330&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25.01&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.78&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ndra:ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_361">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Number of &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Warrants&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Average&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Exercise &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Average &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Contractual &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Term (Years)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Balance outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;121,818&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;110.80&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.58&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(111,488 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;118.86&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Balance outstanding at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,330&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25.01&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.78&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Exercisable at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,330&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25.01&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.78&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2021-12-31_ndra_WarrantsMember"
      decimals="0"
      id="fid_533"
      unitRef="Shares">121818</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <ndra:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_ndra_WarrantsMember"
      decimals="INF"
      id="fid_537"
      unitRef="USDPShares">110.80</ndra:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <ndra:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning
      contextRef="From2022-01-01to2022-12-31_ndra_WarrantsMember"
      id="fid_544">P0Y6M29D</ndra:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning>
    <ndra:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31_ndra_WarrantsMember"
      decimals="INF"
      id="fid_538"
      unitRef="USDPShares">0</ndra:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <ndra:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31_ndra_WarrantsMember"
      decimals="INF"
      id="fid_539"
      unitRef="USDPShares">0</ndra:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice>
    <ndra:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31_ndra_WarrantsMember"
      decimals="INF"
      id="fid_540"
      unitRef="USDPShares">0</ndra:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice>
    <ndra:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod
      contextRef="From2022-01-01to2022-12-31_ndra_WarrantsMember"
      decimals="0"
      id="fid_534"
      unitRef="Shares">111488</ndra:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod>
    <ndra:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31_ndra_WarrantsMember"
      decimals="INF"
      id="fid_541"
      unitRef="USDPShares">118.86</ndra:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice>
    <ndra:NumberOfWarrantsEndingBalance
      contextRef="From2022-01-01to2022-12-31_ndra_WarrantsMember"
      decimals="0"
      id="fid_536"
      unitRef="Shares">10330</ndra:NumberOfWarrantsEndingBalance>
    <ndra:WeightedAverageExercisableAtJune302022
      contextRef="From2022-01-01to2022-12-31_ndra_WarrantsMember"
      decimals="INF"
      id="fid_543"
      unitRef="USDPShares">25.01</ndra:WeightedAverageExercisableAtJune302022>
    <ndra:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding
      contextRef="From2022-01-01to2022-12-31_ndra_WarrantsMember"
      id="fid_545">P1Y9M10D</ndra:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding>
    <ndra:NumberOfWarrantsExercisable
      contextRef="From2022-01-01to2022-12-31_ndra_WarrantsMember"
      decimals="0"
      id="fid_535"
      unitRef="Shares">10330</ndra:NumberOfWarrantsExercisable>
    <ndra:WeightedAverageExercisePriceOutstanding
      contextRef="From2022-01-01to2022-12-31_ndra_WarrantsMember"
      decimals="INF"
      id="fid_542"
      unitRef="USDPShares">25.01</ndra:WeightedAverageExercisePriceOutstanding>
    <ndra:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermExercisable
      contextRef="From2022-01-01to2022-12-31_ndra_WarrantsMember"
      id="fid_546">P1Y9M10D</ndra:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermExercisable>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_338">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Note 10 - Commitments and Contingencies&lt;/strong&gt; &lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Effective January 1, 2015, the Company entered into an office lease agreement with Green Court, LLC, a Michigan limited liability company, for approximately 3,657 rentable square feet of space, for the initial monthly rent of $5,986, which commenced on January 1, 2015 for an initial term of 60 months. On October 10, 2017 this lease was amended increasing the rentable square feet of space to 3,950 and the monthly rent to $7,798. On July 16, 2019, the Company exercised its option to extend the lease for an additional 5 years past the initial term originally expiring on December 31, 2019.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On March 15, 2021, the Company entered into an amendment to the lease, adding approximately 3,248 rentable square feet, increasing the initial monthly rent to $15,452 effective May 2021, and extending the term of the lease to December 31, 2025. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company records the lease asset and lease liability at the present value of lease payments over the lease term. The lease typically does not provide an implicit rate; therefore, the Company uses its estimated incremental borrowing rate at the time of lease commencement to discount the present value of lease payments. The Company&#x2019;s discount rate for operating leases at December 31, 2022 was 10%. Lease expense is recognized on a straight-line basis over the lease term to the extent that collection is considered probable. As a result, the Company has been recognizing rents as they become payable based on the adoption of ASC Topic 842. The weighted-average remaining lease term is 3.00 years.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;As of December 31, 2022, the maturities of operating lease liabilities are as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Operating&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Lease&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;196,721&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;202,624&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025 and beyond&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;202,624&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;601,969&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less: amount representing interest&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(83,822 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Present value of future minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;518,147&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less: current obligations under leases&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(152,228 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Long-term lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;365,919&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;For the years ended December 31, 2022 and 2021, the Company incurred rent expenses of $213,912 and $178,620, respectively.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&lt;em&gt;Employment and Consulting Agreements&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Francois Michelon&lt;/em&gt;&lt;/strong&gt; - The Company has an employment agreement with Francois Michelon, the Company&#x2019;s Chief Executive Officer and Chairman of the board of directors, dated May 12, 2017 and amended on December 27, 2019.&#160; Effective January 1, 2021, the Compensation Committee increased Mr. Michelon&#x2019;s annual salary to $376,991 and, effective January 1, 2022, it increased Mr. Michelon&#x2019;s annual salary to $423,000. Mr. Michelon is also eligible for an annual cash bonus based upon achievement of performance-based objectives established by the Board of Directors. Under the employment agreement, Mr. Michelon is eligible for an annual cash bonus based upon achievement of performance-based objectives established by the board of directors. Upon termination without cause, any portion of Mr. Michelon&#x2019;s option award scheduled to vest within 12 months will automatically vest, and upon termination without cause within 12 months following a change of control, the entire unvested portion of the option award will automatically vest. Upon termination for any other reason, the entire unvested portion of the option award will terminate.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;If Mr. Michelon&#x2019;s employment is terminated by the Company without cause or Mr. Michelon terminates his employment for good reason, Mr. Michelon will be entitled to receive 12 months&#x2019; continuation of his current base salary and a lump sum payment equal to 12 months of continued healthcare coverage (or 24 months&#x2019; continuation of his current base salary and a lump sum payment equal to 24 months of continued healthcare coverage if such termination occurs within one year following a change in control).&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Under his employment agreement, Mr. Michelon is eligible to receive benefits that are substantially similar to those of the Company&#x2019;s other senior executive officers.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Michael Thornton&lt;/em&gt;&lt;/strong&gt; - The Company has an employment agreement with Michael Thornton, the Company&#x2019;s Chief Technology Officer, dated May 12, 2017 and on December 27, 2019. The employment agreement provides for an annual base salary that is subject to adjustment at the board of directors&#x2019; discretion. Effective January 1, 2021, the Compensation Committee increased Mr. Thornton&#x2019;s annual salary to $289,963 and, effective January 1, 2022, it increased Mr. Thornton&#x2019;s annual salary to $324,000. Under the employment agreement, Mr. Thornton is eligible for an annual cash bonus based upon achievement of performance-based objectives established by the board of directors. Upon termination without cause, any portion of Mr. Thornton&#x2019;s option award scheduled to vest within 12 months will automatically vest, and upon termination without cause within 12 months following a change of control, the entire unvested portion of the option award will automatically vest. Upon termination for any other reason, the entire unvested portion of the option award will terminate.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;If Mr. Thornton&#x2019;s employment is terminated by the Company without cause or Mr. Thornton terminates his employment for good reason, Mr. Thornton will be entitled to receive 12 months&#x2019; continuation of his current base salary and a lump sum payment equal to 12 months of continued healthcare coverage (or 24 months&#x2019; continuation of his current base salary and a lump sum payment equal to 24 months of continued healthcare coverage if such termination occurs within one year following a change in control). &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Under his employment agreement, Mr. Thornton is eligible to receive benefits that are substantially similar to those of the Company&#x2019;s other senior executive officers.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Renaud Maloberti &lt;/em&gt;&lt;/strong&gt;- The Company had&#160;an employment agreement with Renaud Maloberti, dated April 15, 2019, that provided&#160;for an annual base salary of $250,000 and eligibility for an annual cash bonus to be paid based on attainment of Company and individual performance objectives to be established by the Board of Directors. Effective January 1, 2021, the Compensation Committee increased Mr. Maloberti&#x2019;s annual salary to $266,255.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On December 21, 2022, Mr.&#160;Maloberti notified the Company of his resignation as the Company&#x2019;s Chief Commercial Officer, effective January 13, 2023.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Pursuant to his employment agreement, on April 28, 2019, Mr. Maloberti was granted stock options to purchase 35,000 shares of the Company&#x2019;s common stock. The stock options have an exercise price of $1.04 per share, and vest in three equal annual installments beginning on the first anniversary of the grant date.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Litigation&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;From time to time the Company may become a party to litigation in the normal course of business. As of December 31, 2022, there were no legal matters that management believes would have a material effect on the Company&#x2019;s financial position or results of operations.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ndra:RentSpace
      contextRef="From2022-01-01to2022-12-31_ndra_JanuaryOneTwentyFifteenMember"
      decimals="INF"
      id="fid_572"
      unitRef="sqft">3657</ndra:RentSpace>
    <ndra:MonthlyRent
      contextRef="From2022-01-01to2022-12-31_ndra_JanuaryOneTwentyFifteenMember"
      decimals="0"
      id="fid_575"
      unitRef="USD">5986</ndra:MonthlyRent>
    <ndra:RentTerm
      contextRef="From2022-01-01to2022-12-31_ndra_JanuaryOneTwentyFifteenMember"
      id="fid_577">P60M</ndra:RentTerm>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="From2017-10-01to2017-10-10_ndra_JanuaryOneTwentyFifteenMember"
      id="fid_578">On October 10, 2017 this lease was amended increasing the rentable square feet of space to 3,950 and the monthly rent to $7,798. On July 16, 2019, the Company exercised its option to extend the lease for an additional 5 years past the initial term originally expiring on December 31, 2019</us-gaap:LesseeOperatingLeaseDescription>
    <ndra:RentTerm
      contextRef="From2017-10-01to2017-10-10_ndra_JanuaryOneTwentyFifteenMember"
      id="fid_590">P5M</ndra:RentTerm>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="From2021-03-01to2021-03-15_ndra_JanuaryOneTwentyFifteenMember"
      id="fid_579">On March 15, 2021, the Company entered into an amendment to the lease, adding approximately 3,248 rentable square feet, increasing the initial monthly rent to $15,452 effective May 2021, and extending the term of the lease to December 31, 2025</us-gaap:LesseeOperatingLeaseDescription>
    <ndra:OperatingLeaseDiscountRate
      contextRef="From2022-01-01to2022-12-31_ndra_JanuaryOneTwentyFifteenMember"
      decimals="INF"
      id="fid_582"
      unitRef="Pure">0.10</ndra:OperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_362">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Operating&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Lease&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;196,721&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;202,624&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025 and beyond&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;202,624&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;601,969&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less: amount representing interest&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(83,822 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Present value of future minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;518,147&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less: current obligations under leases&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(152,228 &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Long-term lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;365,919&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_547"
      unitRef="USD">196721</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_548"
      unitRef="USD">202624</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <ndra:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_550"
      unitRef="USD">202624</ndra:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_551"
      unitRef="USD">601969</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_552"
      unitRef="USD">83822</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_553"
      unitRef="USD">518147</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_555"
      unitRef="USD">152228</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_557"
      unitRef="USD">365919</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <ndra:RentExpenses
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_560"
      unitRef="USD">213912</ndra:RentExpenses>
    <ndra:RentExpenses
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_561"
      unitRef="USD">178620</ndra:RentExpenses>
    <us-gaap:SalariesAndWages
      contextRef="From2017-05-01to2017-05-12_ndra_EmploymentAgreementsMember_ndra_FrancoisMichelonMember"
      decimals="0"
      id="fid_585"
      unitRef="USD">376991</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2022-01-01to2022-12-31_ndra_EmploymentAgreementsMember_ndra_FrancoisMichelonMember"
      decimals="0"
      id="fid_584"
      unitRef="USD">423000</us-gaap:SalariesAndWages>
    <ndra:EmploymentAgreementDescription
      contextRef="From2017-05-01to2017-05-12_ndra_EmploymentAgreementsMember_ndra_FrancoisMichelonMember"
      id="fid_568">vest within 12 months will automatically vest, and upon termination without cause within 12 months</ndra:EmploymentAgreementDescription>
    <ndra:DescriptionOfEmploymentTerminationTerm
      contextRef="From2017-05-01to2017-05-12_ndra_EmploymentAgreementsMember_ndra_FrancoisMichelonMember"
      id="fid_565">to receive 12 months&#x2019; continuation of his current base salary and a lump sum payment equal to 12 months of continued healthcare coverage (or 24 months&#x2019; continuation of his current base salary and a lump sum payment equal to 24 months</ndra:DescriptionOfEmploymentTerminationTerm>
    <us-gaap:SalariesAndWages
      contextRef="From2017-05-01to2017-05-12_ndra_EmploymentAgreementsMember_ndra_MichaelThorntonMember"
      decimals="0"
      id="fid_562"
      unitRef="USD">289963</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2022-01-01to2022-12-31_ndra_EmploymentAgreementsMember_ndra_MichaelThorntonMember"
      decimals="0"
      id="fid_583"
      unitRef="USD">324000</us-gaap:SalariesAndWages>
    <ndra:EmploymentAgreementDescription
      contextRef="From2017-05-01to2017-05-12_ndra_EmploymentAgreementsMember_ndra_MichaelThorntonMember"
      id="fid_569">to vest within 12 months will automatically vest, and upon termination without cause within 12 months</ndra:EmploymentAgreementDescription>
    <ndra:DescriptionOfEmploymentTerminationTerm
      contextRef="From2019-04-01to2019-04-15_ndra_EmploymentAgreementsMember_ndra_MichaelThorntonMember"
      id="fid_564">Mr. Thornton will be entitled to receive 12 months&#x2019; continuation of his current base salary and a lump sum payment equal to 12 months</ndra:DescriptionOfEmploymentTerminationTerm>
    <us-gaap:SalariesAndWages
      contextRef="From2019-04-01to2019-04-15_ndra_EmploymentgreementsMember_ndra_RenaudMalobertiMember"
      decimals="0"
      id="fid_563"
      unitRef="USD">250000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2022-01-01to2022-12-31_ndra_EmploymentgreementsMember_ndra_RenaudMalobertiMember"
      decimals="0"
      id="fid_586"
      unitRef="USD">266255</us-gaap:SalariesAndWages>
    <ndra:StockOptionGranted
      contextRef="From2019-04-01to2019-04-28_ndra_EmploymentgreementsMember_ndra_RenaudMalobertiMember"
      decimals="0"
      id="fid_587"
      unitRef="Shares">35000</ndra:StockOptionGranted>
    <ndra:ExercisePrice
      contextRef="AsOf2019-04-28_ndra_EmploymentgreementsMember_ndra_RenaudMalobertiMember"
      decimals="INF"
      id="fid_589"
      unitRef="USDPShares">1.04</ndra:ExercisePrice>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_342">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Note 11 - Income Taxes&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#x2019;s deferred tax assets as of December 31, 2022 and 2021 are summarized below.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net operating loss carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(17,251,804&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(14,200,629&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;28,720&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Fair value of options&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;311,958&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;346,869&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(16,939,846&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(13,825,040&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;16,939,846&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,825,040&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net deferred tax asset&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In assessing the potential realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the Company attaining future taxable income during the periods in which those temporary differences become deductible. As of December 31, 2022 and 2021, management was unable to determine if it is more likely than not that the Company&#x2019;s deferred tax assets will be realized, and has therefore recorded an appropriate valuation allowance against deferred tax assets at such dates.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company has not completed its evaluation of net operating loss (&#x201c;NOL&#x201d;) utilization limitations under Internal Revenue Code, as amended (the &#x201c;Code&#x201d;), Section 382/383, change of ownership rules. If the Company has had a change in ownership, the NOL&#x2019;s would be limited as to the amount that could be utilized each year, or possibly eliminated, based on the Code, as amended.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;No federal or state/local tax provision has been provided for the years ended December 31, 2022 and 2021 due to the losses incurred during such periods. Reconciled below is the difference between the income tax rate computed by applying the U.S. federal statutory rate and the effective tax rate for the years ended December 31, 2021 and 2020.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;U.S. federal statutory income tax&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-21.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-21.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;State tax, net of federal tax benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-5.80&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-5.80&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;26.80&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;26.80&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Effective tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;At December 31, 2022, the Company has available net operating loss carryforwards for federal and state income tax purposes of approximately $65.2 million, of which $16 million will begin to expire in 2028 through 2038.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;ENDRA Life Sciences Canada Inc., the Company&#x2019;s wholly-owned subsidiary which was incorporated in 2017, is subject to income taxes in the jurisdictions in which it operates,&#160;Canada, at a current rate of approximately 26.6 percent for 2022. Significant judgment is required in determining the provision for income tax. There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. The Company recognizes liabilities for anticipated tax audit issues based on its current understanding of the tax law. Where the final tax outcome of these matters is different from the carrying amounts, such differences will impact the current and deferred tax provisions in the period in which such determination is made.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;ENDRA Life Sciences Canada Inc.&#x2019;s operations were not material for tax purposes as of December 31, 2022 and 2021 and therefore the entity had no significant impact on the year-end 2022 and 2021 tax provision. Generally, all expenses relating to research &amp;amp; development that are incurred in Canada are the responsibility and owned by the United States parent company, since it is the owner of all of the Company&#x2019;s intangibles.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_363">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net operating loss carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(17,251,804&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(14,200,629&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;28,720&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Fair value of options&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;311,958&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;346,869&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(16,939,846&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(13,825,040&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;16,939,846&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,825,040&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net deferred tax asset&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_592"
      unitRef="USD">17251804</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_593"
      unitRef="USD">14200629</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <ndra:StockBasedCompensation
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_594"
      unitRef="USD">0</ndra:StockBasedCompensation>
    <ndra:StockBasedCompensation
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_595"
      unitRef="USD">28720</ndra:StockBasedCompensation>
    <ndra:FairValueOfOptions
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_596"
      unitRef="USD">311958</ndra:FairValueOfOptions>
    <ndra:FairValueOfOptions
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_597"
      unitRef="USD">346869</ndra:FairValueOfOptions>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_598"
      unitRef="USD">16939846</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_599"
      unitRef="USD">13825040</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_600"
      unitRef="USD">16939846</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_601"
      unitRef="USD">13825040</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_602"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_603"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_364">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;U.S. federal statutory income tax&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-21.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-21.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;State tax, net of federal tax benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-5.80&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-5.80&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;26.80&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;26.80&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Effective tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      id="fid_604"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="fid_605"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      id="fid_606"
      unitRef="Pure">-0.0580</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="fid_607"
      unitRef="Pure">-0.0580</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      id="fid_608"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="fid_609"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      id="fid_610"
      unitRef="Pure">0.2680</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="fid_611"
      unitRef="Pure">0.2680</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      id="fid_612"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="fid_613"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31"
      decimals="-5"
      id="fid_614"
      unitRef="USD">65200000</us-gaap:OperatingLossCarryforwards>
    <ndra:NetOperatingLossCarryforwardBegainToExpire
      contextRef="AsOf2022-12-31"
      decimals="-6"
      id="fid_615"
      unitRef="USD">16000000</ndra:NetOperatingLossCarryforwardBegainToExpire>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>59
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MN##\&#;J^?@;,):J\;<Q&$9 /^?XX;*ZW<266IE6X?@Q;-6+-2]!6!)F-V(
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M#++-^*WB\,UO&AZ(WKJ1H(C.5:ES=JXF'['YF<#FA>2K;./\C$O)X^SIDI*
M"GV ^GS.N=R]T%^0_UBC_S]02P,$%     @ 7(9P5E,6='[^!0  V!P  !@
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M"EP+U/,U8_)EH$]"Y<G7^P=02P,$%     @ 7(9P5M<RJ^%V!   (Q   !@
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M^!T3HZA;\<3'[_KG=(EL >AP0>7U"BZH2LA*X)#+3K6:<7FS$RG;]/G_J&M
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M%8#W"RG-[L9^H#TWG?\/4$L#!!0    ( %R&<%;.*L? *0,  ,X&   8
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MP;J$'D/75G=H#F/P9VC1\T/8\0/OJ (T%4@/@F^#-+TT#01[#$,@T1JK;',
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M<!W3L.4/#KF8P/':\NT>)W&#Z1.V_A=02P,$%     @ 7(9P5@)VZL4A%P
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M/IO%!Q.+JY1R8NCA?&A4]75R7ZTL+TL)F"'C85Z4V<H[.4DV)&Z5\E5QL#D
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MAJ.Q0%;#A=H F4W(LDRB)V'OZAVE/NCXWQIO-[!C<DLBF8.S/+X8C>)Q-@[
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M 9ANCW6*TW6[.];:T29JQ2VM?C0^@/REIH^C5WR!X<]D^1M02P,$%     @
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MT@9<7RN<8ZH'$M#\0G+[#U!+ P04    " !<AG!6,0[+(%P$   3"@  &0
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M7_VT(HW+'55P@?"A*=@;7Y;/Y+?H)KSS>D77N*:P7$5_H7* L[]=^.>P8!2
M*^G*&NJXW!^F?19+#,DPZ:3C&%Y#FH;Q"$9AFL#OQ_*,T[@S&0U@'$9CF(31
MH*66T[WB_F@:KY#;=GWEO KA:DF[ Z+NI<.*D\Y@D,*Y5_F/U!+H3\A[E!"U
M?ARFGEK<$&!+@:>MXG'4&:7.*HU#"G 0#B=PZC+O/1K4)>K"/T=<MU/IUC.[
MW6U?/)?UH/^N7C^7KIDN.)VDP!691N%H$% =^R=(O;!JZ\?^4EEZ1/C/-;W:
M4#L%DJ\47=;'A7/0O@/G_P)02P,$%     @ 7(9P5J(N/O7A @  J@8  !D
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M/-1J#=I%$YM;^%(]FL1QZ0YE9C5Y.>'L>*K*DE[.S*KL$1Z8UDQ:,PPM4;N
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M? "_KXWQW0,;Z%^Q7OT+4$L#!!0    ( %R&<%9BC0X.SP<  /(2   9
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M.X:T[G)  RCWC1AAE&&"N@^- <!_-3T>9IBVRQ).)?P\LO:K=-JM=A2XA/_
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M"-C@@/M;@^)'(QPPO4GE+U!+ P04    " !<AG!60@JOQ_H7  #,1@  &0
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MSFIZ$A01^G1T\F2F!'8)#$9Y0@ /(:&_P8$Z "L[2QSJGV-^:5N9\@QJUG:
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M9E]7ZT%N*2F?R/%!%R@48M#X\*U8*N3*)-\57#[9]+'/ Q\^W/GL[X2]LCN
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M2:VHIP9BO<NE3QO]U-<_92S^/1I]5/?8R ?'XHZ98CKJA($3.7P8?\YU3L+
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M3&7S278/$JG'!&D]@'MZKX+\%VL.PW[*:MU1V:W#X9 %$C 261<=8%2,Z<U
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M""B- YVOA=!'PP2H/S'CWU!+ P04    " !<AG!6:TQ&(KH"   M!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6R-56UOVD ,_BM6-DVMQ/(&M%$'
MD:#M7CYT1="NVL<C<>#4))?=74K[[^>[O)1I%%5(<#[;CQ_[;#/9"?FHMH@:
MGHN\5%-GJW5UX7DJV6+!E"LJ+$F3"5DP3:+<>*J2R%+K5.1>Z/MG7L%XZ<03
M>[>0\434.N<E+B2HNBB8?)EC+G93)W"ZBR7?;+6Y\.))Q3:X0GU?+21)7H^2
M\@)+Q44)$K.I,PLNYB-C;PU^<=RIO3.83-9"/!KA1SIU?$,(<TRT06#T\X27
MF.<&B&C\:3&=/J1QW#]WZ%]M[I3+FBF\%/D#3_5VZD0.I)BQ.M=+L?N.;3YC
M@Y>(7-EOV#6VX[$#2:VT*%IG8E#PLOEESVT=]APB_PV'L'4(+>\FD&5YQ32+
M)U+L0!IK0C,'FZKU)G*\-(^RTI*TG/QT?"F*@HJSTB)YA <F)2NU@I,[MLY1
MG4X\33&,I9>T>/,&+WP#+PCA1I1ZJ^"Z3#']%\ C<CW#L&,X#X\B7F'BPC 8
M0.B'X1&\89_QT.(-WY/Q;65Z0P$K4UBBTI(G&M-6>5]R4XOEZOYP)9HXH\-Q
MS#1=J(HE.'5H7!3*)W3B3Q^",__+D2Q&?1:C8^CQBJ8SK7.$VZQ[-IB9#N?Z
MY1#7HVB'N<+/NEBC!)&]-L:#[7*JT.P))0TM7#^C3+A"6%#I\'_])36#I-&K
M60YW* LX^8U,JE.8LYR5Y$&+0FDJ/R\WP#30:Z.-VKYX $$8#*(@@H\0!+X;
M^>"[XPB^&3X4Y[/]="PZF08V0[ZOK[@DZ20(@L$HBN"4P"(W.B/=.XF$$/B#
MX= G'N'8]8F7>QYU@<VTO-_IT/-[>R-<H-S81:4@$76IFVGN;_M=.&M6P*MY
MLTAOF-QPZND<,W+UW7-:/;)93HV@1647PEIH6B_VN*5]CM(8D#X30G>""=#_
M0\1_ 5!+ P04    " !<AG!6)G',\J\"  #H!0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6R=5,MNVS 0_)6%&A0IH$8//V*[MH#8:=$""6(D:7NF
MI95,A!15DHJ3O^^2LET7=7SH1>22G-D94KO3C=)/9HUHX46*VLR"M;7-)(I,
MOD;)S(5JL*:=4FG)+(6ZBDRCD14>)$64QO$PDHS703;U:TN=355K!:]QJ<&T
M4C+].D>A-K,@"78+][Q:6[<09=.&5?B ]GNSU!1%>Y:"2ZP-5S5H+&?!53*9
M]]UY?^ 'QXTYF(-SLE+JR07?BED0.T$H,+>.@='PC L4PA&1C%];SF"?T@$/
MYSOV+]X[>5DQ@PLE?O+"KF?!*( "2]8*>Z\V7W'K9^#X<B6,_\*F.SN@C'EK
MK));,,62U]W(7K;W<  8Q6\ TBT@];J[1%[E-;,LFVJU >U.$YN;>*L>3>)X
M[1[EP6K:Y82SV4))R2W=LC7 Z@(6JK:\KK#..1HX?V0K@>;#-+*4RR&B?,L[
M[WC3-WB3%&Z):FW@<UU@\3=!1"+W2M.=TGEZDO$:\POH)2&D<9J>X.OMG?<\
M7^]_G!\SW-'UC].YXIF8AN4X"Z@Z#.IG#++W[Y)A_.F$V/Y>;/\4>_9 Q5BT
M N&NA+L&-7-2X0;I?X0;SE9<<.L>[);95OOI,0<G<QQW\$\VNOT>).-A>)DF
M+NB[3SCLQH&_R16^*AIVZX_*,@%G,(R3<#P<$X\Q$V!2M;6ENO:Y_-4#KRU2
M9.%\U M':0H?8-GMPC,3+8(JH6S)(;I2X+*5(+RHAKUV#SE(1F'2O]SFR%NM
M'5BM!*^8ZP(&6OH==0>C_SL9I&&:CBC1C:JKCY1^1WF(.8/><!".DS$<>\KH
MH/HDZLKW& .Y\]<5XGYUW\:NNNK]<[SK@;=,5YP2"BP)&E]<#@+075_I JL:
M7\LK9:DS^.F:6C%J=X#V2Z7L+G )]LT]^PU02P,$%     @ 7(9P5K,FU^,C
M P  @0<  !D   !X;"]W;W)K<VAE971S+W-H965T,C8N>&ULC571;MLZ#/T5
MPKL;.L"-;25QG2X)L'8;MH==%$NW/2LV'0N5I4Q2FO;O1\F)F]VFN7M()%KD
MX2$I4M.M-G>V073PT$IE9U'CW/HR26S98,OM0*]1T4FM3<L=B6:5V+5!7@6C
M5B8L3?.DY4)%\VGX=F/F4[UQ4BB\,6 W;<O-XQ5*O9U%6;3_\$VL&N<_)//I
MFJ]P@>[[^L:0E/0HE6A16:$5&*QGT?OL\FKL]8/"#X%;>[ ''\E2ZSLO?*EF
M4>H)H<32>01.RSU>HY0>B&C\VF%&O4MO>+C?HW\*L5,L2V[Q6LN?HG+-+"HB
MJ+#F&^F^Z>UGW,43")9:VO /VTXWOXB@W%BGVYTQ,6B%ZE;^L,O#@4&1OF#
M=@8L\.X<!98?N./SJ=%;,%Z;T/PFA!JLB9Q0OB@+9^A4D)V;?U&E;A%N^0-:
M.+OE2XGV[31Q!.T5DG('<]7!L!=@,@9?M7*-A8^JPNI/@(0X]<38GM@5.XGX
M <L!#+,86,K8";QA'^@PX W_(M!C\776H^/6OC4N[9J7.(OH[ELT]QC-W[S*
M\O3="6ZCGMOH%/I\0:U6;22"KOV-0F.P L<?@%N+UEG@J@(I^%)(X<1Q_B<]
M'.<?4NO_,OB7VI\:W7 GU JDMA9*;LPC=?V6FPK^@;/L(F;C+"[2$;P-\BBF
MSH]S-B%YX71Y%]JC LHSC0S+0]>= ROB"Y;")RX,W'.Y"5'JM3^U5. LGHP+
M&([RN,@G<*L=E\]S0"DXR_)X,IS$Q2@G?V?9,"[8.$Y'*4D_"+9SQR5-&:Y*
M)(8'!B0\Z?M8GWL@G?/P.U'/<5_/\5_7\_M@,8 :*\JM!.NXVSAM'H$RC:&L
MKD' NL8PG0(=?W2LPB=]_F^%7^ ANK;P?L]9-DA3>/VT63C/DLYB4/Z"U#V
MUU^BPEHX.!\/BF"V6U^\"VF'NENN&ZY62 3"K?AO^5C>@>W7C\]2]"?<L:HE
M!V.Q1;,*PY\NMMXHUTW(_FO_OKSOQNJ3>O<X?>5F)>B^2JS)-!U<4#%,-_ [
MP>EU&+)+[6ADAVU#;R0:KT#GM=9N+W@'_:L[_PU02P,$%     @ 7(9P5HSH
MN,0, P  _0D  !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&ULM59=;]L@
M%/TKR).F3=IJ&^?#Z1)+2=II?:@6-=OZ3.R;&!4;%W"2_?L!=KQ\>JO4OB2
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M=F>'A?XA@3 %^OZ6<_4\,3UO^,6E_P!02P,$%     @ 7(9P5ES- J8_ @
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M<J4[T2XK/2M!F 1]ON)<[0-SP3!]\S]02P,$%     @ 7(9P5O1T4>O  @
M3 @  !D   !X;"]W;W)K<VAE971S+W-H965T,S(N>&ULK99O;]HP$,:_BI5-
M4RMM39S_=!"IP*I6VB34KMMK$PZPZMB9[4#[[6<G- *2MDC;&_ Y=X]_SYG8
M#+="/JHU@$9/!>-JY*RU+B]=5^5K*(BZ$"5P\V0I9$&T">7*5:4$LJB+"N;Z
MGA>[!:'<R8;UW$QF0U%I1CG,)%)541#Y/ 8FMB,'.R\3=W2UUG;"S88E6<$]
MZ(=R)DWDMBH+6@!75' D83ERKO#E)+7Y=<(O"ENU-T;6R5R(1QO<+D:.9X&
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M#](FF.=+(?1+8&^4]@]$]A=02P,$%     @ 7(9P5KS=.0II P  1@H  !D
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M6W7\ VL](\>7*&'\+QPKV]$X@&1OK"IJ,'E0<%G]LX<Z#F> :?0$(*X!\3>
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M6!(<+ G,EA19)KJ3NCG?;['8PQMPM>?;@B;_:MO@M5'0UJ2@9=)4;]* 0,6
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M68HOG7!@UK+VQZ5:W*@I#2M$88<_$IVAF9T[K\A'PGB2;T"Q!F(;I\E2\(2
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MO"*T#!"_KXN"/W\I=W!X.V7^'U!+ P04    " !<AG!6-/ Q_.$#  !5#P
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M ]< ]7S!F'R;Z/.B_WN0_P502P,$%     @ 7(9P5D?F@$O& @  :P@  !D
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M 9 F =<+(?1^8A[0_%^D?P%02P,$%     @ 7(9P5MUPAY<= @  K00  !D
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M4>_\G7J'>*U\>/8\UGC_=U(=;]?ZY^WOR\=F[[G<<7;PEV7U"U!+ P04
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M_TMHU[A697/T9]T/F_DG4$L! A0#%     @ 7(9P5@=!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !<
MAG!6@W4X+.\    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " !<AG!6F5R<(Q &  "<)P  $P
M@ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( %R&<%8DZ P6
M<@<  +@Q   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " !<AG!64Q9T?OX%  #8'   &
M@(&V#P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 7(9P
M5I;"/;%! P  !0\  !@              ("!ZA4  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( %R&<%;7,JOA=@0  ",0   8
M      " @6$9  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M" !<AG!69?W^0,L'  !R-0  &               @($-'@  >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ 7(9P5@5BK@W+!@  0QT  !@
M             ("!#B8  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( %R&<%;.*L? *0,  ,X&   8              " @0\M  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !<AG!6 G;JQ2$7   $
M00  &               @(%N,   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ 7(9P5C$H6%Z0 @  W04  !@              ("!Q4<
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( %R&<%;&2FX^
MS (  "8&   9              " @8M*  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ 7(9P5O+(3[BS @  6 8  !D
M ("!CDT  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !<
MAG!6;C3U;H\$  !2"@  &0              @(%X4   >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( %R&<%:=8:NDI@@  "T9   9
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M970Q-RYX;6Q02P$"% ,4    " !<AG!6?IQ/@?8!  "?!   &0
M    @('R=0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M %R&<%9""J_'^A<  ,Q&   9              " @1]X  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ 7(9P5@"A3?2H @  \04  !D
M             ("!4)   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    " !<AG!625*WGH@"  "#!0  &0              @($ODP  >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( %R&<%;'?+7@F@(
M -4%   9              " @>Z5  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ 7(9P5F:ZXO78 @  ;@8  !D              ("!
MOY@  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !<AG!6
M:TQ&(KH"   M!@  &0              @('.FP  >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( %R&<%8F<<SRKP(  .@%   9
M      " @;^>  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ 7(9P5K,FU^,C P  @0<  !D              ("!I:$  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !<AG!6C.BXQ P#  #]"0
M&0              @('_I   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( %R&<%:$Z"%D)00  /P.   9              " @4*H  !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ 7(9P5E<0NB;^
M 0  U@0  !D              ("!GJP  'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    " !<AG!6ML/BHY<"  #N!@  &0
M@('3K@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( %R&
M<%9<S0*F/P(  (D%   9              " @:&Q  !X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ 7(9P5O1T4>O  @  3 @  !D
M         ("!%[0  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M    " !<AG!6O-TY"FD#  !&"@  &0              @($.MP  >&PO=V]R
M:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( %R&<%:QF<G?:P<  *DR
M   9              " @:ZZ  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
M4$L! A0#%     @ 7(9P5C3P,?SA P  50\  !D              ("!4,(
M 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " !<AG!6&, [
ME/\"  !/"0  &0              @(%HQ@  >&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;%!+ 0(4 Q0    ( %R&<%:B&4NB4@,  #$,   9
M  " @9[)  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
M7(9P5D7!'J8+ P  40H  !D              ("!)\T  'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"% ,4    " !<AG!6U%J9(U\(  !8/   &0
M            @(%IT   >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4
M Q0    ( %R&<%9;>+EIP@(  "H(   9              " @?_8  !X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ 7(9P5D?F@$O& @
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M96QS+RYR96QS4$L! A0#%     @ 7(9P5@.WI3J3 P  %AP   \
M     ( !F>4  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( %R&<%:^RS-!
MF0$  '49   :              "  5GI  !X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( %R&<%8CU6X-J $  +@9   3
M  "  2KK  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     R #( E0T   /M
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>76</ContextCount>
  <ElementCount>262</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>25</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000005 - Statement - Consolidated Statements of Stockholders Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000007 - Disclosure - Nature of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/NatureOfTheBusiness</Role>
      <ShortName>Nature of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000009 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000010 - Disclosure - Fixed Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/FixedAssets</Role>
      <ShortName>Fixed Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000011 - Disclosure - Accounts Payable and Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/AccountsPayableAndAccruedLiabilities</Role>
      <ShortName>Accounts Payable and Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000012 - Disclosure - Bank Loans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/BankLoans</Role>
      <ShortName>Bank Loans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000013 - Disclosure - Capital Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/CapitalStock</Role>
      <ShortName>Capital Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000014 - Disclosure - Common Stock Options and Restricted Stock Units (RSUs)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsus</Role>
      <ShortName>Common Stock Options and Restricted Stock Units (RSUs)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000015 - Disclosure - Common Stock Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/CommonStockWarrants</Role>
      <ShortName>Common Stock Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000016 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000017 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000018 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000019 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://novaworks.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000020 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novaworks.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000021 - Disclosure - Fixed Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/FixedAssetsTables</Role>
      <ShortName>Fixed Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novaworks.com/role/FixedAssets</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000022 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/AccountsPayableAndAccruedLiabilitiesTables</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novaworks.com/role/AccountsPayableAndAccruedLiabilities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000023 - Disclosure - Common Stock Options and Restricted Stock Units (RSUs)(Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusTables</Role>
      <ShortName>Common Stock Options and Restricted Stock Units (RSUs)(Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsus</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000024 - Disclosure - Common Stock Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/CommonStockWarrantsTables</Role>
      <ShortName>Common Stock Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novaworks.com/role/CommonStockWarrants</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000025 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novaworks.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>000026 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novaworks.com/role/IncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>000027 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>000028 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>000029 - Disclosure - Inventory (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/InventoryDetailsNarrative</Role>
      <ShortName>Inventory (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novaworks.com/role/Inventory</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>000030 - Disclosure - Fixed Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/FixedAssetsDetails</Role>
      <ShortName>Fixed Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novaworks.com/role/FixedAssetsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>000031 - Disclosure - Fixed Assets (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/FixedAssetsDetailsNarrative</Role>
      <ShortName>Fixed Assets (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novaworks.com/role/FixedAssetsTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>000032 - Disclosure - Accounts Payable and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/AccountsPayableAndAccruedLiabilitiesDetails</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novaworks.com/role/AccountsPayableAndAccruedLiabilitiesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>000033 - Disclosure - Bank Loans (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/BankLoansDetailsNarrative</Role>
      <ShortName>Bank Loans (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novaworks.com/role/BankLoans</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>000034 - Disclosure - Capital Stock (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/CapitalStockDetailsNarrative</Role>
      <ShortName>Capital Stock (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novaworks.com/role/CapitalStock</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>000035 - Disclosure - Common Stock Options and Restricted Stock Units (RSUs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetails</Role>
      <ShortName>Common Stock Options and Restricted Stock Units (RSUs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>000036 - Disclosure - Common Stock Options and Restricted Stock Units (RSUs) (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetailsNarrative</Role>
      <ShortName>Common Stock Options and Restricted Stock Units (RSUs) (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>000037 - Disclosure - Common Stock Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/CommonStockWarrantsDetails</Role>
      <ShortName>Common Stock Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novaworks.com/role/CommonStockWarrantsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>000038 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novaworks.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>000039 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novaworks.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>000040 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novaworks.com/role/IncomeTaxesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>000041 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novaworks.com/role/IncomeTaxesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ndra_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>000042 - Disclosure - Income Taxes (Details narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novaworks.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novaworks.com/role/IncomeTaxesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0540-CurrentFiscalYearEndDate-Registrant-Value] In submission type 10-K, CurrentFiscalYearEndDate value "--12-31", should match the Entity Registrant Fiscal Year End Date "12/08" on record within EDGAR. ndra_10k.htm 1</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 48 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, ndra:ExpectedDividendYield, ndra:MonthlyRent, ndra:RentSpace, ndra:SharesAvailableForIssuanceIncreasedUnderTheOmnibusPlan, ndra:WeightedAverageRemainingLeaseTerm, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesOutstanding, us-gaap:DebtInstrumentMaturityDate, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:PreferredStockSharesIssued, us-gaap:PreferredStockSharesOutstanding, us-gaap:SubsequentEventsTextBlock -  ndra_10k.htm 1</Log>
    <Log type="Warning">[dq-0712-Presentation-Base-Set-Order] Role '000022 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)', a level 3, Table role, appears before '000023 - Disclosure - Common Stock Options and Restricted Stock Units (RSUs)(Tables)', a level 1, Note role. ndra-20221231.xsd 137, 143</Log>
    <Log type="Warning">[dqc-0009-Element-A-Must-Be-Less-Than-Or-Equal-To-Element-B] The value of PreferredStockSharesIssued, 141397, should be less than or equal to PreferredStockSharesAuthorized, 10000. The properties of this PreferredStockSharesIssued fact are:, Context: AsOf2021-12-31_us-gaap_PreferredClassAMember, Unit: Shares, Rule Element Id: 22. ndra_10k.htm 1</Log>
    <Log type="Warning">[dqc-0009-Element-A-Must-Be-Less-Than-Or-Equal-To-Element-B] The value of PreferredStockSharesIssued, 141397, should be less than or equal to PreferredStockSharesAuthorized, 10000. The properties of this PreferredStockSharesIssued fact are:, Context: AsOf2022-12-31_us-gaap_PreferredClassAMember, Unit: Shares, Rule Element Id: 22. ndra_10k.htm 1</Log>
    <Log type="Warning">[dqc-0009-Element-A-Must-Be-Less-Than-Or-Equal-To-Element-B] The value of PreferredStockSharesOutstanding, 141397, should be less than or equal to PreferredStockSharesAuthorized, 10000. The properties of this PreferredStockSharesOutstanding fact are:, Context: AsOf2022-12-31_us-gaap_PreferredClassAMember, Unit: Shares, Rule Element Id: 23. ndra_10k.htm 1</Log>
    <Log type="Warning">[dqc-0009-Element-A-Must-Be-Less-Than-Or-Equal-To-Element-B] The value of PreferredStockSharesOutstanding, 141397, should be less than or equal to PreferredStockSharesAuthorized, 10000. The properties of this PreferredStockSharesOutstanding fact are:, Context: AsOf2021-12-31_us-gaap_PreferredClassAMember, Unit: Shares, Rule Element Id: 23. ndra_10k.htm 1</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="ndra_10k.htm">ndra_10k.htm</File>
    <File>ndra-20221231.xsd</File>
    <File>ndra-20221231_cal.xml</File>
    <File>ndra-20221231_def.xml</File>
    <File>ndra-20221231_lab.xml</File>
    <File>ndra-20221231_pre.xml</File>
    <File>ndra_ex106.htm</File>
    <File>ndra_ex211.htm</File>
    <File>ndra_ex231.htm</File>
    <File>ndra_ex232.htm</File>
    <File>ndra_ex311.htm</File>
    <File>ndra_ex312.htm</File>
    <File>ndra_ex321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ndra_10kimg5.jpg</File>
    <File>ndra_10kimg6.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="379">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>65
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ndra_10k.htm": {
   "axisCustom": 0,
   "axisStandard": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 379,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 76,
   "dts": {
    "calculationLink": {
     "local": [
      "ndra-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ndra-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ndra_10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ndra-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ndra-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ndra-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 336,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 40,
    "http://novaworks.com/20221231": 7,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 52
   },
   "keyCustom": 73,
   "keyStandard": 189,
   "memberCustom": 15,
   "memberStandard": 10,
   "nsprefix": "ndra",
   "nsuri": "http://novaworks.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://novaworks.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000010 - Disclosure - Fixed Assets",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://novaworks.com/role/FixedAssets",
     "shortName": "Fixed Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000011 - Disclosure - Accounts Payable and Accrued Liabilities",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://novaworks.com/role/AccountsPayableAndAccruedLiabilities",
     "shortName": "Accounts Payable and Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000012 - Disclosure - Bank Loans",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://novaworks.com/role/BankLoans",
     "shortName": "Bank Loans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000013 - Disclosure - Capital Stock",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://novaworks.com/role/CapitalStock",
     "shortName": "Capital Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ndra:ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000014 - Disclosure - Common Stock Options and Restricted Stock Units (RSUs)",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsus",
     "shortName": "Common Stock Options and Restricted Stock Units (RSUs)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ndra:ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ndra:ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000015 - Disclosure - Common Stock Warrants",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://novaworks.com/role/CommonStockWarrants",
     "shortName": "Common Stock Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ndra:ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000016 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://novaworks.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000017 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://novaworks.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000018 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://novaworks.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000019 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "19",
     "role": "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000002 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://novaworks.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000020 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000021 - Disclosure - Fixed Assets (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://novaworks.com/role/FixedAssetsTables",
     "shortName": "Fixed Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000022 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://novaworks.com/role/AccountsPayableAndAccruedLiabilitiesTables",
     "shortName": "Accounts Payable and Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ndra:ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000023 - Disclosure - Common Stock Options and Restricted Stock Units (RSUs)(Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusTables",
     "shortName": "Common Stock Options and Restricted Stock Units (RSUs)(Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ndra:ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ndra:ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000024 - Disclosure - Common Stock Warrants (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://novaworks.com/role/CommonStockWarrantsTables",
     "shortName": "Common Stock Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ndra:ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000025 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://novaworks.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000026 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://novaworks.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "strong",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000027 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31_ndra_WarrantsToPurchaseCommonStockMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000028 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ResearchAndDevelopmentExpensePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "ndra:ResearchAndDevelopmentExpense1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryNet",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000029 - Disclosure - Inventory (Details Narrative)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://novaworks.com/role/InventoryDetailsNarrative",
     "shortName": "Inventory (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://novaworks.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_PreferredClassAMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000030 - Disclosure - Fixed Assets (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://novaworks.com/role/FixedAssetsDetails",
     "shortName": "Fixed Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000031 - Disclosure - Fixed Assets (Details Narrative)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://novaworks.com/role/FixedAssetsDetailsNarrative",
     "shortName": "Fixed Assets (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000032 - Disclosure - Accounts Payable and Accrued Liabilities (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://novaworks.com/role/AccountsPayableAndAccruedLiabilitiesDetails",
     "shortName": "Accounts Payable and Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ShortTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromCollectionOfNotesReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000033 - Disclosure - Bank Loans (Details Narrative)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://novaworks.com/role/BankLoansDetailsNarrative",
     "shortName": "Bank Loans (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ShortTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromCollectionOfNotesReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalUnitsAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000034 - Disclosure - Capital Stock (Details Narrative)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://novaworks.com/role/CapitalStockDetailsNarrative",
     "shortName": "Capital Stock (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalUnitsAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ndra:ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000035 - Disclosure - Common Stock Options and Restricted Stock Units (RSUs) (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetails",
     "shortName": "Common Stock Options and Restricted Stock Units (RSUs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ndra:ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ndra:ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ndra:AggregateFairValueOfStockOptionsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000036 - Disclosure - Common Stock Options and Restricted Stock Units (RSUs) (Details Narrative)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetailsNarrative",
     "shortName": "Common Stock Options and Restricted Stock Units (RSUs) (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ndra:ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ndra:AggregateFairValueOfStockOptionsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ndra:ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "AsOf2021-12-31_ndra_WarrantsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000037 - Disclosure - Common Stock Warrants (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://novaworks.com/role/CommonStockWarrantsDetails",
     "shortName": "Common Stock Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ndra:ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "AsOf2021-12-31_ndra_WarrantsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000038 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://novaworks.com/role/CommitmentsAndContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ndra:RentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000039 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ndra:RentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000004 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://novaworks.com/role/ConsolidatedStatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000040 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://novaworks.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000041 - Disclosure - Income Taxes (Details 1)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://novaworks.com/role/IncomeTaxesDetails1",
     "shortName": "Income Taxes (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000042 - Disclosure - Income Taxes (Details narrative)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://novaworks.com/role/IncomeTaxesDetailsNarrative",
     "shortName": "Income Taxes (Details narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "AsOf2020-12-31_ndra_PreferredsStockSeriesAMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000005 - Statement - Consolidated Statements of Stockholders Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "AsOf2020-12-31_ndra_PreferredsStockSeriesAMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000006 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000007 - Disclosure - Nature of the Business",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://novaworks.com/role/NatureOfTheBusiness",
     "shortName": "Nature of the Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000008 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://novaworks.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000009 - Disclosure - Inventory",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://novaworks.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ndra_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 25,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm Id"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line 1"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line 2"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novaworks.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ndra_AggregateFairValueOfStockOptionsGranted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Fair Value Of Stock Options Granted"
       }
      }
     },
     "localname": "AggregateFairValueOfStockOptionsGranted",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_BankLoanDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank Loan, Description"
       }
      }
     },
     "localname": "BankLoanDescription",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/BankLoansDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ndra_CommonStockIssuedForCashNetOfFundingCostsAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for cash, net of funding costs, amount"
       }
      }
     },
     "localname": "CommonStockIssuedForCashNetOfFundingCostsAmount",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_CommonStockIssuedForCashNetOfFundingCostsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for cash, net of funding costs, shares"
       }
      }
     },
     "localname": "CommonStockIssuedForCashNetOfFundingCostsShares",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ndra_CommonStockIssuedForOptionExerciseAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for option exercise, amount"
       }
      }
     },
     "localname": "CommonStockIssuedForOptionExerciseAmount",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_CommonStockIssuedForOptionExerciseShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for option exercise, shares"
       }
      }
     },
     "localname": "CommonStockIssuedForOptionExerciseShares",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ndra_CommonStockIssuedForServicesAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for services, amount"
       }
      }
     },
     "localname": "CommonStockIssuedForServicesAmount",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_CommonStockIssuedForServicesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for services, shares"
       }
      }
     },
     "localname": "CommonStockIssuedForServicesShares",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ndra_CommonStockIssuedForWarrantExerciseAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for warrant exercise, amount"
       }
      }
     },
     "localname": "CommonStockIssuedForWarrantExerciseAmount",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_CommonStockIssuedForWarrantExerciseShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for warrant exercise, shares"
       }
      }
     },
     "localname": "CommonStockIssuedForWarrantExerciseShares",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ndra_CommonStockServicesValued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock services valued"
       }
      }
     },
     "localname": "CommonStockServicesValued",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_CommonStockSharesUponCashlessOptionExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Shares Upon Cashless Option Exercise"
       }
      }
     },
     "localname": "CommonStockSharesUponCashlessOptionExercise",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ndra_CommonStockSharesUponCashlessWarrantExercise": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock shares upon cashless warrant exercise"
       }
      }
     },
     "localname": "CommonStockSharesUponCashlessWarrantExercise",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_CommonStockSharesUponVestingOfRestrictedUnits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock shares upon vesting of restricted units"
       }
      }
     },
     "localname": "CommonStockSharesUponVestingOfRestrictedUnits",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_CommonStockSharesUponWarrantExerciseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Shares Upon Warrant Exercise, Amount"
       }
      }
     },
     "localname": "CommonStockSharesUponWarrantExerciseAmount",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_CommonStockSharesUponWarratExerciseShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Shares Upon Warrant Exercise, Shares"
       }
      }
     },
     "localname": "CommonStockSharesUponWarratExerciseShares",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ndra_ConversionOfCommonStockIntoPreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion Of Common Stock Into Preferred Stock"
       }
      }
     },
     "localname": "ConversionOfCommonStockIntoPreferredStock",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ndra_ConversionOfSeriesAConvertiblePreferredStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConversionOfSeriesAConvertiblePreferredStock",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_DeemedDividend": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Deemed dividend]",
        "verboseLabel": "Deemed dividend"
       }
      }
     },
     "localname": "DeemedDividend",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_DescriptionOfEmploymentTerminationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of Employment Termination Term"
       }
      }
     },
     "localname": "DescriptionOfEmploymentTerminationTerm",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ndra_EmploymentAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employment Agreement, Description"
       }
      }
     },
     "localname": "EmploymentAgreementDescription",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ndra_EmploymentAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employment Agreements [Member]"
       }
      }
     },
     "localname": "EmploymentAgreementsMember",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ndra_EmploymentgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Employment Agreements [Member]]",
        "verboseLabel": "Employment Agreements [Member]"
       }
      }
     },
     "localname": "EmploymentgreementsMember",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ndra_ExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price"
       }
      }
     },
     "localname": "ExercisePrice",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "ndra_ExpectedDividendYield": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected Dividend Yield"
       }
      }
     },
     "localname": "ExpectedDividendYield",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "ndra_FairValueOfOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of options"
       }
      }
     },
     "localname": "FairValueOfOptions",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_FairValueOfVestedStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of vested stock options"
       }
      }
     },
     "localname": "FairValueOfVestedStockOptions",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_FixedAssetsWriteOff": {
     "auth_ref": [],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed assets write off"
       }
      }
     },
     "localname": "FixedAssetsWriteOff",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_FrancoisMichelonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Francois Michelon [Member]"
       }
      }
     },
     "localname": "FrancoisMichelonMember",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ndra_GrossProceedsFromSalesOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Proceeds From Sales Of Common Stock"
       }
      }
     },
     "localname": "GrossProceedsFromSalesOfCommonStock",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_IncomeTaxesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxesAbstract",
     "nsuri": "http://novaworks.com/20221231",
     "xbrltype": "stringItemType"
    },
    "ndra_InitialTermInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Term Interest Rate"
       }
      }
     },
     "localname": "InitialTermInterestRate",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/BankLoansDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "ndra_JanuaryOneTwentyFifteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 1, 2015 [Member]"
       }
      }
     },
     "localname": "JanuaryOneTwentyFifteenMember",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ndra_JuneTwentyTwentyOneATMAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "June 2021 ATM Agreement [Member]"
       }
      }
     },
     "localname": "JuneTwentyTwentyOneATMAgreementMember",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ndra_LeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "2025 And Beyond"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_MichaelThorntonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Michael Thornton [Member]"
       }
      }
     },
     "localname": "MichaelThorntonMember",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ndra_MonthlyRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Monthly Rent"
       }
      }
     },
     "localname": "MonthlyRent",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_NetOperatingLossCarryforwardBegainToExpire": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforward begain to expire"
       }
      }
     },
     "localname": "NetOperatingLossCarryforwardBegainToExpire",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_NetProceedsFromSalesOfCommonStock3": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Proceeds From Sales Of Common Stock"
       }
      }
     },
     "localname": "NetProceedsFromSalesOfCommonStock3",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_NumberOfWarrantsEndingBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants ending balance"
       }
      }
     },
     "localname": "NumberOfWarrantsEndingBalance",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ndra_NumberOfWarrantsExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants exercisable"
       }
      }
     },
     "localname": "NumberOfWarrantsExercisable",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ndra_OperatingLeaseDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Discount Rate"
       }
      }
     },
     "localname": "OperatingLeaseDiscountRate",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "ndra_OptionsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options to purchase common stock"
       }
      }
     },
     "localname": "OptionsToPurchaseCommonStockMember",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ndra_PreferredStockSharesUndesignated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock shares, undesignated"
       }
      }
     },
     "localname": "PreferredStockSharesUndesignated",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ndra_PreferredsStockSeriesAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredsStockSeriesAMember",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ndra_PrincipalAggregateAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal Aggregate Amount"
       }
      }
     },
     "localname": "PrincipalAggregateAmount",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/BankLoansDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_RenaudMalobertiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Renaud Maloberti [Member]"
       }
      }
     },
     "localname": "RenaudMalobertiMember",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ndra_RentExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Rent Expense"
       }
      }
     },
     "localname": "RentExpenses",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_RentSpace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rent Space"
       }
      }
     },
     "localname": "RentSpace",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "ndra_RentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rent Term"
       }
      }
     },
     "localname": "RentTerm",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "ndra_ResearchAndDevelopmentExpense1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense1",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_RestictedStockUnitsValued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Resticted stock units valued"
       }
      }
     },
     "localname": "RestictedStockUnitsValued",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Options and Restricted Stock Units (RSU's)"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsDisclosureTextBlock",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsus"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ndra_ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Common Stock Warrants]",
        "verboseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationWarrantsDisclosureTextBlock",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommonStockWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ndra_SeriesAConvertiblePreferredStockConvertedToCommonStockAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Convertible Preferred Stock converted to common stock, amount"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredStockConvertedToCommonStockAmount",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_SeriesAConvertiblePreferredStockConvertedToCommonStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Convertible Preferred Stock converted to common stock, shares"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredStockConvertedToCommonStockShares",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ndra_SeriesBPreferredStocksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Convertible Preferred Stocks"
       }
      }
     },
     "localname": "SeriesBPreferredStocksMember",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Expired]",
        "negatedLabel": "Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ndra_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Weighted Average Exercise Price Outstanding, Beginning]",
        "periodStartLabel": "Weighted Average Exercise Price Outstanding, Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Weighted Average Exercise Price Exercised]",
        "verboseLabel": "Weighted Average Exercise Price Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Weighted Average Exercise Price Forfeited]",
        "verboseLabel": "Weighted Average Exercise Price Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ndra_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Weighted Average Exercise Price Granted]",
        "verboseLabel": "Weighted Average Exercise Price Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Weighted Average Remaining Contractual Term Outstanding, Beginning]",
        "verboseLabel": "Weighted Average Remaining Contractual Term Outstanding, Beginning"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Weighted Average Remaining Contractual Term Outstanding, Ending]",
        "verboseLabel": "Weighted Average Remaining Contractual Term Outstanding, Ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Weighted Average Remaining Contractual Term Outstanding, Exercisable]",
        "verboseLabel": "Weighted Average Remaining Contractual Term Outstanding, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermExercisable",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Term Outstanding, Granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ndra_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Term Outstanding, Beginning"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ndra_SharesAvailableForIssuanceIncreasedUnderTheOmnibusPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Available For Issuance Increased Under The Omnibus Plan"
       }
      }
     },
     "localname": "SharesAvailableForIssuanceIncreasedUnderTheOmnibusPlan",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ndra_SharesForServicesValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares For Services Value"
       }
      }
     },
     "localname": "SharesForServicesValue",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_SharesInReturn": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares in return"
       }
      }
     },
     "localname": "SharesInReturn",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_SharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issuable upon Conversion of Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "SharesIssuableUponConversionOfSeriesAConvertiblePreferredStockMember",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ndra_StockBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation"
       }
      }
     },
     "localname": "StockBasedCompensation",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_StockDividendPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Stock dividend payable"
       }
      }
     },
     "localname": "StockDividendPayable",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_StockIssuedForRsuAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued for RSU, amount"
       }
      }
     },
     "localname": "StockIssuedForRsuAmount",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_StockIssuedForRsuShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued for RSU, shares"
       }
      }
     },
     "localname": "StockIssuedForRsuShares",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ndra_StockOptionGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option granted"
       }
      }
     },
     "localname": "StockOptionGranted",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ndra_StockPayable": {
     "auth_ref": [],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedBalanceSheets": {
       "order": 19.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock payable"
       }
      }
     },
     "localname": "StockPayable",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_StockPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Payable [Member]"
       }
      }
     },
     "localname": "StockPayableMember",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ndra_StockPayableShare": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Payable"
       }
      }
     },
     "localname": "StockPayableShare",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ndra_SupplementalDisclosuresOfNoncashItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosures of non-cash items"
       }
      }
     },
     "localname": "SupplementalDisclosuresOfNoncashItemsAbstract",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ndra_TDBankLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TD Bank Loan [Member]"
       }
      }
     },
     "localname": "TDBankLoanMember",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/BankLoansDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ndra_TotalCommonStockSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Common Stock Shares Issued"
       }
      }
     },
     "localname": "TotalCommonStockSharesIssued",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ndra_WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants"
       }
      }
     },
     "localname": "WarrantsMember",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ndra_WarrantsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants To Purchase Common Stock"
       }
      }
     },
     "localname": "WarrantsToPurchaseCommonStockMember",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ndra_WeightedAverageExercisableAtJune302022": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercisable at June 30, 2022"
       }
      }
     },
     "localname": "WeightedAverageExercisableAtJune302022",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ndra_WeightedAverageExercisePriceOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price outstanding"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOutstanding",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ndra_WeightedAverageRemainingLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average Remaining Lease Term"
       }
      }
     },
     "localname": "WeightedAverageRemainingLeaseTerm",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "ndra_WorkingCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Working Capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://novaworks.com/20221231",
     "presentation": [
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r199",
      "r229",
      "r343",
      "r351",
      "r363",
      "r364",
      "r379",
      "r380",
      "r385",
      "r418",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r199",
      "r229",
      "r343",
      "r351",
      "r363",
      "r364",
      "r379",
      "r380",
      "r385",
      "r418",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r199",
      "r228",
      "r229",
      "r255",
      "r256",
      "r257",
      "r319",
      "r343",
      "r351",
      "r363",
      "r364",
      "r379",
      "r380",
      "r385",
      "r414",
      "r418",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r199",
      "r228",
      "r229",
      "r255",
      "r256",
      "r257",
      "r319",
      "r343",
      "r351",
      "r363",
      "r364",
      "r379",
      "r380",
      "r385",
      "r414",
      "r418",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "[Accounts Payable and Accrued Liabilities, Current]",
        "verboseLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/AccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r84",
      "r98"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.",
        "label": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable And Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/AccountsPayableAndAccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r11",
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/AccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrentAndNoncurrent": {
     "auth_ref": [
      "r85",
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements.",
        "label": "Accrued Bonuses"
       }
      }
     },
     "localname": "AccruedBonusesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/AccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r16"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/AccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedInsuranceCurrentAndNoncurrent": {
     "auth_ref": [
      "r1",
      "r3",
      "r81",
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees.",
        "label": "Insurance Premium Financing"
       }
      }
     },
     "localname": "AccruedInsuranceCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/AccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r52",
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "[Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment]",
        "negatedLabel": "Accumulated Depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r6",
      "r384"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedBalanceSheets": {
       "order": 18.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r406",
      "r407",
      "r408",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Potential Equivalent Shares Excluded",
        "verboseLabel": "Potential Equivalent Shares Excluded"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r80",
      "r90",
      "r112",
      "r134",
      "r171",
      "r173",
      "r175",
      "r179",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r283",
      "r287",
      "r294",
      "r384",
      "r416",
      "r417",
      "r456"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "[Assets]",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r106",
      "r119",
      "r134",
      "r179",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r283",
      "r287",
      "r294",
      "r384",
      "r416",
      "r417",
      "r456"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "[Assets, Current]",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date Axis"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type Axis"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r76",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Nature Of The Business"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/NatureOfTheBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalUnitsAuthorized": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.",
        "label": "[Capital Units, Authorized]",
        "verboseLabel": "Capital Stock"
       }
      }
     },
     "localname": "CapitalUnitsAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r357",
      "r358",
      "r384",
      "r396"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r28",
      "r34",
      "r40"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents]",
        "periodEndLabel": "Cash, end of year",
        "periodStartLabel": "Cash, beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r28",
      "r78"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]",
        "totalLabel": "Net increase (decrease) in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r134",
      "r152",
      "r153",
      "r156",
      "r158",
      "r163",
      "r164",
      "r179",
      "r200",
      "r202",
      "r203",
      "r204",
      "r207",
      "r208",
      "r212",
      "r213",
      "r215",
      "r219",
      "r226",
      "r294",
      "r365",
      "r395",
      "r404",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative",
      "http://novaworks.com/role/ConsolidatedBalanceSheets",
      "http://novaworks.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r55",
      "r194",
      "r195",
      "r359",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r406",
      "r407",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock shares, par value",
        "verboseLabel": "Common Stock Shares, Par Value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative",
      "http://novaworks.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock shares, authorized",
        "verboseLabel": "Common Stock Shares, Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative",
      "http://novaworks.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock shares, issued",
        "verboseLabel": "Common Stock Shares, Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative",
      "http://novaworks.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r384"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedBalanceSheets": {
       "order": 17.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.0001 par value; 80,000,000 shares authorized; 3,169,103 and 2,127,725 shares issued and outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r77",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Principles Of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r37",
      "r38",
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion Of Common Stock"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CumulativeDividends": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative cash dividends distributed to shareholders.",
        "label": "Cumulative Net Loss"
       }
      }
     },
     "localname": "CumulativeDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r120",
      "r376",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Expiration Date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "[Deferred Tax Assets, Gross]",
        "negatedLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r447"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r75",
      "r448"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "[Deferred Tax Assets, Operating Loss Carryforwards]",
        "negatedLabel": "Net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r32",
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation Expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/FixedAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r32",
      "r169"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DevelopmentInProcess": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current amount of expenditures for a real estate project that has not yet been completed.",
        "label": "Taeus Development And Testing"
       }
      }
     },
     "localname": "DevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Options and Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r60",
      "r88"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations": {
       "order": 13.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "[Dividends]",
        "negatedLabel": "Deemed dividend",
        "verboseLabel": "Deemed dividend"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows",
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPreferredStock": {
     "auth_ref": [
      "r60",
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Stock payable towards preference dividend"
       }
      }
     },
     "localname": "DividendsPreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r126",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r150",
      "r152",
      "r156",
      "r157",
      "r158",
      "r160",
      "r292",
      "r293",
      "r346",
      "r349",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Net loss per share - basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r44",
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Net Earnings (loss) Per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r135",
      "r265",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "[Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent]",
        "negatedLabel": "U.S. federal statutory income tax"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r446",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r446",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "[Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent]",
        "verboseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r446",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "State tax, net of federal tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r16"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Payroll"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/AccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r59",
      "r104",
      "r123",
      "r124",
      "r125",
      "r137",
      "r138",
      "r139",
      "r141",
      "r147",
      "r149",
      "r162",
      "r180",
      "r227",
      "r259",
      "r260",
      "r261",
      "r271",
      "r272",
      "r291",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r308",
      "r352",
      "r353",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r303",
      "r306",
      "r383"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Right of use asset"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r177",
      "r178",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r210",
      "r224",
      "r289",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r375",
      "r410",
      "r411",
      "r412",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument Axis"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r32",
      "r56",
      "r57"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain on extinguishment of debt",
        "verboseLabel": "Gain on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows",
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r20",
      "r79",
      "r86",
      "r100",
      "r171",
      "r172",
      "r174",
      "r176",
      "r347",
      "r374"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations": {
       "order": 10.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "[Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest]",
        "totalLabel": "Loss from operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r135",
      "r266",
      "r267",
      "r270",
      "r273",
      "r276",
      "r278",
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r136",
      "r148",
      "r149",
      "r170",
      "r264",
      "r274",
      "r277",
      "r350"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations": {
       "order": 11.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r29",
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income tax paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "[Increase (Decrease) in Inventories]",
        "negatedLabel": "Increase in inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r402",
      "r453"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Decrease in lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "[Increase (Decrease) in Prepaid Expense]",
        "negatedLabel": "Decrease in prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r127",
      "r130",
      "r131"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r117",
      "r366",
      "r384"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "[Inventory, Net]",
        "terseLabel": "Inventory",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheets",
      "http://novaworks.com/role/InventoryDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r108",
      "r116",
      "r161",
      "r189",
      "r190",
      "r191",
      "r344",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Office Lease, Description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Schedule Of Operating Lease Liabilities Maturities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "[Lessee, Operating Lease, Liability, to be Paid]",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]",
        "negatedLabel": "Less: Amount Representing Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r15",
      "r134",
      "r179",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r284",
      "r287",
      "r288",
      "r294",
      "r373",
      "r416",
      "r456",
      "r457"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedBalanceSheets": {
       "order": 21.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "[Liabilities]",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r10",
      "r83",
      "r94",
      "r384",
      "r405",
      "r413",
      "r452"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "[Liabilities and Equity]",
        "totalLabel": "Total Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r17",
      "r107",
      "r134",
      "r179",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r284",
      "r287",
      "r288",
      "r294",
      "r384",
      "r416",
      "r456",
      "r457"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedBalanceSheets": {
       "order": 14.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "[Liabilities, Current]",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt"
       }
      }
     },
     "localname": "LiabilitiesOtherThanLongTermDebtNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityInitiationDate1": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the credit facility first became available, in YYYY-MM-DD format.",
        "label": "Expiration Initial Term"
       }
      }
     },
     "localname": "LineOfCreditFacilityInitiationDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/BankLoansDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LoansPayable": {
     "auth_ref": [
      "r2",
      "r82",
      "r89"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedBalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).",
        "label": "Loans"
       }
      }
     },
     "localname": "LoansPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r2",
      "r82",
      "r92",
      "r209",
      "r211",
      "r377",
      "r378"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedBalanceSheets": {
       "order": 15.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "[Long-Term Debt]",
        "totalLabel": "Total Long Term Debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermLoansPayable": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedBalanceSheets": {
       "order": 12.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Loans, long term"
       }
      }
     },
     "localname": "LongTermLoansPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "[Net Cash Provided by (Used in) Financing Activities]",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "[Net Cash Provided by (Used in) Investing Activities]",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r28",
      "r30",
      "r33"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "[Net Cash Provided by (Used in) Operating Activities]",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r21",
      "r33",
      "r87",
      "r99",
      "r105",
      "r121",
      "r122",
      "r125",
      "r134",
      "r140",
      "r142",
      "r143",
      "r144",
      "r145",
      "r148",
      "r149",
      "r154",
      "r171",
      "r172",
      "r174",
      "r176",
      "r179",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r293",
      "r294",
      "r374",
      "r416"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations": {
       "order": 12.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "[Net Income (Loss) Attributable to Parent]",
        "totalLabel": "Net Loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations",
      "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r145",
      "r150",
      "r151",
      "r155",
      "r158",
      "r171",
      "r172",
      "r174",
      "r176",
      "r374"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "[Net Income (Loss) Available to Common Stockholders, Basic]",
        "totalLabel": "Net Loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "[Nonoperating Income (Expense)]",
        "totalLabel": "Total other expenses"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "[Operating Expenses]",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r171",
      "r172",
      "r174",
      "r176",
      "r374"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "[Operating Income (Loss)]",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "[Operating Lease, Liability]",
        "terseLabel": "Present Value Of Future Minimum Lease Payments",
        "verboseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetails",
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r302"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Lease liabilities, current portion",
        "negatedLabel": "Less: Current Obligations Under Lease"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetails",
      "http://novaworks.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r302"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedBalanceSheets": {
       "order": 13.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Lease liabilities",
        "verboseLabel": "Long-term Lease Obligations"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetails",
      "http://novaworks.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r301"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right of use assets",
        "verboseLabel": "Right Of Use Assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheets",
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Amortization of right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "[Operating Loss Carryforwards]",
        "verboseLabel": "Net operating loss carryforward"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of the Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Current Assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations": {
       "order": 7.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expenses"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "[Payments to Acquire Property, Plant, and Equipment]",
        "negatedLabel": "Purchases of fixed assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name Axis"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/BankLoansDetailsNarrative",
      "http://novaworks.com/role/CapitalStockDetailsNarrative",
      "http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/BankLoansDetailsNarrative",
      "http://novaworks.com/role/CapitalStockDetailsNarrative",
      "http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable preferred class A stock or outstanding convertible preferred class A stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Preferred Class A"
       }
      }
     },
     "localname": "PreferredClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable preferred class B stock or outstanding preferred class B stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Preferred Class B"
       }
      }
     },
     "localname": "PreferredClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r4",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock shares, par value",
        "verboseLabel": "Preferred Stock Shares, Par Value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative",
      "http://novaworks.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock shares, authorized",
        "verboseLabel": "Preferred stock authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative",
      "http://novaworks.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r4",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock shares, issued",
        "verboseLabel": "Preferred Stock Shares, issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative",
      "http://novaworks.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock shares, outstanding",
        "verboseLabel": "Preferred stock shares, outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative",
      "http://novaworks.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r4",
      "r384"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedBalanceSheets": {
       "order": 16.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Series A Convertible Preferred Stock, $0.0001 par value; 10,000 shares authorized; 141.397 shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r118",
      "r192",
      "r193",
      "r367"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollectionOfNotesReceivable": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.",
        "label": "Paycheck protection program note to first republic bank"
       }
      }
     },
     "localname": "ProceedsFromCollectionOfNotesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/BankLoansDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of common stock",
        "verboseLabel": "Net proceeds from sale of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative",
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r401"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from warrant exercise"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r105",
      "r121",
      "r122",
      "r128",
      "r134",
      "r140",
      "r148",
      "r149",
      "r171",
      "r172",
      "r174",
      "r176",
      "r179",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r282",
      "r285",
      "r286",
      "r293",
      "r294",
      "r347",
      "r374",
      "r381",
      "r382",
      "r399",
      "r416"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]",
        "negatedLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r54",
      "r360",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "verboseLabel": "Fixed Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/FixedAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r51",
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Leasehold And Capitalized Software"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r53",
      "r95",
      "r348",
      "r384"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Fixed assets, net",
        "verboseLabel": "Fixed Assets, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheets",
      "http://novaworks.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r53",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Capitalization Of Fixed Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Fixed Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/FixedAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank Loans"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r103",
      "r309",
      "r310",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction Axis"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r71",
      "r102",
      "r464"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r60",
      "r93",
      "r355",
      "r356",
      "r384"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r104",
      "r137",
      "r138",
      "r139",
      "r141",
      "r147",
      "r149",
      "r180",
      "r259",
      "r260",
      "r261",
      "r271",
      "r272",
      "r291",
      "r352",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SalariesAndWages": {
     "auth_ref": [
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Annual Basic Salary"
       }
      }
     },
     "localname": "SalariesAndWages",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule Of Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/AccountsPayableAndAccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Anti-dilutive Shares"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of deferred tax assests and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of U.S. federal statutory rate and the effective tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r65",
      "r66",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Schedule Of Warrant Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommonStockWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r64",
      "r66",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Summary Of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r397",
      "r398",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative",
      "http://novaworks.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [
      "r397",
      "r398",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock.",
        "label": "Series B Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative",
      "http://novaworks.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [
      "r397",
      "r398",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C preferred stock.",
        "label": "Series C Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock compensation expense including common stock issued for RSUs"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r62",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Share based compensation, description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r242",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number]",
        "periodStartLabel": "Balance Outstanding, Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.",
        "label": "Discount Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk Free Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number]",
        "periodEndLabel": "Number Of Options Outstanding, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price]",
        "periodEndLabel": "Weighted Average Exercise Price Outstanding, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period]",
        "negatedLabel": "Number Of Options Cancelled Or Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Weighted Average Exercise Price Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number Of Options Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number]",
        "periodEndLabel": "Number Of Options Outstanding, Ending",
        "periodStartLabel": "Number Of Options Outstanding, Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price]",
        "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending",
        "periodStartLabel": "Weighted Average Exercise Price Outstanding, Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted Average Exercise Price Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Weighted Average Exercise Price Cancelled Or Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted Average Exercise Price Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r233",
      "r252",
      "r253",
      "r254",
      "r255",
      "r258",
      "r262",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected Life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Contractual Term Outstanding, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Contractual Term Outstanding, Ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Number Of Options, Forfeited"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "[Shares, Issued]",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTextBlock": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for short-term debt.",
        "label": "Short-Term Debt [Text Block]",
        "verboseLabel": "Bank Loans"
       }
      }
     },
     "localname": "ShortTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/BankLoans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r41",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Summary Of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r134",
      "r152",
      "r153",
      "r156",
      "r158",
      "r163",
      "r164",
      "r179",
      "r200",
      "r202",
      "r203",
      "r204",
      "r207",
      "r208",
      "r212",
      "r213",
      "r215",
      "r219",
      "r226",
      "r294",
      "r365",
      "r395",
      "r404",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative",
      "http://novaworks.com/role/ConsolidatedBalanceSheets",
      "http://novaworks.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r19",
      "r59",
      "r104",
      "r123",
      "r124",
      "r125",
      "r137",
      "r138",
      "r139",
      "r141",
      "r147",
      "r149",
      "r162",
      "r180",
      "r227",
      "r259",
      "r260",
      "r261",
      "r271",
      "r272",
      "r291",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r308",
      "r352",
      "r353",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/BankLoansDetailsNarrative",
      "http://novaworks.com/role/CapitalStockDetailsNarrative",
      "http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetailsNarrative",
      "http://novaworks.com/role/CommonStockWarrantsDetails",
      "http://novaworks.com/role/ConsolidatedBalanceSheets",
      "http://novaworks.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Stockholders Equity"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r162",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/BankLoansDetailsNarrative",
      "http://novaworks.com/role/CapitalStockDetailsNarrative",
      "http://novaworks.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetailsNarrative",
      "http://novaworks.com/role/CommonStockWarrantsDetails",
      "http://novaworks.com/role/ConsolidatedBalanceSheets",
      "http://novaworks.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r4",
      "r5",
      "r59",
      "r60",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Number Of Options Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CommonStockOptionsAndRestrictedStockUnitsRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r4",
      "r5",
      "r60",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Based Compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CapitalStockDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r5",
      "r8",
      "r9",
      "r49",
      "r384",
      "r405",
      "r413",
      "r452"
     ],
     "calculation": {
      "http://novaworks.com/role/ConsolidatedBalanceSheets": {
       "order": 22.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "[Stockholders' Equity Attributable to Parent]",
        "periodEndLabel": "Balance, amount",
        "periodStartLabel": "Balance, amount",
        "totalLabel": "Total Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheets",
      "http://novaworks.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r61",
      "r133",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r225",
      "r227",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Capital Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/CapitalStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "verboseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.",
        "label": "Going Concern"
       }
      }
     },
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosures of cash items"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r177",
      "r178",
      "r210",
      "r224",
      "r289",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r410",
      "r411",
      "r412",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r46",
      "r47",
      "r48",
      "r165",
      "r166",
      "r167",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "auth_ref": [
      "r42",
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).",
        "label": "Weighted average common shares - basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://novaworks.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=51888271",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.16(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r386": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r387": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r388": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r389": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r391": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r392": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r393": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r394": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2646-109256",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(1),(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16)(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.10)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>66
<FILENAME>0001654954-23-003044-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001654954-23-003044-xbrl.zip
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M*G?UD=@>KTIX/7-B?UD3UQ&!U,V?'N)OY;CET!OQ>U\=O[AXRY?? UD)R"O
MUK<N>3&,NXC,"-N'ZK!)J982VZ.50.L1<(_"Z7*^ACK<]_')JS B\E^YTT/,
M=@D3S.*++T4B(-:I,*'08Y# X-G;; !]$W,76F&QW;<!YA-;!84(KYY$E[81
M#&"I2&M$ZH<T4H%@-<=%HJU(MJ6%]^@ET+O#.V$?H<&Z%'TU8O QC4'(V[LX
MX>);] J="6-A/!0O,+EY?)QVL^*V?/;>TPE/!\-=A"UO8.'""79$"?6@<X_
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M<D&>;$E]B\HG3FBD%%&#(L9=IZ3(U+E8,6O9GI@Q9!?0$*V<%>0E=QT5@)?
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MP_\*1D67[C;"*MNK197,H/T7RC +#@OH0AF>&K,!(6&Z/)R]#_=R3GA K?O
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MK*\ZM"XHI0,[7%N63L+BPI8ZNQ^GM-$&GTO?TAE8=4&V_GVA4YI1,\/UM#P
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M1#9?>!M=G:F2[K07>)[G3^MU\9MQ+#RYL>QT)!R"O3;D4NZ#F>NX1+T%\V+
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M)T[LTQLGT77]($6;?O#>KRG:7\!W*Y?MCJ"[7%CAH31XC;@3+6!OY)W2-\Z
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MW9BQ2.AUFBL@O7Q!L>,G#&?=HZFKLB9V=*Y.P1IE379TL9AN/9,1RD[!K+
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M7G5J?'U_^QYX3!\D>0' IR40KABV, /R9?BFU6F_+!\X-ISV#%F7YBO O'#
M%.B"D*B Z@?.2";)[!N@^$A=Z0Q\0;CFTH!.UHPO4@NT"]U/&$%0R G?#YQ6
MI%TCJJWJ78>2J#QV8#[;K* - 8R'JTGS?(R,&#RMG(&0W )XQ=Q#EB5[%"+/
MMW=A\CD*7>0>L-@^0-F;'GZ.[XLHX:XNA_\*N[>?K;<S76\6%*([C5U-/<>N
M6HQK/TZ-WMZV&6)KAYY)SPP-53MA'53Y8OX$\@S0C[ZC7\T#)8)2)I4WM3*Z
M>""PK\+^9W&#?\6N8=NC@;J.V0Z?8+<W^\D"C;[%'VC4]JY<?=RR@O"^GMY/
MV76*R&\(DJW(#P]^>)_=M3?O-_L48'I\R*K53GV>-NOXY6+KVN!AVA=WP^.T
MF&?(SB VY?/5S4>FQ;UD#U<+.X.PRN&^+0>NSOY:=KAG#<HT&X[C^OA:Z7>K
MPEP6 CU']] /[R+J_<[U%^ZBK<GIIGN%"F<<=57F!359K#WCGNE]07<T:F!/
MRR*92! M3=-T5&K61E?38X\/_K/OHI"DG>2G].0(_8/_$O_D3G(CASXLR3W^
M:FW,Z3T!NK]D24 B#W="\@"B0^KAQ2I9OZ8/". ^>:0N5K'KAR1ZDIN5D)#^
MP>N.1[R\3<A&\R$*7!0G1)@H/D$:])UD%4E?WS>ZL/R'3_A?^(_YG_#_(>=+
M?_E_4$L#!!0    ( %R&<%:H-NP<BC8  &D. P 5    ;F1R82TR,#(R,3(S
M,5]P<F4N>&UL[7UM<]PXDN;WB[C_4-?WX68BSFV^OTSL[(4LV1W:M26OK.[>
MO2\(D 0E7E.DAF3)UOSZ UC%*E81 ,&7*H":V8EUVQ(2Q).)!!*)S,2__)\?
M3^GJ!15EDF=__4G_6?MIA;(PCY+LX:\_K<MWL R3Y*=56<$L@FF>H;_^](K*
MG_[/O_[W__8O_^/=N__\</=Y=96'ZR>45:O+ L$*1:OO2?6X(K_Z LL*%>_>
M;5O_MOG.7U;&S^;/FK?[^0=88JH\JVGP+_7=;ZYP?ZL\7H6DYYI4,]_KSGM#
M,\Q=HV]Y7'V'!5K!(GQ,*A16ZP*FJPB5R4.VP@-?;0#]977QO\+5U2,LGN!S
M@9Y@1D"M+EZJGW=]7>;/KT7R\%BM_A3^>44^L[I^=_/Q?O5A7289*LO5MSQ=
MDZ&4_WMUG84_KR[2='5'*,K5'2I1\8*B;7=IDOWQ%_)'@/&M,*.S\B\_RN2O
M/SU6U?-?WK___OW[S]_-G_/B >/1]/?_^>7SM_ 1C^M=DA&&A^BGAHKT0J/3
M?=]_7_^V:=II^2,HTN8;YOMF.+AYF?REK#_W.0]KY@J0K9@MR+_>-<W>D1^]
MTXUWIO[SCS+Z"7-CM=KPH\A3=(?B%?GOKW?7NV]F^0O\GA=_E#^'^=-[\MOW
MESF>F'B@-=UC@>*__I1%!<2=&X9N;+K^GP>-JM=G/$'+Y.DYQ0C?C_UL5N9I
M$I&I_ &F1 [?'A&JROZA]!">=GA?L0IDU2.JDA"FH\=*[67V@7^K\)]DS2AO
MX]MG5-3S;Q"#^3V<=,#?JCS\XS%/([R<??S;.JE>QPZ<W=-) 5S"\O%3FG\?
MS?!.![,,]P;BA1O=QO>/J%EM^P;((9EE2-_63T^P>,62PEM)$F.=R*J+,,S7
M684WE*^8-V&">D<YK)=9!GZ=O6!1Y47OU.PTG.7SGY(?*+HH2X%5D])TEB%L
M&8P7M%<8I.@BB_!/BC6*/B<P2-*D$A#<D#YF&?0'F/WQ.8?]2V&GX3P+!GQ.
M*IC6RU+OVD!I.].J]?249W6_M\_UJH[YCDVKJDC">AW"O_@U2ZKRKEP+K& C
M.IL;QN^P*+#*#QGL,<EL0TJJ>@W'7,"+.UE^L+DOH D"I#.M6_BOZ![^Z!\2
MI>E,:WY0HK^M,=2/9&D46-WI[<^X <V[$9UD0Q+[]#U99F>"<=C7W-N:V$B9
M!&?;XL3&.;RG\R_U8D@F='FJ97_PP.F$I]X"Q(<IU,'<VX'8\)@$9US$KE %
MDW2F5>RHL_/#N"&3L4I>T*QX.KW.>^H9.O9>PKFW#\$YPJ8XT8"$.29 >K8]
M3I"9([J:]U WE,>]A+,?^H:.4(3V_):"X'R8TJ<T4.*BF:/S4YE$PR7$H#RU
M431@H&(]G&G @Z;)P*[FMNP$><RF.-& ].$CTD\\I $&32\I>XC/!2KQA*BO
M5#[C'QP0H!\5RB(4-=V0D0K?XE5)15IKF__35^_VE\?O5G7+U5?X@%;769P7
M3_4 -I>'S=#2/#P834KN+O.C6T(RF!*/IKZA+%'X\T/^\CY"";DV-LA?:E[5
M?,+_ /5W+P*\,L*P:GI*88#2NG^ VQPU>7_R,7W$>EB]WJ&'A'PSJV[@$Z(/
MC=[R<(1M@5X4X2HO(E1@,30]PB(\$&/W>G?;XOUS?3WX+GQ,TMT,B(O\B<6I
M+5_RGN&VV8<_=3X.7V(T!4RO\8S^\>_HE<?B3E,A'NO2>,R =E8F-]I]CWND
M\_:PA1!+#0DLI0$Y*R<O\-<C,H)/*7R@L_*HB1 O30F\I$*1H/N_Y2D^#L+B
M]5.2HJ+DZ7ZGJ1!S+6FZSX!V5B9?K@N"Y5-2AC#]+P2+CUE$XKD8.RRSM1"K
M;0FL[@,H84K_CM+TW[/\>_8-P3+/4'1=ENN]^46;VDP2(;X[TJ9X#U0)S/_V
M!-/T. R%QO*CAD*,=J4QF@I+!GL?L<3Q<?499EP[[;"=$',]><RE@)+ VX]/
MJ'C !_]?BOQ[]2C 9 :!$+=]:=SFPI1Q^MCL('?H.2^(WX7$V*VY2P>+0NPL
M(N_ QT<JY4SR%15)'G&-$D93,6;+./EQL4F8X+7Y>8G'\-"*,*3-ZZ.&8AR6
M<1#DX)(RBS?6YT;>G_#/&*L'I[D8KV4<%'LQ2N0XL?>%^=UJ+,9M&2?''GPR
MML?]]<^W1PROO%U7=282WD"XFR273DP",@Z4XJ@E"./K.DB3\%.:0X:/G-),
MC-7RSI 43%*6E(LL6\-T8QSQUY/#EF+\E7%TY"&3XX$N8%8FA#4B;.ZV%F.U
MC(-D'T))9M_-^BG@>Y[:K<38*^_DV$4D@:WD4K? HJWY4N=C79* I@)O&1'W
M=K"'4.S61=[A40BW!'G<PQ_7$098!SN2L?7/>2:)F SDW2;V8)6B#14B0TY>
M$#[EPJV'@:\&= HQWLL[;?*1GI7UUV%<7*RC!/=S456HW+")?2?):R_&=AD'
MSWZ4$N;[111A%I7;_WQ.,J3S)CNUN1C+Y=U;<C JP7%C&,<-48[+.VUR,,KC
M^"7^ZVUQGW_/!/C=;BS&;7D'3B8^>;RN[:G;XFN1OR2;DB-]#.]0B'%=W@TF
M'ZD\UG_-\<Z2_M_DN<]^I[<78[N\NTT>RO-&HI#!% BRV7S80HRQ,@ZC-"1G
M9>7GG'CB'_.,>[[OMA(+1I-QQ&0A.BM;OZ%P76#9ZD9P3T*DZ6SMMA)CJXQ3
M(PO16=EZ7T#B-?_V^A3D*9VG1TW$&"KC*$C%(F62?OP1/L+L ;%CTNDMQ7@K
MX[S'0W;>*-_-H?-34CQ=1W3>'C418ZJ,$QT5BPQNLN?I00,Q3LHXJ5%PR.#C
MYVV=0"XO]XW$^"GC+,; T^'IO[SO#!T?D/\X7:947_W 5O:4L7JWVI5DJY.G
M]L2K+?5J2SYQ@L2P#&HIK,MW#Q ^;V8)2JNR^<E^NFQ_ '9#NXT_)1D>3(*-
MK'QS/<5)M=J2BU #'05V;$V?_Y/@U44F!(#4[0#R\/]Z%^W.;)Q70<;P^%"%
M^.!VP8::9-D09]8U_BLM1.<8PJXM0*%AN*9B,CKD,%\:72B[&SSI(KE,8=G4
MO;SXD8A(YI@$>*'M.9U];T$"8B)JW;3*D%)[7%?Y$TQH._VV<;<M"$Q7[_=X
MGUDN3%Y31<1!)5DVWU"1H/+B*^X-%<6V?,,7Q'#!-%Q@$P$/+P8N5$-:'+;3
M-4D 5^O&7)Z\/HR1%Y4(.+&KDXN+Y<J+CZMURRY#7IM*1MN;]7X#E=H<&+:F
MC(PXY@!51GQ$^V1V*1L3+!\Y6Q'^+? 1=*&G!NOYK*1O/&T,^S1W&<S&6OH,
MD^CCCV>4E8@=5;-M3VT./-_6+'^QXN"#VJ?.RY#/KE3=#>*(I=T*Z"X,G-[H
M#V6E0<6R3[%_;K:5SQLN,,=9#_(%%4%>HKJM EN-X!8#C, TR WZ0D5(![//
MW1\FPRJO8"I1@K?5(RHVD&[R+!0U&KADP-8CV^ZXLQ8C83%P^ZH!<K:V_!D5
MU>O7E)0FS2+RY,8SL9&X2RF/"B#-BI B&YV8"!@;G@#&?24"*4JW>>0E>_B,
M8(GJ%Y=NXU]+5 /F*!V/#%BZYB-[\>(3 [DO=J#,HCEPL02.Y6KZ&Y 7%]R^
M3((\\Z3/+@&FYYA1O'A)'*%I%4I8EDG2*F&,E^_NNU+]UHEH#\#T32/LN$$7
M)_G!>%MU'21+6-A-Q:8!<:A'4!%S<[ H^@3* MLJ'"%E:14H0-X,/8M$=LFQ
M/0+7# )3D4LT <'1U^ZIX%NU+>1;M,V@7WL] WPZ  TSUA1Q%8P5K2#$5KD,
M*4LRJ<V_G7V<1;C5"CB1A_R%"X<*J%4W0XW=<<BN" (OUL.EBX4-JU5I8[%F
M;6WJW3_"['.>/=RCXND*!=40]]OPOC"_-=U0Y) SP[08"KM50$3.\KH9I>@R
MVVV-C]2!;2IR+3A!$(QEF .X59!$(=-&R/'31PH<%/J:>K;K+$(51]^JB2)3
M.0G(?J4DK8"N69:GWFHZJS(> &W%C"UVVQ7:3X%M^*&MB$]H=M%2<+:BRY8E
MV3&>08Y#QH QLM2SFV>1NP!LR4%KAP%UO\%TS;&/*(V!H>F1K\CMI0"[&5>7
M;%RM&C)2XM;VE1Q[A'/<$NBQ&R!%%&NL9)B@6G5FI+AAHZC.<H'I5YA$U]GV
M$4..EY5. #046IHB!LU8(?5A:U6H&2&K[L-DY">;78A]HB-MVDVP/AM^-W=E
M(8QFHFF5HY&A!G?D7;@,11]AD>$#1WD1ANNG=4H2"*]0G(0)QR3HIP5Q@!Q-
MD:OZL<HQ &:KRHT:=MT0>PX@PPG\A0N+ ZM5"V=9YGK?S>CXZWR@Z\AP%;D
M'BMR89"MFCU3)X J2>%?:\8^HBH)][9+.T/<%,\07_WIH+<_O]&,<3-RXUC2
M66!DQKAN(,-6QL0<P&/&$DT%M_",\3#0?'564BJ'^=+H0GE;&>.A[VI0&3?'
M" $Q$;7B%1>8,>XZKN^H)A<FK^D^#C8JR;+9^<7J(5[TY1Y3FP,[UBU5XJTY
MK.8[!JF()$=S'@[NPS#I;)N#P UU5;SOTZ1SC$ARH&;+<XD-X]NB7ARBVHGY
M%17UJSQ"OEP6,7 L#5JJF75=,Z#/K=N+3W+>^/%+2A?KZC$ODK_OCU]<\1T3
M 3=T W_Y8F/BDIMYWAEA_:+O$%%M"$!L>+&I2+[S9#$=89*;?#[P1386IA85
M@(X>ZKWE%Q<B+!JP?::Z_#OBX;N9&#TP(N1U+=UE2'$@Q'W6NGQYBF]K?#K@
M6GH$@[<@/R8TV;GGW4'V[6]L&N#%L0W?A+Y18<E--:<-4&BCZR$$>NQ'4+7Z
MGQ.D1L-VG&4N\;YD!Q$?3+>!M?BWM+L2BW=7LN]FE<>K5D=2JO]@I&@WHOZ+
M$08!L!'TNX4KS@-B%^2\+;!4"M1.89$ Y,6>HXCWO8_95,7JAR;W%'V'.8FY
M\'B115?H!:5Y71AD.UA>B B'#/B^':L2'=(O *K<Q #*/5)_0RGN[@$/\0LL
M_D MD)Q[%"8-\ /HJ.*V&BDU 71RC]B_H P#2TDV<_249 D!15Y^[)5;#R%P
M0EU3)<=QI/!$(<H]<G? #=C62.BRJ\I!>J24V* 66_"M0;39X#_GI8A,]XV!
MYFI:_$:D2H&U/UHO3*XD3^0FS_)#;%O&"%;TZZ4'R(Y]4Q$7YUCI#T,J]_S^
M"TRRDDQ0?$+-/OX@PUTGY>,F=(F?L-A+"AS3-"Q55'F85.A[JC!B!>K',;&.
MU5%@V[9C*Q*#,H<X!>'*K3$W0HQL2'X8(E<1I]H<$NQ'NM@J=7O3X1/FW&6>
M88QK#'/O4_N XKQ FW;W\ <J\8I40 PXR6#Q6KLI21XGIL2 TII#%<*B[O6
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M@ E)C? W(M61V!M9SUK@KS>8D+0ZBIB+(\.P9?N9YE0Q!KZ&X;L#S9F+BMS
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MD$123)E$ ,(0RGJWEC(N 37B40'HASI4Q'<FPG:&?U, X=@'\6CNF#/K6ZM
M"$7C=.U8X^KVJRV!G* X>D!XO^KUD@(GTB)+TA.LS-$-4L@AO0#;-[Q(D:)&
MXL*AJNDHW M6VR%)JFU]UH_UN>EHM>UI!;-HM>UKU>Y,3F(-&5+9H(.I@,'*
M(0(!<AQ+TDE31&*#5'UDAY@)L0T5">L6$195WZ>"EVSE?H#9'Y]SF%%UU#C6
M4=)ZM6DN8>+^QQH6%2K2UYT[H'7I.,3T'=@1<+7(#21E W][S(OJ'A5/I#B.
MR'F2VIZ\F.SHBN1ICF4__5#)Q[O@G?42/B<5<7FUY-W63O-8.[<$JPV%$O7,
M16I#LV@ ]%S'D51UH3NLF[Q"@[9%X2X 0AI2)K:C7QYT/1R,=LFJN<_@V3Z0
M=A#^6?_BURRIRKMR3=U9K8[NUCUN5'>U[;.V@/>];G]9][OZT]VW7\L_RU#R
M_;#K3*9=K<<[E)(LYOV;P &I!MGD4?<O!-/Z!=".S6[YS4GQ!^$CBM8I'@Z]
MN&5;_&(+0WU3.:U7$(>>$<N^<IU79)1(AYF8)-FX;BT3V]1.ZF)@<Q>#'>4_
M=7V?.6W'T5EUO1'"?'K.Z1'8(3)5>=AE)E$-UW$1!BW<A$@VM3*Q[7"9UY=A
M*&-<\.H.;8W8TM=VPF$/,E*2V("&G,T'=0,TPW4T27XTH9$*G!.&]0,LU[9B
MV1&GDX1%/3^,Y,*"5X!6P@)-XSO!7)OVJPW!;#M?:Q0]^0J4ED"+-.1(NRC>
MCF?@13&;"CB^I?FR*UKU\9IQ.RP :\'*\FT=E.AO:]S?QQ?$L*,I05 -T6I+
M)25M\G#D(GF2= J@FY8AJP;,\:!$'& L$F [D>\J<O/3RVVZNZL7VZ*5320.
MD1./J'?BH\3C$5=_:OXFQ;TU<VBB&<0Q[$0VG ?*KR4^7'TLJ^0)G]0X26N'
M[8!EQE[7IE8NU+#A+%4]&9#DOC=X$.-<XWD5.AZPJ8")H!TK$LX]5E9" />O
M$4H)SH=E4M[&1PA?A64H1@]"/[(C5=[R&"G-@5#EOM>W+=QQ7,5(6#5%R(%A
MV9ZK2"F$T3HZ".FDA_?F"R 6EB.+ L30<AQ%+EO&BJX7W/[UO:4]M,2,M126
MO&@/(+"CT%JX$@\&*_?5OL^H+-$F*59\2>80 3_R'%^1*..Q,A3!)_?QO#N$
MUYLU(L]_X7/>(%.WEQ2$R(]5>=AHK C%4>Z?P),CR!)AAI!]_PH/.<WKM6+[
M]-9FR#Q1]A(#S0_\;ECETH0ICE/NTW,?89%A>*1&9WWA*JR5/80@U,+ 53\U
MD2M&48RMA^:D5-F 2?$;3-?H"]X U@7:;]["TA3N D!#][M)@,N2ZW"TK1?D
MU'F,>A/JA->8ZRS$")(71&RXLF\1'M$9<'W=BA:^*$_!+?FU-W*O4&'S/('I
M5;X.JHL@7U>_Y)@%ESD>=I$)WKN(]0'TT+ "11X-'2WMX7"EO_#VO06VR#/\
MUW!3UF+@:CZT)Z#;4 MEWW!/%/AHT*U'WA2^5[NO$]$HMVI&)P=ZR*W:IMNW
M<*>F>U'L2+I3VT<M7N#!14FZ)AO)-Q2NBSK5;U/K'D7DQ0^R^:R;$C;'%J;(
M.C[[MT#LNH[?J26LG/HW$J:O]Z=CB^1X\58)!/8BT$F<;A="D*KF)ZV(8-K0
M,SHA(Y*!3?$PMR)&H&]$BJ1_B0MBF(NYBU:RKHGD;;.5L),9+5J]0*Z"SEW&
M (6AHTGRA;2V 5%1#MMS!_<*3#\.+47N[T7$UK>]CN> .HE7_?F9;"WO9EB/
MRM*4J?**9G Y0>SJDG;S(<F%V^<]7H<O'V/[!BB&7K?TTR*3OQHI]ZPSDUFE
MSFK3)*VQUQ1^YG=#+]5,4'3-@'@N=9\%4F/-F'N=8$SXP(-.H(CW;B9ICEH;
M>MBCP'K 2&5CKPO4)'!F@J?4]4%*IF=HF Z2%-*R";JYQ2=;2,9X6"3^"ZFQ
M/D#U1W0&=$N'4)&KV'%BXP0SC6.%].K NP0]MDYWDK;;*9Q35/@DN9R^9MI0
M5A7MW8)_M0U!Q6/;N#3Q))MTCA_4(8!^I)NR \SZ)-2S9XY#+#<W9C_ZS</
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M@T/O%C>IB)60R,XQ-F [ON,J$L<\[XP_*_O&5N(\U<M=)^3.KJBXFG-_T/"
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M.43NEWP*5K=5%9XVQ$@K[@;8]6>[%'9;E_*)XW_G)6]=9 \A)(<I$6HR@7/
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M!1,@6IK$XR>F-0_S740VIO];/Y%M&R+;NS\J@SF<1?GGX B,PC1[S)0V>/T
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M+X&-\$+;XBG/*)UDQ"BS.LN0QS$ -N*<LG&FRBXPU;%<QW++TSUB$]BEUV/
M5T+(XV73E:",*;^$(,.ST531->H>\:]S> !?5AA;&GNQD3<,#754$C"^9?"E
MG.,LC&*NFY<Z/#"\\0>4]7^5Z PKX^T%BV-.TSC4@@C'+QLI3&2[QN>&4QJ#
MN.C$0B<6.K'0>!,#;Z,S/0C34<G8^]3L5,?J"FT!^ _=Q%$RC881W+T!-A9(
M&0]>%57.Q)S0" /<8W699FA$/,#(UR]@"&08R_*;9'1AJ]];V.H;YW7J1XL0
MB4U"P&CTSM0H2S4P23J+1BYR_&V^X+4=V,-XYSULS-T22IL)>*3R*:M9^ _4
MYRY!<TRN+\ 1 $+/=8*IQ%%1<MJ$16VXT@'>%ZQUKAP(4SHZONCXHC5\06BZ
M"?=YF&&\'_-YN2P:9?L9-LI22.6?/F?8J,9"%( !E.@)]X@QF+KLA61(DX!O
M!%MOQ[\SSE!DL!JKK4Q-ZGEAS,S+Q&G(5NI8JV.MUK#6:3W#QL^VRRJA0,;T
M\8+WHSA"5D$S)IE\F\>]Q238D?5C(6NK.)F[P"*LLVTP2K,YF,R8LI9*W"F?
MHSDM^#B$[EKF&'XSD#DS!@?X,29V(/_IP#%V;LM&CQ\<8TU>*;O%QA7#G"W'
MK@HU>6)&#*-\'JO%+BA<,3#8DR *X8G!DW<?]\XN@F/+ZRWMQKB78\'SBEZ&
MO:!,8I09J"-B= QVR'7#!,$ 9E(F< L!UE?G ;9LW=I\>_CAX&RO1W\,WIH/
MKW3]DS*O?P(:I?W(!+KE*P3*5,G"? L$R)BT-%;P/AKKX'P4:8HE'">CC5Z@
MG/?02#7*UZ&X0\&MEZ(P4IE-BFW1R7PKZ6T]>7=<Z%DPV/";(+::"*M+E7<1
M.X9@DO"I[7)>-*[SW2E<D]BAL^WK0NAFZH.0V$M5$C>;Z!)Y<&MS\Q5U)R6/
M-[8E8P183"S+B+:YI@3[G=CN)CJ98@0M#,#.RE2>E@3;?AF-=.X#1GM0)IB!
M*DA8IO=H!3,:NYR9MPM>%Z@E_OM]4.AAEJI0)Z9[$O58RG,#?IFKL0XLZ!<S
M-0Q<F'9J*DC*V1!KT<859!?77,EX)W'0492-REE><,CPBMI,N*R[_^EGBG%O
M2];*9]A(8CY=!$^-$+D0^?%,$HDFB<:E(79,0JFV!G37_.+D[-C^I-+/31H#
M^QMDOZ>6K"78T K_"Q2!*QE&Z3S'YH^<V61;+.-AS.:(.(B/M4X0'2-9#C:I
M8&D(.F-2@QY'3'#3A^>#_E+FP6#K=9 O<I!"SI4P&U+/W!C5B3ZWRL/=FZ4*
M%%+</.E0ZT@,@1C#,#/WCSD7Q$'/N8=(KE4VHH9<>5&&5#(!,I'@W69IJ&.B
MF JK5/H-@'R,8FXA)+<?L5F!=QNG9_G3H_63$T48"GD99@-2:D*!&NYL[9C,
M-"BC+N9;;R_H=<&>O"\X-%S[R2Z9B(K*K?_\AS<O!CM\*\)O;8(I(]:RP2EL
M7^7>185W_=VL AGEY9RZ%5,+[[4P)P7A7 =Q40ZXI(5!7AR?[E_@2H&S[*G"
MG\S,Y@.8#>?<"%L$9<Z",,J)\MQZ2%Z.-)&4%*[2+9_C)4&5=;Q4RNI1F$%G
M*MOKU,H2>/"F(MW&Z:C,!?[/-,;07T9QF;/M)"ZT6I/(IAZ0K>/LTX9)XF'E
M0:;""):.APB7CA.?9T=6%L[+..<+!@YDAF6-<-A4O@^LPH>E@GR&*5+C3-R3
M3T6;!!DR^-,SDV^A9D"AM&O(1Y,%D]*5L5.!A)-\AFW?\=J16P5-B2 L,Q9"
M1$HY4":UO#;T=G9D7JBPAW7>>"B46 */%63RAEK/91!:2@_> #+:7)*66L?!
MM(3=A*$57#(P0(&PM,4T]T('? &F/!=@E$M.^JZP)<\7)BJ[B5>#&N9I-F1C
MG&<AB28)>@?,)GBLC8RIXMS(6D95*&RP#Z:)>$=9=63IU8#MBK&:!(3 A!H,
MJQ$L(.="4N$*.@[@1V0><V:\C?P +\(.Z6L).>?1Y;F9-NZ@]AL[H81D;&S0
M;85NZFA0*IZD&:@]TA%*]%YQNZ4V,[BRQW#O+_I $G"_^A.BX5O'B&S"$.>A
MM(HCO-.XU>P\3;@CI5$G?D9.^PP63EABRP_D-K1V:&<.X09 <NH%[]_O]\11
M(L3#D,8SUZ@G\UYZ#OL\CO(I D 2V.IA I/3.J-,9K:F\#Z&@YP-I<BIT'G!
MQM=?<G-K#5Z]> MW/)*5$ _*6A]$  YD0R9V;I>*)'NIB<.'"%< .ETRD7L@
M 4F0?6:UE_>)L?[0 -"FZ!)+*I6C4'J.[LY7;W.LTA0WE2W!,-H)KZGD>RK*
M*C57,ZWAKC +)+7#S)SG@45@-B^="9RYS- \2<=9FD0%I8PBG^:<%YYP9Q2Y
MB&.ZM1&6VATX#:@%G-Z>&9FMJ_:Z.CO,=<OI>7<IXFZ"=@YWF[*F!!:#C:(Y
MV2:24A[J&=>SPO]G+=6Y_F*M0G&DP)QEDB9&U#[.VLMQXT=91 (5;NBKGJ35
M9T"]JSO)\K6/BTR0?F"/QJ1?CI7M$!U;Z9E3KB!UK8-CETS"!,70*)TB[!W^
M#/:/?V%45'.G?M@[>G]@KU62X>AX(3T,H7 0!,^\&\GA@__B\P*>2J<:;2^X
M++R7GO_-O+,'JP4;C2"7P7[*IE;7XPF-D!BR#6#S8 ]D;HPZT$M2=\D-9D2W
M"O;3&&B!S%50XLY$_P[V8&K,5D10)FWI$$N:,YBC.&YZ%*2DFY2[#R%M_G(8
M>%@EUDF-W72M_P>>^84#E';(?9I9\'24$B 9:6(]XRBJO--M CD0Y(ZL#HN,
MK' 1H0B$B)''I.;#M KGVT8D&5 BVPP>T= 6?D@O-:G,L(NO!.6!A2^\7MHK
M:5J E((>BU)QX722?6\8)D=KOQZ?7!SN.X,TM6#7HI&@)12Q3XYW>1^D7JC$
MY#J#;<2EV(T\ELP(T'1H;DY%8@]" !?#A&T]HE-:XNFH2&6%KVF%HDN@R(#O
ML>Q%:N/@S"XT*^Q[ K%87<_QQ9Y=S!C85XY%9FVWW-@YS+:5E>(I,<3& @MN
M@7$T7BFUU5B3R.@TU67U@DD9V6ZR5M_PM?J>+=%1F7FPJD:"$LJJT!C]*B(S
MR3(-KA3E)*(89F?KR+$2-H;'R:X^&_S!>_@U6C6G"4P]2GNR0V3\<&406]2F
MB A?2PR4SOO<=G.,T%O))+>PESPU>/<YJ*Z69M^(.H?JF+ 70F?@V9 [!W_D
M)UUCY,3HM;FY*:)D7A:$\)[+H[QL=R B"X7(<!_I>,98+IV7PUG$@G2<VH?V
M#^E^ZKGL'4MVUJ##LUP&+,.13VA+MS:W-C>\ZYNB&[;NBU45*L$*'<48/P-I
M%Y(.+O1EOP*1.D?UF:CQ QP&2$7@8/A]+S@L$2J1#F,/,S-PLN)0)U7+-]@-
M35?); 4)$\7U06,K8(D':%K#SA_!!75D[2WGP^I_/#ARQIMM-$6@4,9HY3.!
MNXJX_.]EHFG#1(B9C5'!SF#SZ>=GH"MJ41@^I 5Y!MAJ<*<GQMK1P9Y=]8HC
MV@B.4C32**E%$V?F3EKB"XAIDH2A)/FKB%K.H2)H3&[OC31K"_L:LA6#+Y/9
MPXTYO5+,FNAIP*_2.>@2!#='@X2E-DM(4F0AL/90"9/!5E&;0D\.3/=(#[,2
M[1?8Q"T4'PG8(",S%6P71"8N52UH<2+@0*F=&P'6P-J!T-'_[_:81)%!W_O*
M?%JGDQTJX)AJ \$&#4R0_HP?J:E+MS$6I%K4-D'#QA&P<_ FP@8G'X-/:C_3
M78A(26!08QGIF).KG3U$QCZ(7T7=7H:*C7C?YB8>1"P&7T'&19%5:QP%OD/8
MO7W_@@X0N+(7V"Q<,.; Z"DX"U&FBPOR%BY[,6.#\,IO8$7]5ED5B/UFJW6N
M8.<76F%&!K!X@OOT4T)<,R8^%/=#O2L536Y_&B5J[53UNP[EO^Q"^>N.)<*,
M#UQD9DG)!H:45;4T>.A-ODF:>,*D1^[/6O2$7)[!?+K(P;I'3P (B3A-44A0
MSSF%OHX\3:R7A#RJ\! JPMJ/ F0!Z/(DU!+RC? %-$S+QC" F188G)]U F]-
M4/*QB8DB$'T@Y#_5Z*LQMG#J5=8#15$C']9#B\6<R'%I#Q:X!+,\]IUQ9S"R
MV96)1MKUY8O9O$AGKG[>=V?2XH>:(PR*%(8-%-/>:)%T),I+DH<H1E'S(!@!
M["X6);^5[(XS\13X!LP1#I*-IN@M [$,JYL)A ][3 EX@+=G@P[2&U-_&6$4
M2Q4R*WPV3\>%\0N#" <YHBPN MX&I.Z:J8!6RF %6>A]BH\.,3<X*,I9BN/"
M4M%]SHC[6%>%1PA76A'3OW8"&!P,$?8QD__/NMS=3\HYTL_VIGFX=8K')R3@
MH@0MCMP%O!1W&9M+7=R16>X G4;DC*$N<-:=R+YD2GY9L/X1YVD- @852Q;,
M$A6/3-,3ID[8^CW:?%;IJ2$57]]?*)LT7@1_'&"6=VRT/K/S\@/<_Q2]%;3W
M?]PVSVZL6E>,AJ]4.H :C7<"* ^7Y+$I*'4;. Z9VL;PB.C\V%\:6D64Q(J-
MR7E(EZ!1F60"U$[4&)>2HW>:O!]N;C@$V=>@EFDNHV6>C.#B0B<+]W3 JZNW
M:DUE3BY@,!Z_Z+ ?)7W0)T$M5NCN_@V[_HF8<I.";??QL^P14GRJ=E(9G 3"
M9-,1H^NYQ+UB:RQW"AS-0/P%KFFO<)M)C1CJ$*4OCP_K9 ]*09%/2A5)DWA1
M(X"7V[W-S4U')2S!=C;I4W\K1*&[2K,8#)#J2W8V_X3C&=,9EYJ.?%RS3QOG
M'$/XNYJK]MD,OZ[BU:]P)E 1DI1$DX457:X%6)T9R5:P;7M?"X93YQ ,=M*^
M#39>!T-AS+E.Y^2W&(\I9,+N$K;'3):<K=D B_M2PP^-Z<9W$8L#N:W8$L]-
MR$4R(&H.9IXMWY_F3M/8* 7A9/![,_>-X&^@T,,+>WXTOF$O*11* 1 IJ?5G
M&N5^E@K=?WYV@ #:^9XA'(S.A224S)BN#-N=,YK195HWHI;GMA%\%!8" <MP
M'6*9PVY$_Z5"$T4X/K YDH\AX4]/OL[*G/K"F''9%AIK;&/!\]\(SN$[$))X
M00PK BE@1='E#'%#0B9 $VG%*<_ O@4-HF=/E;T5,XWQU=^ !@KTV*&(XC)G
M=#NI#"8_@E_ AW"7"FC0M5,5SA4*3\?,;97[H75L[&OG+N_%<WVW6R??2WP5
M6\[9)BB CDF?7ZE+;:/Q0_+YP/&,779$FDV4X#</02>W,ABU4,E@6!YEI.8%
MP=' DW#>L&.IV..D^\*GY!(4>8@M;5$*;GCI1<V:I56LF<++D7%Q686<I]M#
M[AD9V Y2>8$-$;L:F.: /66X!R5CT/:(Z_L6H,N6U @1@S!#7V^O'IV7W!])
M/<%,(I.?[*G[5JEGM9BY/DM!YJ)4*AJT?[EX.?N2H@A]S"6M).^E:6Q.C?$]
M43F0L1,"^L)D%MM!5 [-B4#?/43*M A3 [O=(D+^M.3)(O6'6NU0.B=J(39!
MT=-7.7E'1V00NC0N*Z4O2)5A5:ER6;ZT6FQS0JF9ANFNCMM+F"IIJ!85*O8G
M3/574L.2.-6;W><<SEN^2R341;E)L J,G= R&V:#-$Q!#M\:^N. =2]2\&%[
M07B;E,9K7C'4Q14"Q?[QU8[]]1^W-NE5*]=')@6=RBP=H@9$V]^D!I.D2!:2
M_8/Z.B]_B#^]M/<3%[1A?Q;44(AEL)@-_DO)APB%Q6EOSD!I%B A2A]!Q<HI
MVXER?6?:,#BHQ6#3HICS'9Z5%-H<D7DJ6<OFI1J;0S7<[#4G!T=6X4X'24>
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M!.B0Y4&)V)285DYIPC'"E3C'6I3[CF &U>&W^4**!NPW8:4;:")*4P^B$-G
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MJV%L+#MRZD*OCC_I2,+6$AC89H+4G_!MT5"58DB_>G37TK-4C2%&18*0>G$
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M>2DVT!\'F[:)1D\J/MD IO[<_1>>K?+T%TR82^#>/"( OA[H,BJ6^@R9VC^
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M+""D,F "9',[")>AVG</7OCO5OZ;Q;W";]EC;"OG.ZE/WM#CQOE&ST/8$-)
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M',7MV7A<9*""^CR*YF1UU9FDR:' #-HZA_AM\WJ<]?20DG>J@;5VQ\ O. I
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M!'Z'8&E,> +3;9- 4U\%MSPTPM'F'X/Z -M.MQW@,ZK^G;3+9UMZ D0,:-G
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M#CS&%'\:>C^\YWM2'WR'9V2S?Z)TM7[0P;?BD^7$9&[L@X3?/7XK&)&NJ.8
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MOQJ:(S%8;K"5%-K<OSEOZD#O67N+?5:7?= _N:5N"]3!,&2RP>E_7WT88_R
M7M8L+#4"/^#NIJ47XK5$ZY<8M(0Y(&H/CU:_88R*+D%/J(S:.&?-V883($Z3
MS+R02!)SQD6O[&<H^ !5C$,;=^J)EQKA4B/\%X-:ZF#NU(]X(WCGSO=L/_ J
M)^IY1K6[),:-[=!3I$LA8-QV(B,)MSCR]N'7>HN:.%/.^(BNV;+?VKDM"/3
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M#!C BHX^ 4H)T,]Q'O0_.'!]1R\\JG59\4M*9(9B(.E>;CFI1?11<H$1+ +
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MAC8;'JTSN&L^PLSYG23>/? BIHR(RIF$79SC3&+SW;RKU3\V[L;;KCP(+H6
M2:5*_@2OKNPH- (OO_E_R\/QS\]7UQ)I])4?R[+C:C]%>,PLH 6=0GORNT$9
M:FW7A6R$4!<(M 1Z24*H$V&_64_>4"$ZA](F]2QV@V,R*S#S .!.S'%<@(I"
MMC)_[WT?^_HIQ7%<V42UIY2/Z2]L]R>M&'Z^-<'1,5P21(\I%/(GPZ\'Q"MF
MS=$U_LPY=631XVDMT_#=EJ<RC$O-LJ(MNCAQV!B:<CCM6R;R,FQX' J#-8&"
MEM"-06%)B%7N$:IA N4;U/<B=3,30@0."6:+D$62C$0!0B$EZ.'-/0H0PS('
MT/ILG;!D85 1-&J4DI*"%8$YCUOL<M!^[LCB16D*(6LE)RV*1^46B+-@=SY&
M++M"]20H5J' :Y*)>I<T!('XD)E;E?6BI'5%!/!]*)+&P,82_5[N+RKPU*93
M(1*TX9TX+G?:Q7-+JTL<V[MJ\V[MMW[_(+VK=\^VI%4F42_;#JUBIG6B!:,<
MD;JP<S.7,R1X"^08O*_6/B L_4!O*7_6\(E>FJJ*T&*,?Z3\^W9L)>VM?Z)U
M5O4]D]B&XK(2G_L9H\6#IR8-+1ET?J'IT16^/&K<>(6S ATB.3;Q:]'?28D4
M[>%DZR@J/R3N.9X0XBW%6<?\A)^%33D(K39E[-^)@ Z5_>3=>9Y 41>V&,.F
M'8$A,#MP:V+JAH92)PV3!BM;C/3[=,B,<.:.J8A19Z1?27MYI(>!=Z%SA##I
M1G6XP![9\FXP$&\Z96# O8O+E"F):+*UZ-KA%@)=.D%)B^N7<@=>YOX93@-4
M4DDU!23<A?(U0A+'#TGD^..C*(FYR]F&]9"0K?0OWYWTR,."[H4(YN@M$QHA
M>X1*F80BI6<,D211TO:5)DGL[W>)Q)YW%\H5/K>0Z%L"#I4WC7\/.@W"3B31
M)9M^75:'U'=IOFM7N7H;IR\%!8*?Q-%08=A -93,:@QGV*D'#UY$G6SI/4RY
M_[?E@2);;@<\#IRE*D;-4SKS$RRLLYN%[^P1E\/37FBR;(1Z*&MUS6:N3 ;2
M[W.2Y.1I\Z-+78'-*;!UE74J&C!*N!IF";O8R6J"=))<7)6L5J!3[H(;T 1V
MIJ[ ^4:WY8SCP2P\^C&K$%&GV]%/J*.LS1LHG?*]R!MRSU^<3_)OQ?1R(._<
ME57/"F+DV+!$U]1M;Q]*.IK\N.R<+'M'B:%R<QZOJ&G))G#XT"%YQQ3,*KLD
MH@AI8^*$& 3M!139JB@$^WQ'M9;;MKZ5\?+.4N?)K(+IN8^,Z$&1P$_ED#*8
MQJ]7HD]JB-3O''MS$#:']!EBI1TXKJ5^=AQ\@+RAB_#DACUAVD7$72#S$*LU
MN!!.QCU<K9[SS$LW,-V;6B3AU?V@2(1(0:4(5+C. M%*YJ='5DID2S/=L)WC
MN%&V#+WU>#S;+JB#JC=,AS7*:85?"4QF;02_ N=+PA\_XC-[<0OB&;/'X5%[
M+0LHBUZVW8A-7.8/_]Z?8+MM+2H&S!S:54P!@_ACX#XDTELMQIXDJ1@L_:8+
MDO07X9V=<@9>( 68);KB*=YJ/J.[8%<>@\#^:6#QK"S,D71?9*@NJ?3"><%9
MSO93O-5\1G>QI<?8$M/><NR5I3W61IUOV8P6 UH,:((T!&EVI#!QA&)58SX?
MQ3/D+*?W*=YJ/J.[&,_#CTOJ<90[D>TG'M4#MTY [X@V$Y_?9SGA3_%6\QG=
MQ9P> >HWJ3?"OYY(8YCD.K></.\4:5%MJF,I.L628%YL:K&IQ:;&CZL)<*I;
MUS4ENZO3?MMYJZJE#$R28&D)G^L07,'GQ@+  A;JC\7*%BN[P/O&A1AAM)WE
M/#[%6\UG=!<K>42+],_[<N@U64=5\/*VK&I4"ZM&>XL" +!D99[EU+18U6)5
M]W+IIYV\%LI+4#@- :G%L^:^G;8S>-B$47OA'%@,;3&T2]D^M_%GI:"%P/J6
M@OGIW6;H !7ZA%@& FZ-<%7<K <]>5'!-;"RL#U7$,Z"M)31DV91'/4[-17>
MRKZ%[&Z!G3Y>"FV.A+3B)DY"C6$ XRTV!&4N;Z01/7Y.1.4;E<0"A@P8.R+3
M;P>"6F[J09#EJ2:\0=B7#(%*.R0$JF=N_/>I-^]-2S)#L\ZK#:N>,IPM1#.
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MHA!^[4/CICWX=<@UL;:;7X/ CR)3%'2.4 #&F^H@,:EI(21\(!;Y6=B4";7
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M.%3R@^HH-2,']L@Q;ZLEA:VH."CM](2R-F2O8 SQPU;RL3V_1LR-9$TXS%;
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M4QZ]Z=2?4*=,AI*[<Y/XN.0<80%23A*ENW+C$DKJ0)(24#!ZTBALF?92UTU
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MFCJU8^=ZUH,NF&V9^6$X_2Q_I/Y2)MQE6EE\,UZ"?\%?0,@AV,?8^:5N)&@
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MI[Y0%@CC=6?6R=1"([ S4BB4WRSED0Q?ROUC&8G#J*V!5SOQ6=%0#B!LX6<
M@\C04:M+ ,KFR>'909Q?"+ W4Z%+L>-=1S4O/E8(#'I2J"FOYG-3UVU;WZ;
M#*!X_7*8D'A.Z56:5#;*=F8K')MUF\8/?23F0,R_P!_L,POL'M/(*&@UB6*5
M<4N2/B7\)0XYQXYI1LQ+Y]B <.YZ -L0*%[8LVK\@XXE66];H]H8FA%59S6*
M&7-3T<X[#2'OZEU]*QR$L)7 * ]L1"&M-WI+;3,D&T_:F*1!IFTR[$S*=0-)
MUTK-"?)$1?0]K!&8- D$6$ZQVI:'\@;_4?4W;7<C0BW>)SJTI@O92U@B[F=_
M9Q99)U.&[@0DQ86<9@*8$N'F"?I$T!'*Z#%9)@5&1MQ>>-+884Z>M>P.]/!X
MO[W3+DO!%/'*<JST)!/H5YX/A6O+H&69;A(VF<U%,CJ%:8Q:/"Z24<S.\5C0
MU_.,N<,UMY7_HWB!26!0 .P$%H"$R,@:^Z.OIM@?YJQ+U<ME\&<._/J.I]\O
MN0TGCVQW&K?/7N!_LZZ:K!J>;.<7WS_+;DO"T.*_ [%2EV"E2DAOBYRM&)HP
M8!4^G-B(V:FY/6)*;'6#P5)@(2OHR> OB!SVAO\3C39DFIQ?BM@);SW(GH'D
MB)=&<?F=<)NR3GC0-FU=*]M6YS;G#7]\HKQF&%5]!*-QT]M6GJD[9M%0^XMG
M[BBTE#'522V;)\.6%(-W'@UF4JX._INGJN\')WL+?M73$D!]6']4]2TU,YW]
M%-:;=M_6@)/U+L%0DN,DKMF3]$5/$U@689S929%M90^+2_& 4L/;CAEYA HE
MI_AY>!U=K?X>I,$YF?L8=^ 'R;N6G]I*!K\GEEM9PW3C=CA)>R!@B2484BA@
MOO%G+0>&Z%_@TY0!3#T:OM"TS3/SVKGFI0VKU$MAH+%U<M(D[K<<[.,(!9EW
MG@T%;*)GS='IBW<[JU)K[\.9W^HF-E1:RY/@[L7C??B&>K;!&$"4:S[2I+T1
M?(?>U1428%"#+HH)W2H9CEYV6R$/0.$ I&7)JU,@U&Y8!1C3$<X "2] WKH9
MOQ5Y_"=?)>!JF3EGU&&'Z"K\O8M->$>_^G.B'?%91*;C#6:SH396,D@Z!+)#
M4$*U$&N"BDIPGKQ^W.B5TQ5HX*KC&4QY)RZ0Y8R(7V<;8WR/!?%]+))\=P>_
M3-OEFT#.4^#?+\/;?F^:9.DO_R":-3KDR5>:F]G& 3F_UW\.WKQ=)R!)KC^%
M.)'<SJX>*,XE_V\)MHM M\:@RL[M:J4X@C>MS^!-=1URKTWD/$JBTI1?[18V
M!8^L1G"1+6GNP=:8_#@ SJ55@#;#9CBXCK9_VL"IY56VU@5>O53@?TD2EV)M
MV7C$@M!*CC0N.__>EH2E4Y4CJJ5E=:F/+/61>^LC0TX,G!S&A IAEC/\%&\U
MG]%=[.?AQQ6PJR2#V[HN?1B"O&\A[.[2?,/G%EM:B,F!$R54P3$?T$S<N*.\
M0J'-13+9YBJ/QKU^M-7RZX;#?KW 86<6C/]7N<7'QNB_:O](541DE ?F&>1\
MFY$46*G.7=7LD Q#T$%)IZ'B.FUH%N9\(;)G)7=<SW+;?(JWFL_H+D')8V35
M#8-ZB.1[R=&,M!9;C2OD%$#Y9G>J3N R2(O?$JEPAASU^)2RED[JE/AY%$.M
M4AA,R/9(&DU43F:Y$)_BK>8SNHN9OS?=E#2W6M9HUJ@,>C!6(8@1)0_H[^46
MJ[CG4-XYNQ/+NP>)UYU5UIOETGJ*MYK/Z"Z&^_#CJH:HWT#_+WOOXMRVD>6-
M_BLH3W+7J8(4OD4Z&5?)>J2TGRWY6LID9V_=V@*)IH0Q"7  4K+VK__ZG-/=
M:) @!5($U01[:I+8$HEN]'GT>?[.9*IGD19G@QA)XRHN9<[I6@G:# @NBY(N
MKRXK4E:DK$BM;TUZ4ZP%Q@=DITK!^.9LS0.5V\BY NK31K)"%9<RYW2MH!6[
MN_+C*/ ,?>#BD'E84"=GL:NAO#-J=\_&:K#_ >KIM?D6LEY"?@RJ+/WGD!_/
M0"5] = MF<;/V>ZS$+,@HF .F[8R8:%4)>"H!*C.OP\&&)4-K>A;T;>BO]1L
M'4,#.^5^5=XWK>O-*VBB.;K88ZCB.&+86!3F5B"FI>I&\DH5ES+G=*TDOKQ=
M.;DG"$6 ,QA@92]BI[*5.1$C:5[%I<PY72M1+V^7IEV,'":P4UQE6&K)O+2E
MPHJ1%2,K1ODFXD,0BZY+;1)LS,0P<+B2OK-GAXTGH^B9L4R2?BZ*@U8BM4E#
MIV<"D&=C(WFCBDN9<[I6\E[>+G22WJM9Q2**(CI"%2R%D=2MXE+FG*Z5G8U+
M442[/U2;R!Y2BU5GA<@*4>YV/?]1 ^>($12-2Q$\8"KQ*>5T+^5; 4J![\7^
M/J'#G88X:T:,*">8 =DJ3,WX\R/(* ;C)0^. E\BC#BP>0F_AMO*T!J3JAPQ
M&$Y#Y^LS '>:A4/O,8II-A:+QQ+=( ]BP@]&6*5^[)RJ!T.;.$)Z8)=],HOC
M:*:@J#38* U)&%M6@W$ \5SA" _3!,XX B:-!M]=*JRCK<"4"S712\QDUL<Q
MTZ?< AWF^A("^00:B*8&#FR?;^2G/=/;//"#5'W[&4 )%W\'+5,X6AP+$L69
M,-60SXFO?I;%JQCB*"(OB7!,_%PC<=KQGNGZQYI(&LU.9-(P+5R!& +L+.*+
M&1(0BW.?#5Y0QS.)DJ1,%( M8P'L@C;'SB64J?ZG%\X 'ZWN.HU:H\$_$..P
MOW/^6(#4=IKB-R[F2KTC'V;<QQY*)>X0LYW)@Q>S)$\L7% ,GO.-H=IQ;O'5
M;B=<I(X\_U]<TP*P@9<$B?/>2Q"-:98@DB<;10"5YUQ-V=@Y$5UZ HCXVDM\
M[]_.F=!#7TCP/XLR"7CWG/52X.*(#B+_*=IA"Y1'V A_LY^:Q_4.050]\-L>
M?U1O'W=K+I%?'KFN2I:@8<R3XHY@J?A.A0[COY=1/]G*J&DW#6-.34IW</H.
MW*DS@*-#=0<9KS@ %"'(:DT!F477: A, SP4#:<L) ;*2"DLNT1*A_IB:A-<
MF6<!:!#6,UU2EU\XJG2#0D0%:0#B70>%7^ JXP!B]$M, Q[1,:M34BT01T>(
MHQ3D K&",*,6?.(OCZLYWV>A!"UBA. X%A!IXBLI;BFX#O?W #@%+/D ,P3D
MM:\0(.@[[,> ,=6=$LY0&:22G@XV$&"E8@(=0&S20I+.6,)$2VG@:="/B\/1
MV3B8R9$&XBER#7BRST8!EV2:I_Z ")B .!XC0E$ D&*((QO2+2'4 ZV6_'O&
MV/^R8R'W FHL\SM!BE'*[G2ZG#)B->1AR%:EU(-/QM XC*BQ\W(]).E!4$44
ML("T6A2&A.*B1F-IL#<T2T$@O=)*S\=<(6'SGCK(!X&?*\_)EP>%A,MN$O86
MSFT'Q]I*^PI6&Q$:5A:K$P9+I(BV 8P3#.Z#4*%U$8Y<DGM:/@-4.P9(OHQ?
M$6!D)FJF0[I-Y#"^Q[Z'T,%_/<#M],1D\X,P&6@TV8A&>L]B^;)/$J\1JWT
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MWFRF]']N4V'V.(,LXD#:AX4*+P&S*$@>LFDT 5P% _M4\$?S#]"IT,>NIIX
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MTRTYP%4VDRXRKD!OF7&5JPWC4A$!;MC/$FHFEK 2I!I(ZZ-:SP1-TOL@"L&
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M<"@-+;@E2_3G#,DU/IJ;10BEPU$L/99MT)9*VE0J2-;SP@)B[F9*9DY@_H9
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ME:K2>XNOZ T(I@/@C<7,.X!LANN9.W]<P5+/"8V@A!2:R(IHHYT)]W_?V>8
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MZ$,3.=>W3W39G-W\X^K\J-YSP-MF8_[6#X SR.W7P52T1*F.)+V>DFL%F/$
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M>>.)?C9Y ]72YA-BD:M0 !<AZ]+IY YBFT Y.#0R>T$,-(#)D*.1&MH(!:D
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M[.Y0D4=2"]!Z9<)1Y:R<?P/D[^>G9;RVMJ$K6SA$T.M28$&3>QWX_U-_EPF
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MWB;FPC99JK5EEM*R#J1_-T9=?;$WS0"J'L+*V^+!(P/>Q9R53=4'[9?U 2F
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M3+>4VR_*%;\'+:OLFE4RA3,F,(NEW?[2[A %_<6TX]J<H_/?#K@(@@(KF>?
MHHD5I&_=5/H6=,O+K21-W2QGR#_EW$Q8[$TAN'(ZF :/P31@R6KM2C[.SV]7
M8K#JQBI7+'?_ZO;0=_WJ9H/0F'!".2MO,TU0_(YY,<E4+XXK,I\C^!I'PV#Z
MBF:&=7H8-CK'Q:R1Y8.E?)"/ZE#7^*!>&A_4W0;W61KM I"2K^ #,QM83OU_
MS9(I!7FGD1,S3H5!,&+\XP)5B_\4_CP NV26,-\)0B=21HFGC)(/AJJ^MZZT
MK.8M?* K'Q*)S32TSMF$*ZG P_O#"WW'&T=\G?_%'YAP;";SYZL+.>K%0246
M\# UPO$_CQC\X33T3S7Z;7J%]SINI_-R2]-!L4*5F3 ?+:* M5@F$W+9X(9D
M@3E?)NOQG1F>E\$/;DMR1F'<\GR*^4DXT7!H" =7678*0UED9^,!N4Z16G\!
ML6XXDVP\$:_9L[K:D)7+Y[=\Q(H5NGK;_-9SNR<OUW\:K95W9EW3&$:HZ&1A
M0C8V^P%_9MSM'XQF4"T%OQ[S7R3XV0#[\X TSK?;/TV-?U9(H.:!+(I;X-@1
M^<E+F'^F$7@'@TT/B?Y5YKS\H1L%S.YM<UZKU7+;)VO$[4U4ZKN+\6K.#53R
M(J'A#[.$"0O<$!:NLO!L/$A$50!\9ER"OL%"-\,_$X;6D4[;"[JI-\^'G;CM
MWLNMRP?%%U7FR/S<:P%UOC..K'7=^HEY'&FF[?Z'!YDY,-B!-+,@>8"T'NAY
MG_6GAG!UE>6I\&2">7D"RB60PF;)#9<9G7PWPW-.O'*&1AT2]?>?[Y873\PC
MH!17Y&LRW@9=VDVNPCNU0ZRL.'OPPGO^VVRY!,6[(6\Y"KQ^,+*E$P>75S_0
ME0^)Q"8:B([\APK:S]D@!NL=]-,D9A,O\&6HUT8#RK<5"\\[F+^RKT*BFZ3?
M5?B5J/<Z7TN[L=MMM]ZP45U#5MZ!^9B?$2Y@/I;$BQ][;<!M>1E9JFI&XYR*
MEL<+*CH('[E1'L7/AK!EI05BXR$+BP)Q)>C&K?Q7U$MT:FZ]V3N<-H4J<5,S
M/U^[D7K= C=U>BVWUU[C>B];M[Z-^:OK5H"PFD$#Q(1@$ZFL>#"(H;!!<],-
M8=G]%Y;ELI*?8=Y(\YX*J@HL3"CR)))^3BFZ>:EGW6V?O RS>E#<466^S$_>
M;J3#R^3+5J_NU@N '1H=#WD;8UN/AXSP#U+S&V9ROX#]8(#@;0&=HH!9M7'G
M\*)(9O/94@Y?#U'+]8;;;+Z<_,C%O-AS6]ZR*;'IQHW-.V336HVSZ<LNP;;9
MU&@WH:E@'5[L?+;W@XF"5W@Z>\ZD3 #A^1I'CX'/_$_/?W+::]*7XO"\7O(:
M[DFGYS9/-AS'9N^(2K!J?D]M@3MBEZS*/8L&-V>Z&T*IOT&HOF)>KK'^==5>
M]Q!7/B02FVAW+@< A)A_8C@ H.7;RA^T);%QJNEM J5?9_'@P4L8#H48:B@.
M)IR?]2WF?8NUX1X4L)[WC+!P=]'IX-^S(&;<R^!^Q?3YZ\@+IZ>A#Y.9)O"1
M3;,5?&VW7:"]Q[J^U67/M=$A=L>>K;9;*]"Y8*.B5)V6V*BH^?+6VA@\8DFH
M27DG6PPUV7O!\NG&4!,[Y--]N"!L.-0ZI'9E2^+*A$,O:6*L#8<>/-\>Z,J'
M1.)]"(?&$5>)OM!.3UX<>^'483]8/ @29L(AFLRMKR_-;KUF@@Q2#K[Q%]'M
M0I ML8 K^[MR^2SWFF$U!5ENC2BZ>])MNYV&A<EZM?8&+%MN7.*(>AWDUA#&
M/L00T7(AW+B^4Q?"*T'QF^$9TAOQCS>5Q*[;[/7<=OUE7-*5(:%#T-&6E756
MWKC^LS16KM?<3KWM]@KT.)K RT;["7,YLXF(3#O]9V>H@ADV;V:TA&X,U[,D
M':&B6*].1]A;Q_+T9CR],>Q/^3Q=;[JM6MWMU/:#J3=U=*HI7L9(435CH@>Z
M\B&1V$1SEBS80,+FO/=%6_(O4/\%AJT)!V<RAVZC*F9C8#*XK^$?*(I\]$90
M./F-)=,X&$R9#[\X#?WL#[1/?F5Q$/GS_>@7/\0\*/X'A#K^YDW9Q7#(!J]'
MC<;I+FZKV;&09^;RZ5(V;6^,>+87;/JQX3::+;=1-P\CU1JB9LM6U5[W$%<^
M)!*;:8B"WG>=/N,_""%V&@V=9^;%)AS8TB!3?\3/:P]"3?G[W(Y9,%?3?9K<
M#$LR!38?%=OJU-UV\Y48%X>@!BV;+V/S1BZ;UPQB\Q.WT3AQF_67W2L3V-P:
MM=;B.8R#MB0V3I_LS*C5^QU<AX4^F+5I8X/X+]FY1G8[O)Q572=$]Y,!&=)V
M,_<F+R/$NG&/NMOM]MQ:[Y7@G8>@XJK+IBWK5UF#LTHK'Y(U<J K'Q*)S30X
M;V>3R8@!0(XW<OP@&8RB9!83K!<6JO*S&1M6C6H9M;H';4ELG"YZJ]%<4\;U
MT-2!29(FG%FEG8?\WI-"8U2(3%\YE:[9QL44[9Y;K[\\ZM,$O\!R8"D<F-];
M46A"RG8X\,3MM&V?T]:T]R :,V?J_;#Z>Q?2LS&^*Q'JSOO!$A"@4A /3) 9
MRW>E\-W&P*V'PG<VBFC=NL,X:$MBX_2)$5%$KJ&/;"3Q()GU0%<^)!+O023Q
MG''-Y'.U!'WJH?5%2_8).OF@W05\T7-!H7)P]TSP!BS'E<)QC4V]T"4<MP9$
M1:/NUEX[M]5$5?TV8<.S*.2K)$!=;CG>LCC@WSMUZ,?3H#]BSM>8#5D<<X5^
MNX^@?'LG6VL#JX9^['U("7DS)#*>:D14-,Q!)[/:WG+D:OR#SMK JZ]DR0V@
M"W8_MF8/#'$\6F6'.Q/OV>,G;^6E9 V^-D0JB@L22]I'7XE4FW>:G?1>.2''
MJFSS67"%REX;VW3;/)BJYJ9;Z[RR46*'XYIVJ)Z_P9; [IXEC(:Y6KDH635O
M#"A**(OL,V#;(-UNAG\F[!2(=CJ.^+[^UX.E-BZ&J;7=[IXT!EO6+(4U-\8%
M+9DU.ZVFV]J34L$]L,F13,XH\/K!*)@^6[$J6:S6QNY#0PBI]%D2:6.M7N^Z
M]=8K75.KU?>8_4[6QN3;(OMUVC6W]=J!OKO4W+].^Y'_#/\%QT-;Y/+F^N[H
M]NJ_+_CF8!4'?W!Y^N7J\S\_.//K.%].O_UQ=?T!M.YOCD:N 8/2Y=\RJY>V
MQMT#-^H'@V@\\<)GP,L*HRE_A!?S'\/H[BF[C[V1,_%B] &F#XS?"YQ7D >]
M*?/EF +^H63*?X!SUX^SFW[]Z>-1R\?UH]AG,5*;[_A##1^(CUXX ,$@M=K/
MG,.Y6$T\'^ >@0WY0XF.N3?Q.UTD'R;]ASC=S^H[_-T*73&/+.3<7?S7W='5
M]?G%]1T1*8]&ET?M0HMJ)S[Q[ME1/V;>]R-OR)_RP?%&3]YS\NYC$3-$/(V-
M/_[N.0\QB.K?[F[.+F\YOR A."><@;[@I/[]5X\_"CY:0$)>SPBE"<+O"DR#
M2X(DO#?U[I4F]H-D,O*>/W"I& 4A>T?ZL_/NX\7U^;=3YW,P9,[M(&#<RDV<
MJW# A0">]3$+R5'Z"URC $\CH% JI9=*2F^5E.YX8Y=1#/H#X?@2 #'AVSIG
M S;NL]AIUET'K!RN=7SX0WW)YE[/073-7/]?]MZ].6TEW1?^*JKL6;N<.C+#
MW3AY]ZHBCI/QG"1VQ<Z:V>>?*8$:T$1(+%WL>#[]^URZ6RV0,&"P9<S4KKUB
M&Z2^//?+[TFG(O*&6@>VVL4Z< 6G^T,: SG$\5DX'< IH_+ZJ&O=;N!Y'WS*
M'8AXZ,S@>TF4BBUBPN!]6PWKV/KF)/!"*:4MM:J=G>.VZ>7?:9QXH_OWY?QD
M'?WW?_6:S?I[^@#]N_'>DE0E_W3&FDS^\:TU<6(P/FZ%'\Z W)"XO)CNV0M2
M5'? )_+/L);A) "G:WR/EHQ",Z</P?/A[MC0\607-,@ M+HLUW/&00AK'UJI
MGT1.C-X;/G<0A8XK M"=\)T@034+]X%_P>?%#FQ/?A>6A"M+X'T)<B8^W['
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M24&!B=/J=0?.=C?U5!B9GQ##X0^:'O&5"A3U\+@G1,GL;#Q<!I=/JS<6_]Q
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M*FSTR4@=V%AH^\(1L=>Y('4&?UE$G:T*PN_I6O7*I4SSF'QJJV-W.R\,J?=
ML<]%L>UZ<3GZNO&<QZ356PV[43BCJ\(4NQ*V] LO-C'UOF[)7*F07:6ZK3LG
M+B_A:-<WQG@VE[8IW9UV[6YW<8[C\K*3=KT8W6,%#/=MK+G1Z-K-5F4+4#:^
M3UDX&5\Q^ X:EXP0]"7K77KR6I2.=:PJ.F/KRH %DFNSC,7M99U* 1)3M<M5
MBN<4K=*J.)P(-_7%Y6@52J1>UD,ARZ'RX*56'AP*60[D="AD>:)8?P[ZL%H^
M;\6+#=KUM7*G<ZK[C*V7C</GC99]6N ?5/#V#G0S3S=K94*W2S<GIPV[WGGA
MN= GBVLK5PK$8P2.1$7)_+FS1-MDC;5RF.<2%>J[H$R0X0,]5KK6[6Y!'*,"
M-_ :W[Q[JELK][@SJFO4&W:[<UHYLJNL[4JR>1 &:8PAKDK0ZCYSR5K90WD]
M'_AV)&?T _=;& P?*9Q[+?OD()VK\N:=TUUCK1S@[NBN==JUZ^U6Y>BNVJ:S
M1NX<B$",O.0@J'?/,&NUR<N+4E;-!WE-C[1E.O9)Y]!"4Y$W[Y[BUD([>$T4
M5TW;^2*0 '"(S#/UTFF& 581DGWMA;+EK+96AZ1D-7W?V[2'&IV>?=HLJN6K
M7D'4@98K2<MK=6ONE)8;)W:C];!M7P5:KJ:]KQ*N-V'B^(>R[RH5T38>DZ<L
M+#%Z;*#3[C1;=KU1E(:J<%7M@82?CX0?DS+=#0F#FVVW6T7]RQ4FX94*PW=8
MFOO*!YZ<KCBBY%4,/"FLT7[$=,HP2FY$-/TH!DM@W+9:@MVUCJT/3O#3^A(Z
MP4LLLM9R%^Z=!G]<?^AC+?EP(H"^KR+8) MB^.<X<J:20'99P??$7207@=6?
M19Z/->5U>PYQG'"9'8M/9HH#&S](T':K[TX1&S:1F.YJ>@J<GYZ;LN0<+2(?
M<P0I'CS^4G\[":U/7A0GUG<Q8_AFHC3S.U^PP272W\#>%QSRZ 0*W5:.@<&1
MR3SH<=GHCW;S,0"=0R'<&+]Q%OH^;_9RA!N*O^OARQLG7NH]NUO4;#M_@,B&
M^CBRR6#++D)=W-55-O!F!MM(_;&3GR]V%@+1.[=>E,+M>ZX-%^-[8D0-">=P
M;N$4[NB:1S/<6_TAG393E1/CY#W&XI8PW\O6],D7OSR)X6\\9R_&Z5T&UE?G
M'AYF<PL6C^86!#_NT?P&.8]"W2?!!-/4$2">L8=#%8"Z<:!!V:Q)'F"-U[(X
M=1*N>2^.T<2:5^#MYH0/\/ZQ."7"<3\TDB*F01OCU*&Y>2(;^:+.V<:I2_0L
M4P;.G'MZW@A,-*)'.2A2S@,>X_2<8"JAW>4O62SMQ3&;^O$&^3\)CS^&4\;"
MUYI__[3BI=:*)W:!9B2#ED#4:2 8CD/Q:)H':Q_BQ)N/?$"& '4"Q_7@[S3.
M0 3#>T.=LL=F%V@N/3<ZTV%G_8]6N:M87,Q5/ZZWCYLG_\+15?^Z^8AKP[O[
M2HT)N;E65^K=??7J/KUY _4%"WWS>[MNUPNTEVVY*3?LR>)['N!"TRY_S;QL
M6 P/J_5P4!W)-ARR4&(_MQO%/6:T>:G#5SH(I=F_P/5<CL[@LKWDDY0!%[06
M@MN LVGDCP4'.DQA 1/7N<<F7!&\^7VAB6_>PU1#Y+ ?E\06G$#"W;L%0]E:
M.(6&)PQA58$3X=PX),A8SY](@YD#DFS@^*0:I$J)Y-#<_X@H1)E(<SE*$4G:
MS>*ZD]4)B0_*1Z?D0B[P.RS!)):+;Y\,<KE*(_@K."S(U,?--[\O4LUO-)@>
MR ;HSQP.:Q)(Z=SN=K-XE,7:Y$';4W_*3>;^(=E=W4\09I<SXW'>/+P0B9\G
M;^4G>;=KU@\M,F"M/"1**W"?5%5R!\^Y/Q[1G%=UD<T.'([Q,3TM*C,<1E:,
M8YD6OGJ"7_5P_A/1#4B?3)WE6 _)NWC(]S/T,V\^^A)'Y2)J+=@%YS13#"WU
MASN8]=PEMY_(^:2#TQ-'-+?M6)^ 8RWG"EJTV+W2KJ95\1WGM<6"=VE=ST#
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MLF47\ZW]Y#B9B..O3O13)!8W%5N7HY&@3,L*\%%5[FFY#&22K# QE$/#P#_
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M4U]K"O 6J4YI8*D1E7%'UM:CX6O;[5JC:(QPY:CB-;QYRS2\$/B;G\6^:A'
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MJ:P$>2J'7CT]W.GI/-RI6LGNT4SWZE$W.1Q'*48(-0H>%0-3^!9#:JI18QI
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M4S^"Y(P\TJ!O?K\,K,MA$J('"6X#GO@)T)\72Z:^<T#"31G]R N&$?R28)6
M0I<2L@4"HF6?=NHD'_'C.4*&O_[EQ#XY[=4L6,#?4_A]HTMO/YV3.*HNU/)
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M#5I;B';O57"_FMEH$/^M*IQ.E4AR!UG!8D2L312O3*3$'U/Q#1X'YK%_*RC
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MB[C&5=O'AZ@%%O.RKLV6'OX4[HH0^X!MP[LG5 =E>&PK)SL67 H93K\<*6H
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M4X_Q9G61MJX7U^5V>717*F$',D'<U2E*DB1R@MB1VT#9 *0W3'VS>C-Q?HK
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M!Z%/*^NUWNLXYN("=[.N"84Q'.M:!&#@61^ENX/B**LK0F*]A%_3:'G,GV'
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MJ*C\LXKZ@N(/^1=;"?MB#QG9I@]"SY=LA3I;/4.-D]".GBU]2 Z-6M<<FT;
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M@KYL'6*BEB>:F@)4SC:K%;U('ZA\HP2W+BC10'<@%9B0Y]R!=D'!+D23)T2
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MYVY=\B?8)=B-ADZ!$<*E9K."@OF%P @-=?:,>,40$\^CU,\I:QU&5-0QDV'
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M#K@SCRM6:1Z*59Y%V]V0<-##(YD&14)5B4G>4))-'"JEDQ>+#+$'=I9L&_)
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MAX9 '<X8N0[#&.!?>$Z7/_#@9"A<HMN,&MT*4Q!JY$\:!!35%WVO>Y2L<+-
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M#D7 A-ZFS0:C:Z" C-C,WS[WHM$C(N4C'/AQR,0=:',)NIV[BG8H36?SEDI
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M,>1A)*I]UK160U]0(%0CC:9F-1J+ZH?R,(Q%34-1;G2ZC*PL(1O*.J%89W4
M;3!1=CAY3%:7#&1!=JPJFOU\JMSL;+%34;U4;[YO<(&X>,O&ZL9)@=MP/:PZ
M-"?I:[0UPVHO)G!=:Q@+"[3F@,"::9AY([$U2>+F(O**&;2TEE7+)8'71(W:
M)#7$W6AEGF]]>KZU^D+^H@ TM5KMG2)<#((T9A%'-Q8BCF%J5FT1XN< <4Q+
M:]?>J;";@YSF)(TM$+I%ED>2N+X0E'9/8DO/':2W)NG;THS:\K+E^97B-5&D
M?41.;=L/1+GUR!>S>+![S(EA#(;U*^ER%_@ \TNZUQ,.=X9D-F5*(]^"BOQ[
MIB1]2)*<GP7D3(K3.TZ 'B[.=]04#TG=('\"\5[\(.J1>P=ZNA\RC=S K'ZC
M_4'8XT!AW6HU]341QM"/2%+X\6^?"[;Y6.Y+,(:$ S\.646.$3?A_^>GEFDT
M/X>C"<"8+9CK TPK&,(<'R(8\T/,(R"KK@,5SZ%Q%P(9G,4Y,5M U74-'9QO
M'%BR]3)O:"8,@5PZH%Y."$,+&(O2T9T=&SB\WV""D0]L??R+-)NZWJP4EARF
M)(=<XILW,J-6-PWR.P@A&Y)S'M@NCJ)"+N@SA]^NOA(+?M8D69DHZ_52[:+I
MF3CZ@U7;;9>&(7P^Z/2"\7@P!EZ\1CNQ%#M5\+'C4D##<=E'\GCYU^/Q]<W%
MY<VCC/7G%=&K-U?J,T/P 7UBQYV T>_'M N-G!#JO@ X'F368E]M#1,U*>D%
MK/O+P4^/M^??K@Z^/$HDQK+%,#@P-_^NTC2G<]1HCE<%1B<FL*IFREX:T:>#
MM&&'AP.7#D\(]USNL0/"'7C"- ^^7$>L#T!?(><LB"A8G'OF4F&Y>GP@#R**
M3T#5'\$4A]067VKBFXODP"*Y]APV +AAGHU5-F$87Q;48EPCM=:T^/0W !WO
M#K/E,T&,[2'IPL3N&4# "\I&2H4[<>IR@AB;+3LY'M^ZB3"AIY95:=:Q@;E=
MHVT^\\%<("DN1N=4>W@BU0%7!PA#R4O  < ],I#T$Z8A8$_X%K@604) >6R5
M1!/2]-(#9X*$#!RSKK#Q?AR Q^3;X(F@T4%I"R/XO[!8R!GT5 +!'9#% 3SZ
M3%WTI@*07O [A SC8*DWS/8%[_P3P_C%D#K8Q #Z@S]!]+%/\'< 2D,Y>.$-
M79YCL_"U'",NNZ%[!\_..:$+3SJ3U$G^EFTDO_>!$ %X1M";1SWTD> [^ @<
M7TWV[/(^QU&Q'S:3CF2%W")))&EYXE?B ,_] *8 +9)??;!PV" 3]+I!KQ+H
M )X=UF-'WC!TOEPW(9QX?3P6()!PO.0#"YE%#F%:#OAVGJ2:9,2BQ\>\D4,_
MDF>;88XL2+YCDFKAZ*^N=*:]*!@B77S!P\5=5 !^Y!O/\(XDC-]!,!-.K? J
MGR551G+2?0?I@.B>'Y$NHR'OH(OP7NK;&(/@526OD<YS-,+?,U2' 5/A<] <
M'B62+B8_ %:CC]6G0ZDIPU<&(8B;-H>=O/28X!VR9<R^I"VZI*7WT.N% [DB
M^ITE<@"A2NR!CE (&YZ(+P:"<HO:!A-U&.N'DQ,=#7<YJ8&W^ G,,L2H9$ #
MX1.(B,B'@(X^4^Z*C[J I#!@$GNTBV A6H18+7".X:UH"%^DK UI7Q G!&5V
M:4!L<"WC/L*8G4":#!K1YTA%<G*,_R<< 4.J:EG>%,S>+#6Z^VU?T<J J8P3
MWRO!UU>D-C$"B45#"+5=/P1[B7++/=N-'39M_T!W<$GEB?6%T 6R^<3?&ULY
M@9I]5#;X[-EWGQ-;Q)Q0?.="Z 12#D)[2(_(SX:I:QA20GN'G:/LUE0JUQ24
M'?SW,?*"CGG#4306^1' ,CBNZ ' G(:,!L?@4(Y,/3BU &0OOM!.ER%!NC!?
M> D?#<<C!QAXH<(0HY&4R$=0,[G-H<M(Z-WHZ1G ZE$'WQ7 TX-!OV+ 4^VL
MD-/IEGAX0@XYVKM91T$;>0E9CP',"V+V-)$T: ;;R2RIB.!;D+_O([MQ/[#^
M*75W1 2PB-+/OL#8$$8$[AIGH6A>CI/W^\Q!1"/2)2=]UN_(?MXSBV!C(T8Y
MX\]'XET0,AX-I2H@C(ME"7@ K"R@AHO+5YVA>#)I'T2*/?G89'*#RH1_M_1!
MZ=&%<0=!/!I-*]&=!*C'?1<-H-\"6!P-]^_4BREX:898%32T+/\$L=!A&BE?
MXF;C=V%L]\8*(^SF8L-6X C;2B/L6H7<!4 S((,KEEP!6A&-KECB"CRPX!F4
M*BQ$^/P&0;D_>_A&:.R(<$9&6&G, TH4"3LTCN@0S DN)#CD@MD2?2PI7:9<
M(>Z"2OLOPK.7RV?CF%'8F:<G##D1PI"R'2X P,=@;<#$GH*T"<D7@ QB@-B_
M&*3@A>=[Q_*O,.$*RBV.06X>"5&7!A8'@DAEZI_].#KVN\<#7$>,Q&?&9]&M
M%XH& +X"J0$!SC!(HI.0C7J1,P0O&&UX D*C$:"OS9$P.%9&07\@R 5\"D0X
MZ+#0#GA'?#TB$+J+2*0MXM#R-<W,VR[K1IM;XYR_4CE>H]Q::M-HO3.%$%!X
M<IXP;NY5)ND P!Q%3-".G8!$O@1T+1FO<]*]T@5A!PE]\"KM7BG*/F?R8 ]=
M1+5?#LQMD!@5=2EI[TXO+JYO?LW.[?/VR*WX^W'^&GGE;SX/8YT*8R9\C4/C
M:*XT2KS]M ,]2'N>+V[SQ_/SM'!WNQ/"O;H,CW)/:PT,87-(E[WEB&'F@2/Y
M/+@B-/HX731#S<ZI#&W=S'U8[HYS,)<=4G&3ICPEL5C;T3^3/,PYGQ;[D?Y(
M[+6I[/4\+;7T/!B'7/6\8W-=SP-#\FFM'W%[0TG-W)-WRNW.&4?,_"CRPJ2[
MM2]A_G?ZAZR8HIF9ZGK6+&4KM4_K("J>PUOO:5&YDB#6UM,=9O$'+DH/ K_+
MPI#CS2_C=6NYV,W&6[ER93W)H:*>%T]L!6CDGY@&$0O<89*F!!]AQHS8)\#E
M=Q!S+I,H9*X4?A:,\O0<WXZ3/061NIY-Y*KL3+S>E/6;;Y$RURU2Z.K."M2A
M'VA"9' U5R,,*-D7L2Y^>[2RO$';(F. H[QHXF_JX(,R_P;^'+@@@T#3E85#
M)7Y_+/&[I1*_-Y15-;-2_N;]ZMK!E[O3^T=R_7^WM@^][2WY>KHE7Z^0RQ\]
MWN%H=*Y&N](/XUUIL2^?G(;:WL;\>X&9'I&O/(SF&4$:BB0+N:?,PR3K^21O
M4S J\_EP&#*6[K(O9E0\&+CB;\Q(N0!12/?@:40$QUM)[I>=YJ ZI >6@GN8
M!@#  +^#D3C*&U7,N509"R8Y'/^:'.&;2R21SM9AS".^2*]U\.0AC4.99L@]
ML)=].B]'/F31.,-"T"M)A:9 <8@IDG.,\&'8\U^\-%,5LW5%)A#F(LP=D4@6
MBU@HVXW\W)'>&D-$WH8VF0O#,2_-3;2?)4->H/RGTN6^WPP&;-&]79\129A,
M"EU;IKK$5?M)%S\99RVS:6]M8]/^.@N[F':5XNU<FD_7VLPUX;>YBKG,'Y]E
MLM2OULSJSYI+-=W$F*BW/)M)C,1<2PBZ> GM58)LL)[M)))<B'P\<71K!;H8
MNZ;+(D'99F(<&BLYA=\ &7#=1E%N-<J!XZ9(M1*I$O54U%I5)=&YA%AJGI7.
MY\;Y:)&G%T6#DVKUY>6E$C*[\N0_5T\#N\>?65AESA,-J@[$B%6CT8+_S"H0
MWVC4:^UZS6CJ>JT.'WE.0/_+?EAFI1?U,1@PY/K03FY?S#UYKOP80\33ODS?
MES<'B'5]1UPN($]EB^6VL2^8'-+.'!O9!HF+TN:*HK!N]6\=_Z>D,[,J9DEG
MIM>KAEDUFGG/A/@X_I@F_&8VS2I+ <A(\=E4^+R$/E,@+(!:K"2FBX;O!'"%
MV#O7_C(C]L9K1^QH9@#7>JMJFKEWJ,4&6]*&F(C#[$3U3\1E%V)W;1V>90,]
MRW8;D0MQJY;BNB4A)ME_RX4T[,[]GD^DN:A]-G3IR_2Y>@77.U?]A^.R@IHU
M>8%_B6:&<-T ?2R_@RT0QF@W$X2I)>YC32U_+*'.PX#9T*\WX2D'++GT5]Q?
M,O\6807..5/T\H)SK;R^M%$UC?>#<Y$6IZ?@IY:"LUK[6$P=W"!#H/U37B=/
M3I\")I.HT%U./\5LI8"'B-4TDS$S>R%5[&%R#5[_+J]SP;],W6C"[UQ<"C6(
M.RZW\9HL<<N+ O6= T290;VL2]H?!/4">]SU%-0M!>H+J9."^A^X!(573[,@
M3"!Z!.D)1D<^L9/KS1T6PN08&ZV*Q)G7T\S5:<!7X)YKH"@SN%LEG=D>>>PM
MW3!UO9WF2]0:*;K7%;HO)L\6X?W6CGR\:!)@OJ5P/4<8H1__[YK/FN9F;K5*
MHZQ3 VC';)06V0/'O:WKK7JC-@*O8S,%]Z8"]R7TF5Z1&2^F_!Z[0T3B-MZ7
M_(RKZ'<NM<5JC8+DG>MV>1--RKN.HC>K9KMJM/? U6[KAM4R1ZG)XZW+ED+C
MQ>292NZ[$#YT4H@$_GX ?QA&=8JW)(BIX0'/.W%>&L\(/^ VIH+FG:MYF:&Y
MK.L[F+)MO!^:B^4I3V+/R%%N*VA>3)[%?O*H/(;PE5?!:'*KEC;RHOAE!NNR
M^M$?!.N"^=$UTZK/^M&&KM!Z,7U6<Z3/E".=:STO,S:7V)$V&WOC2$]@S\B1
M-E1^]A+ZO-&37@K2RI/.C^:7&:U+[$E_!*T+Y$GC86RSW6Y6I\YB UJKA.TE
M]%G-DSY7WG/N=+N\>%S>H^AZNVHVWW\4O4#>,^"-7C.:F2VPL?NLDJV7$2AS
MH:%$X+0:^Y8Q=]VROW6 WT"6W,81=[-K$AMW<S<)G5;5T@$ZBU%5;NW73QAZ
M<L3.T-7Q\&7TN;RYN#\E7WF7D0>;X[W'(=ZB5,%%AP:Y[7N\$XM/\+3XLTAZ
M\\B_E#^[<]^HO(=+0&7591W%=6A-PVK#/RU=K[=J9M5A7:-&]09\WOJON/K-
M!; 9@?.>KS:\@5A7/ BCR=OQW@/>"KMW#P,7EU?$J)V6=':G@\&/"BGK[/ (
MB5XU6GOH4M='J*V6));0)]W12[;DY-+$Z0L-''GJ3Z%SOC6\U)YUO:Q3VP//
M>@'L-$:P7%.PO)@^*2SC+:0!MZ-1TL0?'H\4/A='U4N-SXVR3NUC^%P@M]F$
M7]O&^&RQH9LC@%8W:RPCT(WO'5_V!ZX_9(Q<\(#9D1^(6S&8%\J:+'>^R^VA
M1D 8X%M$Y=-!P%W2UK >MZ[@.0>:KA__;VFG5MK4-[U5-6I54R^,_SP"C['[
MVR@1NDY/[UW8^#OU8BPZ;>F:G B"I+5MD%RWJ/XH\-@+G]51N@F4U0V=NIW2
MT%NEQ,FUTR==)KCV'-;W9*ZO6, =W<W<&8KKF3LL>L&B]9F;V\3GC-H]; !O
M7W82H [E-S^8'0M@]KO0+@M"Y:_NWO,I]7)"JZQ3VY\[F*?*FAJZ,0)R=9?;
M,@+-+3TE?6B!XR-$UX@COOM&A\0P-7&MLO8:S%\%U+-]'I)OW.XQUU=+PSF
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M;4,1C"\Y38V/YD0.,NV_F_FK19.R^=:GS[DULS-1T]@/F;T8<7):YJ=US*&
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M:Q["]P,_$+UWF#CK(4]]<.B]PWK4[>(U*]B0N,E&/B!:#ECLP5NB01I'/3^
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M0@VC^72%ARE_#2-HGYM38'Z"LD;*<S@[>F5/Y8^F6K=+5G?\.TJHDJ_/T,H
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M3FCRCWNT4).VPS:R2TMZW_O4X. Z@4%7_N2V$'XFG?!<Y#TFL'9^%L&G"]M
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MJ-AG)+[3T[1;"_G43"%1"MA'^YKY*6X$^R'!HS:[$W)K9,W@6<W$]>N8[U)
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MX:A+HS?./_>Z%-"F-<+(-@^,1=>S&+"UWK^+7D2X+%%?(\XE;D\8EOFAH3V
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MKRTJMW<Y9_=Y0,+2=;[1F#O_X$(7Z^'T1+5#-'UT:Y[Z2'I8$NVQ.(84(\A
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ML[4>HX&I50]!"WK*?GV?M99\S7WERM6BJ^?E%T=S0C@MAVIBTI8@*B--V@;
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M"M_6V5R1X2X.,SF9!J X@I?+CGO#HLSLD'PS.\HN5EA\[[>G8\4)X)0/*QN
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M/&='QW"!:H*Y]CJ,*%QU(:SS_K1">>E4*)3?;5Y,PU)&*G??[&=\ZH ^,"$
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M0, CC3DK^R"/+ZV&K<2*1<*R$",20@R?C,&F'(9US8D *8OZ4$*G<>-%W]3
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M9&;^WTOYLMUBR,S0A+*_\L#6' AM,(79&^\>%?E_'\B%-3]3#:W]]0;8HAQ
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MJ[LL7[D\U^5")?8YB7>5\8O<VR3?<#,-^A3VEP!%"B':/ZOHCX6+!T1K4_H
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MN _;P\\+"E=)+5:C[S+HM0HA5\(EZ"?ZXJTECM2I:GT #';WAJ<FP^[I4 \
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MI,0@NJ7@NA:G2]IN\F&MC:971WDZ1U<N1:U0I6K P&/.*>"3C(DJ1Q0"7I8
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MP# W-_E$\O0XS""#QX2X7NQ/M"=-/N4JQ:;N5M<RO0[=)B[1GHTX)$.+X0U
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MVBK;V?F&[^LK%E7<G'B65#*^V47UX$61[;M/+)G86'^LUUI3["C[M+8"%5S
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M-LS@MX[>OA@KH</@"+[%B\GJB_U@\>JCPB@$<^=OKR?=.OE,RC[Z,^M@R1I
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M'?SGY^\PQI:*B(M<_YI!5QDY+26'&]C*/]-&P40BSS6_?;>[I$NS':SC\4P
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MR10&_Z#_)OR!?_EI<@([I9W4>PT,ZU.F*K.U?N'% CI;[Q>V)/-Z,GDRK2_
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MX]&X0CT#=U:,:M%(T1X/J K6BT(4ZPWQQY%E8\NI9TYD9=[@EG3/H31]9^1
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MAG'>RF09F9[:#MMPMDIP"/F\_'F-PDV9LB^&/@R[*T%7 WY?Q5 4'1W-E,]
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M/K=.-*\!]8'J%^39!;9GO#&ZA=]8W_I;6=;$376E&/G>/I?@"'V&M%V25K:
MS0GXT9>BGO/5S;'B+9HF6NOVUZQJGYYX1#T!;=//2Y.DG12W)#XN[W>Q-UQO
M?*3@E=LDQ*&K6[\3K2=!*]]^++X-@V'I?Y],M-*<(?VW5A#L:G["4YPT1&GP
M*(ZVIJJVEC2S]<F_?O:1X\.O_C/.5+Z34::OO1^<R&6;VCY9CZMF$+@]G;7
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M9=7H.7Y.9,KX"-'_!:SFK\#] 5!+ P04    " !<AG!6938(+V4'  !0+0
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M;Y#YJUUNBY\2V_\"4$L! A0#%     @ 7(9P5C\KET]K#P  /*P  !$
M         ( !     &YD<F$M,C R,C$R,S$N>'-D4$L! A0#%     @ 7(9P
M5A1Z]K2(#   .Y4  !4              ( !F@\  &YD<F$M,C R,C$R,S%?
M8V%L+GAM;%!+ 0(4 Q0    ( %R&<%9S06]'91@  (:% 0 5
M  "  54<  !N9')A+3(P,C(Q,C,Q7V1E9BYX;6Q02P$"% ,4    " !<AG!6
MRD!O^0M(  " \ , %0              @ 'M-   ;F1R82TR,#(R,3(S,5]L
M86(N>&UL4$L! A0#%     @ 7(9P5J@V[!R*-@  :0X# !4
M ( !*WT  &YD<F$M,C R,C$R,S%?<')E+GAM;%!+ 0(4 Q0    ( %R&<%8O
MCE%MY 0"  2<$P ,              "  >BS  !N9')A7S$P:RYH=&U02P$"
M% ,4    " !<AG!6^@98MV2?  #7I0  $               @ 'VN ( ;F1R
M85\Q,&MI;6<U+FIP9U!+ 0(4 Q0    ( %R&<%:*F)G!L7(  !Q^   0
M          "  8A8 P!N9')A7S$P:VEM9S8N:G!G4$L! A0#%     @ 7(9P
M5N<LFJ&R!P  ^!\   X              ( !9\L# &YD<F%?97@Q,#8N:'1M
M4$L! A0#%     @ 7(9P5KPZQT#_ 0  F@<   X              ( !1=,#
M &YD<F%?97@R,3$N:'1M4$L! A0#%     @ 7(9P5G%21<2C @  :0@   X
M             ( !<-4# &YD<F%?97@R,S$N:'1M4$L! A0#%     @ 7(9P
M5@ACX\>K @  =0@   X              ( !/]@# &YD<F%?97@R,S(N:'1M
M4$L! A0#%     @ 7(9P5F4V""]E!P  4"T   X              ( !%ML#
M &YD<F%?97@S,3$N:'1M4$L! A0#%     @ 7(9P5M:)L&EH!P  )"4   X
M             ( !I^(# &YD<F%?97@S,3(N:'1M4$L! A0#%     @ 7(9P
M5M")5D.R!   JA0   X              ( !.^H# &YD<F%?97@S,C$N:'1M
64$L%!@     /  \ I0,  !GO P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
